data_1yvc_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 1yvc _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 16.2 Cg_endo . . . . . 0 N--CA 1.475 0.435 0 N-CA-C 113.212 0.428 . . . . 0.0 113.212 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.521 HG11 HD12 ' A' ' 36' ' ' ILE . 16.1 m -114.72 121.0 65.93 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.356 179.846 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 49.0 mt-10 -99.29 118.33 35.73 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.782 -177.686 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -63.84 125.06 23.16 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.674 -0.694 . . . . 0.0 111.028 179.934 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 112.45 -4.44 26.48 Favored Glycine 0 N--CA 1.449 -0.44 0 C-N-CA 120.891 -0.671 . . . . 0.0 111.814 -177.852 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 97.1 mttt -118.59 158.52 25.28 Favored 'General case' 0 C--N 1.324 -0.542 0 N-CA-C 110.289 -0.263 . . . . 0.0 110.289 178.997 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . 0.482 ' HA ' ' O ' ' A' ' 54' ' ' VAL . 0.0 OUTLIER -120.61 130.7 54.28 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-O 121.606 0.717 . . . . 0.0 111.29 179.878 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 45.8 m-85 -122.66 149.63 43.77 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.257 -0.883 . . . . 0.0 110.179 -174.912 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 2.3 mp0 -84.8 119.13 24.96 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 121.138 0.494 . . . . 0.0 109.693 173.857 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 36.0 m -130.43 165.04 31.74 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.879 0 CA-C-N 115.599 -0.728 . . . . 0.0 110.865 -175.097 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 11.7 m -108.35 149.64 28.42 Favored 'General case' 0 C--N 1.316 -0.87 0 CA-C-N 115.999 -0.546 . . . . 0.0 109.935 175.911 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.517 HG13 ' HB3' ' A' ' 46' ' ' ALA . 36.0 mm -110.67 61.6 0.16 Allowed 'Isoleucine or valine' 0 CA--C 1.509 -0.609 0 N-CA-C 107.652 -1.24 . . . . 0.0 107.652 -176.995 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 31.4 tt0 -62.57 -24.79 67.73 Favored 'General case' 0 C--N 1.311 -1.084 0 CA-C-N 113.062 -1.881 . . . . 0.0 111.207 -179.583 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.549 ' HB2' ' HB ' ' A' ' 33' ' ' ILE . 15.3 m-20 -124.33 149.15 46.91 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.33 -0.396 . . . . 0.0 111.18 -175.213 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' MET . . . . . . . . . . . . . 96.0 mmm -123.19 147.85 46.42 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.092 -0.504 . . . . 0.0 109.932 173.975 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.448 -0.544 0 C-N-CA 121.091 -0.576 . . . . 0.0 112.792 -178.02 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . 0.439 ' OD1' ' HA ' ' A' ' 44' ' ' PRO . 27.5 t70 . . . . . 0 N--CA 1.454 -0.251 0 N-CA-C 109.56 -0.533 . . . . 0.0 109.56 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -98.66 132.53 10.97 Favored Glycine 0 N--CA 1.447 -0.615 0 C-N-CA 120.602 -0.808 . . . . 0.0 111.897 -177.293 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.549 ' HB ' ' HB2' ' A' ' 25' ' ' ASP . 1.9 mp -101.83 104.1 15.9 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.737 0 CA-C-O 121.492 0.663 . . . . 0.0 110.625 -178.248 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -84.17 157.19 21.75 Favored 'General case' 0 C--N 1.317 -0.809 0 CA-C-N 115.406 -0.816 . . . . 0.0 109.167 169.036 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 6.0 ttm180 -142.18 107.87 5.11 Favored 'General case' 0 C--N 1.313 -0.982 0 C-N-CA 120.644 -0.422 . . . . 0.0 110.819 -176.769 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.521 HD12 HG11 ' A' ' 13' ' ' VAL . 37.2 mt -99.43 108.68 22.96 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 CA-C-N 115.733 -0.667 . . . . 0.0 110.11 178.093 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 58.2 16.46 3.95 Favored 'General case' 0 N--CA 1.468 0.473 0 CA-C-N 115.26 -0.882 . . . . 0.0 112.079 -176.539 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 110.28 -16.99 29.36 Favored Glycine 0 N--CA 1.449 -0.447 0 C-N-CA 120.856 -0.688 . . . . 0.0 111.764 -178.057 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 34.0 t80 -71.68 117.59 13.44 Favored 'General case' 0 C--N 1.328 -0.362 0 N-CA-C 109.576 -0.527 . . . . 0.0 109.576 179.334 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 0.46 HG13 HG22 ' A' ' 33' ' ' ILE . 29.1 t -70.61 117.59 13.9 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 CA-C-N 115.824 -0.625 . . . . 0.0 111.301 -178.43 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 49.1 t -119.34 108.39 23.65 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 CA-C-N 115.481 -0.781 . . . . 0.0 109.594 -179.812 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 93.7 m-85 -78.58 129.55 34.92 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.086 -175.411 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 5.6 t -125.73 105.57 26.65 Favored Pre-proline 0 C--N 1.321 -0.659 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.246 -177.948 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . 0.439 ' HA ' ' OD1' ' A' ' 31' ' ' ASP . 34.9 Cg_endo -65.75 -8.26 19.01 Favored 'Trans proline' 0 N--CA 1.477 0.538 0 C-N-CA 123.537 2.825 . . . . 0.0 114.476 -172.561 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 1.2 p30 -142.54 20.35 2.03 Favored 'General case' 0 C--N 1.321 -0.65 0 N-CA-C 112.264 0.468 . . . . 0.0 112.264 -167.603 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.517 ' HB3' HG13 ' A' ' 23' ' ' ILE . . . -97.18 155.89 16.64 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.082 176.126 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 48.9 mt-10 -106.38 144.9 32.39 Favored 'General case' 0 N--CA 1.451 -0.421 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.093 178.54 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 60.8 tttm -66.2 137.36 56.93 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.457 -0.338 . . . . 0.0 111.352 -175.676 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 82.86 -2.24 86.84 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 121.017 -0.611 . . . . 0.0 113.121 175.943 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 29.7 m -93.56 152.08 19.27 Favored 'General case' 0 C--N 1.324 -0.538 0 O-C-N 122.654 -0.321 . . . . 0.0 111.085 -179.529 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 46.6 t -98.46 101.65 12.42 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 N-CA-C 108.456 -0.942 . . . . 0.0 108.456 172.897 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.524 ' HA ' HD13 ' A' ' 70' ' ' LEU . 0.8 OUTLIER -115.2 145.23 21.22 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.851 0 CA-C-N 115.789 -0.641 . . . . 0.0 112.018 -170.281 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 58.1 t30 -88.3 112.86 23.31 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 114.923 -1.035 . . . . 0.0 109.005 176.306 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . 0.482 ' O ' ' HA ' ' A' ' 18' ' ' GLU . 35.2 m -115.01 134.56 57.69 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.724 0 CA-C-O 121.115 0.483 . . . . 0.0 111.609 -175.259 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 2.3 ttmp? -93.42 111.06 22.63 Favored 'General case' 0 C--N 1.32 -0.709 0 N-CA-C 109.124 -0.695 . . . . 0.0 109.124 175.52 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.455 HG22 ' HB ' ' A' ' 13' ' ' VAL . 87.6 t -67.88 113.08 3.41 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 N-CA-C 109.189 -0.671 . . . . 0.0 109.189 177.693 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.7 p -109.36 -26.02 10.24 Favored 'General case' 0 C--N 1.324 -0.53 0 N-CA-C 112.455 0.539 . . . . 0.0 112.455 -173.104 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . 0.421 ' HB3' ' HB2' ' A' ' 65' ' ' PHE . . . -143.38 92.17 2.34 Favored 'General case' 0 C--N 1.325 -0.476 0 C-N-CA 120.679 -0.408 . . . . 0.0 111.738 -175.301 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 15.6 t -79.9 125.89 39.07 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.735 0 CA-C-N 116.109 -0.496 . . . . 0.0 109.781 174.079 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 46.0 mmtm -106.01 -164.17 0.99 Allowed 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.439 -179.559 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 40.8 tt0 -66.03 -48.84 69.77 Favored 'General case' 0 CA--C 1.533 0.297 0 N-CA-C 112.623 0.601 . . . . 0.0 112.623 -175.3 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 93.1 mttt -120.6 3.89 10.66 Favored 'General case' 0 C--N 1.328 -0.332 0 N-CA-C 111.934 0.346 . . . . 0.0 111.934 -172.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 15.1 p90 -166.6 169.01 14.06 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 116.42 -0.355 . . . . 0.0 110.21 -174.273 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -129.42 158.76 38.26 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-O 120.878 0.37 . . . . 0.0 111.095 -179.95 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' PHE . . . . . 0.421 ' HB2' ' HB3' ' A' ' 58' ' ' ALA . 95.3 m-85 -114.47 136.14 53.34 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.579 -0.737 . . . . 0.0 109.824 176.827 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' ALA . . . . . 0.461 ' HB2' ' HB ' ' A' ' 54' ' ' VAL . . . -127.35 -179.3 4.82 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.571 -179.155 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' GLU . . . . . 0.436 ' O ' ' HA ' ' A' ' 54' ' ' VAL . 8.1 pt-20 -141.67 143.82 33.79 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 120.861 0.362 . . . . 0.0 111.212 178.85 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . 0.524 ' HB2' HD11 ' A' ' 52' ' ' ILE . 31.2 ttt180 -67.73 106.16 2.15 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.405 -0.816 . . . . 0.0 111.707 178.185 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 2.6 t -83.54 21.66 0.19 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.361 0 CA-C-O 121.501 0.667 . . . . 0.0 110.405 175.286 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . 0.524 HD13 ' HA ' ' A' ' 52' ' ' ILE . 64.2 mt . . . . . 0 C--O 1.249 1.074 0 CA-C-O 118.351 -0.833 . . . . 0.0 110.064 -179.255 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 10.9 Cg_endo . . . . . 0 N--CA 1.473 0.315 0 N-CA-C 113.125 0.394 . . . . 0.0 113.125 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.497 ' HB ' HG22 ' A' ' 56' ' ' VAL . 15.6 m -103.64 126.8 58.09 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-N 116.09 -0.504 . . . . 0.0 111.214 -178.311 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . 0.417 ' CB ' ' HD3' ' A' ' 17' ' ' LYS . 37.6 mt-10 -101.06 123.96 46.05 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.058 176.398 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . 0.47 ' HA ' ' O ' ' A' ' 56' ' ' VAL . . . -60.94 110.16 1.27 Allowed 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.355 177.227 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 123.64 -18.76 7.6 Favored Glycine 0 N--CA 1.447 -0.613 0 C-N-CA 121.029 -0.605 . . . . 0.0 112.436 -178.29 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' LYS . . . . . 0.417 ' HD3' ' CB ' ' A' ' 14' ' ' GLU . 2.4 mptm? -94.1 162.97 13.66 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.935 0.398 . . . . 0.0 111.393 -179.99 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . 0.549 ' HG2' ' HB2' ' A' ' 55' ' ' LYS . 31.4 mt-10 -118.84 128.41 54.43 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.538 -0.755 . . . . 0.0 110.036 179.611 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' TYR . . . . . 0.416 ' O ' HG21 ' A' ' 54' ' ' VAL . 62.0 m-85 -127.87 127.17 42.94 Favored 'General case' 0 C--N 1.322 -0.627 0 N-CA-C 110.065 -0.346 . . . . 0.0 110.065 179.412 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . 0.62 ' HA ' ' HA ' ' A' ' 53' ' ' ASN . 34.8 tt0 -78.24 119.12 21.16 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 121.149 0.5 . . . . 0.0 109.764 177.03 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 23.3 m -129.82 162.81 36.77 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-N 115.499 -0.773 . . . . 0.0 111.702 -170.116 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 9.7 m -97.33 149.12 22.44 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.021 177.215 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.473 HG13 ' HB1' ' A' ' 46' ' ' ALA . 24.0 mm -121.33 65.94 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 108.572 -0.899 . . . . 0.0 108.572 -175.546 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 35.5 tt0 -86.98 -5.34 59.12 Favored 'General case' 0 C--N 1.31 -1.116 0 CA-C-N 114.445 -1.252 . . . . 0.0 110.465 -178.209 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.528 ' CB ' ' HB ' ' A' ' 33' ' ' ILE . 25.1 m-20 -118.59 134.42 55.11 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 115.526 -0.761 . . . . 0.0 109.396 -178.874 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' MET . . . . . . . . . . . . . 98.1 mmm -124.82 147.03 48.95 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-O 120.697 0.284 . . . . 0.0 110.91 -179.842 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.445 -0.757 0 N-CA-C 110.71 -0.956 . . . . 0.0 110.71 175.667 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 4.4 p-10 . . . . . 0 N--CA 1.445 -0.696 0 N-CA-C 109.203 -0.666 . . . . 0.0 109.203 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -109.38 160.87 13.28 Favored Glycine 0 N--CA 1.443 -0.863 0 CA-C-N 115.526 -0.761 . . . . 0.0 112.588 -175.347 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.528 ' HB ' ' CB ' ' A' ' 25' ' ' ASP . 2.5 mp -114.1 110.08 30.81 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.836 0 N-CA-C 109.962 -0.385 . . . . 0.0 109.962 -179.973 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . 0.469 ' HB3' ' CD1' ' A' ' 23' ' ' ILE . . . -94.03 155.17 17.26 Favored 'General case' 0 C--N 1.318 -0.761 0 CA-C-O 121.732 0.777 . . . . 0.0 111.098 173.868 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 29.1 mmt180 -121.4 103.11 8.71 Favored 'General case' 0 N--CA 1.437 -1.114 0 CA-C-N 114.552 -1.204 . . . . 0.0 110.629 -172.52 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.418 HD12 ' CG1' ' A' ' 13' ' ' VAL . 26.1 mt -100.61 101.4 12.04 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.601 0 CA-C-O 121.1 0.476 . . . . 0.0 109.917 175.623 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 33.2 t70 67.06 -4.14 0.86 Allowed 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 114.669 -1.151 . . . . 0.0 111.006 -173.522 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 122.61 -19.28 8.01 Favored Glycine 0 N--CA 1.446 -0.673 0 N-CA-C 110.845 -0.902 . . . . 0.0 110.845 -172.207 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 51.7 t80 -65.84 126.08 27.38 Favored 'General case' 0 C--O 1.237 0.399 0 N-CA-C 109.126 -0.694 . . . . 0.0 109.126 176.702 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 0.473 HG13 HG23 ' A' ' 33' ' ' ILE . 39.9 t -76.77 113.45 15.84 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.757 0 CA-C-N 115.78 -0.646 . . . . 0.0 111.292 -175.344 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 68.0 t -109.31 111.65 37.03 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 CA-C-N 115.48 -0.782 . . . . 0.0 109.885 177.347 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 60.6 m-85 -77.95 120.12 22.37 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.376 -179.625 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.538 ' HB ' ' HB3' ' A' ' 46' ' ' ALA . 8.7 t -120.81 104.56 41.83 Favored Pre-proline 0 C--N 1.319 -0.725 0 CA-C-N 115.587 -0.733 . . . . 0.0 110.398 -177.304 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -77.32 16.84 0.96 Allowed 'Trans proline' 0 CA--C 1.53 0.324 0 C-N-CA 123.379 2.719 . . . . 0.0 113.584 -174.187 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -152.04 21.43 0.67 Allowed 'General case' 0 C--N 1.321 -0.65 0 CA-C-O 121.523 0.678 . . . . 0.0 110.266 -178.042 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.538 ' HB3' ' HB ' ' A' ' 43' ' ' VAL . . . -78.63 168.86 19.14 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 115.224 -0.898 . . . . 0.0 111.488 177.923 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' GLU . . . . . 0.454 ' O ' ' HB ' ' A' ' 23' ' ' ILE . 0.0 OUTLIER -126.16 134.76 51.2 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.549 -0.75 . . . . 0.0 109.594 178.21 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 1.8 tmtp? -63.37 120.84 12.39 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.891 -176.15 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 81.96 5.91 89.36 Favored Glycine 0 N--CA 1.45 -0.412 0 CA-C-N 115.776 -0.647 . . . . 0.0 112.821 177.097 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 20.0 t -101.78 163.34 12.3 Favored 'General case' 0 C--N 1.324 -0.538 0 N-CA-C 110.123 -0.325 . . . . 0.0 110.123 -178.478 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.487 HG11 ' HG2' ' A' ' 20' ' ' GLU . 32.2 t -114.35 101.46 12.46 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.463 0 N-CA-C 109.106 -0.702 . . . . 0.0 109.106 179.269 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.571 HD11 ' HB2' ' A' ' 68' ' ' ARG . 6.4 pt -108.58 145.47 15.5 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-O 121.054 0.454 . . . . 0.0 110.934 -173.131 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . 0.62 ' HA ' ' HA ' ' A' ' 20' ' ' GLU . 39.6 t30 -82.55 115.81 21.69 Favored 'General case' 0 C--N 1.318 -0.765 0 N-CA-C 109.328 -0.619 . . . . 0.0 109.328 172.157 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . 0.503 HG13 HG13 ' A' ' 52' ' ' ILE . 28.8 m -107.97 130.81 59.81 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-O 121.358 0.599 . . . . 0.0 111.816 -177.198 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . 0.549 ' HB2' ' HG2' ' A' ' 18' ' ' GLU . 39.8 ttmt -97.98 106.65 18.98 Favored 'General case' 0 C--N 1.318 -0.772 0 N-CA-C 108.959 -0.756 . . . . 0.0 108.959 172.304 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.497 HG22 ' HB ' ' A' ' 13' ' ' VAL . 47.1 t -68.12 112.88 3.44 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.079 179.559 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 21.0 p -109.41 -17.94 13.67 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 112.071 0.397 . . . . 0.0 112.071 -174.86 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -143.58 92.58 2.37 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.063 0.458 . . . . 0.0 110.984 -177.607 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 13.4 t -85.24 129.61 37.55 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.638 0 CA-C-N 115.854 -0.612 . . . . 0.0 109.913 175.868 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 74.8 mmtt -106.76 -173.07 2.21 Favored 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 109.979 -0.378 . . . . 0.0 109.979 178.437 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -72.42 -41.22 66.45 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.35 -0.386 . . . . 0.0 111.859 179.648 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 56.3 mttp -92.13 -45.3 8.35 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 121.036 0.446 . . . . 0.0 111.295 -178.269 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 10.4 p90 -142.84 -171.3 3.42 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.969 -0.559 . . . . 0.0 110.492 -172.538 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -138.91 158.51 44.07 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-O 120.814 0.34 . . . . 0.0 111.113 -179.462 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 93.2 m-85 -113.85 138.72 49.91 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.694 -0.684 . . . . 0.0 109.43 175.492 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' ALA . . . . . 0.428 ' HB1' ' HB ' ' A' ' 54' ' ' VAL . . . -142.6 159.14 42.82 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 116.553 -0.294 . . . . 0.0 110.906 -178.668 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' GLU . . . . . 0.423 ' O ' ' HA ' ' A' ' 54' ' ' VAL . 10.8 pt-20 -113.72 137.75 51.19 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 121.303 0.573 . . . . 0.0 111.254 179.142 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . 0.571 ' HB2' HD11 ' A' ' 52' ' ' ILE . 25.0 ttt180 -66.41 109.86 2.89 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 115.237 -0.892 . . . . 0.0 109.98 172.458 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 2.8 t -81.92 25.13 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.536 0.41 0 CA-C-O 121.526 0.679 . . . . 0.0 111.867 -174.767 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . 0.441 ' CD2' ' HG3' ' A' ' 68' ' ' ARG . 0.8 OUTLIER . . . . . 0 C--O 1.245 0.838 0 CA-C-O 118.759 -0.639 . . . . 0.0 110.329 179.218 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo . . . . . 0 CA--C 1.516 -0.403 0 CA-C-O 121.621 0.592 . . . . 0.0 112.507 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.594 HG11 HD11 ' A' ' 36' ' ' ILE . 16.1 m -80.5 163.03 3.53 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.896 0 CA-C-N 115.175 -0.921 . . . . 0.0 110.906 -177.989 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 9.8 tp10 -147.14 119.72 8.53 Favored 'General case' 0 C--N 1.322 -0.588 0 N-CA-C 108.918 -0.771 . . . . 0.0 108.918 178.471 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . 0.438 ' HA ' ' O ' ' A' ' 56' ' ' VAL . . . -58.91 117.55 4.78 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-O 121.111 0.482 . . . . 0.0 111.377 -177.207 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 119.09 -24.84 8.1 Favored Glycine 0 N--CA 1.447 -0.625 0 CA-C-N 115.653 -0.703 . . . . 0.0 112.218 -179.246 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 53.1 mtpt -90.55 156.37 18.21 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.871 0.367 . . . . 0.0 110.734 179.077 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . 0.473 ' HA ' ' O ' ' A' ' 54' ' ' VAL . 46.0 mt-10 -113.96 128.34 56.35 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.824 -0.625 . . . . 0.0 109.858 -179.864 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 81.5 m-85 -122.58 143.42 49.75 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 121.173 0.511 . . . . 0.0 111.583 -175.887 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 32.7 tt0 -82.98 111.06 18.49 Favored 'General case' 0 C--N 1.317 -0.808 0 CA-C-N 115.548 -0.751 . . . . 0.0 109.475 175.069 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.49 ' HB ' ' HB1' ' A' ' 34' ' ' ALA . 32.7 m -121.81 151.32 25.28 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-O 121.053 0.454 . . . . 0.0 112.023 -172.714 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 17.0 m -97.62 152.44 19.06 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.658 -0.701 . . . . 0.0 109.721 176.474 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.444 ' CD1' ' HB3' ' A' ' 34' ' ' ALA . 18.9 mm -121.89 64.5 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-O 121.791 0.805 . . . . 0.0 108.908 -174.423 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 26.1 mm-40 -69.02 -19.15 64.11 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-N 114.782 -1.099 . . . . 0.0 111.835 -179.663 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.534 ' HB2' ' HB ' ' A' ' 33' ' ' ILE . 5.6 m-20 -126.34 138.7 53.6 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 116.392 -0.367 . . . . 0.0 111.277 -176.093 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' MET . . . . . . . . . . . . . 92.9 mmm -120.28 142.09 49.39 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 115.814 -0.63 . . . . 0.0 109.917 175.655 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.444 -0.773 0 N-CA-C 111.559 -0.616 . . . . 0.0 111.559 179.537 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 30.3 t70 . . . . . 0 CA--C 1.514 -0.432 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . 0.538 ' HA3' ' HB2' ' A' ' 46' ' ' ALA . . . -114.42 141.71 17.15 Favored Glycine 0 N--CA 1.441 -1.022 0 N-CA-C 111.178 -0.769 . . . . 0.0 111.178 177.994 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.534 ' HB ' ' HB2' ' A' ' 25' ' ' ASP . 2.6 mp -97.93 98.19 7.03 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.767 0 CA-C-O 121.329 0.585 . . . . 0.0 110.276 -178.09 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . 0.49 ' HB1' ' HB ' ' A' ' 21' ' ' VAL . . . -99.85 123.01 43.65 Favored 'General case' 0 CA--C 1.497 -1.065 0 CA-C-N 115.747 -0.661 . . . . 0.0 109.398 171.706 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' ARG . . . . . 0.514 ' HA ' ' O ' ' A' ' 39' ' ' PHE . 0.0 OUTLIER -118.56 108.66 15.23 Favored 'General case' 0 C--N 1.303 -1.453 0 CA-C-N 115.6 -0.727 . . . . 0.0 111.363 -174.11 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.594 HD11 HG11 ' A' ' 13' ' ' VAL . 53.1 mt -84.43 112.62 21.9 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.702 0 CA-C-N 115.208 -0.905 . . . . 0.0 109.604 177.649 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 36.7 t70 60.43 19.07 8.76 Favored 'General case' 0 CA--C 1.539 0.523 0 CA-C-N 115.495 -0.775 . . . . 0.0 110.702 -175.451 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 100.78 -9.26 58.41 Favored Glycine 0 C--N 1.329 0.189 0 C-N-CA 120.583 -0.818 . . . . 0.0 112.143 -178.794 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' PHE . . . . . 0.514 ' O ' ' HA ' ' A' ' 35' ' ' ARG . 60.8 t80 -77.43 114.76 16.59 Favored 'General case' 0 C--N 1.323 -0.576 0 N-CA-C 109.708 -0.479 . . . . 0.0 109.708 178.779 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 0.493 HG12 HG22 ' A' ' 33' ' ' ILE . 21.5 t -68.98 110.09 2.3 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 CA-C-O 121.6 0.714 . . . . 0.0 111.968 -175.347 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.455 ' CG1' ' HB1' ' A' ' 66' ' ' ALA . 17.6 t -108.26 110.42 31.91 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.824 0 CA-C-N 115.092 -0.958 . . . . 0.0 108.896 175.503 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 65.9 m-85 -74.3 134.7 42.57 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-O 121.126 0.489 . . . . 0.0 111.284 -176.653 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.614 HG13 HD11 ' A' ' 52' ' ' ILE . 8.1 t -131.56 113.93 15.55 Favored Pre-proline 0 N--CA 1.449 -0.524 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.794 -174.943 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 59.8 Cg_endo -74.71 -9.41 21.17 Favored 'Trans proline' 0 CA--C 1.531 0.359 0 C-N-CA 122.692 2.262 . . . . 0.0 113.681 -176.943 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' ASN . . . . . 0.533 ' HB2' ' HB3' ' A' ' 68' ' ' ARG . 12.5 m120 -124.64 9.78 8.37 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.008 0.432 . . . . 0.0 111.34 -175.163 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.538 ' HB2' ' HA3' ' A' ' 32' ' ' GLY . . . -71.43 150.63 44.76 Favored 'General case' 0 C--N 1.319 -0.755 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.878 -179.542 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 48.8 mt-10 -123.6 141.77 51.68 Favored 'General case' 0 N--CA 1.448 -0.567 0 CA-C-N 115.669 -0.696 . . . . 0.0 109.972 178.335 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 33.1 ttpt -55.19 129.52 38.54 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.8 -176.818 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 67.08 22.46 72.47 Favored Glycine 0 C--N 1.33 0.218 0 CA-C-N 115.947 -0.57 . . . . 0.0 112.902 174.327 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 18.4 m -113.78 158.89 20.38 Favored 'General case' 0 C--N 1.319 -0.731 0 O-C-N 122.609 -0.348 . . . . 0.0 110.179 179.651 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 51.1 t -118.39 99.87 8.86 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 N-CA-C 109.444 -0.576 . . . . 0.0 109.444 -178.69 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.614 HD11 HG13 ' A' ' 43' ' ' VAL . 0.5 OUTLIER -110.0 152.98 11.89 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.695 0 CA-C-N 116.044 -0.525 . . . . 0.0 109.861 -174.831 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . 0.511 HD21 ' HB ' ' A' ' 69' ' ' VAL . 12.4 t30 -92.56 120.5 33.08 Favored 'General case' 0 C--N 1.317 -0.826 0 N-CA-C 108.926 -0.768 . . . . 0.0 108.926 178.018 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . 0.538 ' HB ' ' HB2' ' A' ' 66' ' ' ALA . 34.9 m -114.67 139.83 38.74 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 N-CA-C 112.405 0.52 . . . . 0.0 112.405 -174.561 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . 0.447 ' HB2' ' HG2' ' A' ' 18' ' ' GLU . 3.2 ttmp? -98.54 109.21 22.0 Favored 'General case' 0 C--N 1.319 -0.758 0 N-CA-C 109.026 -0.731 . . . . 0.0 109.026 171.339 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.438 ' O ' ' HA ' ' A' ' 15' ' ' ALA . 90.7 t -69.39 113.16 4.82 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 178.554 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 17.5 p -101.97 -28.92 12.1 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 116.216 -0.447 . . . . 0.0 112.009 -175.096 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -140.58 94.09 2.69 Favored 'General case' 0 N--CA 1.452 -0.365 0 CA-C-O 121.121 0.486 . . . . 0.0 111.343 -173.536 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 39.5 t -81.34 133.08 30.05 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.833 0 CA-C-N 115.595 -0.73 . . . . 0.0 109.865 174.426 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 72.9 mmtt -112.82 -164.74 0.94 Allowed 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.397 -0.365 . . . . 0.0 110.368 178.555 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 8.9 mm-40 -67.56 -47.21 70.49 Favored 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 112.17 0.433 . . . . 0.0 112.17 -171.873 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 66.6 mttm -124.1 -2.45 8.15 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-O 120.625 0.25 . . . . 0.0 111.636 -176.574 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 9.9 p90 -153.73 174.73 14.14 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 116.26 -0.427 . . . . 0.0 109.871 -174.45 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -142.22 166.76 23.8 Favored 'General case' 0 C--N 1.322 -0.59 0 C-N-CA 120.876 -0.33 . . . . 0.0 111.465 -179.177 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 89.4 m-85 -117.14 131.86 56.79 Favored 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 175.033 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' ALA . . . . . 0.538 ' HB2' ' HB ' ' A' ' 54' ' ' VAL . . . -124.68 155.58 38.99 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-O 121.463 0.649 . . . . 0.0 112.433 -175.926 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' GLU . . . . . 0.413 ' O ' ' HA ' ' A' ' 54' ' ' VAL . 10.8 tt0 -104.71 120.28 40.98 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 114.946 -1.024 . . . . 0.0 110.324 178.557 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . 0.533 ' HB3' ' HB2' ' A' ' 45' ' ' ASN . 41.0 ttt180 -66.19 107.71 2.04 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 121.624 0.726 . . . . 0.0 111.18 174.573 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.566 ' O ' ' HB3' ' A' ' 70' ' ' LEU . 2.6 t -80.57 -177.52 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.759 0 N-CA-C 106.241 -1.762 . . . . 0.0 106.241 167.005 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . 0.572 HD21 ' OXT' ' A' ' 70' ' ' LEU . 0.0 OUTLIER . . . . . 0 C--O 1.247 0.935 0 CA-C-O 118.257 -0.878 . . . . 0.0 110.85 179.614 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 42.0 Cg_endo . . . . . 0 C--O 1.232 0.204 0 N-CA-C 113.584 0.571 . . . . 0.0 113.584 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.449 HG11 HD11 ' A' ' 36' ' ' ILE . 13.9 m -119.97 120.72 63.99 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.819 0 CA-C-O 121.106 0.479 . . . . 0.0 111.017 -176.808 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 15.6 mm-40 -92.15 122.09 34.31 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.035 -177.678 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -67.09 96.74 0.47 Allowed 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.711 -0.677 . . . . 0.0 110.705 179.261 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 142.76 -30.15 2.07 Favored Glycine 0 N--CA 1.443 -0.887 0 C-N-CA 120.977 -0.63 . . . . 0.0 112.278 -178.298 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 8.8 mtpm? -95.7 168.79 10.45 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 121.64 0.733 . . . . 0.0 111.562 -179.478 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . 0.501 ' HB2' ' OD1' ' A' ' 53' ' ' ASN . 0.0 OUTLIER -115.5 149.63 37.82 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 114.557 -1.201 . . . . 0.0 110.621 -179.176 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 80.0 m-85 -137.67 141.21 41.12 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.259 178.125 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 8.1 tt0 -79.05 107.55 11.89 Favored 'General case' 0 C--N 1.325 -0.458 0 N-CA-C 109.408 -0.59 . . . . 0.0 109.408 174.356 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 35.2 m -118.08 164.13 14.64 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 CA-C-O 120.969 0.414 . . . . 0.0 110.756 -176.186 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 6.1 m -112.0 140.12 46.94 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-O 121.207 0.527 . . . . 0.0 110.202 177.833 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.53 HG13 ' HB2' ' A' ' 46' ' ' ALA . 30.7 mm -104.39 59.59 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.804 0 N-CA-C 108.188 -1.041 . . . . 0.0 108.188 -177.487 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 36.8 tt0 -65.69 -7.89 17.84 Favored 'General case' 0 C--N 1.315 -0.902 0 CA-C-N 113.724 -1.58 . . . . 0.0 110.873 -179.089 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.539 ' HB3' ' HB ' ' A' ' 33' ' ' ILE . 28.5 t70 -138.7 138.51 37.81 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 120.849 0.357 . . . . 0.0 110.86 -176.869 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -120.85 114.01 20.97 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.952 -0.567 . . . . 0.0 109.863 178.024 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.446 -0.649 0 C-N-CA 120.981 -0.628 . . . . 0.0 111.848 -178.439 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . 0.475 ' OD1' ' HA ' ' A' ' 44' ' ' PRO . 24.2 t70 . . . . . 0 C--O 1.232 0.144 0 N-CA-C 108.908 -0.775 . . . . 0.0 108.908 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -88.06 129.22 9.45 Favored Glycine 0 N--CA 1.449 -0.476 0 C-N-CA 120.627 -0.797 . . . . 0.0 112.381 -176.461 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.539 ' HB ' ' HB3' ' A' ' 25' ' ' ASP . 1.8 mp -100.16 101.74 12.5 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.46 0 CA-C-O 121.403 0.621 . . . . 0.0 110.423 178.864 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -95.47 151.71 19.06 Favored 'General case' 0 C--N 1.321 -0.66 0 N-CA-C 108.71 -0.848 . . . . 0.0 108.71 167.328 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 11.9 ttp-105 -139.95 104.28 4.83 Favored 'General case' 0 C--N 1.319 -0.726 0 C-N-CA 120.15 -0.62 . . . . 0.0 110.431 -178.883 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.449 HD11 HG11 ' A' ' 13' ' ' VAL . 29.8 mt -86.95 103.5 13.24 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-N 115.594 -0.73 . . . . 0.0 110.765 -175.938 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 13.7 t70 61.41 12.54 4.4 Favored 'General case' 0 N--CA 1.469 0.49 0 CA-C-N 114.372 -1.286 . . . . 0.0 111.737 179.323 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 120.12 -17.61 9.83 Favored Glycine 0 N--CA 1.448 -0.514 0 C-N-CA 120.472 -0.871 . . . . 0.0 112.007 -177.482 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 56.6 t80 -82.58 118.89 23.62 Favored 'General case' 0 C--N 1.326 -0.425 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 178.473 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 19.4 t -73.63 116.75 16.43 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-O 121.205 0.526 . . . . 0.0 111.057 -175.695 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 47.9 t -112.09 107.16 22.27 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 CA-C-N 115.586 -0.734 . . . . 0.0 109.322 178.038 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 94.3 m-85 -77.92 128.29 33.7 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.156 -178.28 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.423 ' CG1' ' HB1' ' A' ' 46' ' ' ALA . 3.3 t -115.82 98.38 50.9 Favored Pre-proline 0 C--N 1.317 -0.822 0 CA-C-N 115.883 -0.599 . . . . 0.0 109.905 -177.946 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . 0.475 ' HA ' ' OD1' ' A' ' 31' ' ' ASP . 48.6 Cg_exo -59.51 -17.73 42.92 Favored 'Trans proline' 0 N--CA 1.476 0.451 0 C-N-CA 124.07 3.18 . . . . 0.0 114.277 -173.486 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -131.62 8.36 4.55 Favored 'General case' 0 C--N 1.317 -0.817 0 N-CA-C 112.707 0.632 . . . . 0.0 112.707 -167.8 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.53 ' HB2' HG13 ' A' ' 23' ' ' ILE . . . -81.93 159.74 23.54 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-O 120.705 0.288 . . . . 0.0 110.892 175.272 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 46.0 mt-10 -108.16 159.48 16.57 Favored 'General case' 0 N--CA 1.448 -0.575 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.505 178.724 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -65.12 123.34 19.25 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.624 -175.211 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 74.49 22.71 76.97 Favored Glycine 0 C--N 1.331 0.29 0 CA-C-N 115.79 -0.641 . . . . 0.0 113.476 175.003 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 68.8 p -96.86 153.51 17.84 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-O 121.089 0.471 . . . . 0.0 111.101 -178.578 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 59.2 t -99.37 106.81 19.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 N-CA-C 108.195 -1.039 . . . . 0.0 108.195 172.562 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.551 HD13 ' HA ' ' A' ' 68' ' ' ARG . 0.8 OUTLIER -128.45 145.81 34.89 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.761 0 CA-C-O 121.772 0.796 . . . . 0.0 112.591 -166.647 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . 0.501 ' OD1' ' HB2' ' A' ' 18' ' ' GLU . 49.3 t30 -94.29 111.2 22.92 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 114.598 -1.183 . . . . 0.0 108.759 175.384 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . 0.56 ' HA ' ' O ' ' A' ' 67' ' ' GLU . 34.6 m -108.69 128.52 64.34 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 CA-C-O 121.169 0.509 . . . . 0.0 111.399 -175.957 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . 0.496 ' HA ' ' HA ' ' A' ' 18' ' ' GLU . 2.7 ttpm? -96.34 106.43 18.65 Favored 'General case' 0 C--N 1.319 -0.757 0 N-CA-C 109.173 -0.677 . . . . 0.0 109.173 175.027 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 55.6 t -70.11 112.82 5.26 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 N-CA-C 109.875 -0.417 . . . . 0.0 109.875 -178.812 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 19.1 p -113.88 -9.6 13.05 Favored 'General case' 0 C--N 1.324 -0.516 0 N-CA-C 111.994 0.368 . . . . 0.0 111.994 -176.518 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -142.04 92.03 2.4 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.129 0.49 . . . . 0.0 111.064 -176.954 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 29.4 t -90.9 131.94 36.76 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.818 0 CA-C-N 115.917 -0.583 . . . . 0.0 109.89 177.363 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 32.2 mmtp -113.56 -178.18 3.31 Favored 'General case' 0 C--N 1.326 -0.452 0 N-CA-C 109.316 -0.624 . . . . 0.0 109.316 177.427 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 35.3 mt-10 -70.98 -26.42 63.14 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 113.054 0.761 . . . . 0.0 113.054 -172.179 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . 0.622 ' HB2' ' CD2' ' A' ' 63' ' ' PHE . 68.9 mmtt -114.97 -28.31 7.06 Favored 'General case' 0 N--CA 1.468 0.444 0 CA-C-O 121.162 0.506 . . . . 0.0 111.313 -177.03 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' PHE . . . . . 0.622 ' CD2' ' HB2' ' A' ' 62' ' ' LYS . 10.7 p90 -153.15 170.44 20.52 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.737 -0.665 . . . . 0.0 109.664 -172.074 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -131.57 160.18 36.04 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-O 120.769 0.318 . . . . 0.0 111.235 -179.01 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 97.8 m-85 -117.45 134.66 54.59 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 115.661 -0.699 . . . . 0.0 109.635 176.152 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' ALA . . . . . 0.46 ' HB3' ' HB ' ' A' ' 54' ' ' VAL . . . -124.73 177.21 6.1 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.806 -178.917 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' GLU . . . . . 0.56 ' O ' ' HA ' ' A' ' 54' ' ' VAL . 11.6 pt-20 -127.05 141.13 51.85 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 121.015 0.436 . . . . 0.0 111.103 -179.129 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . 0.551 ' HA ' HD13 ' A' ' 52' ' ' ILE . 74.5 ttt-85 -71.07 98.21 1.61 Allowed 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.979 176.211 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.402 ' O ' HD22 ' A' ' 70' ' ' LEU . 3.1 t -82.34 64.82 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-N 116.469 -0.332 . . . . 0.0 110.275 177.4 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . 0.503 HD13 ' NE ' ' A' ' 68' ' ' ARG . 73.7 mt . . . . . 0 C--O 1.248 0.982 0 CA-C-O 118.212 -0.899 . . . . 0.0 110.092 -178.245 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 12.3 Cg_endo . . . . . 0 CA--C 1.529 0.271 0 N-CA-C 113.264 0.448 . . . . 0.0 113.264 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 12.3 m -103.07 125.97 57.43 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.602 0 CA-C-O 121.062 0.458 . . . . 0.0 111.097 -178.275 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 47.3 mt-10 -95.3 113.59 25.29 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.511 178.896 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -58.25 121.45 10.8 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.95 -0.568 . . . . 0.0 111.469 -179.016 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 115.26 -31.39 6.24 Favored Glycine 0 N--CA 1.448 -0.534 0 CA-C-N 115.895 -0.593 . . . . 0.0 112.057 -179.328 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -89.04 150.47 22.76 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 121.096 0.474 . . . . 0.0 111.02 -178.126 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . 0.571 ' HA ' ' HA ' ' A' ' 55' ' ' LYS . 0.7 OUTLIER -107.72 142.17 38.13 Favored 'General case' 0 C--N 1.317 -0.823 0 CA-C-N 115.546 -0.752 . . . . 0.0 110.518 179.192 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 67.1 m-85 -128.37 145.51 51.05 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.695 -176.032 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 6.2 tp10 -80.03 105.1 11.05 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 108.534 -0.913 . . . . 0.0 108.534 172.725 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 32.2 m -118.14 170.58 7.37 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-O 121.246 0.546 . . . . 0.0 112.176 -172.614 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 20.7 m -114.56 155.71 25.99 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.214 -0.903 . . . . 0.0 109.539 176.328 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.53 HG13 ' HB2' ' A' ' 46' ' ' ALA . 36.5 mm -118.62 64.66 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-O 122.127 0.965 . . . . 0.0 108.641 -175.239 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 -72.65 -8.51 55.65 Favored 'General case' 0 C--N 1.314 -0.944 0 CA-C-N 113.84 -1.527 . . . . 0.0 112.189 179.759 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.408 ' HB2' ' HB ' ' A' ' 33' ' ' ILE . 5.5 m-20 -134.61 153.93 51.74 Favored 'General case' 0 N--CA 1.465 0.288 0 N-CA-C 109.976 -0.379 . . . . 0.0 109.976 176.401 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' MET . . . . . 0.569 ' SD ' ' HB2' ' A' ' 48' ' ' LYS . 59.1 mtp -138.06 155.33 48.9 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.744 0.307 . . . . 0.0 110.777 174.226 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.35 0 C-N-CA 120.944 -0.646 . . . . 0.0 111.779 177.206 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 7.6 t70 . . . . . 0 C--O 1.236 0.367 0 CA-C-O 120.779 0.323 . . . . 0.0 110.68 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . 0.536 ' HA2' ' HA ' ' A' ' 26' ' ' MET . . . -118.06 156.6 15.57 Favored Glycine 0 N--CA 1.447 -0.613 0 N-CA-C 111.515 -0.634 . . . . 0.0 111.515 178.008 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.431 HG23 HG12 ' A' ' 40' ' ' VAL . 2.3 mp -111.5 110.21 31.37 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 CA-C-O 121.326 0.584 . . . . 0.0 110.859 -177.598 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -83.59 161.21 21.23 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.582 -0.735 . . . . 0.0 110.176 170.627 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -133.84 103.7 5.97 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.431 -179.232 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 65.5 mt -103.32 112.24 36.05 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.714 0 N-CA-C 110.006 -0.368 . . . . 0.0 110.006 177.338 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 28.9 t70 67.35 5.59 4.35 Favored 'General case' 0 N--CA 1.47 0.558 0 O-C-N 123.969 0.793 . . . . 0.0 110.899 -178.565 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 105.42 -6.26 41.9 Favored Glycine 0 C--N 1.333 0.37 0 C-N-CA 120.762 -0.732 . . . . 0.0 111.308 -173.913 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 46.6 t80 -81.57 135.56 35.57 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 109.067 -0.716 . . . . 0.0 109.067 178.09 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 0.431 HG12 HG23 ' A' ' 33' ' ' ILE . 43.4 t -81.98 120.79 34.18 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.196 -175.348 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 52.3 t -122.63 110.66 27.38 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.612 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.679 -179.397 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 73.9 m-85 -76.87 130.3 37.4 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.095 -178.174 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.472 ' HA ' ' HD3' ' A' ' 44' ' ' PRO . 11.7 t -123.41 110.55 30.42 Favored Pre-proline 0 C--N 1.323 -0.579 0 CA-C-N 115.644 -0.707 . . . . 0.0 109.886 -179.378 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . 0.472 ' HD3' ' HA ' ' A' ' 43' ' ' VAL . 32.0 Cg_exo -58.53 -30.94 93.28 Favored 'Trans proline' 0 CA--C 1.531 0.375 0 C-N-CA 123.805 3.004 . . . . 0.0 115.427 -168.154 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 34.1 m-80 -132.63 22.11 4.29 Favored 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 112.687 0.625 . . . . 0.0 112.687 -173.413 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.53 ' HB2' HG13 ' A' ' 23' ' ' ILE . . . -87.03 134.09 33.53 Favored 'General case' 0 C--N 1.318 -0.801 0 CA-C-O 120.721 0.296 . . . . 0.0 111.637 176.104 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 70.4 mm-40 -86.91 156.18 19.93 Favored 'General case' 0 C--O 1.235 0.314 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.806 178.081 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . 0.569 ' HB2' ' SD ' ' A' ' 26' ' ' MET . 49.7 tttm -65.44 123.68 20.26 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.864 0.364 . . . . 0.0 110.462 -179.411 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 90.93 0.05 75.39 Favored Glycine 0 N--CA 1.446 -0.67 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.784 178.097 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 69.3 m -78.82 138.52 38.21 Favored 'General case' 0 C--N 1.322 -0.601 0 C-N-CA 120.784 -0.367 . . . . 0.0 110.82 177.967 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 44.5 t -92.16 100.7 11.65 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 N-CA-C 107.859 -1.163 . . . . 0.0 107.859 173.149 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.598 HD12 ' HB2' ' A' ' 68' ' ' ARG . 2.9 tt -123.27 140.17 47.71 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.824 0 CA-C-O 121.969 0.89 . . . . 0.0 112.636 -168.455 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 48.4 t30 -86.93 114.88 23.93 Favored 'General case' 0 C--N 1.313 -0.999 0 CA-C-N 113.801 -1.545 . . . . 0.0 108.588 175.389 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . 0.457 ' O ' ' HA ' ' A' ' 18' ' ' GLU . 35.7 m -118.87 132.15 69.58 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.723 0 CA-C-O 120.763 0.316 . . . . 0.0 111.329 -176.287 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . 0.571 ' HA ' ' HA ' ' A' ' 18' ' ' GLU . 22.5 ttmm -96.78 106.92 19.3 Favored 'General case' 0 C--N 1.324 -0.519 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 177.071 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.469 ' HA ' ' HA ' ' A' ' 66' ' ' ALA . 48.5 t -70.83 107.12 2.0 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 N-CA-C 109.901 -0.407 . . . . 0.0 109.901 -177.985 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 8.9 p -103.22 -21.86 13.81 Favored 'General case' 0 C--N 1.323 -0.578 0 N-CA-C 112.13 0.419 . . . . 0.0 112.13 -174.293 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -135.41 92.15 2.81 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 121.225 0.536 . . . . 0.0 110.781 -175.882 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 45.3 t -88.49 117.16 31.53 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.735 0 CA-C-N 115.583 -0.735 . . . . 0.0 110.591 177.509 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . 0.52 ' HB2' ' O ' ' A' ' 63' ' ' PHE . 4.9 mptp? -97.59 -168.84 1.74 Allowed 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 109.61 -0.515 . . . . 0.0 109.61 174.894 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 34.6 mt-10 -70.54 -53.77 14.79 Favored 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 111.979 0.362 . . . . 0.0 111.979 -176.903 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -93.46 -29.35 15.6 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 120.976 0.417 . . . . 0.0 112.113 -174.293 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' PHE . . . . . 0.52 ' O ' ' HB2' ' A' ' 60' ' ' LYS . 16.2 p90 -151.75 164.65 36.53 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.735 -174.66 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -125.45 163.91 21.6 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-O 120.749 0.309 . . . . 0.0 110.958 -178.648 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 98.4 m-85 -116.06 130.17 56.68 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-N 115.783 -0.644 . . . . 0.0 109.286 176.214 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' ALA . . . . . 0.469 ' HA ' ' HA ' ' A' ' 56' ' ' VAL . . . -121.4 154.64 36.24 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-O 121.195 0.521 . . . . 0.0 111.778 -175.504 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 30.1 tt0 -101.87 116.41 32.64 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-N 115.243 -0.89 . . . . 0.0 111.531 -177.294 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . 0.598 ' HB2' HD12 ' A' ' 52' ' ' ILE . 15.5 ttt-85 -54.03 108.06 0.33 Allowed 'General case' 0 CA--C 1.536 0.405 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.678 172.159 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.418 ' O ' HG12 ' A' ' 69' ' ' VAL . 12.2 t -82.01 12.26 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.328 0 CA-C-O 122.211 1.005 . . . . 0.0 110.324 179.707 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . 0.402 ' HG ' HG13 ' A' ' 52' ' ' ILE . 54.9 mt . . . . . 0 C--N 1.316 -0.877 0 CA-C-N 114.932 -1.031 . . . . 0.0 109.148 176.773 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo . . . . . 0 N--CA 1.473 0.267 0 N-CA-C 113.143 0.401 . . . . 0.0 113.143 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 24.0 m -130.51 134.78 61.73 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.584 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.09 -178.577 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . 0.604 ' HB2' ' HG3' ' A' ' 17' ' ' LYS . 2.9 mp0 -110.24 136.33 49.62 Favored 'General case' 0 C--N 1.318 -0.798 0 CA-C-O 120.827 0.346 . . . . 0.0 110.671 179.191 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . 0.447 ' HA ' ' O ' ' A' ' 56' ' ' VAL . . . -64.12 117.77 7.58 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 115.795 -0.638 . . . . 0.0 110.551 176.578 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 112.23 -7.49 26.9 Favored Glycine 0 N--CA 1.446 -0.652 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.633 179.753 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' LYS . . . . . 0.604 ' HG3' ' HB2' ' A' ' 14' ' ' GLU . 12.8 mmmm -93.08 155.69 17.34 Favored 'General case' 0 C--N 1.326 -0.448 0 O-C-N 122.604 -0.35 . . . . 0.0 110.448 -179.867 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . 0.484 ' HA ' ' O ' ' A' ' 54' ' ' VAL . 0.7 OUTLIER -113.85 118.49 34.37 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 109.065 -0.717 . . . . 0.0 109.065 172.71 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 64.7 m-85 -112.37 140.77 46.82 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-O 121.142 0.496 . . . . 0.0 111.614 -177.334 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 36.2 tt0 -84.42 99.21 10.52 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.09 -0.959 . . . . 0.0 109.193 176.727 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 35.8 m -114.58 171.25 4.45 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.57 0 CA-C-O 121.21 0.529 . . . . 0.0 112.168 -170.986 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 23.4 m -115.36 153.37 31.13 Favored 'General case' 0 N--CA 1.45 -0.445 0 CA-C-N 115.244 -0.889 . . . . 0.0 109.749 175.917 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.557 HG13 ' HB3' ' A' ' 46' ' ' ALA . 37.5 mm -119.1 65.33 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-O 122.056 0.931 . . . . 0.0 108.927 -173.984 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -64.46 -17.43 63.83 Favored 'General case' 0 C--N 1.318 -0.796 0 CA-C-N 113.977 -1.465 . . . . 0.0 111.816 177.737 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.533 ' HB3' ' HB ' ' A' ' 33' ' ' ILE . 27.0 t0 -136.02 151.46 49.9 Favored 'General case' 0 C--N 1.324 -0.517 0 C-N-CA 121.064 -0.254 . . . . 0.0 110.824 -176.539 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' MET . . . . . 0.653 ' SD ' ' HB2' ' A' ' 48' ' ' LYS . 70.1 mtp -137.33 152.75 50.07 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.724 0.297 . . . . 0.0 110.22 175.521 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.448 -0.507 0 C-N-CA 120.969 -0.634 . . . . 0.0 111.56 177.726 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . 0.535 ' HA ' ' HA ' ' A' ' 44' ' ' PRO . 27.6 m-20 . . . . . 0 CA--C 1.522 -0.103 0 CA-C-O 121.021 0.439 . . . . 0.0 111.331 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -106.62 143.24 15.76 Favored Glycine 0 N--CA 1.444 -0.778 0 N-CA-C 110.2 -1.16 . . . . 0.0 110.2 171.614 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.533 ' HB ' ' HB3' ' A' ' 25' ' ' ASP . 2.1 mp -103.49 105.36 18.19 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.752 0 CA-C-O 121.354 0.597 . . . . 0.0 111.123 -173.761 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -86.99 155.77 20.04 Favored 'General case' 0 N--CA 1.444 -0.733 0 N-CA-C 108.134 -1.061 . . . . 0.0 108.134 166.572 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 37.0 ttt180 -141.93 118.36 10.88 Favored 'General case' 0 C--N 1.314 -0.956 0 C-N-CA 120.031 -0.668 . . . . 0.0 110.376 179.278 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 27.0 mt -109.27 108.7 26.0 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.664 0 CA-C-N 115.458 -0.792 . . . . 0.0 110.397 -179.37 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 31.7 t70 65.29 19.55 11.7 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.121 -0.945 . . . . 0.0 110.932 179.006 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 99.81 -9.39 60.16 Favored Glycine 0 N--CA 1.449 -0.445 0 C-N-CA 120.207 -0.997 . . . . 0.0 111.788 -177.43 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 54.1 t80 -82.75 118.84 23.66 Favored 'General case' 0 C--N 1.322 -0.62 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 177.672 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 17.0 t -75.08 122.93 29.74 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-O 120.993 0.425 . . . . 0.0 111.193 -174.961 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 45.3 t -115.86 109.29 27.69 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-N 116.202 -0.454 . . . . 0.0 109.863 179.646 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 85.6 m-85 -80.35 119.22 22.78 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 121.039 0.447 . . . . 0.0 110.752 -178.327 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.426 ' HA ' ' HD3' ' A' ' 44' ' ' PRO . 3.2 t -115.13 101.41 54.47 Favored Pre-proline 0 C--N 1.32 -0.706 0 CA-C-N 115.677 -0.692 . . . . 0.0 109.379 178.567 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . 0.535 ' HA ' ' HA ' ' A' ' 31' ' ' ASP . 16.9 Cg_exo -68.12 5.27 1.19 Allowed 'Trans proline' 0 CA--C 1.531 0.374 0 C-N-CA 123.383 2.722 . . . . 0.0 114.818 -168.721 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 47.5 m-80 -143.43 14.61 1.81 Allowed 'General case' 0 N--CA 1.464 0.225 0 CA-C-O 120.632 0.253 . . . . 0.0 111.609 179.553 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.557 ' HB3' HG13 ' A' ' 23' ' ' ILE . . . -86.43 134.1 33.72 Favored 'General case' 0 C--N 1.32 -0.713 0 N-CA-C 112.018 0.377 . . . . 0.0 112.018 -178.86 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 44.2 mt-10 -92.83 146.18 23.83 Favored 'General case' 0 N--CA 1.454 -0.266 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.976 177.281 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . 0.653 ' HB2' ' SD ' ' A' ' 26' ' ' MET . 46.8 tttp -65.43 129.93 41.51 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.051 -0.522 . . . . 0.0 111.136 -177.916 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 88.17 -5.42 84.83 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.827 -0.702 . . . . 0.0 113.397 176.005 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 51.1 m -95.14 147.78 23.08 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.872 0.336 . . . . 0.0 110.796 -179.329 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 46.0 t -91.91 109.59 21.54 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 N-CA-C 109.23 -0.656 . . . . 0.0 109.23 178.14 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.845 HG13 HD22 ' A' ' 70' ' ' LEU . 2.5 tt -119.57 143.41 31.13 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.819 0 CA-C-O 121.853 0.835 . . . . 0.0 112.403 -170.568 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . 0.471 ' OD1' ' HB3' ' A' ' 18' ' ' GLU . 23.5 t-20 -89.56 114.19 25.72 Favored 'General case' 0 C--N 1.316 -0.869 0 CA-C-N 114.051 -1.432 . . . . 0.0 108.543 175.406 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . 0.484 ' O ' ' HA ' ' A' ' 18' ' ' GLU . 32.6 m -114.67 128.26 71.84 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 CA-C-O 121.264 0.554 . . . . 0.0 111.856 -175.601 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . 0.577 ' HA ' ' O ' ' A' ' 17' ' ' LYS . 38.2 ttmt -95.13 104.44 16.32 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 115.912 -0.585 . . . . 0.0 109.496 173.976 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.447 ' O ' ' HA ' ' A' ' 15' ' ' ALA . 66.0 t -66.09 110.48 1.35 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 N-CA-C 109.681 -0.489 . . . . 0.0 109.681 179.575 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 11.5 p -105.83 -28.86 10.39 Favored 'General case' 0 C--N 1.324 -0.54 0 N-CA-C 112.247 0.462 . . . . 0.0 112.247 -174.449 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -136.99 92.42 2.73 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 121.12 0.486 . . . . 0.0 110.978 -175.47 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 22.4 t -81.62 125.1 39.58 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.667 0 CA-C-N 115.623 -0.717 . . . . 0.0 110.017 176.225 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 32.2 mmtp -109.47 -150.21 0.45 Allowed 'General case' 0 C--N 1.325 -0.458 0 N-CA-C 109.951 -0.389 . . . . 0.0 109.951 178.484 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 20.2 mm-40 -70.78 -76.89 0.09 Allowed 'General case' 0 C--N 1.331 -0.239 0 N-CA-C 112.18 0.437 . . . . 0.0 112.18 -176.105 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 63.7 mttm -98.22 -2.57 39.39 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 121.182 0.515 . . . . 0.0 110.821 -175.652 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 35.7 p90 -151.37 164.97 35.5 Favored 'General case' 0 C--N 1.318 -0.761 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.725 -173.138 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -137.91 171.02 15.04 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.603 178.182 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 96.8 m-85 -118.92 133.81 55.59 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 109.493 -0.558 . . . . 0.0 109.493 176.702 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' ALA . . . . . 0.443 ' HB1' ' HB ' ' A' ' 54' ' ' VAL . . . -133.95 145.11 49.24 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.464 -179.001 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' GLU . . . . . 0.47 ' HG2' ' HB3' ' A' ' 55' ' ' LYS . 9.6 pt-20 -93.67 142.22 27.6 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-O 121.179 0.514 . . . . 0.0 111.408 -177.83 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . 0.517 ' HB2' HD12 ' A' ' 52' ' ' ILE . 17.8 ttt180 -71.17 109.96 5.54 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.341 -0.845 . . . . 0.0 110.043 173.721 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.511 ' O ' HG13 ' A' ' 69' ' ' VAL . 40.7 t -81.66 12.75 0.58 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.518 0 CA-C-O 122.076 0.941 . . . . 0.0 111.505 -176.415 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . 0.845 HD22 HG13 ' A' ' 52' ' ' ILE . 1.0 OUTLIER . . . . . 0 C--N 1.314 -0.952 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.397 -179.333 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 94.8 Cg_endo . . . . . 0 N--CA 1.47 0.134 0 N-CA-C 113.18 0.415 . . . . 0.0 113.18 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.532 ' HB ' HG23 ' A' ' 56' ' ' VAL . 17.0 m -97.34 124.36 50.2 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.724 0 CA-C-N 115.857 -0.611 . . . . 0.0 110.779 -175.714 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . 0.462 ' OE2' ' HE2' ' A' ' 17' ' ' LYS . 31.7 tt0 -104.04 129.04 51.65 Favored 'General case' 0 C--N 1.322 -0.613 0 C-N-CA 120.85 -0.34 . . . . 0.0 110.105 -179.734 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -54.42 118.49 4.18 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.79 -0.641 . . . . 0.0 111.155 -178.477 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.31 -25.75 10.98 Favored Glycine 0 N--CA 1.444 -0.826 0 C-N-CA 120.671 -0.776 . . . . 0.0 112.448 179.941 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' LYS . . . . . 0.462 ' HE2' ' OE2' ' A' ' 14' ' ' GLU . 68.6 mttm -85.55 160.48 19.64 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 120.938 0.399 . . . . 0.0 110.457 179.034 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . 0.501 ' HA ' ' HA ' ' A' ' 55' ' ' LYS . 0.0 OUTLIER -126.87 133.32 50.74 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.449 179.052 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' TYR . . . . . 0.409 ' CE2' ' HA ' ' A' ' 13' ' ' VAL . 64.4 m-85 -123.14 162.6 22.19 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.331 -176.589 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 45.4 tt0 -96.58 122.39 39.44 Favored 'General case' 0 C--N 1.321 -0.665 0 N-CA-C 109.398 -0.593 . . . . 0.0 109.398 176.323 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.509 ' HB ' ' HB2' ' A' ' 34' ' ' ALA . 28.0 m -128.84 168.88 21.21 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-O 121.131 0.491 . . . . 0.0 111.587 -174.62 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 26.2 m -118.88 143.22 47.11 Favored 'General case' 0 N--CA 1.446 -0.65 0 CA-C-N 115.755 -0.657 . . . . 0.0 109.359 175.313 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.527 HG13 ' HB2' ' A' ' 46' ' ' ALA . 19.9 mm -111.77 59.53 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.664 0 CA-C-O 121.997 0.903 . . . . 0.0 108.755 -173.284 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -78.17 9.69 3.57 Favored 'General case' 0 C--N 1.315 -0.921 0 CA-C-N 114.573 -1.194 . . . . 0.0 112.229 -177.555 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.444 ' HB3' ' HB ' ' A' ' 33' ' ' ILE . 29.1 t0 -150.11 148.31 28.82 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.444 -0.344 . . . . 0.0 110.119 176.91 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' MET . . . . . 0.622 ' HA ' ' HA2' ' A' ' 32' ' ' GLY . 39.4 mtp -123.99 151.93 43.13 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.999 0.428 . . . . 0.0 111.157 178.649 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.445 -0.758 0 CA-C-N 115.554 -0.748 . . . . 0.0 112.709 -177.421 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.7 p30 . . . . . 0 N--CA 1.452 -0.333 0 CA-C-O 120.882 0.372 . . . . 0.0 110.013 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . 0.622 ' HA2' ' HA ' ' A' ' 26' ' ' MET . . . -128.57 172.78 19.33 Favored Glycine 0 N--CA 1.442 -0.95 0 C-N-CA 120.824 -0.703 . . . . 0.0 112.46 -177.384 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.444 ' HB ' ' HB3' ' A' ' 25' ' ' ASP . 2.2 mp -114.03 121.93 67.14 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.71 0 CA-C-O 120.947 0.403 . . . . 0.0 110.34 -179.949 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . 0.509 ' HB2' ' HB ' ' A' ' 21' ' ' VAL . . . -116.92 117.18 28.98 Favored 'General case' 0 C--N 1.317 -0.805 0 N-CA-C 108.804 -0.813 . . . . 0.0 108.804 172.663 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 28.2 ttp180 -104.25 110.67 22.97 Favored 'General case' 0 C--N 1.318 -0.795 0 CA-C-O 121.143 0.497 . . . . 0.0 111.224 -172.735 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 43.7 mt -99.75 110.11 26.19 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-N 115.443 -0.799 . . . . 0.0 110.385 178.992 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 56.6 27.71 12.87 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.217 -0.902 . . . . 0.0 112.081 -179.837 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 100.17 -14.61 59.71 Favored Glycine 0 C--N 1.33 0.207 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.014 -179.627 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 65.9 t80 -85.04 135.44 34.01 Favored 'General case' 0 C--N 1.321 -0.65 0 N-CA-C 109.554 -0.536 . . . . 0.0 109.554 -178.585 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 34.0 t -88.2 117.06 31.17 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-O 121.162 0.506 . . . . 0.0 111.239 -175.424 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 40.8 t -112.51 118.78 58.7 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.686 0 CA-C-N 115.695 -0.684 . . . . 0.0 109.273 174.952 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 76.3 m-85 -87.07 132.04 33.94 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-O 121.194 0.521 . . . . 0.0 111.47 -177.474 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.493 HG13 HD13 ' A' ' 52' ' ' ILE . 15.5 m -111.54 124.2 33.09 Favored Pre-proline 0 C--N 1.324 -0.513 0 CA-C-N 115.461 -0.79 . . . . 0.0 110.336 178.377 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . 0.484 ' HD3' ' HA ' ' A' ' 43' ' ' VAL . 13.5 Cg_exo -71.42 -34.54 9.47 Favored 'Trans proline' 0 CA--C 1.527 0.175 0 C-N-CA 123.05 2.5 . . . . 0.0 113.667 -175.495 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 4.5 p30 -136.12 34.36 2.82 Favored 'General case' 0 C--N 1.325 -0.46 0 N-CA-C 112.887 0.699 . . . . 0.0 112.887 -167.092 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.527 ' HB2' HG13 ' A' ' 23' ' ' ILE . . . -90.41 161.33 15.62 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 120.991 0.424 . . . . 0.0 112.125 175.562 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' GLU . . . . . 0.518 ' CD ' HH12 ' A' ' 68' ' ' ARG . 2.1 mp0 -102.61 147.16 27.14 Favored 'General case' 0 C--O 1.235 0.302 0 CA-C-N 115.871 -0.604 . . . . 0.0 109.741 170.867 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . 0.507 ' HE3' ' SD ' ' A' ' 26' ' ' MET . 9.3 ptpp? -66.54 139.98 57.95 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.15 0.5 . . . . 0.0 111.061 -179.859 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 73.33 13.94 79.53 Favored Glycine 0 N--CA 1.45 -0.375 0 CA-C-N 115.861 -0.609 . . . . 0.0 112.764 177.513 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 8.5 t -107.46 151.2 25.87 Favored 'General case' 0 C--N 1.323 -0.57 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 178.647 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 57.9 t -104.1 104.92 17.52 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 N-CA-C 109.554 -0.535 . . . . 0.0 109.554 179.266 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.532 HD12 ' HB2' ' A' ' 68' ' ' ARG . 0.9 OUTLIER -113.97 154.94 15.27 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.512 -174.556 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . 0.41 HD21 ' HB ' ' A' ' 69' ' ' VAL . 9.2 t30 -95.29 119.95 34.68 Favored 'General case' 0 C--N 1.321 -0.665 0 N-CA-C 109.001 -0.741 . . . . 0.0 109.001 174.508 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . 0.43 ' HB ' ' CB ' ' A' ' 66' ' ' ALA . 27.8 m -112.08 131.92 62.18 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.664 0 CA-C-O 121.08 0.467 . . . . 0.0 111.738 -175.43 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . 0.501 ' HA ' ' HA ' ' A' ' 18' ' ' GLU . 6.3 ttpm? -100.06 109.54 21.85 Favored 'General case' 0 C--N 1.318 -0.786 0 N-CA-C 108.74 -0.837 . . . . 0.0 108.74 173.321 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.532 HG23 ' HB ' ' A' ' 13' ' ' VAL . 39.1 t -72.28 114.02 10.45 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.551 -176.321 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 7.9 p -108.15 -18.14 13.85 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 116.196 -0.456 . . . . 0.0 112.004 -177.523 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -134.57 91.1 2.74 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 121.217 0.532 . . . . 0.0 110.591 -177.85 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 19.0 t -90.25 134.61 28.67 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.781 0 CA-C-N 115.298 -0.865 . . . . 0.0 110.801 179.156 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . 0.509 ' HB2' ' O ' ' A' ' 63' ' ' PHE . 75.4 mmtt -119.03 172.52 7.49 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 121.172 0.51 . . . . 0.0 110.563 174.351 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 42.2 tt0 -69.75 -29.34 66.68 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.072 -0.967 . . . . 0.0 109.428 173.691 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . 0.465 ' O ' ' CG ' ' A' ' 63' ' ' PHE . 38.6 mtmt -129.11 87.26 2.54 Favored 'General case' 0 N--CA 1.416 -2.154 0 N-CA-C 105.314 -2.106 . . . . 0.0 105.314 177.587 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' PHE . . . . . 0.509 ' O ' ' HB2' ' A' ' 60' ' ' LYS . 20.5 p90 78.89 142.25 0.08 Allowed 'General case' 0 N--CA 1.488 1.462 0 CA-C-N 112.903 -1.953 . . . . 0.0 112.17 164.658 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -117.1 169.58 9.32 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.452 -0.795 . . . . 0.0 111.894 -170.322 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 79.5 m-85 -120.26 133.55 55.45 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 115.359 -0.837 . . . . 0.0 109.396 177.949 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' ALA . . . . . 0.496 ' HB1' HG22 ' A' ' 56' ' ' VAL . . . -134.81 148.04 50.09 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 120.922 0.391 . . . . 0.0 111.23 -177.271 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 11.1 pt-20 -94.27 132.63 38.65 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.914 -178.826 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . 0.883 ' HE ' HD12 ' A' ' 70' ' ' LEU . 31.0 ttt180 -67.02 106.39 1.93 Allowed 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.449 -0.796 . . . . 0.0 110.728 175.717 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.41 ' HB ' HD21 ' A' ' 53' ' ' ASN . 18.9 t -80.53 66.45 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.535 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.015 179.55 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . 0.883 HD12 ' HE ' ' A' ' 68' ' ' ARG . 70.8 mt . . . . . 0 C--O 1.246 0.896 0 CA-C-N 115.687 -0.688 . . . . 0.0 109.466 178.266 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . 0.405 ' HG2' ' HB2' ' A' ' 39' ' ' PHE . 16.9 Cg_exo . . . . . 0 C--O 1.233 0.253 0 CA-C-O 121.364 0.485 . . . . 0.0 112.095 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.773 HG12 HD11 ' A' ' 36' ' ' ILE . 31.0 m -107.49 149.84 10.55 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 CA-C-N 115.267 -0.878 . . . . 0.0 110.465 -176.715 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -124.35 136.71 54.3 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-O 120.862 0.363 . . . . 0.0 110.393 177.905 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -70.54 106.59 3.51 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.996 -178.217 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 120.68 -13.1 10.02 Favored Glycine 0 N--CA 1.446 -0.653 0 C-N-CA 120.924 -0.655 . . . . 0.0 112.329 -179.719 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' LYS . . . . . 0.451 ' HB3' ' HZ3' ' A' ' 17' ' ' LYS . 8.1 mtpm? -102.56 156.74 17.41 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.724 0.297 . . . . 0.0 110.907 -178.87 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . 0.543 ' HA ' ' O ' ' A' ' 54' ' ' VAL . 0.0 OUTLIER -112.16 142.01 45.14 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 121.166 0.508 . . . . 0.0 111.375 -179.074 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' TYR . . . . . 0.537 ' O ' ' HA ' ' A' ' 53' ' ' ASN . 81.4 m-85 -130.64 141.74 50.43 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 116.051 -0.522 . . . . 0.0 111.121 -176.085 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 37.7 mt-10 -79.79 98.85 7.21 Favored 'General case' 0 C--N 1.326 -0.456 0 N-CA-C 109.3 -0.63 . . . . 0.0 109.3 174.835 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.473 ' HB ' ' HB3' ' A' ' 34' ' ' ALA . 35.8 m -110.3 156.2 11.36 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.81 0 CA-C-N 115.787 -0.642 . . . . 0.0 111.526 -174.275 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 24.2 m -105.09 148.73 26.51 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 115.407 -0.815 . . . . 0.0 109.77 176.07 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.514 HG13 ' HB2' ' A' ' 46' ' ' ALA . 33.6 mm -114.45 65.91 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.783 0 N-CA-C 108.053 -1.091 . . . . 0.0 108.053 -174.662 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 -62.25 -24.89 67.52 Favored 'General case' 0 C--N 1.312 -1.025 0 CA-C-N 113.621 -1.627 . . . . 0.0 111.552 178.974 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.522 ' HB3' ' HB ' ' A' ' 33' ' ' ILE . 5.9 t70 -133.7 152.03 51.78 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.521 -0.309 . . . . 0.0 111.125 -170.166 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' MET . . . . . 0.503 ' SD ' ' HB2' ' A' ' 48' ' ' LYS . 18.0 mtp -129.84 161.7 30.18 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 121.018 0.437 . . . . 0.0 110.73 176.341 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.448 -0.52 0 CA-C-N 115.74 -0.664 . . . . 0.0 111.957 177.282 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 16.2 m-20 . . . . . 0 CA--C 1.514 -0.442 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -96.53 122.35 7.34 Favored Glycine 0 N--CA 1.444 -0.815 0 N-CA-C 110.563 -1.015 . . . . 0.0 110.563 174.468 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.522 ' HB ' ' HB3' ' A' ' 25' ' ' ASP . 1.9 mp -95.84 100.67 11.32 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.698 0 CA-C-O 121.426 0.631 . . . . 0.0 110.462 -176.798 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . 0.473 ' HB3' ' HB ' ' A' ' 21' ' ' VAL . . . -99.4 162.04 13.27 Favored 'General case' 0 CA--C 1.495 -1.16 0 CA-C-N 115.265 -0.879 . . . . 0.0 108.947 168.563 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 29.0 ptt180 -156.65 119.64 4.12 Favored 'General case' 0 N--CA 1.43 -1.47 0 CA-C-O 121.423 0.63 . . . . 0.0 110.859 -177.379 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.773 HD11 HG12 ' A' ' 13' ' ' VAL . 43.9 mt -96.67 111.21 26.25 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.829 0 CA-C-N 115.186 -0.915 . . . . 0.0 110.349 -175.175 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 25.9 t0 57.97 29.18 17.3 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 114.685 -1.143 . . . . 0.0 110.836 -177.871 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 103.63 -22.69 34.98 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.957 -0.639 . . . . 0.0 112.347 179.401 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' PHE . . . . . 0.405 ' HB2' ' HG2' ' A' ' 12' ' ' PRO . 63.3 t80 -74.86 112.54 11.19 Favored 'General case' 0 C--N 1.324 -0.519 0 N-CA-C 109.959 -0.386 . . . . 0.0 109.959 -178.299 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 41.2 t -69.14 123.9 23.71 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 CA-C-O 121.42 0.628 . . . . 0.0 111.84 -174.791 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 25.5 t -121.8 109.23 24.0 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.691 0 CA-C-N 115.233 -0.894 . . . . 0.0 109.18 -179.884 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 87.9 m-85 -77.11 124.47 27.85 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.176 -176.39 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.431 ' CG1' ' HB1' ' A' ' 46' ' ' ALA . 2.7 t -122.01 98.96 44.37 Favored Pre-proline 0 C--N 1.325 -0.48 0 CA-C-N 115.753 -0.658 . . . . 0.0 110.534 -179.377 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -74.11 -0.16 9.2 Favored 'Trans proline' 0 CA--C 1.53 0.312 0 C-N-CA 122.704 2.269 . . . . 0.0 113.458 -175.752 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' ASN . . . . . 0.405 ' HB2' ' HB3' ' A' ' 68' ' ' ARG . 12.6 m120 -125.57 8.25 7.66 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 121.099 0.476 . . . . 0.0 110.91 -175.132 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.514 ' HB2' HG13 ' A' ' 23' ' ' ILE . . . -91.03 153.25 20.27 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 112.069 0.396 . . . . 0.0 112.069 -176.176 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 5.4 mm-40 -105.04 135.9 45.52 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.444 -0.798 . . . . 0.0 110.433 176.426 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . 0.503 ' HB2' ' SD ' ' A' ' 26' ' ' MET . 14.3 tmtt? -65.14 136.65 56.95 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.494 -179.895 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 70.64 23.44 77.73 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.993 -0.622 . . . . 0.0 112.522 179.069 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 23.3 t -122.36 145.89 47.83 Favored 'General case' 0 C--N 1.321 -0.654 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 179.518 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 52.8 t -90.44 101.62 12.51 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 N-CA-C 109.53 -0.545 . . . . 0.0 109.53 177.839 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.506 HD11 ' HB2' ' A' ' 68' ' ' ARG . 0.9 OUTLIER -119.29 140.96 41.48 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.749 0 CA-C-N 115.768 -0.651 . . . . 0.0 111.034 -175.29 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . 0.537 ' HA ' ' O ' ' A' ' 19' ' ' TYR . 7.1 p-10 -97.81 118.06 33.5 Favored 'General case' 0 C--N 1.313 -0.99 0 CA-C-N 115.128 -0.942 . . . . 0.0 109.016 176.288 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . 0.543 ' O ' ' HA ' ' A' ' 18' ' ' GLU . 35.3 m -111.67 140.96 28.66 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.765 0 CA-C-N 115.304 -0.862 . . . . 0.0 111.731 -173.481 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 25.6 ttmt -94.96 109.22 21.26 Favored 'General case' 0 C--N 1.319 -0.724 0 N-CA-C 109.212 -0.662 . . . . 0.0 109.212 177.389 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.433 HG21 ' HB ' ' A' ' 13' ' ' VAL . 60.5 t -70.56 113.26 6.37 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 N-CA-C 109.53 -0.544 . . . . 0.0 109.53 179.516 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.9 p -111.42 -14.97 13.66 Favored 'General case' 0 C--N 1.323 -0.587 0 N-CA-C 112.32 0.489 . . . . 0.0 112.32 -173.077 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . 0.415 ' HB2' ' HB2' ' A' ' 65' ' ' PHE . . . -145.82 93.38 2.33 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.947 0.403 . . . . 0.0 111.048 -176.214 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 21.9 t -87.6 122.93 39.93 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 CA-C-N 116.061 -0.518 . . . . 0.0 109.919 176.085 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 32.3 mmtp -109.15 -165.26 1.0 Allowed 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.668 -0.242 . . . . 0.0 110.375 179.832 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . 0.406 ' H ' ' CD ' ' A' ' 61' ' ' GLU . 4.1 mp0 -64.25 -54.05 39.44 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.752 -175.925 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 88.9 mttt -108.82 -19.78 13.29 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.838 -171.533 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 23.9 p90 -150.13 175.02 12.13 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.589 -175.111 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -137.29 167.45 21.56 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-O 120.808 0.337 . . . . 0.0 111.024 179.378 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' PHE . . . . . 0.415 ' HB2' ' HB2' ' A' ' 58' ' ' ALA . 90.8 m-85 -119.63 135.17 54.92 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.753 -0.658 . . . . 0.0 109.822 177.211 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' ALA . . . . . 0.462 ' HB2' ' HB ' ' A' ' 54' ' ' VAL . . . -132.38 154.99 49.24 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.321 -0.399 . . . . 0.0 111.043 -178.926 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 13.7 pt-20 -111.81 143.49 42.67 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 121.088 0.471 . . . . 0.0 111.11 -179.408 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . 0.506 ' HB2' HD11 ' A' ' 52' ' ' ILE . 27.3 ttt180 -66.69 114.18 5.4 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.469 -0.787 . . . . 0.0 111.135 174.255 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.48 ' HB ' ' ND2' ' A' ' 53' ' ' ASN . 3.7 t -83.14 5.85 1.9 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 121.7 0.762 . . . . 0.0 110.915 176.761 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 68.7 mt . . . . . 0 C--N 1.315 -0.935 0 CA-C-N 115.305 -0.861 . . . . 0.0 110.588 -177.602 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo . . . . . 0 C--O 1.231 0.173 0 CA-C-O 121.342 0.476 . . . . 0.0 112.51 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.562 HG13 HD11 ' A' ' 36' ' ' ILE . 6.0 m -73.51 130.9 35.61 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.718 0 CA-C-N 115.06 -0.973 . . . . 0.0 111.932 -173.525 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -102.45 119.09 38.22 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.754 -0.657 . . . . 0.0 109.372 177.858 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -68.17 108.69 3.24 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 120.975 0.417 . . . . 0.0 110.752 -178.565 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 127.54 -23.87 5.33 Favored Glycine 0 N--CA 1.443 -0.854 0 C-N-CA 120.814 -0.708 . . . . 0.0 112.409 -179.695 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' LYS . . . . . 0.42 ' HE3' ' HB3' ' A' ' 17' ' ' LYS . 24.0 mtpp -104.19 165.95 10.72 Favored 'General case' 0 C--O 1.235 0.336 0 CA-C-O 121.019 0.438 . . . . 0.0 111.28 179.613 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . 0.524 ' HA ' ' HA ' ' A' ' 55' ' ' LYS . 0.2 OUTLIER -117.8 151.06 38.09 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.719 -0.673 . . . . 0.0 111.067 -177.584 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 72.6 m-85 -139.01 145.68 39.94 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.694 -0.684 . . . . 0.0 109.504 179.245 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . 0.547 ' HA ' ' HA ' ' A' ' 53' ' ' ASN . 42.6 tt0 -85.32 108.18 17.68 Favored 'General case' 0 C--N 1.32 -0.692 0 N-CA-C 109.529 -0.545 . . . . 0.0 109.529 176.756 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 34.4 m -122.8 165.66 18.56 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.968 -172.61 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 9.0 m -102.31 148.01 25.99 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-O 120.965 0.412 . . . . 0.0 110.543 179.801 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.441 HG13 ' HB3' ' A' ' 46' ' ' ALA . 29.3 mm -112.97 61.59 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 N-CA-C 107.916 -1.142 . . . . 0.0 107.916 -177.471 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 13.1 tp10 -64.12 -17.07 63.09 Favored 'General case' 0 C--N 1.317 -0.843 0 CA-C-N 113.283 -1.78 . . . . 0.0 111.67 -177.29 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 33.3 t70 -145.41 152.21 39.47 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 116.483 -0.326 . . . . 0.0 110.196 -173.236 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' MET . . . . . 0.626 ' HA ' ' HA2' ' A' ' 32' ' ' GLY . 33.3 mtp -128.25 157.18 41.61 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 121.171 0.51 . . . . 0.0 110.974 177.866 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . 0.501 ' HA3' ' OD2' ' A' ' 31' ' ' ASP . . . . . . . . 0 N--CA 1.445 -0.732 0 CA-C-N 115.66 -0.7 . . . . 0.0 112.724 -176.564 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . 0.501 ' OD2' ' HA3' ' A' ' 27' ' ' GLY . 12.1 p-10 . . . . . 0 N--CA 1.453 -0.311 0 N-CA-C 109.611 -0.514 . . . . 0.0 109.611 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . 0.626 ' HA2' ' HA ' ' A' ' 26' ' ' MET . . . -117.78 158.79 14.46 Favored Glycine 0 N--CA 1.445 -0.709 0 C-N-CA 121.032 -0.604 . . . . 0.0 112.154 -179.154 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 2.2 mp -108.88 106.89 21.56 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.5 0 CA-C-O 121.175 0.512 . . . . 0.0 110.103 178.682 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . 0.439 ' HB3' ' HB ' ' A' ' 41' ' ' VAL . . . -90.84 152.92 20.57 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.6 -0.727 . . . . 0.0 109.842 172.278 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -122.14 113.46 19.53 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.556 -178.274 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.562 HD11 HG13 ' A' ' 13' ' ' VAL . 38.7 mt -110.39 105.81 19.53 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.758 0 CA-C-O 121.085 0.469 . . . . 0.0 109.985 175.2 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 26.9 t0 55.18 36.69 27.55 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 114.852 -1.067 . . . . 0.0 110.663 -178.528 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 94.27 -19.93 50.68 Favored Glycine 0 C--N 1.333 0.394 0 C-N-CA 120.976 -0.63 . . . . 0.0 112.787 -179.807 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 78.3 t80 -77.13 142.54 39.66 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 110.098 -0.334 . . . . 0.0 110.098 -175.258 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 11.1 t -88.25 114.64 27.12 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 CA-C-N 115.888 -0.596 . . . . 0.0 111.113 -175.7 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.439 ' HB ' ' HB3' ' A' ' 34' ' ' ALA . 54.6 t -109.8 108.14 24.64 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.649 0 CA-C-N 116.033 -0.531 . . . . 0.0 109.913 177.265 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 67.6 m-85 -76.84 119.03 20.04 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 121.351 0.596 . . . . 0.0 110.256 178.822 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.576 ' HB ' ' HB2' ' A' ' 46' ' ' ALA . 17.5 t -117.9 100.49 52.17 Favored Pre-proline 0 C--N 1.315 -0.93 0 CA-C-N 115.474 -0.784 . . . . 0.0 110.512 -175.769 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 33.7 Cg_exo -64.62 -9.32 20.22 Favored 'Trans proline' 0 N--CA 1.476 0.476 0 C-N-CA 123.799 2.999 . . . . 0.0 114.412 -175.563 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' ASN . . . . . 0.401 ' HB2' ' HB3' ' A' ' 68' ' ' ARG . 0.9 OUTLIER -128.35 17.77 6.49 Favored 'General case' 0 C--N 1.324 -0.511 0 C-N-CA 120.907 -0.317 . . . . 0.0 110.7 -175.192 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.576 ' HB2' ' HB ' ' A' ' 43' ' ' VAL . . . -67.75 154.32 41.77 Favored 'General case' 0 C--N 1.32 -0.696 0 N-CA-C 113.334 0.864 . . . . 0.0 113.334 -175.655 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 10.9 mm-40 -105.76 121.33 43.8 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 114.695 -1.139 . . . . 0.0 109.64 174.522 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . 0.621 ' HB2' ' SD ' ' A' ' 26' ' ' MET . 63.2 tttm -60.84 123.99 19.14 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 120.947 0.404 . . . . 0.0 110.918 -177.119 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 89.06 -33.62 4.2 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 121.006 -0.616 . . . . 0.0 112.853 178.122 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 17.7 m -71.08 155.62 40.58 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 120.906 0.384 . . . . 0.0 110.627 -179.05 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.507 HG11 ' HG2' ' A' ' 20' ' ' GLU . 21.8 t -102.82 87.95 1.25 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 177.498 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.551 HD13 HG11 ' A' ' 43' ' ' VAL . 0.1 OUTLIER -92.49 144.98 8.18 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-N 115.622 -0.717 . . . . 0.0 110.688 -171.002 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . 0.547 ' HA ' ' HA ' ' A' ' 20' ' ' GLU . 8.5 t30 -83.36 112.52 19.99 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-N 115.691 -0.686 . . . . 0.0 109.794 175.229 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . 0.454 ' O ' ' HA ' ' A' ' 18' ' ' GLU . 33.9 m -104.44 137.38 33.71 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.264 -176.72 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . 0.524 ' HA ' ' HA ' ' A' ' 18' ' ' GLU . 35.9 ttpt -103.49 110.93 23.15 Favored 'General case' 0 C--N 1.318 -0.8 0 N-CA-C 108.958 -0.756 . . . . 0.0 108.958 172.644 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 60.4 t -65.21 118.08 7.0 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 CA-C-N 116.45 -0.341 . . . . 0.0 110.157 -179.294 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 12.3 p -104.35 -24.53 13.08 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 116.248 -0.433 . . . . 0.0 112.001 -174.992 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -154.75 102.31 2.36 Favored 'General case' 0 N--CA 1.451 -0.422 0 CA-C-O 121.097 0.475 . . . . 0.0 111.007 -175.131 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 17.9 t -88.22 122.72 40.12 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.705 0 CA-C-N 115.676 -0.693 . . . . 0.0 110.2 174.755 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . 0.424 ' HD2' ' N ' ' A' ' 60' ' ' LYS . 0.6 OUTLIER -101.35 -171.23 1.95 Allowed 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 176.634 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 39.4 mm-40 -59.51 -48.81 80.19 Favored 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 112.667 0.618 . . . . 0.0 112.667 -174.466 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 64.4 mttm -116.03 -5.45 11.96 Favored 'General case' 0 C--N 1.328 -0.326 0 N-CA-C 112.346 0.499 . . . . 0.0 112.346 -171.811 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 16.1 p90 -162.63 156.11 20.28 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 120.682 0.277 . . . . 0.0 110.761 -176.059 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -121.39 159.0 27.07 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.698 -178.65 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 96.2 m-85 -116.39 137.15 52.39 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.269 -0.423 . . . . 0.0 109.926 176.374 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' ALA . . . . . 0.417 ' HB2' ' HB ' ' A' ' 54' ' ' VAL . . . -137.48 152.89 50.02 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 116.443 -0.344 . . . . 0.0 111.161 -177.962 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' GLU . . . . . 0.419 ' O ' ' HA ' ' A' ' 54' ' ' VAL . 9.6 pt-20 -102.84 144.07 31.63 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.932 -179.11 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . 0.503 ' HB2' HD12 ' A' ' 52' ' ' ILE . 9.2 ttp180 -70.95 109.29 4.98 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.341 172.793 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.497 ' HB ' HD21 ' A' ' 53' ' ' ASN . 3.8 t -81.95 28.34 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.468 0 CA-C-O 121.506 0.67 . . . . 0.0 110.856 -179.587 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . 0.424 HD22 ' N ' ' A' ' 70' ' ' LEU . 1.3 pt? . . . . . 0 C--O 1.243 0.744 0 CA-C-N 116.136 -0.484 . . . . 0.0 109.748 178.75 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo . . . . . 0 CA--C 1.519 -0.254 0 CA-C-O 121.449 0.52 . . . . 0.0 112.379 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 9.4 m -121.8 -175.61 1.04 Allowed 'Isoleucine or valine' 0 C--N 1.314 -0.94 0 CA-C-N 115.16 -0.927 . . . . 0.0 109.722 179.806 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . 0.537 ' HG3' ' HD2' ' A' ' 17' ' ' LYS . 74.5 mm-40 -116.82 -159.46 0.73 Allowed 'General case' 0 C--N 1.314 -0.94 0 N-CA-C 109.587 -0.523 . . . . 0.0 109.587 177.21 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . 0.444 ' HA ' ' O ' ' A' ' 56' ' ' VAL . . . -162.56 101.11 1.04 Allowed 'General case' 0 C--N 1.317 -0.837 0 CA-C-N 115.591 -0.732 . . . . 0.0 109.315 174.862 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 124.81 -18.41 7.12 Favored Glycine 0 N--CA 1.446 -0.65 0 CA-C-N 114.82 -1.082 . . . . 0.0 111.571 -173.623 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' LYS . . . . . 0.537 ' HD2' ' HG3' ' A' ' 14' ' ' GLU . 61.6 mttm -102.31 164.11 11.86 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 120.597 0.237 . . . . 0.0 110.663 -178.76 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . 0.497 ' HA ' ' O ' ' A' ' 54' ' ' VAL . 2.1 mp0 -111.15 144.22 40.63 Favored 'General case' 0 N--CA 1.455 -0.179 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.072 -179.383 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 98.0 m-85 -132.58 -179.66 5.59 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.69 -0.686 . . . . 0.0 109.492 173.775 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 6.5 pt-20 -124.8 113.32 17.76 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-O 121.583 0.706 . . . . 0.0 109.495 175.07 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.434 ' O ' ' HA ' ' A' ' 51' ' ' VAL . 30.2 m -116.82 173.9 3.88 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.91 0 CA-C-N 115.26 -0.882 . . . . 0.0 111.202 -173.031 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 5.8 m -112.82 152.19 29.49 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.028 179.431 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.531 HG13 ' HB1' ' A' ' 46' ' ' ALA . 19.9 mm -115.23 61.22 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.678 0 N-CA-C 108.355 -0.98 . . . . 0.0 108.355 -176.064 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 6.9 mm-40 -66.12 -18.18 65.18 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 114.006 -1.452 . . . . 0.0 111.405 -179.259 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.508 ' HB3' ' HB ' ' A' ' 33' ' ' ILE . 26.0 t0 -138.53 137.01 36.66 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.472 -172.397 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' MET . . . . . 0.41 ' HE3' HG23 ' A' ' 23' ' ' ILE . 10.8 mmt -114.89 144.03 44.19 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.886 174.929 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.447 -0.607 0 N-CA-C 110.809 -0.916 . . . . 0.0 110.809 172.934 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . 0.407 ' HA ' ' HA ' ' A' ' 44' ' ' PRO . 4.7 t70 . . . . . 0 C--O 1.236 0.358 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -98.67 154.18 19.98 Favored Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.924 -173.732 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.508 ' HB ' ' HB3' ' A' ' 25' ' ' ASP . 2.5 mp -105.94 113.53 42.96 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.582 0 CA-C-O 121.136 0.493 . . . . 0.0 110.451 179.258 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . 0.41 ' HB1' ' HB ' ' A' ' 21' ' ' VAL . . . -106.37 160.62 15.24 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.775 -0.648 . . . . 0.0 109.9 175.902 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' ARG . . . . . 0.402 HH11 ' HD3' ' A' ' 35' ' ' ARG . 0.1 OUTLIER -130.05 128.02 41.1 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-O 120.652 0.263 . . . . 0.0 111.062 -175.027 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 54.7 mt -127.25 110.1 21.95 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 172.145 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 57.95 23.48 9.92 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 115.319 -0.855 . . . . 0.0 111.539 -175.946 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 99.88 -12.94 60.89 Favored Glycine 0 C--N 1.333 0.393 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.008 -178.605 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 52.6 t80 -76.18 139.28 41.16 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 109.652 -0.499 . . . . 0.0 109.652 -178.202 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 26.0 t -89.44 114.84 28.07 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 CA-C-O 121.097 0.475 . . . . 0.0 111.029 -175.475 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 37.1 t -115.24 118.23 58.13 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.661 0 CA-C-N 115.924 -0.58 . . . . 0.0 109.828 179.28 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 94.6 m-85 -87.09 142.31 28.02 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.773 -177.535 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.434 HG13 HD12 ' A' ' 52' ' ' ILE . 1.4 m -138.55 102.8 7.84 Favored Pre-proline 0 C--N 1.325 -0.496 0 CA-C-N 115.762 -0.654 . . . . 0.0 110.79 -179.115 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . 0.407 ' HA ' ' HA ' ' A' ' 31' ' ' ASP . 4.9 Cg_exo -77.23 3.39 6.75 Favored 'Trans proline' 0 CA--C 1.531 0.354 0 C-N-CA 123.564 2.842 . . . . 0.0 113.956 -170.943 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' ASN . . . . . 0.447 ' O ' ' HD3' ' A' ' 68' ' ' ARG . 57.2 m-80 -136.53 25.49 3.15 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 121.263 0.554 . . . . 0.0 110.489 -179.431 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.531 ' HB1' HG13 ' A' ' 23' ' ' ILE . . . -86.01 163.8 17.75 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 115.98 -0.554 . . . . 0.0 111.741 -179.682 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 42.9 mt-10 -116.93 134.4 54.8 Favored 'General case' 0 N--CA 1.446 -0.647 0 CA-C-N 115.472 -0.785 . . . . 0.0 109.297 172.224 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 27.0 ttpp -65.56 140.07 58.51 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-O 120.967 0.413 . . . . 0.0 111.493 -174.207 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 70.52 35.79 68.27 Favored Glycine 0 N--CA 1.448 -0.504 0 CA-C-N 115.525 -0.761 . . . . 0.0 112.704 177.367 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 50.8 m -142.18 162.23 35.99 Favored 'General case' 0 C--N 1.321 -0.663 0 O-C-N 122.772 -0.252 . . . . 0.0 110.747 179.07 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.434 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 88.9 t -98.86 122.9 51.1 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 N-CA-C 108.994 -0.743 . . . . 0.0 108.994 174.327 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.554 HD11 ' HB2' ' A' ' 68' ' ' ARG . 3.4 pt -121.62 142.97 35.67 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.703 0 C-N-CA 120.615 -0.434 . . . . 0.0 110.371 -178.8 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . 0.4 ' O ' ' HA ' ' A' ' 68' ' ' ARG . 16.5 t-20 -76.71 129.48 36.4 Favored 'General case' 0 C--N 1.323 -0.556 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 174.053 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . 0.54 ' HB ' ' HB1' ' A' ' 66' ' ' ALA . 25.0 m -128.24 128.49 68.61 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 CA-C-O 121.163 0.506 . . . . 0.0 112.032 -176.202 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . 0.414 ' HB2' ' HG3' ' A' ' 18' ' ' GLU . 22.8 ttmm -98.95 102.14 13.77 Favored 'General case' 0 C--N 1.314 -0.945 0 N-CA-C 108.611 -0.885 . . . . 0.0 108.611 170.044 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.448 HG22 ' HB3' ' A' ' 66' ' ' ALA . 68.1 t -66.27 108.21 0.96 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 N-CA-C 109.459 -0.571 . . . . 0.0 109.459 178.368 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 12.9 p -109.87 -13.81 14.39 Favored 'General case' 0 C--N 1.321 -0.634 0 N-CA-C 112.304 0.483 . . . . 0.0 112.304 -174.405 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . 0.418 ' HB2' ' HB2' ' A' ' 65' ' ' PHE . . . -143.13 92.24 2.36 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.134 0.493 . . . . 0.0 111.256 -176.608 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 20.3 t -84.58 142.8 12.84 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.768 0 CA-C-N 115.95 -0.568 . . . . 0.0 109.7 177.645 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 42.5 mmtm -127.72 -162.33 1.16 Allowed 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 116.716 -0.22 . . . . 0.0 110.779 -179.364 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 6.5 mm-40 -47.34 -64.09 0.87 Allowed 'General case' 0 N--CA 1.468 0.435 0 C-N-CA 123.699 0.799 . . . . 0.0 112.761 -172.302 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 59.9 pttt -138.31 20.59 2.77 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 121.666 0.746 . . . . 0.0 110.198 -178.926 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 28.9 p90 -153.12 153.19 32.3 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 114.939 -1.028 . . . . 0.0 108.906 -179.745 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -127.41 155.66 43.29 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-O 120.825 0.345 . . . . 0.0 111.112 -177.69 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' PHE . . . . . 0.418 ' HB2' ' HB2' ' A' ' 58' ' ' ALA . 99.0 m-85 -108.97 124.69 51.09 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 115.836 -0.62 . . . . 0.0 109.476 176.412 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' ALA . . . . . 0.54 ' HB1' ' HB ' ' A' ' 54' ' ' VAL . . . -125.12 151.24 46.0 Favored 'General case' 0 C--N 1.318 -0.793 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.707 -179.001 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 5.3 pt-20 -110.27 128.51 55.56 Favored 'General case' 0 C--N 1.316 -0.882 0 CA-C-O 121.263 0.554 . . . . 0.0 111.117 -178.888 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . 0.554 ' HB2' HD11 ' A' ' 52' ' ' ILE . 22.4 ttt180 -61.74 115.4 3.95 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.008 -0.996 . . . . 0.0 111.515 178.262 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.481 ' O ' HG13 ' A' ' 69' ' ' VAL . 22.0 t -82.07 12.29 0.64 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-N 114.922 -1.036 . . . . 0.0 110.876 179.32 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . 0.438 ' HB2' ' HE ' ' A' ' 68' ' ' ARG . 60.4 mt . . . . . 0 C--O 1.249 1.045 0 CA-C-O 118.317 -0.849 . . . . 0.0 110.692 -178.447 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 15.5 tpt . . . . . 0 N--CA 1.479 1.003 0 CA-C-O 120.877 0.37 . . . . 0.0 110.196 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -156.31 126.27 6.45 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.727 -178.734 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 3.2 p90 -95.22 65.26 2.8 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 121.456 0.646 . . . . 0.0 109.986 176.773 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 96.99 -64.9 0.97 Allowed Glycine 0 N--CA 1.447 -0.601 0 N-CA-C 110.769 -0.932 . . . . 0.0 110.769 -173.379 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.403 ' HA ' ' HD3' ' A' ' 6' ' ' PRO . 98.7 mttt -142.09 150.69 56.65 Favored Pre-proline 0 C--N 1.328 -0.335 0 N-CA-C 109.276 -0.639 . . . . 0.0 109.276 175.422 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.403 ' HD3' ' HA ' ' A' ' 5' ' ' LYS . 5.7 Cg_exo -76.49 94.66 1.04 Allowed 'Trans proline' 0 N--CA 1.459 -0.552 0 C-N-CA 122.553 2.169 . . . . 0.0 111.671 177.72 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . 63.55 -165.14 0.24 Allowed 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.676 -0.693 . . . . 0.0 111.139 178.454 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' MET . . . . . . . . . . . . . 26.4 ttt -99.26 39.8 1.26 Allowed 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 121.327 0.584 . . . . 0.0 109.786 179.579 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . 0.403 ' HE3' ' HB3' ' A' ' 9' ' ' LYS . 10.5 ttpp 66.7 22.79 10.33 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-N 115.165 -0.925 . . . . 0.0 110.932 177.442 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 2.4 m120 60.52 99.1 0.03 OUTLIER 'General case' 0 N--CA 1.467 0.424 0 CA-C-N 115.707 -0.679 . . . . 0.0 112.126 -178.221 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.479 HG12 HG12 ' A' ' 59' ' ' VAL . 21.2 t -76.02 126.86 86.31 Favored Pre-proline 0 C--N 1.321 -0.641 0 CA-C-N 115.719 -0.673 . . . . 0.0 109.251 175.22 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 16.2 Cg_endo -58.54 -22.15 58.27 Favored 'Trans proline' 0 N--CA 1.475 0.435 0 C-N-CA 123.281 2.654 . . . . 0.0 113.212 -178.562 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.521 HG11 HD12 ' A' ' 36' ' ' ILE . 16.1 m -114.72 121.0 65.93 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.356 179.846 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 49.0 mt-10 -99.29 118.33 35.73 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.782 -177.686 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -63.84 125.06 23.16 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.674 -0.694 . . . . 0.0 111.028 179.934 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 112.45 -4.44 26.48 Favored Glycine 0 N--CA 1.449 -0.44 0 C-N-CA 120.891 -0.671 . . . . 0.0 111.814 -177.852 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 97.1 mttt -118.59 158.52 25.28 Favored 'General case' 0 C--N 1.324 -0.542 0 N-CA-C 110.289 -0.263 . . . . 0.0 110.289 178.997 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . 0.482 ' HA ' ' O ' ' A' ' 54' ' ' VAL . 0.0 OUTLIER -120.61 130.7 54.28 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-O 121.606 0.717 . . . . 0.0 111.29 179.878 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 45.8 m-85 -122.66 149.63 43.77 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.257 -0.883 . . . . 0.0 110.179 -174.912 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 2.3 mp0 -84.8 119.13 24.96 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 121.138 0.494 . . . . 0.0 109.693 173.857 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 36.0 m -130.43 165.04 31.74 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.879 0 CA-C-N 115.599 -0.728 . . . . 0.0 110.865 -175.097 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 11.7 m -108.35 149.64 28.42 Favored 'General case' 0 C--N 1.316 -0.87 0 CA-C-N 115.999 -0.546 . . . . 0.0 109.935 175.911 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.517 HG13 ' HB3' ' A' ' 46' ' ' ALA . 36.0 mm -110.67 61.6 0.16 Allowed 'Isoleucine or valine' 0 CA--C 1.509 -0.609 0 N-CA-C 107.652 -1.24 . . . . 0.0 107.652 -176.995 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 31.4 tt0 -62.57 -24.79 67.73 Favored 'General case' 0 C--N 1.311 -1.084 0 CA-C-N 113.062 -1.881 . . . . 0.0 111.207 -179.583 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.549 ' HB2' ' HB ' ' A' ' 33' ' ' ILE . 15.3 m-20 -124.33 149.15 46.91 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.33 -0.396 . . . . 0.0 111.18 -175.213 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' MET . . . . . . . . . . . . . 96.0 mmm -123.19 147.85 46.42 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.092 -0.504 . . . . 0.0 109.932 173.975 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -96.46 173.42 29.86 Favored Glycine 0 N--CA 1.448 -0.544 0 C-N-CA 121.091 -0.576 . . . . 0.0 112.792 -178.02 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 61.4 mttm -75.99 18.29 0.28 Allowed 'General case' 0 N--CA 1.465 0.303 0 N-CA-C 112.484 0.55 . . . . 0.0 112.484 -175.281 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -144.1 28.24 1.98 Allowed Glycine 0 C--N 1.312 -0.754 0 C-N-CA 120.872 -0.68 . . . . 0.0 112.488 -178.898 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 68.47 20.12 73.34 Favored Glycine 0 CA--C 1.518 0.277 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.6 -179.276 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . 0.439 ' OD1' ' HA ' ' A' ' 44' ' ' PRO . 27.5 t70 -97.13 144.53 26.89 Favored 'General case' 0 C--N 1.32 -0.694 0 N-CA-C 109.56 -0.533 . . . . 0.0 109.56 -179.413 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -98.66 132.53 10.97 Favored Glycine 0 N--CA 1.447 -0.615 0 C-N-CA 120.602 -0.808 . . . . 0.0 111.897 -177.293 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.549 ' HB ' ' HB2' ' A' ' 25' ' ' ASP . 1.9 mp -101.83 104.1 15.9 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.737 0 CA-C-O 121.492 0.663 . . . . 0.0 110.625 -178.248 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -84.17 157.19 21.75 Favored 'General case' 0 C--N 1.317 -0.809 0 CA-C-N 115.406 -0.816 . . . . 0.0 109.167 169.036 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 6.0 ttm180 -142.18 107.87 5.11 Favored 'General case' 0 C--N 1.313 -0.982 0 C-N-CA 120.644 -0.422 . . . . 0.0 110.819 -176.769 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.521 HD12 HG11 ' A' ' 13' ' ' VAL . 37.2 mt -99.43 108.68 22.96 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 CA-C-N 115.733 -0.667 . . . . 0.0 110.11 178.093 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 58.2 16.46 3.95 Favored 'General case' 0 N--CA 1.468 0.473 0 CA-C-N 115.26 -0.882 . . . . 0.0 112.079 -176.539 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 110.28 -16.99 29.36 Favored Glycine 0 N--CA 1.449 -0.447 0 C-N-CA 120.856 -0.688 . . . . 0.0 111.764 -178.057 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 34.0 t80 -71.68 117.59 13.44 Favored 'General case' 0 C--N 1.328 -0.362 0 N-CA-C 109.576 -0.527 . . . . 0.0 109.576 179.334 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 0.46 HG13 HG22 ' A' ' 33' ' ' ILE . 29.1 t -70.61 117.59 13.9 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 CA-C-N 115.824 -0.625 . . . . 0.0 111.301 -178.43 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 49.1 t -119.34 108.39 23.65 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 CA-C-N 115.481 -0.781 . . . . 0.0 109.594 -179.812 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 93.7 m-85 -78.58 129.55 34.92 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.086 -175.411 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 5.6 t -125.73 105.57 26.65 Favored Pre-proline 0 C--N 1.321 -0.659 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.246 -177.948 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . 0.439 ' HA ' ' OD1' ' A' ' 31' ' ' ASP . 34.9 Cg_endo -65.75 -8.26 19.01 Favored 'Trans proline' 0 N--CA 1.477 0.538 0 C-N-CA 123.537 2.825 . . . . 0.0 114.476 -172.561 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 1.2 p30 -142.54 20.35 2.03 Favored 'General case' 0 C--N 1.321 -0.65 0 N-CA-C 112.264 0.468 . . . . 0.0 112.264 -167.603 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.517 ' HB3' HG13 ' A' ' 23' ' ' ILE . . . -97.18 155.89 16.64 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.082 176.126 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 48.9 mt-10 -106.38 144.9 32.39 Favored 'General case' 0 N--CA 1.451 -0.421 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.093 178.54 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 60.8 tttm -66.2 137.36 56.93 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.457 -0.338 . . . . 0.0 111.352 -175.676 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 82.86 -2.24 86.84 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 121.017 -0.611 . . . . 0.0 113.121 175.943 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 29.7 m -93.56 152.08 19.27 Favored 'General case' 0 C--N 1.324 -0.538 0 O-C-N 122.654 -0.321 . . . . 0.0 111.085 -179.529 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 46.6 t -98.46 101.65 12.42 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 N-CA-C 108.456 -0.942 . . . . 0.0 108.456 172.897 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.524 ' HA ' HD13 ' A' ' 70' ' ' LEU . 0.8 OUTLIER -115.2 145.23 21.22 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.851 0 CA-C-N 115.789 -0.641 . . . . 0.0 112.018 -170.281 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 58.1 t30 -88.3 112.86 23.31 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 114.923 -1.035 . . . . 0.0 109.005 176.306 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . 0.482 ' O ' ' HA ' ' A' ' 18' ' ' GLU . 35.2 m -115.01 134.56 57.69 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.724 0 CA-C-O 121.115 0.483 . . . . 0.0 111.609 -175.259 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 2.3 ttmp? -93.42 111.06 22.63 Favored 'General case' 0 C--N 1.32 -0.709 0 N-CA-C 109.124 -0.695 . . . . 0.0 109.124 175.52 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.455 HG22 ' HB ' ' A' ' 13' ' ' VAL . 87.6 t -67.88 113.08 3.41 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 N-CA-C 109.189 -0.671 . . . . 0.0 109.189 177.693 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.7 p -109.36 -26.02 10.24 Favored 'General case' 0 C--N 1.324 -0.53 0 N-CA-C 112.455 0.539 . . . . 0.0 112.455 -173.104 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . 0.421 ' HB3' ' HB2' ' A' ' 65' ' ' PHE . . . -143.38 92.17 2.34 Favored 'General case' 0 C--N 1.325 -0.476 0 C-N-CA 120.679 -0.408 . . . . 0.0 111.738 -175.301 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.479 HG12 HG12 ' A' ' 11' ' ' VAL . 15.6 t -79.9 125.89 39.07 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.735 0 CA-C-N 116.109 -0.496 . . . . 0.0 109.781 174.079 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 46.0 mmtm -106.01 -164.17 0.99 Allowed 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.439 -179.559 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 40.8 tt0 -66.03 -48.84 69.77 Favored 'General case' 0 CA--C 1.533 0.297 0 N-CA-C 112.623 0.601 . . . . 0.0 112.623 -175.3 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 93.1 mttt -120.6 3.89 10.66 Favored 'General case' 0 C--N 1.328 -0.332 0 N-CA-C 111.934 0.346 . . . . 0.0 111.934 -172.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 15.1 p90 -166.6 169.01 14.06 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 116.42 -0.355 . . . . 0.0 110.21 -174.273 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -129.42 158.76 38.26 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-O 120.878 0.37 . . . . 0.0 111.095 -179.95 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . 0.421 ' HB2' ' HB3' ' A' ' 58' ' ' ALA . 95.3 m-85 -114.47 136.14 53.34 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.579 -0.737 . . . . 0.0 109.824 176.827 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' ALA . . . . . 0.461 ' HB2' ' HB ' ' A' ' 54' ' ' VAL . . . -127.35 -179.3 4.82 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.571 -179.155 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' GLU . . . . . 0.436 ' O ' ' HA ' ' A' ' 54' ' ' VAL . 8.1 pt-20 -141.67 143.82 33.79 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 120.861 0.362 . . . . 0.0 111.212 178.85 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . 0.524 ' HB2' HD11 ' A' ' 52' ' ' ILE . 31.2 ttt180 -67.73 106.16 2.15 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.405 -0.816 . . . . 0.0 111.707 178.185 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 2.6 t -83.54 21.66 0.19 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.361 0 CA-C-O 121.501 0.667 . . . . 0.0 110.405 175.286 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.524 HD13 ' HA ' ' A' ' 52' ' ' ILE . 64.2 mt . . . . . 0 C--O 1.249 1.074 0 CA-C-O 118.351 -0.833 . . . . 0.0 110.064 -179.255 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.479 1.015 0 CA-C-O 120.616 0.246 . . . . 0.0 110.573 . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -106.68 -80.86 0.56 Allowed 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.529 -179.96 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . 0.573 ' HA ' ' HD2' ' A' ' 6' ' ' PRO . 34.6 m-85 -124.1 -174.11 2.92 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 120.951 0.405 . . . . 0.0 111.49 -173.004 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 123.39 -24.68 6.48 Favored Glycine 0 N--CA 1.451 -0.358 0 N-CA-C 109.807 -1.317 . . . . 0.0 109.807 -171.579 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.545 ' HB2' ' HD3' ' A' ' 6' ' ' PRO . 32.4 mmmt -121.94 -47.18 0.04 OUTLIER Pre-proline 0 C--N 1.325 -0.49 0 CA-C-N 114.201 -1.0 . . . . 0.0 110.274 172.802 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.573 ' HD2' ' HA ' ' A' ' 3' ' ' PHE . 6.7 Cg_endo -92.84 164.98 2.68 Favored 'Trans proline' 0 C--N 1.355 0.88 0 C-N-CA 122.649 2.233 . . . . 0.0 111.923 174.46 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . 62.68 14.28 7.07 Favored 'General case' 0 N--CA 1.47 0.553 0 C-N-CA 123.446 0.698 . . . . 0.0 112.677 175.956 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' MET . . . . . . . . . . . . . 23.6 ttt -100.13 32.83 2.82 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 121.573 0.701 . . . . 0.0 109.907 -179.821 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -107.67 27.77 8.84 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.604 179.56 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 20.3 p-10 -79.25 53.98 1.59 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.449 178.289 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.49 HG13 HG11 ' A' ' 59' ' ' VAL . 69.6 t -159.28 124.79 2.3 Favored Pre-proline 0 C--N 1.328 -0.352 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 -172.713 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 10.9 Cg_endo -55.11 -31.49 75.51 Favored 'Trans proline' 0 C--N 1.345 0.393 0 C-N-CA 123.518 2.812 . . . . 0.0 113.125 -176.625 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.497 ' HB ' HG22 ' A' ' 56' ' ' VAL . 15.6 m -103.64 126.8 58.09 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-N 116.09 -0.504 . . . . 0.0 111.214 -178.311 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . 0.417 ' CB ' ' HD3' ' A' ' 17' ' ' LYS . 37.6 mt-10 -101.06 123.96 46.05 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.058 176.398 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . 0.47 ' HA ' ' O ' ' A' ' 56' ' ' VAL . . . -60.94 110.16 1.27 Allowed 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.355 177.227 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 123.64 -18.76 7.6 Favored Glycine 0 N--CA 1.447 -0.613 0 C-N-CA 121.029 -0.605 . . . . 0.0 112.436 -178.29 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . 0.417 ' HD3' ' CB ' ' A' ' 14' ' ' GLU . 2.4 mptm? -94.1 162.97 13.66 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.935 0.398 . . . . 0.0 111.393 -179.99 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . 0.549 ' HG2' ' HB2' ' A' ' 55' ' ' LYS . 31.4 mt-10 -118.84 128.41 54.43 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.538 -0.755 . . . . 0.0 110.036 179.611 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' TYR . . . . . 0.416 ' O ' HG21 ' A' ' 54' ' ' VAL . 62.0 m-85 -127.87 127.17 42.94 Favored 'General case' 0 C--N 1.322 -0.627 0 N-CA-C 110.065 -0.346 . . . . 0.0 110.065 179.412 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . 0.62 ' HA ' ' HA ' ' A' ' 53' ' ' ASN . 34.8 tt0 -78.24 119.12 21.16 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 121.149 0.5 . . . . 0.0 109.764 177.03 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 23.3 m -129.82 162.81 36.77 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-N 115.499 -0.773 . . . . 0.0 111.702 -170.116 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 9.7 m -97.33 149.12 22.44 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.021 177.215 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.473 HG13 ' HB1' ' A' ' 46' ' ' ALA . 24.0 mm -121.33 65.94 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 108.572 -0.899 . . . . 0.0 108.572 -175.546 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 35.5 tt0 -86.98 -5.34 59.12 Favored 'General case' 0 C--N 1.31 -1.116 0 CA-C-N 114.445 -1.252 . . . . 0.0 110.465 -178.209 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.528 ' CB ' ' HB ' ' A' ' 33' ' ' ILE . 25.1 m-20 -118.59 134.42 55.11 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 115.526 -0.761 . . . . 0.0 109.396 -178.874 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' MET . . . . . . . . . . . . . 98.1 mmm -124.82 147.03 48.95 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-O 120.697 0.284 . . . . 0.0 110.91 -179.842 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -87.64 -50.92 3.4 Favored Glycine 0 N--CA 1.445 -0.757 0 N-CA-C 110.71 -0.956 . . . . 0.0 110.71 175.667 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 51.5 tptt -164.76 -79.27 0.03 OUTLIER 'General case' 0 CA--C 1.514 -0.431 0 CA-C-O 121.243 0.544 . . . . 0.0 111.411 173.439 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -124.85 73.42 0.42 Allowed Glycine 0 C--N 1.306 -1.118 0 CA-C-N 115.338 -0.846 . . . . 0.0 113.588 -171.906 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 107.0 -29.9 10.1 Favored Glycine 0 CA--C 1.507 -0.449 0 C-N-CA 120.906 -0.664 . . . . 0.0 111.586 174.783 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 4.4 p-10 -73.54 105.62 4.97 Favored 'General case' 0 C--N 1.317 -0.814 0 N-CA-C 109.203 -0.666 . . . . 0.0 109.203 173.394 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -109.38 160.87 13.28 Favored Glycine 0 N--CA 1.443 -0.863 0 CA-C-N 115.526 -0.761 . . . . 0.0 112.588 -175.347 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.528 ' HB ' ' CB ' ' A' ' 25' ' ' ASP . 2.5 mp -114.1 110.08 30.81 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.836 0 N-CA-C 109.962 -0.385 . . . . 0.0 109.962 -179.973 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . 0.469 ' HB3' ' CD1' ' A' ' 23' ' ' ILE . . . -94.03 155.17 17.26 Favored 'General case' 0 C--N 1.318 -0.761 0 CA-C-O 121.732 0.777 . . . . 0.0 111.098 173.868 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 29.1 mmt180 -121.4 103.11 8.71 Favored 'General case' 0 N--CA 1.437 -1.114 0 CA-C-N 114.552 -1.204 . . . . 0.0 110.629 -172.52 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.418 HD12 ' CG1' ' A' ' 13' ' ' VAL . 26.1 mt -100.61 101.4 12.04 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.601 0 CA-C-O 121.1 0.476 . . . . 0.0 109.917 175.623 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 33.2 t70 67.06 -4.14 0.86 Allowed 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 114.669 -1.151 . . . . 0.0 111.006 -173.522 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 122.61 -19.28 8.01 Favored Glycine 0 N--CA 1.446 -0.673 0 N-CA-C 110.845 -0.902 . . . . 0.0 110.845 -172.207 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 51.7 t80 -65.84 126.08 27.38 Favored 'General case' 0 C--O 1.237 0.399 0 N-CA-C 109.126 -0.694 . . . . 0.0 109.126 176.702 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 0.473 HG13 HG23 ' A' ' 33' ' ' ILE . 39.9 t -76.77 113.45 15.84 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.757 0 CA-C-N 115.78 -0.646 . . . . 0.0 111.292 -175.344 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 68.0 t -109.31 111.65 37.03 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 CA-C-N 115.48 -0.782 . . . . 0.0 109.885 177.347 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 60.6 m-85 -77.95 120.12 22.37 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.376 -179.625 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.538 ' HB ' ' HB3' ' A' ' 46' ' ' ALA . 8.7 t -120.81 104.56 41.83 Favored Pre-proline 0 C--N 1.319 -0.725 0 CA-C-N 115.587 -0.733 . . . . 0.0 110.398 -177.304 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -77.32 16.84 0.96 Allowed 'Trans proline' 0 CA--C 1.53 0.324 0 C-N-CA 123.379 2.719 . . . . 0.0 113.584 -174.187 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -152.04 21.43 0.67 Allowed 'General case' 0 C--N 1.321 -0.65 0 CA-C-O 121.523 0.678 . . . . 0.0 110.266 -178.042 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.538 ' HB3' ' HB ' ' A' ' 43' ' ' VAL . . . -78.63 168.86 19.14 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 115.224 -0.898 . . . . 0.0 111.488 177.923 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . 0.454 ' O ' ' HB ' ' A' ' 23' ' ' ILE . 0.0 OUTLIER -126.16 134.76 51.2 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.549 -0.75 . . . . 0.0 109.594 178.21 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 1.8 tmtp? -63.37 120.84 12.39 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.891 -176.15 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 81.96 5.91 89.36 Favored Glycine 0 N--CA 1.45 -0.412 0 CA-C-N 115.776 -0.647 . . . . 0.0 112.821 177.097 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 20.0 t -101.78 163.34 12.3 Favored 'General case' 0 C--N 1.324 -0.538 0 N-CA-C 110.123 -0.325 . . . . 0.0 110.123 -178.478 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.487 HG11 ' HG2' ' A' ' 20' ' ' GLU . 32.2 t -114.35 101.46 12.46 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.463 0 N-CA-C 109.106 -0.702 . . . . 0.0 109.106 179.269 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.571 HD11 ' HB2' ' A' ' 68' ' ' ARG . 6.4 pt -108.58 145.47 15.5 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-O 121.054 0.454 . . . . 0.0 110.934 -173.131 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . 0.62 ' HA ' ' HA ' ' A' ' 20' ' ' GLU . 39.6 t30 -82.55 115.81 21.69 Favored 'General case' 0 C--N 1.318 -0.765 0 N-CA-C 109.328 -0.619 . . . . 0.0 109.328 172.157 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . 0.503 HG13 HG13 ' A' ' 52' ' ' ILE . 28.8 m -107.97 130.81 59.81 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-O 121.358 0.599 . . . . 0.0 111.816 -177.198 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . 0.549 ' HB2' ' HG2' ' A' ' 18' ' ' GLU . 39.8 ttmt -97.98 106.65 18.98 Favored 'General case' 0 C--N 1.318 -0.772 0 N-CA-C 108.959 -0.756 . . . . 0.0 108.959 172.304 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.497 HG22 ' HB ' ' A' ' 13' ' ' VAL . 47.1 t -68.12 112.88 3.44 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.079 179.559 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 21.0 p -109.41 -17.94 13.67 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 112.071 0.397 . . . . 0.0 112.071 -174.86 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -143.58 92.58 2.37 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.063 0.458 . . . . 0.0 110.984 -177.607 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.49 HG11 HG13 ' A' ' 11' ' ' VAL . 13.4 t -85.24 129.61 37.55 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.638 0 CA-C-N 115.854 -0.612 . . . . 0.0 109.913 175.868 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 74.8 mmtt -106.76 -173.07 2.21 Favored 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 109.979 -0.378 . . . . 0.0 109.979 178.437 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -72.42 -41.22 66.45 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.35 -0.386 . . . . 0.0 111.859 179.648 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 56.3 mttp -92.13 -45.3 8.35 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 121.036 0.446 . . . . 0.0 111.295 -178.269 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 10.4 p90 -142.84 -171.3 3.42 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.969 -0.559 . . . . 0.0 110.492 -172.538 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -138.91 158.51 44.07 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-O 120.814 0.34 . . . . 0.0 111.113 -179.462 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 93.2 m-85 -113.85 138.72 49.91 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.694 -0.684 . . . . 0.0 109.43 175.492 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' ALA . . . . . 0.428 ' HB1' ' HB ' ' A' ' 54' ' ' VAL . . . -142.6 159.14 42.82 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 116.553 -0.294 . . . . 0.0 110.906 -178.668 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' GLU . . . . . 0.423 ' O ' ' HA ' ' A' ' 54' ' ' VAL . 10.8 pt-20 -113.72 137.75 51.19 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 121.303 0.573 . . . . 0.0 111.254 179.142 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . 0.571 ' HB2' HD11 ' A' ' 52' ' ' ILE . 25.0 ttt180 -66.41 109.86 2.89 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 115.237 -0.892 . . . . 0.0 109.98 172.458 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 2.8 t -81.92 25.13 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.536 0.41 0 CA-C-O 121.526 0.679 . . . . 0.0 111.867 -174.767 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.441 ' CD2' ' HG3' ' A' ' 68' ' ' ARG . 0.8 OUTLIER . . . . . 0 C--O 1.245 0.838 0 CA-C-O 118.759 -0.639 . . . . 0.0 110.329 179.218 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 25.4 ttt . . . . . 0 N--CA 1.478 0.93 0 CA-C-O 120.705 0.288 . . . . 0.0 110.624 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -146.04 -168.06 2.89 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.902 0.382 . . . . 0.0 110.985 -179.51 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 17.6 p90 -84.13 50.75 1.91 Allowed 'General case' 0 C--N 1.324 -0.505 0 CA-C-O 121.467 0.651 . . . . 0.0 110.754 -179.441 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 97.65 -64.47 0.9 Allowed Glycine 0 N--CA 1.446 -0.687 0 CA-C-N 115.752 -0.658 . . . . 0.0 111.711 -178.56 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 64.0 tttp -124.16 116.82 27.08 Favored Pre-proline 0 C--N 1.321 -0.653 0 N-CA-C 110.026 -0.361 . . . . 0.0 110.026 179.164 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.426 ' HD2' ' OD1' ' A' ' 10' ' ' ASN . 18.9 Cg_endo -90.34 -162.55 0.12 Allowed 'Trans proline' 0 N--CA 1.453 -0.905 0 C-N-CA 122.987 2.458 . . . . 0.0 112.717 178.533 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -98.26 -144.1 0.31 Allowed 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.322 -0.854 . . . . 0.0 110.71 -178.656 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' MET . . . . . . . . . . . . . 60.5 mtt 69.65 18.98 7.49 Favored 'General case' 0 N--CA 1.468 0.433 0 C-N-CA 122.838 0.455 . . . . 0.0 111.028 177.564 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . 0.463 ' C ' ' H ' ' A' ' 11' ' ' VAL . 12.5 mmmm 54.5 85.23 0.06 Allowed 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.328 -0.851 . . . . 0.0 112.028 -177.782 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . 0.426 ' OD1' ' HD2' ' A' ' 6' ' ' PRO . 5.8 m120 -81.55 40.84 0.6 Allowed 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 121.543 0.687 . . . . 0.0 109.175 171.158 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.463 ' H ' ' C ' ' A' ' 9' ' ' LYS . 47.2 t -160.58 106.25 1.33 Allowed Pre-proline 0 C--N 1.327 -0.397 0 N-CA-C 107.276 -1.379 . . . . 0.0 107.276 -174.587 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -68.08 -31.44 30.04 Favored 'Trans proline' 0 CA--C 1.516 -0.403 0 C-N-CA 123.218 2.612 . . . . 0.0 112.507 -173.625 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.594 HG11 HD11 ' A' ' 36' ' ' ILE . 16.1 m -80.5 163.03 3.53 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.896 0 CA-C-N 115.175 -0.921 . . . . 0.0 110.906 -177.989 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 9.8 tp10 -147.14 119.72 8.53 Favored 'General case' 0 C--N 1.322 -0.588 0 N-CA-C 108.918 -0.771 . . . . 0.0 108.918 178.471 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . 0.438 ' HA ' ' O ' ' A' ' 56' ' ' VAL . . . -58.91 117.55 4.78 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-O 121.111 0.482 . . . . 0.0 111.377 -177.207 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 119.09 -24.84 8.1 Favored Glycine 0 N--CA 1.447 -0.625 0 CA-C-N 115.653 -0.703 . . . . 0.0 112.218 -179.246 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 53.1 mtpt -90.55 156.37 18.21 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.871 0.367 . . . . 0.0 110.734 179.077 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . 0.473 ' HA ' ' O ' ' A' ' 54' ' ' VAL . 46.0 mt-10 -113.96 128.34 56.35 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.824 -0.625 . . . . 0.0 109.858 -179.864 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 81.5 m-85 -122.58 143.42 49.75 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 121.173 0.511 . . . . 0.0 111.583 -175.887 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 32.7 tt0 -82.98 111.06 18.49 Favored 'General case' 0 C--N 1.317 -0.808 0 CA-C-N 115.548 -0.751 . . . . 0.0 109.475 175.069 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.49 ' HB ' ' HB1' ' A' ' 34' ' ' ALA . 32.7 m -121.81 151.32 25.28 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-O 121.053 0.454 . . . . 0.0 112.023 -172.714 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 17.0 m -97.62 152.44 19.06 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.658 -0.701 . . . . 0.0 109.721 176.474 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.444 ' CD1' ' HB3' ' A' ' 34' ' ' ALA . 18.9 mm -121.89 64.5 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-O 121.791 0.805 . . . . 0.0 108.908 -174.423 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 26.1 mm-40 -69.02 -19.15 64.11 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-N 114.782 -1.099 . . . . 0.0 111.835 -179.663 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.534 ' HB2' ' HB ' ' A' ' 33' ' ' ILE . 5.6 m-20 -126.34 138.7 53.6 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 116.392 -0.367 . . . . 0.0 111.277 -176.093 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' MET . . . . . . . . . . . . . 92.9 mmm -120.28 142.09 49.39 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 115.814 -0.63 . . . . 0.0 109.917 175.655 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -81.19 -67.07 1.56 Allowed Glycine 0 N--CA 1.444 -0.773 0 N-CA-C 111.559 -0.616 . . . . 0.0 111.559 179.537 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 37.2 ttmt -170.2 78.57 0.09 Allowed 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 121.972 0.891 . . . . 0.0 110.571 178.591 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 82.54 -64.85 4.21 Favored Glycine 0 C--N 1.304 -1.205 0 CA-C-N 114.194 -1.366 . . . . 0.0 113.304 173.741 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -111.47 38.19 3.38 Favored Glycine 0 C--N 1.321 -0.294 0 C-N-CA 120.896 -0.669 . . . . 0.0 112.642 -173.96 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 30.3 t70 -156.64 117.84 3.77 Favored 'General case' 0 C--N 1.319 -0.74 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 179.069 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . 0.538 ' HA3' ' HB2' ' A' ' 46' ' ' ALA . . . -114.42 141.71 17.15 Favored Glycine 0 N--CA 1.441 -1.022 0 N-CA-C 111.178 -0.769 . . . . 0.0 111.178 177.994 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.534 ' HB ' ' HB2' ' A' ' 25' ' ' ASP . 2.6 mp -97.93 98.19 7.03 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.767 0 CA-C-O 121.329 0.585 . . . . 0.0 110.276 -178.09 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . 0.49 ' HB1' ' HB ' ' A' ' 21' ' ' VAL . . . -99.85 123.01 43.65 Favored 'General case' 0 CA--C 1.497 -1.065 0 CA-C-N 115.747 -0.661 . . . . 0.0 109.398 171.706 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' ARG . . . . . 0.514 ' HA ' ' O ' ' A' ' 39' ' ' PHE . 0.0 OUTLIER -118.56 108.66 15.23 Favored 'General case' 0 C--N 1.303 -1.453 0 CA-C-N 115.6 -0.727 . . . . 0.0 111.363 -174.11 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.594 HD11 HG11 ' A' ' 13' ' ' VAL . 53.1 mt -84.43 112.62 21.9 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.702 0 CA-C-N 115.208 -0.905 . . . . 0.0 109.604 177.649 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 36.7 t70 60.43 19.07 8.76 Favored 'General case' 0 CA--C 1.539 0.523 0 CA-C-N 115.495 -0.775 . . . . 0.0 110.702 -175.451 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 100.78 -9.26 58.41 Favored Glycine 0 C--N 1.329 0.189 0 C-N-CA 120.583 -0.818 . . . . 0.0 112.143 -178.794 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . 0.514 ' O ' ' HA ' ' A' ' 35' ' ' ARG . 60.8 t80 -77.43 114.76 16.59 Favored 'General case' 0 C--N 1.323 -0.576 0 N-CA-C 109.708 -0.479 . . . . 0.0 109.708 178.779 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 0.493 HG12 HG22 ' A' ' 33' ' ' ILE . 21.5 t -68.98 110.09 2.3 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 CA-C-O 121.6 0.714 . . . . 0.0 111.968 -175.347 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.455 ' CG1' ' HB1' ' A' ' 66' ' ' ALA . 17.6 t -108.26 110.42 31.91 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.824 0 CA-C-N 115.092 -0.958 . . . . 0.0 108.896 175.503 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 65.9 m-85 -74.3 134.7 42.57 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-O 121.126 0.489 . . . . 0.0 111.284 -176.653 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.614 HG13 HD11 ' A' ' 52' ' ' ILE . 8.1 t -131.56 113.93 15.55 Favored Pre-proline 0 N--CA 1.449 -0.524 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.794 -174.943 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 59.8 Cg_endo -74.71 -9.41 21.17 Favored 'Trans proline' 0 CA--C 1.531 0.359 0 C-N-CA 122.692 2.262 . . . . 0.0 113.681 -176.943 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' ASN . . . . . 0.533 ' HB2' ' HB3' ' A' ' 68' ' ' ARG . 12.5 m120 -124.64 9.78 8.37 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.008 0.432 . . . . 0.0 111.34 -175.163 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.538 ' HB2' ' HA3' ' A' ' 32' ' ' GLY . . . -71.43 150.63 44.76 Favored 'General case' 0 C--N 1.319 -0.755 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.878 -179.542 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 48.8 mt-10 -123.6 141.77 51.68 Favored 'General case' 0 N--CA 1.448 -0.567 0 CA-C-N 115.669 -0.696 . . . . 0.0 109.972 178.335 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 33.1 ttpt -55.19 129.52 38.54 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.8 -176.818 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 67.08 22.46 72.47 Favored Glycine 0 C--N 1.33 0.218 0 CA-C-N 115.947 -0.57 . . . . 0.0 112.902 174.327 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 18.4 m -113.78 158.89 20.38 Favored 'General case' 0 C--N 1.319 -0.731 0 O-C-N 122.609 -0.348 . . . . 0.0 110.179 179.651 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 51.1 t -118.39 99.87 8.86 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 N-CA-C 109.444 -0.576 . . . . 0.0 109.444 -178.69 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.614 HD11 HG13 ' A' ' 43' ' ' VAL . 0.5 OUTLIER -110.0 152.98 11.89 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.695 0 CA-C-N 116.044 -0.525 . . . . 0.0 109.861 -174.831 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . 0.511 HD21 ' HB ' ' A' ' 69' ' ' VAL . 12.4 t30 -92.56 120.5 33.08 Favored 'General case' 0 C--N 1.317 -0.826 0 N-CA-C 108.926 -0.768 . . . . 0.0 108.926 178.018 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . 0.538 ' HB ' ' HB2' ' A' ' 66' ' ' ALA . 34.9 m -114.67 139.83 38.74 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 N-CA-C 112.405 0.52 . . . . 0.0 112.405 -174.561 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . 0.447 ' HB2' ' HG2' ' A' ' 18' ' ' GLU . 3.2 ttmp? -98.54 109.21 22.0 Favored 'General case' 0 C--N 1.319 -0.758 0 N-CA-C 109.026 -0.731 . . . . 0.0 109.026 171.339 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.438 ' O ' ' HA ' ' A' ' 15' ' ' ALA . 90.7 t -69.39 113.16 4.82 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 178.554 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 17.5 p -101.97 -28.92 12.1 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 116.216 -0.447 . . . . 0.0 112.009 -175.096 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -140.58 94.09 2.69 Favored 'General case' 0 N--CA 1.452 -0.365 0 CA-C-O 121.121 0.486 . . . . 0.0 111.343 -173.536 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 39.5 t -81.34 133.08 30.05 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.833 0 CA-C-N 115.595 -0.73 . . . . 0.0 109.865 174.426 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 72.9 mmtt -112.82 -164.74 0.94 Allowed 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.397 -0.365 . . . . 0.0 110.368 178.555 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 8.9 mm-40 -67.56 -47.21 70.49 Favored 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 112.17 0.433 . . . . 0.0 112.17 -171.873 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 66.6 mttm -124.1 -2.45 8.15 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-O 120.625 0.25 . . . . 0.0 111.636 -176.574 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 9.9 p90 -153.73 174.73 14.14 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 116.26 -0.427 . . . . 0.0 109.871 -174.45 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -142.22 166.76 23.8 Favored 'General case' 0 C--N 1.322 -0.59 0 C-N-CA 120.876 -0.33 . . . . 0.0 111.465 -179.177 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 89.4 m-85 -117.14 131.86 56.79 Favored 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 175.033 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' ALA . . . . . 0.538 ' HB2' ' HB ' ' A' ' 54' ' ' VAL . . . -124.68 155.58 38.99 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-O 121.463 0.649 . . . . 0.0 112.433 -175.926 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' GLU . . . . . 0.413 ' O ' ' HA ' ' A' ' 54' ' ' VAL . 10.8 tt0 -104.71 120.28 40.98 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 114.946 -1.024 . . . . 0.0 110.324 178.557 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . 0.533 ' HB3' ' HB2' ' A' ' 45' ' ' ASN . 41.0 ttt180 -66.19 107.71 2.04 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 121.624 0.726 . . . . 0.0 111.18 174.573 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.566 ' O ' ' HB3' ' A' ' 70' ' ' LEU . 2.6 t -80.57 -177.52 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.759 0 N-CA-C 106.241 -1.762 . . . . 0.0 106.241 167.005 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.572 HD21 ' OXT' ' A' ' 70' ' ' LEU . 0.0 OUTLIER . . . . . 0 C--O 1.247 0.935 0 CA-C-O 118.257 -0.878 . . . . 0.0 110.85 179.614 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 85.5 mtp . . . . . 0 N--CA 1.482 1.14 0 CA-C-O 120.888 0.375 . . . . 0.0 110.393 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -90.18 162.09 15.42 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.318 -0.401 . . . . 0.0 109.974 178.811 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 77.4 t80 -155.64 -37.63 0.09 Allowed 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 121.017 0.437 . . . . 0.0 110.814 -177.411 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 124.5 -15.03 7.65 Favored Glycine 0 N--CA 1.449 -0.483 0 N-CA-C 110.669 -0.972 . . . . 0.0 110.669 -175.411 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.56 ' HB3' ' HD3' ' A' ' 6' ' ' PRO . 31.7 ttmt -71.09 -45.14 14.47 Favored Pre-proline 0 CA--C 1.537 0.472 0 CA-C-N 114.848 -0.676 . . . . 0.0 111.063 176.15 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.56 ' HD3' ' HB3' ' A' ' 5' ' ' LYS . 6.4 Cg_exo -78.21 171.32 17.22 Favored 'Trans proline' 0 C--N 1.353 0.786 0 C-N-CA 122.26 1.973 . . . . 0.0 111.199 171.297 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . 65.69 -177.09 0.18 Allowed 'General case' 0 N--CA 1.467 0.4 0 O-C-N 123.627 0.579 . . . . 0.0 110.572 -174.19 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' MET . . . . . 0.4 ' O ' ' HG3' ' A' ' 8' ' ' MET . 15.7 tpt 56.55 52.51 9.71 Favored 'General case' 0 N--CA 1.465 0.31 0 CA-C-O 121.439 0.638 . . . . 0.0 109.823 -178.175 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . 0.454 ' NZ ' ' HB3' ' A' ' 9' ' ' LYS . 3.0 mmmp? 64.67 8.39 4.43 Favored 'General case' 0 N--CA 1.471 0.615 0 CA-C-N 115.402 -0.817 . . . . 0.0 111.539 -177.876 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 15.7 t-20 61.39 13.02 4.68 Favored 'General case' 0 N--CA 1.468 0.469 0 CA-C-N 115.363 -0.835 . . . . 0.0 110.233 -176.523 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 96.8 t -160.87 111.84 1.3 Allowed Pre-proline 0 C--N 1.326 -0.427 0 CA-C-N 114.755 -1.111 . . . . 0.0 108.423 -173.388 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 42.0 Cg_endo -68.5 -10.22 28.38 Favored 'Trans proline' 0 C--O 1.232 0.204 0 C-N-CA 122.92 2.414 . . . . 0.0 113.584 -174.34 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.449 HG11 HD11 ' A' ' 36' ' ' ILE . 13.9 m -119.97 120.72 63.99 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.819 0 CA-C-O 121.106 0.479 . . . . 0.0 111.017 -176.808 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 15.6 mm-40 -92.15 122.09 34.31 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.035 -177.678 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -67.09 96.74 0.47 Allowed 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.711 -0.677 . . . . 0.0 110.705 179.261 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 142.76 -30.15 2.07 Favored Glycine 0 N--CA 1.443 -0.887 0 C-N-CA 120.977 -0.63 . . . . 0.0 112.278 -178.298 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 8.8 mtpm? -95.7 168.79 10.45 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 121.64 0.733 . . . . 0.0 111.562 -179.478 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . 0.501 ' HB2' ' OD1' ' A' ' 53' ' ' ASN . 0.0 OUTLIER -115.5 149.63 37.82 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 114.557 -1.201 . . . . 0.0 110.621 -179.176 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 80.0 m-85 -137.67 141.21 41.12 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.259 178.125 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 8.1 tt0 -79.05 107.55 11.89 Favored 'General case' 0 C--N 1.325 -0.458 0 N-CA-C 109.408 -0.59 . . . . 0.0 109.408 174.356 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 35.2 m -118.08 164.13 14.64 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 CA-C-O 120.969 0.414 . . . . 0.0 110.756 -176.186 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 6.1 m -112.0 140.12 46.94 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-O 121.207 0.527 . . . . 0.0 110.202 177.833 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.53 HG13 ' HB2' ' A' ' 46' ' ' ALA . 30.7 mm -104.39 59.59 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.804 0 N-CA-C 108.188 -1.041 . . . . 0.0 108.188 -177.487 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 36.8 tt0 -65.69 -7.89 17.84 Favored 'General case' 0 C--N 1.315 -0.902 0 CA-C-N 113.724 -1.58 . . . . 0.0 110.873 -179.089 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.539 ' HB3' ' HB ' ' A' ' 33' ' ' ILE . 28.5 t70 -138.7 138.51 37.81 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 120.849 0.357 . . . . 0.0 110.86 -176.869 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -120.85 114.01 20.97 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.952 -0.567 . . . . 0.0 109.863 178.024 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -112.51 173.09 15.06 Favored Glycine 0 N--CA 1.446 -0.649 0 C-N-CA 120.981 -0.628 . . . . 0.0 111.848 -178.439 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.461 ' HD2' ' CB ' ' A' ' 31' ' ' ASP . 77.5 mttt 57.2 14.57 2.11 Favored 'General case' 0 N--CA 1.462 0.153 0 N-CA-C 112.894 0.702 . . . . 0.0 112.894 175.685 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 83.08 -16.92 25.66 Favored Glycine 0 C--N 1.317 -0.504 0 C-N-CA 121.172 -0.537 . . . . 0.0 113.527 -179.768 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -170.31 31.75 0.15 Allowed Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.111 -1.042 . . . . 0.0 113.173 -178.406 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . 0.475 ' OD1' ' HA ' ' A' ' 44' ' ' PRO . 24.2 t70 -120.65 132.01 54.89 Favored 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 108.908 -0.775 . . . . 0.0 108.908 178.459 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -88.06 129.22 9.45 Favored Glycine 0 N--CA 1.449 -0.476 0 C-N-CA 120.627 -0.797 . . . . 0.0 112.381 -176.461 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.539 ' HB ' ' HB3' ' A' ' 25' ' ' ASP . 1.8 mp -100.16 101.74 12.5 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.46 0 CA-C-O 121.403 0.621 . . . . 0.0 110.423 178.864 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -95.47 151.71 19.06 Favored 'General case' 0 C--N 1.321 -0.66 0 N-CA-C 108.71 -0.848 . . . . 0.0 108.71 167.328 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 11.9 ttp-105 -139.95 104.28 4.83 Favored 'General case' 0 C--N 1.319 -0.726 0 C-N-CA 120.15 -0.62 . . . . 0.0 110.431 -178.883 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.449 HD11 HG11 ' A' ' 13' ' ' VAL . 29.8 mt -86.95 103.5 13.24 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-N 115.594 -0.73 . . . . 0.0 110.765 -175.938 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 13.7 t70 61.41 12.54 4.4 Favored 'General case' 0 N--CA 1.469 0.49 0 CA-C-N 114.372 -1.286 . . . . 0.0 111.737 179.323 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 120.12 -17.61 9.83 Favored Glycine 0 N--CA 1.448 -0.514 0 C-N-CA 120.472 -0.871 . . . . 0.0 112.007 -177.482 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 56.6 t80 -82.58 118.89 23.62 Favored 'General case' 0 C--N 1.326 -0.425 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 178.473 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 19.4 t -73.63 116.75 16.43 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-O 121.205 0.526 . . . . 0.0 111.057 -175.695 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 47.9 t -112.09 107.16 22.27 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 CA-C-N 115.586 -0.734 . . . . 0.0 109.322 178.038 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 94.3 m-85 -77.92 128.29 33.7 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.156 -178.28 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.423 ' CG1' ' HB1' ' A' ' 46' ' ' ALA . 3.3 t -115.82 98.38 50.9 Favored Pre-proline 0 C--N 1.317 -0.822 0 CA-C-N 115.883 -0.599 . . . . 0.0 109.905 -177.946 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . 0.475 ' HA ' ' OD1' ' A' ' 31' ' ' ASP . 48.6 Cg_exo -59.51 -17.73 42.92 Favored 'Trans proline' 0 N--CA 1.476 0.451 0 C-N-CA 124.07 3.18 . . . . 0.0 114.277 -173.486 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -131.62 8.36 4.55 Favored 'General case' 0 C--N 1.317 -0.817 0 N-CA-C 112.707 0.632 . . . . 0.0 112.707 -167.8 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.53 ' HB2' HG13 ' A' ' 23' ' ' ILE . . . -81.93 159.74 23.54 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-O 120.705 0.288 . . . . 0.0 110.892 175.272 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 46.0 mt-10 -108.16 159.48 16.57 Favored 'General case' 0 N--CA 1.448 -0.575 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.505 178.724 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -65.12 123.34 19.25 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.624 -175.211 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 74.49 22.71 76.97 Favored Glycine 0 C--N 1.331 0.29 0 CA-C-N 115.79 -0.641 . . . . 0.0 113.476 175.003 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 68.8 p -96.86 153.51 17.84 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-O 121.089 0.471 . . . . 0.0 111.101 -178.578 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 59.2 t -99.37 106.81 19.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 N-CA-C 108.195 -1.039 . . . . 0.0 108.195 172.562 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.551 HD13 ' HA ' ' A' ' 68' ' ' ARG . 0.8 OUTLIER -128.45 145.81 34.89 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.761 0 CA-C-O 121.772 0.796 . . . . 0.0 112.591 -166.647 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . 0.501 ' OD1' ' HB2' ' A' ' 18' ' ' GLU . 49.3 t30 -94.29 111.2 22.92 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 114.598 -1.183 . . . . 0.0 108.759 175.384 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . 0.56 ' HA ' ' O ' ' A' ' 67' ' ' GLU . 34.6 m -108.69 128.52 64.34 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 CA-C-O 121.169 0.509 . . . . 0.0 111.399 -175.957 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . 0.496 ' HA ' ' HA ' ' A' ' 18' ' ' GLU . 2.7 ttpm? -96.34 106.43 18.65 Favored 'General case' 0 C--N 1.319 -0.757 0 N-CA-C 109.173 -0.677 . . . . 0.0 109.173 175.027 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 55.6 t -70.11 112.82 5.26 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 N-CA-C 109.875 -0.417 . . . . 0.0 109.875 -178.812 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 19.1 p -113.88 -9.6 13.05 Favored 'General case' 0 C--N 1.324 -0.516 0 N-CA-C 111.994 0.368 . . . . 0.0 111.994 -176.518 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -142.04 92.03 2.4 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.129 0.49 . . . . 0.0 111.064 -176.954 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 29.4 t -90.9 131.94 36.76 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.818 0 CA-C-N 115.917 -0.583 . . . . 0.0 109.89 177.363 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 32.2 mmtp -113.56 -178.18 3.31 Favored 'General case' 0 C--N 1.326 -0.452 0 N-CA-C 109.316 -0.624 . . . . 0.0 109.316 177.427 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 35.3 mt-10 -70.98 -26.42 63.14 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 113.054 0.761 . . . . 0.0 113.054 -172.179 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . 0.622 ' HB2' ' CD2' ' A' ' 63' ' ' PHE . 68.9 mmtt -114.97 -28.31 7.06 Favored 'General case' 0 N--CA 1.468 0.444 0 CA-C-O 121.162 0.506 . . . . 0.0 111.313 -177.03 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' PHE . . . . . 0.622 ' CD2' ' HB2' ' A' ' 62' ' ' LYS . 10.7 p90 -153.15 170.44 20.52 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.737 -0.665 . . . . 0.0 109.664 -172.074 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -131.57 160.18 36.04 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-O 120.769 0.318 . . . . 0.0 111.235 -179.01 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 97.8 m-85 -117.45 134.66 54.59 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 115.661 -0.699 . . . . 0.0 109.635 176.152 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' ALA . . . . . 0.46 ' HB3' ' HB ' ' A' ' 54' ' ' VAL . . . -124.73 177.21 6.1 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.806 -178.917 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' GLU . . . . . 0.56 ' O ' ' HA ' ' A' ' 54' ' ' VAL . 11.6 pt-20 -127.05 141.13 51.85 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 121.015 0.436 . . . . 0.0 111.103 -179.129 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . 0.551 ' HA ' HD13 ' A' ' 52' ' ' ILE . 74.5 ttt-85 -71.07 98.21 1.61 Allowed 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.979 176.211 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.402 ' O ' HD22 ' A' ' 70' ' ' LEU . 3.1 t -82.34 64.82 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-N 116.469 -0.332 . . . . 0.0 110.275 177.4 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.503 HD13 ' NE ' ' A' ' 68' ' ' ARG . 73.7 mt . . . . . 0 C--O 1.248 0.982 0 CA-C-O 118.212 -0.899 . . . . 0.0 110.092 -178.245 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 22.9 mmt . . . . . 0 N--CA 1.482 1.171 0 CA-C-O 120.91 0.386 . . . . 0.0 110.96 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -97.18 4.25 51.2 Favored 'General case' 0 C--N 1.33 -0.27 0 N-CA-C 112.908 0.707 . . . . 0.0 112.908 -171.233 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 56.7 t80 -83.31 108.64 16.65 Favored 'General case' 0 C--N 1.326 -0.437 0 C-N-CA 120.091 -0.644 . . . . 0.0 110.246 -178.793 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 136.27 -42.73 1.3 Allowed Glycine 0 N--CA 1.444 -0.809 0 N-CA-C 110.009 -1.236 . . . . 0.0 110.009 -174.531 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.539 ' HG3' ' O ' ' A' ' 5' ' ' LYS . 1.8 pttp -166.13 90.96 0.84 Allowed Pre-proline 0 C--N 1.328 -0.355 0 CA-C-O 121.434 0.635 . . . . 0.0 109.928 173.96 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 5.6 Cg_exo -78.58 29.08 0.46 Allowed 'Trans proline' 0 N--CA 1.463 -0.316 0 C-N-CA 123.06 2.507 . . . . 0.0 111.705 178.468 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . 0.424 ' H ' ' C ' ' A' ' 5' ' ' LYS . . . -157.59 -153.37 0.4 Allowed 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.582 -0.735 . . . . 0.0 110.162 -175.395 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' MET . . . . . . . . . . . . . 18.7 ttt 81.48 21.13 0.35 Allowed 'General case' 0 N--CA 1.468 0.446 0 O-C-N 124.332 1.02 . . . . 0.0 110.762 179.251 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 56.8 mtpt 54.31 49.74 17.85 Favored 'General case' 0 N--CA 1.464 0.236 0 CA-C-N 115.113 -0.949 . . . . 0.0 112.146 171.256 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 3.8 p-10 -81.63 60.67 4.7 Favored 'General case' 0 C--O 1.235 0.334 0 CA-C-O 121.687 0.756 . . . . 0.0 111.355 -178.259 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.494 HG12 HG12 ' A' ' 59' ' ' VAL . 60.9 t -65.38 128.52 93.87 Favored Pre-proline 0 C--N 1.326 -0.43 0 CA-C-N 115.503 -0.772 . . . . 0.0 109.658 175.424 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 12.3 Cg_endo -56.9 -31.35 88.97 Favored 'Trans proline' 0 CA--C 1.529 0.271 0 C-N-CA 123.052 2.501 . . . . 0.0 113.264 -176.484 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 12.3 m -103.07 125.97 57.43 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.602 0 CA-C-O 121.062 0.458 . . . . 0.0 111.097 -178.275 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 47.3 mt-10 -95.3 113.59 25.29 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.511 178.896 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -58.25 121.45 10.8 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.95 -0.568 . . . . 0.0 111.469 -179.016 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 115.26 -31.39 6.24 Favored Glycine 0 N--CA 1.448 -0.534 0 CA-C-N 115.895 -0.593 . . . . 0.0 112.057 -179.328 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -89.04 150.47 22.76 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 121.096 0.474 . . . . 0.0 111.02 -178.126 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . 0.571 ' HA ' ' HA ' ' A' ' 55' ' ' LYS . 0.7 OUTLIER -107.72 142.17 38.13 Favored 'General case' 0 C--N 1.317 -0.823 0 CA-C-N 115.546 -0.752 . . . . 0.0 110.518 179.192 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 67.1 m-85 -128.37 145.51 51.05 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.695 -176.032 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 6.2 tp10 -80.03 105.1 11.05 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 108.534 -0.913 . . . . 0.0 108.534 172.725 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 32.2 m -118.14 170.58 7.37 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-O 121.246 0.546 . . . . 0.0 112.176 -172.614 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 20.7 m -114.56 155.71 25.99 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.214 -0.903 . . . . 0.0 109.539 176.328 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.53 HG13 ' HB2' ' A' ' 46' ' ' ALA . 36.5 mm -118.62 64.66 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-O 122.127 0.965 . . . . 0.0 108.641 -175.239 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 -72.65 -8.51 55.65 Favored 'General case' 0 C--N 1.314 -0.944 0 CA-C-N 113.84 -1.527 . . . . 0.0 112.189 179.759 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.408 ' HB2' ' HB ' ' A' ' 33' ' ' ILE . 5.5 m-20 -134.61 153.93 51.74 Favored 'General case' 0 N--CA 1.465 0.288 0 N-CA-C 109.976 -0.379 . . . . 0.0 109.976 176.401 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' MET . . . . . 0.569 ' SD ' ' HB2' ' A' ' 48' ' ' LYS . 59.1 mtp -138.06 155.33 48.9 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.744 0.307 . . . . 0.0 110.777 174.226 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -86.31 0.19 87.06 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.944 -0.646 . . . . 0.0 111.779 177.206 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 55.5 tttp 68.75 14.13 8.94 Favored 'General case' 0 N--CA 1.466 0.359 0 CA-C-O 121.783 0.802 . . . . 0.0 111.578 175.674 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -127.2 24.05 5.4 Favored Glycine 0 C--N 1.314 -0.642 0 CA-C-N 115.451 -0.795 . . . . 0.0 111.903 178.815 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 98.21 -35.84 4.34 Favored Glycine 0 N--CA 1.451 -0.351 0 N-CA-C 110.946 -0.862 . . . . 0.0 110.946 -175.722 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 7.6 t70 -70.13 137.57 51.2 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.405 -0.397 . . . . 0.0 110.68 175.926 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . 0.536 ' HA2' ' HA ' ' A' ' 26' ' ' MET . . . -118.06 156.6 15.57 Favored Glycine 0 N--CA 1.447 -0.613 0 N-CA-C 111.515 -0.634 . . . . 0.0 111.515 178.008 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.431 HG23 HG12 ' A' ' 40' ' ' VAL . 2.3 mp -111.5 110.21 31.37 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 CA-C-O 121.326 0.584 . . . . 0.0 110.859 -177.598 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -83.59 161.21 21.23 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.582 -0.735 . . . . 0.0 110.176 170.627 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -133.84 103.7 5.97 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.431 -179.232 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 65.5 mt -103.32 112.24 36.05 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.714 0 N-CA-C 110.006 -0.368 . . . . 0.0 110.006 177.338 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 28.9 t70 67.35 5.59 4.35 Favored 'General case' 0 N--CA 1.47 0.558 0 O-C-N 123.969 0.793 . . . . 0.0 110.899 -178.565 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 105.42 -6.26 41.9 Favored Glycine 0 C--N 1.333 0.37 0 C-N-CA 120.762 -0.732 . . . . 0.0 111.308 -173.913 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 46.6 t80 -81.57 135.56 35.57 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 109.067 -0.716 . . . . 0.0 109.067 178.09 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 0.431 HG12 HG23 ' A' ' 33' ' ' ILE . 43.4 t -81.98 120.79 34.18 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.196 -175.348 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 52.3 t -122.63 110.66 27.38 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.612 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.679 -179.397 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 73.9 m-85 -76.87 130.3 37.4 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.095 -178.174 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.472 ' HA ' ' HD3' ' A' ' 44' ' ' PRO . 11.7 t -123.41 110.55 30.42 Favored Pre-proline 0 C--N 1.323 -0.579 0 CA-C-N 115.644 -0.707 . . . . 0.0 109.886 -179.378 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . 0.472 ' HD3' ' HA ' ' A' ' 43' ' ' VAL . 32.0 Cg_exo -58.53 -30.94 93.28 Favored 'Trans proline' 0 CA--C 1.531 0.375 0 C-N-CA 123.805 3.004 . . . . 0.0 115.427 -168.154 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 34.1 m-80 -132.63 22.11 4.29 Favored 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 112.687 0.625 . . . . 0.0 112.687 -173.413 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.53 ' HB2' HG13 ' A' ' 23' ' ' ILE . . . -87.03 134.09 33.53 Favored 'General case' 0 C--N 1.318 -0.801 0 CA-C-O 120.721 0.296 . . . . 0.0 111.637 176.104 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 70.4 mm-40 -86.91 156.18 19.93 Favored 'General case' 0 C--O 1.235 0.314 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.806 178.081 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . 0.569 ' HB2' ' SD ' ' A' ' 26' ' ' MET . 49.7 tttm -65.44 123.68 20.26 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.864 0.364 . . . . 0.0 110.462 -179.411 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 90.93 0.05 75.39 Favored Glycine 0 N--CA 1.446 -0.67 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.784 178.097 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 69.3 m -78.82 138.52 38.21 Favored 'General case' 0 C--N 1.322 -0.601 0 C-N-CA 120.784 -0.367 . . . . 0.0 110.82 177.967 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 44.5 t -92.16 100.7 11.65 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 N-CA-C 107.859 -1.163 . . . . 0.0 107.859 173.149 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.598 HD12 ' HB2' ' A' ' 68' ' ' ARG . 2.9 tt -123.27 140.17 47.71 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.824 0 CA-C-O 121.969 0.89 . . . . 0.0 112.636 -168.455 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 48.4 t30 -86.93 114.88 23.93 Favored 'General case' 0 C--N 1.313 -0.999 0 CA-C-N 113.801 -1.545 . . . . 0.0 108.588 175.389 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . 0.457 ' O ' ' HA ' ' A' ' 18' ' ' GLU . 35.7 m -118.87 132.15 69.58 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.723 0 CA-C-O 120.763 0.316 . . . . 0.0 111.329 -176.287 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . 0.571 ' HA ' ' HA ' ' A' ' 18' ' ' GLU . 22.5 ttmm -96.78 106.92 19.3 Favored 'General case' 0 C--N 1.324 -0.519 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 177.071 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.469 ' HA ' ' HA ' ' A' ' 66' ' ' ALA . 48.5 t -70.83 107.12 2.0 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 N-CA-C 109.901 -0.407 . . . . 0.0 109.901 -177.985 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 8.9 p -103.22 -21.86 13.81 Favored 'General case' 0 C--N 1.323 -0.578 0 N-CA-C 112.13 0.419 . . . . 0.0 112.13 -174.293 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -135.41 92.15 2.81 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 121.225 0.536 . . . . 0.0 110.781 -175.882 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.494 HG12 HG12 ' A' ' 11' ' ' VAL . 45.3 t -88.49 117.16 31.53 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.735 0 CA-C-N 115.583 -0.735 . . . . 0.0 110.591 177.509 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . 0.52 ' HB2' ' O ' ' A' ' 63' ' ' PHE . 4.9 mptp? -97.59 -168.84 1.74 Allowed 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 109.61 -0.515 . . . . 0.0 109.61 174.894 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 34.6 mt-10 -70.54 -53.77 14.79 Favored 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 111.979 0.362 . . . . 0.0 111.979 -176.903 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -93.46 -29.35 15.6 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 120.976 0.417 . . . . 0.0 112.113 -174.293 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' PHE . . . . . 0.52 ' O ' ' HB2' ' A' ' 60' ' ' LYS . 16.2 p90 -151.75 164.65 36.53 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.735 -174.66 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -125.45 163.91 21.6 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-O 120.749 0.309 . . . . 0.0 110.958 -178.648 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 98.4 m-85 -116.06 130.17 56.68 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-N 115.783 -0.644 . . . . 0.0 109.286 176.214 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' ALA . . . . . 0.469 ' HA ' ' HA ' ' A' ' 56' ' ' VAL . . . -121.4 154.64 36.24 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-O 121.195 0.521 . . . . 0.0 111.778 -175.504 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 30.1 tt0 -101.87 116.41 32.64 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-N 115.243 -0.89 . . . . 0.0 111.531 -177.294 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . 0.598 ' HB2' HD12 ' A' ' 52' ' ' ILE . 15.5 ttt-85 -54.03 108.06 0.33 Allowed 'General case' 0 CA--C 1.536 0.405 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.678 172.159 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.418 ' O ' HG12 ' A' ' 69' ' ' VAL . 12.2 t -82.01 12.26 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.328 0 CA-C-O 122.211 1.005 . . . . 0.0 110.324 179.707 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.402 ' HG ' HG13 ' A' ' 52' ' ' ILE . 54.9 mt . . . . . 0 C--N 1.316 -0.877 0 CA-C-N 114.932 -1.031 . . . . 0.0 109.148 176.773 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 52.5 mtt . . . . . 0 N--CA 1.483 1.197 0 CA-C-O 121.133 0.492 . . . . 0.0 111.434 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -110.54 99.5 8.47 Favored 'General case' 0 C--N 1.321 -0.661 0 N-CA-C 109.253 -0.647 . . . . 0.0 109.253 174.851 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 71.1 m-85 -85.34 39.95 0.81 Allowed 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.894 -0.594 . . . . 0.0 111.093 -174.627 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 96.54 -48.63 1.67 Allowed Glycine 0 N--CA 1.449 -0.481 0 N-CA-C 110.96 -0.856 . . . . 0.0 110.96 -177.802 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 18.2 ptpt -115.2 124.66 29.88 Favored Pre-proline 0 C--N 1.321 -0.666 0 CA-C-N 115.089 -0.556 . . . . 0.0 110.004 177.6 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 25.8 Cg_exo -65.0 139.37 61.2 Favored 'Trans proline' 0 C--O 1.239 0.534 0 C-N-CA 122.394 2.063 . . . . 0.0 110.907 173.279 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . 61.97 -147.68 0.39 Allowed 'General case' 0 CA--C 1.533 0.3 0 O-C-N 123.685 0.616 . . . . 0.0 110.757 -176.639 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' MET . . . . . . . . . . . . . 25.7 mmt 62.81 43.46 7.06 Favored 'General case' 0 C--O 1.234 0.26 0 CA-C-O 121.234 0.54 . . . . 0.0 111.168 178.817 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 16.2 pttp -115.09 71.42 0.76 Allowed 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 121.447 0.641 . . . . 0.0 110.556 178.936 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 3.3 t30 72.98 110.32 0.07 Allowed 'General case' 0 C--O 1.232 0.158 0 CA-C-N 114.741 -1.118 . . . . 0.0 110.731 179.58 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.418 HG12 ' H ' ' A' ' 13' ' ' VAL . 39.0 t -57.88 126.16 75.78 Favored Pre-proline 0 C--N 1.326 -0.432 0 CA-C-N 115.493 -0.776 . . . . 0.0 110.29 178.213 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -69.86 -9.82 26.99 Favored 'Trans proline' 0 C--N 1.345 0.374 0 C-N-CA 123.072 2.515 . . . . 0.0 113.143 -175.406 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.418 ' H ' HG12 ' A' ' 11' ' ' VAL . 24.0 m -130.51 134.78 61.73 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.584 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.09 -178.577 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . 0.604 ' HB2' ' HG3' ' A' ' 17' ' ' LYS . 2.9 mp0 -110.24 136.33 49.62 Favored 'General case' 0 C--N 1.318 -0.798 0 CA-C-O 120.827 0.346 . . . . 0.0 110.671 179.191 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . 0.447 ' HA ' ' O ' ' A' ' 56' ' ' VAL . . . -64.12 117.77 7.58 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 115.795 -0.638 . . . . 0.0 110.551 176.578 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 112.23 -7.49 26.9 Favored Glycine 0 N--CA 1.446 -0.652 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.633 179.753 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . 0.604 ' HG3' ' HB2' ' A' ' 14' ' ' GLU . 12.8 mmmm -93.08 155.69 17.34 Favored 'General case' 0 C--N 1.326 -0.448 0 O-C-N 122.604 -0.35 . . . . 0.0 110.448 -179.867 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . 0.484 ' HA ' ' O ' ' A' ' 54' ' ' VAL . 0.7 OUTLIER -113.85 118.49 34.37 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 109.065 -0.717 . . . . 0.0 109.065 172.71 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 64.7 m-85 -112.37 140.77 46.82 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-O 121.142 0.496 . . . . 0.0 111.614 -177.334 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 36.2 tt0 -84.42 99.21 10.52 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.09 -0.959 . . . . 0.0 109.193 176.727 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 35.8 m -114.58 171.25 4.45 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.57 0 CA-C-O 121.21 0.529 . . . . 0.0 112.168 -170.986 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 23.4 m -115.36 153.37 31.13 Favored 'General case' 0 N--CA 1.45 -0.445 0 CA-C-N 115.244 -0.889 . . . . 0.0 109.749 175.917 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.557 HG13 ' HB3' ' A' ' 46' ' ' ALA . 37.5 mm -119.1 65.33 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-O 122.056 0.931 . . . . 0.0 108.927 -173.984 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -64.46 -17.43 63.83 Favored 'General case' 0 C--N 1.318 -0.796 0 CA-C-N 113.977 -1.465 . . . . 0.0 111.816 177.737 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.533 ' HB3' ' HB ' ' A' ' 33' ' ' ILE . 27.0 t0 -136.02 151.46 49.9 Favored 'General case' 0 C--N 1.324 -0.517 0 C-N-CA 121.064 -0.254 . . . . 0.0 110.824 -176.539 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' MET . . . . . 0.653 ' SD ' ' HB2' ' A' ' 48' ' ' LYS . 70.1 mtp -137.33 152.75 50.07 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.724 0.297 . . . . 0.0 110.22 175.521 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -86.75 -1.33 85.35 Favored Glycine 0 N--CA 1.448 -0.507 0 C-N-CA 120.969 -0.634 . . . . 0.0 111.56 177.726 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 97.7 mttt 58.64 23.51 11.06 Favored 'General case' 0 CA--C 1.523 -0.073 0 CA-C-O 121.712 0.768 . . . . 0.0 111.938 178.89 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -138.65 35.28 2.02 Favored Glycine 0 N--CA 1.445 -0.736 0 CA-C-N 114.884 -1.053 . . . . 0.0 111.026 175.894 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 98.02 -41.52 2.26 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 121.06 -0.59 . . . . 0.0 111.975 -178.252 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . 0.535 ' HA ' ' HA ' ' A' ' 44' ' ' PRO . 27.6 m-20 -73.53 127.68 33.41 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 121.021 0.439 . . . . 0.0 111.331 -179.216 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -106.62 143.24 15.76 Favored Glycine 0 N--CA 1.444 -0.778 0 N-CA-C 110.2 -1.16 . . . . 0.0 110.2 171.614 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.533 ' HB ' ' HB3' ' A' ' 25' ' ' ASP . 2.1 mp -103.49 105.36 18.19 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.752 0 CA-C-O 121.354 0.597 . . . . 0.0 111.123 -173.761 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -86.99 155.77 20.04 Favored 'General case' 0 N--CA 1.444 -0.733 0 N-CA-C 108.134 -1.061 . . . . 0.0 108.134 166.572 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 37.0 ttt180 -141.93 118.36 10.88 Favored 'General case' 0 C--N 1.314 -0.956 0 C-N-CA 120.031 -0.668 . . . . 0.0 110.376 179.278 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 27.0 mt -109.27 108.7 26.0 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.664 0 CA-C-N 115.458 -0.792 . . . . 0.0 110.397 -179.37 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 31.7 t70 65.29 19.55 11.7 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.121 -0.945 . . . . 0.0 110.932 179.006 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 99.81 -9.39 60.16 Favored Glycine 0 N--CA 1.449 -0.445 0 C-N-CA 120.207 -0.997 . . . . 0.0 111.788 -177.43 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 54.1 t80 -82.75 118.84 23.66 Favored 'General case' 0 C--N 1.322 -0.62 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 177.672 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 17.0 t -75.08 122.93 29.74 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-O 120.993 0.425 . . . . 0.0 111.193 -174.961 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 45.3 t -115.86 109.29 27.69 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-N 116.202 -0.454 . . . . 0.0 109.863 179.646 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 85.6 m-85 -80.35 119.22 22.78 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 121.039 0.447 . . . . 0.0 110.752 -178.327 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.426 ' HA ' ' HD3' ' A' ' 44' ' ' PRO . 3.2 t -115.13 101.41 54.47 Favored Pre-proline 0 C--N 1.32 -0.706 0 CA-C-N 115.677 -0.692 . . . . 0.0 109.379 178.567 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . 0.535 ' HA ' ' HA ' ' A' ' 31' ' ' ASP . 16.9 Cg_exo -68.12 5.27 1.19 Allowed 'Trans proline' 0 CA--C 1.531 0.374 0 C-N-CA 123.383 2.722 . . . . 0.0 114.818 -168.721 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 47.5 m-80 -143.43 14.61 1.81 Allowed 'General case' 0 N--CA 1.464 0.225 0 CA-C-O 120.632 0.253 . . . . 0.0 111.609 179.553 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.557 ' HB3' HG13 ' A' ' 23' ' ' ILE . . . -86.43 134.1 33.72 Favored 'General case' 0 C--N 1.32 -0.713 0 N-CA-C 112.018 0.377 . . . . 0.0 112.018 -178.86 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 44.2 mt-10 -92.83 146.18 23.83 Favored 'General case' 0 N--CA 1.454 -0.266 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.976 177.281 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . 0.653 ' HB2' ' SD ' ' A' ' 26' ' ' MET . 46.8 tttp -65.43 129.93 41.51 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.051 -0.522 . . . . 0.0 111.136 -177.916 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 88.17 -5.42 84.83 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.827 -0.702 . . . . 0.0 113.397 176.005 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 51.1 m -95.14 147.78 23.08 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.872 0.336 . . . . 0.0 110.796 -179.329 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 46.0 t -91.91 109.59 21.54 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 N-CA-C 109.23 -0.656 . . . . 0.0 109.23 178.14 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.845 HG13 HD22 ' A' ' 70' ' ' LEU . 2.5 tt -119.57 143.41 31.13 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.819 0 CA-C-O 121.853 0.835 . . . . 0.0 112.403 -170.568 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . 0.471 ' OD1' ' HB3' ' A' ' 18' ' ' GLU . 23.5 t-20 -89.56 114.19 25.72 Favored 'General case' 0 C--N 1.316 -0.869 0 CA-C-N 114.051 -1.432 . . . . 0.0 108.543 175.406 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . 0.484 ' O ' ' HA ' ' A' ' 18' ' ' GLU . 32.6 m -114.67 128.26 71.84 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 CA-C-O 121.264 0.554 . . . . 0.0 111.856 -175.601 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . 0.577 ' HA ' ' O ' ' A' ' 17' ' ' LYS . 38.2 ttmt -95.13 104.44 16.32 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 115.912 -0.585 . . . . 0.0 109.496 173.976 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.447 ' O ' ' HA ' ' A' ' 15' ' ' ALA . 66.0 t -66.09 110.48 1.35 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 N-CA-C 109.681 -0.489 . . . . 0.0 109.681 179.575 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 11.5 p -105.83 -28.86 10.39 Favored 'General case' 0 C--N 1.324 -0.54 0 N-CA-C 112.247 0.462 . . . . 0.0 112.247 -174.449 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -136.99 92.42 2.73 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 121.12 0.486 . . . . 0.0 110.978 -175.47 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 22.4 t -81.62 125.1 39.58 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.667 0 CA-C-N 115.623 -0.717 . . . . 0.0 110.017 176.225 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 32.2 mmtp -109.47 -150.21 0.45 Allowed 'General case' 0 C--N 1.325 -0.458 0 N-CA-C 109.951 -0.389 . . . . 0.0 109.951 178.484 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 20.2 mm-40 -70.78 -76.89 0.09 Allowed 'General case' 0 C--N 1.331 -0.239 0 N-CA-C 112.18 0.437 . . . . 0.0 112.18 -176.105 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 63.7 mttm -98.22 -2.57 39.39 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 121.182 0.515 . . . . 0.0 110.821 -175.652 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 35.7 p90 -151.37 164.97 35.5 Favored 'General case' 0 C--N 1.318 -0.761 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.725 -173.138 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -137.91 171.02 15.04 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.603 178.182 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 96.8 m-85 -118.92 133.81 55.59 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 109.493 -0.558 . . . . 0.0 109.493 176.702 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' ALA . . . . . 0.443 ' HB1' ' HB ' ' A' ' 54' ' ' VAL . . . -133.95 145.11 49.24 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.464 -179.001 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' GLU . . . . . 0.47 ' HG2' ' HB3' ' A' ' 55' ' ' LYS . 9.6 pt-20 -93.67 142.22 27.6 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-O 121.179 0.514 . . . . 0.0 111.408 -177.83 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . 0.517 ' HB2' HD12 ' A' ' 52' ' ' ILE . 17.8 ttt180 -71.17 109.96 5.54 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.341 -0.845 . . . . 0.0 110.043 173.721 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.511 ' O ' HG13 ' A' ' 69' ' ' VAL . 40.7 t -81.66 12.75 0.58 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.518 0 CA-C-O 122.076 0.941 . . . . 0.0 111.505 -176.415 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.845 HD22 HG13 ' A' ' 52' ' ' ILE . 1.0 OUTLIER . . . . . 0 C--N 1.314 -0.952 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.397 -179.333 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 25.9 ttt . . . . . 0 N--CA 1.479 1.01 0 CA-C-O 120.924 0.393 . . . . 0.0 110.479 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -85.85 137.97 32.38 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.397 178.998 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 79.9 m-85 -83.98 121.67 27.7 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.756 -172.853 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 97.38 -15.92 61.45 Favored Glycine 0 N--CA 1.448 -0.524 0 C-N-CA 120.875 -0.679 . . . . 0.0 111.785 -179.657 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 22.6 tptm 61.51 95.34 0.05 OUTLIER Pre-proline 0 C--O 1.234 0.241 0 C-N-CA 123.071 0.548 . . . . 0.0 110.97 -178.277 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.524 ' HG2' ' HG3' ' A' ' 8' ' ' MET . 92.3 Cg_endo -79.88 -162.84 0.2 Allowed 'Trans proline' 0 N--CA 1.46 -0.48 0 C-N-CA 122.671 2.247 . . . . 0.0 111.549 177.753 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -80.45 -65.17 1.04 Allowed 'General case' 0 C--N 1.322 -0.626 0 CA-C-O 120.562 0.22 . . . . 0.0 110.473 -179.756 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' MET . . . . . 0.524 ' HG3' ' HG2' ' A' ' 6' ' ' PRO . 84.0 mtp 58.92 24.6 12.73 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.632 -179.368 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 26.5 mtpp 63.9 -90.8 0.03 OUTLIER 'General case' 0 CA--C 1.516 -0.341 0 CA-C-N 115.389 -0.823 . . . . 0.0 110.188 -171.998 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 7.1 t30 62.39 11.01 4.28 Favored 'General case' 0 C--N 1.316 -0.859 0 CA-C-N 115.016 -0.993 . . . . 0.0 111.066 176.649 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 54.9 t -159.69 123.91 2.1 Favored Pre-proline 0 C--N 1.32 -0.677 0 CA-C-N 115.034 -0.985 . . . . 0.0 109.185 -171.107 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 94.8 Cg_endo -78.65 -21.37 9.98 Favored 'Trans proline' 0 C--N 1.343 0.246 0 C-N-CA 123.272 2.648 . . . . 0.0 113.18 -177.677 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.532 ' HB ' HG23 ' A' ' 56' ' ' VAL . 17.0 m -97.34 124.36 50.2 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.724 0 CA-C-N 115.857 -0.611 . . . . 0.0 110.779 -175.714 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . 0.462 ' OE2' ' HE2' ' A' ' 17' ' ' LYS . 31.7 tt0 -104.04 129.04 51.65 Favored 'General case' 0 C--N 1.322 -0.613 0 C-N-CA 120.85 -0.34 . . . . 0.0 110.105 -179.734 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -54.42 118.49 4.18 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.79 -0.641 . . . . 0.0 111.155 -178.477 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.31 -25.75 10.98 Favored Glycine 0 N--CA 1.444 -0.826 0 C-N-CA 120.671 -0.776 . . . . 0.0 112.448 179.941 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . 0.462 ' HE2' ' OE2' ' A' ' 14' ' ' GLU . 68.6 mttm -85.55 160.48 19.64 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 120.938 0.399 . . . . 0.0 110.457 179.034 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . 0.501 ' HA ' ' HA ' ' A' ' 55' ' ' LYS . 0.0 OUTLIER -126.87 133.32 50.74 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.449 179.052 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' TYR . . . . . 0.409 ' CE2' ' HA ' ' A' ' 13' ' ' VAL . 64.4 m-85 -123.14 162.6 22.19 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.331 -176.589 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 45.4 tt0 -96.58 122.39 39.44 Favored 'General case' 0 C--N 1.321 -0.665 0 N-CA-C 109.398 -0.593 . . . . 0.0 109.398 176.323 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.509 ' HB ' ' HB2' ' A' ' 34' ' ' ALA . 28.0 m -128.84 168.88 21.21 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-O 121.131 0.491 . . . . 0.0 111.587 -174.62 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 26.2 m -118.88 143.22 47.11 Favored 'General case' 0 N--CA 1.446 -0.65 0 CA-C-N 115.755 -0.657 . . . . 0.0 109.359 175.313 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.527 HG13 ' HB2' ' A' ' 46' ' ' ALA . 19.9 mm -111.77 59.53 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.664 0 CA-C-O 121.997 0.903 . . . . 0.0 108.755 -173.284 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -78.17 9.69 3.57 Favored 'General case' 0 C--N 1.315 -0.921 0 CA-C-N 114.573 -1.194 . . . . 0.0 112.229 -177.555 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.444 ' HB3' ' HB ' ' A' ' 33' ' ' ILE . 29.1 t0 -150.11 148.31 28.82 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.444 -0.344 . . . . 0.0 110.119 176.91 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' MET . . . . . 0.622 ' HA ' ' HA2' ' A' ' 32' ' ' GLY . 39.4 mtp -123.99 151.93 43.13 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.999 0.428 . . . . 0.0 111.157 178.649 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -87.49 -63.25 1.43 Allowed Glycine 0 N--CA 1.445 -0.758 0 CA-C-N 115.554 -0.748 . . . . 0.0 112.709 -177.421 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.436 ' HG3' ' OD2' ' A' ' 31' ' ' ASP . 16.7 pttp -163.71 79.88 0.43 Allowed 'General case' 0 N--CA 1.443 -0.782 0 CA-C-O 121.842 0.83 . . . . 0.0 112.876 -175.828 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 64.6 40.53 97.63 Favored Glycine 0 C--N 1.307 -1.054 0 CA-C-N 114.626 -1.17 . . . . 0.0 114.591 169.021 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 158.94 -47.91 0.42 Allowed Glycine 0 CA--C 1.505 -0.541 0 C-N-CA 120.268 -0.968 . . . . 0.0 111.76 173.88 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . 0.436 ' OD2' ' HG3' ' A' ' 28' ' ' LYS . 1.7 p30 -80.91 146.77 30.64 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-O 120.882 0.372 . . . . 0.0 110.013 177.13 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . 0.622 ' HA2' ' HA ' ' A' ' 26' ' ' MET . . . -128.57 172.78 19.33 Favored Glycine 0 N--CA 1.442 -0.95 0 C-N-CA 120.824 -0.703 . . . . 0.0 112.46 -177.384 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.444 ' HB ' ' HB3' ' A' ' 25' ' ' ASP . 2.2 mp -114.03 121.93 67.14 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.71 0 CA-C-O 120.947 0.403 . . . . 0.0 110.34 -179.949 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . 0.509 ' HB2' ' HB ' ' A' ' 21' ' ' VAL . . . -116.92 117.18 28.98 Favored 'General case' 0 C--N 1.317 -0.805 0 N-CA-C 108.804 -0.813 . . . . 0.0 108.804 172.663 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 28.2 ttp180 -104.25 110.67 22.97 Favored 'General case' 0 C--N 1.318 -0.795 0 CA-C-O 121.143 0.497 . . . . 0.0 111.224 -172.735 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 43.7 mt -99.75 110.11 26.19 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-N 115.443 -0.799 . . . . 0.0 110.385 178.992 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 56.6 27.71 12.87 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.217 -0.902 . . . . 0.0 112.081 -179.837 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 100.17 -14.61 59.71 Favored Glycine 0 C--N 1.33 0.207 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.014 -179.627 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 65.9 t80 -85.04 135.44 34.01 Favored 'General case' 0 C--N 1.321 -0.65 0 N-CA-C 109.554 -0.536 . . . . 0.0 109.554 -178.585 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 34.0 t -88.2 117.06 31.17 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-O 121.162 0.506 . . . . 0.0 111.239 -175.424 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 40.8 t -112.51 118.78 58.7 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.686 0 CA-C-N 115.695 -0.684 . . . . 0.0 109.273 174.952 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 76.3 m-85 -87.07 132.04 33.94 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-O 121.194 0.521 . . . . 0.0 111.47 -177.474 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.493 HG13 HD13 ' A' ' 52' ' ' ILE . 15.5 m -111.54 124.2 33.09 Favored Pre-proline 0 C--N 1.324 -0.513 0 CA-C-N 115.461 -0.79 . . . . 0.0 110.336 178.377 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . 0.484 ' HD3' ' HA ' ' A' ' 43' ' ' VAL . 13.5 Cg_exo -71.42 -34.54 9.47 Favored 'Trans proline' 0 CA--C 1.527 0.175 0 C-N-CA 123.05 2.5 . . . . 0.0 113.667 -175.495 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 4.5 p30 -136.12 34.36 2.82 Favored 'General case' 0 C--N 1.325 -0.46 0 N-CA-C 112.887 0.699 . . . . 0.0 112.887 -167.092 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.527 ' HB2' HG13 ' A' ' 23' ' ' ILE . . . -90.41 161.33 15.62 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 120.991 0.424 . . . . 0.0 112.125 175.562 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . 0.518 ' CD ' HH12 ' A' ' 68' ' ' ARG . 2.1 mp0 -102.61 147.16 27.14 Favored 'General case' 0 C--O 1.235 0.302 0 CA-C-N 115.871 -0.604 . . . . 0.0 109.741 170.867 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . 0.507 ' HE3' ' SD ' ' A' ' 26' ' ' MET . 9.3 ptpp? -66.54 139.98 57.95 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.15 0.5 . . . . 0.0 111.061 -179.859 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 73.33 13.94 79.53 Favored Glycine 0 N--CA 1.45 -0.375 0 CA-C-N 115.861 -0.609 . . . . 0.0 112.764 177.513 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 8.5 t -107.46 151.2 25.87 Favored 'General case' 0 C--N 1.323 -0.57 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 178.647 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 57.9 t -104.1 104.92 17.52 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 N-CA-C 109.554 -0.535 . . . . 0.0 109.554 179.266 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.532 HD12 ' HB2' ' A' ' 68' ' ' ARG . 0.9 OUTLIER -113.97 154.94 15.27 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.512 -174.556 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . 0.41 HD21 ' HB ' ' A' ' 69' ' ' VAL . 9.2 t30 -95.29 119.95 34.68 Favored 'General case' 0 C--N 1.321 -0.665 0 N-CA-C 109.001 -0.741 . . . . 0.0 109.001 174.508 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . 0.43 ' HB ' ' CB ' ' A' ' 66' ' ' ALA . 27.8 m -112.08 131.92 62.18 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.664 0 CA-C-O 121.08 0.467 . . . . 0.0 111.738 -175.43 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . 0.501 ' HA ' ' HA ' ' A' ' 18' ' ' GLU . 6.3 ttpm? -100.06 109.54 21.85 Favored 'General case' 0 C--N 1.318 -0.786 0 N-CA-C 108.74 -0.837 . . . . 0.0 108.74 173.321 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.532 HG23 ' HB ' ' A' ' 13' ' ' VAL . 39.1 t -72.28 114.02 10.45 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.551 -176.321 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 7.9 p -108.15 -18.14 13.85 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 116.196 -0.456 . . . . 0.0 112.004 -177.523 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -134.57 91.1 2.74 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 121.217 0.532 . . . . 0.0 110.591 -177.85 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 19.0 t -90.25 134.61 28.67 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.781 0 CA-C-N 115.298 -0.865 . . . . 0.0 110.801 179.156 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . 0.509 ' HB2' ' O ' ' A' ' 63' ' ' PHE . 75.4 mmtt -119.03 172.52 7.49 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 121.172 0.51 . . . . 0.0 110.563 174.351 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 42.2 tt0 -69.75 -29.34 66.68 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.072 -0.967 . . . . 0.0 109.428 173.691 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . 0.465 ' O ' ' CG ' ' A' ' 63' ' ' PHE . 38.6 mtmt -129.11 87.26 2.54 Favored 'General case' 0 N--CA 1.416 -2.154 0 N-CA-C 105.314 -2.106 . . . . 0.0 105.314 177.587 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' PHE . . . . . 0.509 ' O ' ' HB2' ' A' ' 60' ' ' LYS . 20.5 p90 78.89 142.25 0.08 Allowed 'General case' 0 N--CA 1.488 1.462 0 CA-C-N 112.903 -1.953 . . . . 0.0 112.17 164.658 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -117.1 169.58 9.32 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.452 -0.795 . . . . 0.0 111.894 -170.322 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 79.5 m-85 -120.26 133.55 55.45 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 115.359 -0.837 . . . . 0.0 109.396 177.949 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' ALA . . . . . 0.496 ' HB1' HG22 ' A' ' 56' ' ' VAL . . . -134.81 148.04 50.09 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 120.922 0.391 . . . . 0.0 111.23 -177.271 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 11.1 pt-20 -94.27 132.63 38.65 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.914 -178.826 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . 0.883 ' HE ' HD12 ' A' ' 70' ' ' LEU . 31.0 ttt180 -67.02 106.39 1.93 Allowed 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.449 -0.796 . . . . 0.0 110.728 175.717 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.41 ' HB ' HD21 ' A' ' 53' ' ' ASN . 18.9 t -80.53 66.45 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.535 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.015 179.55 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.883 HD12 ' HE ' ' A' ' 68' ' ' ARG . 70.8 mt . . . . . 0 C--O 1.246 0.896 0 CA-C-N 115.687 -0.688 . . . . 0.0 109.466 178.266 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 15.5 tpt . . . . . 0 N--CA 1.478 0.935 0 N-CA-C 110.378 -0.23 . . . . 0.0 110.378 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -153.32 98.18 2.23 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.867 0.365 . . . . 0.0 111.063 -179.384 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 85.4 m-85 -106.92 120.81 43.05 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.715 178.225 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 95.77 -5.02 66.44 Favored Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 120.576 -0.821 . . . . 0.0 112.512 175.905 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 49.3 mtpt 57.92 74.66 0.61 Allowed Pre-proline 0 C--O 1.234 0.253 0 CA-C-O 121.194 0.521 . . . . 0.0 109.98 -173.724 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 98.3 Cg_endo -93.41 166.81 2.32 Favored 'Trans proline' 0 N--CA 1.454 -0.85 0 C-N-CA 122.988 2.459 . . . . 0.0 113.774 -171.94 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . 70.7 127.61 0.03 OUTLIER 'General case' 0 N--CA 1.464 0.264 0 CA-C-N 114.956 -1.02 . . . . 0.0 112.854 173.731 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' MET . . . . . 0.543 ' HE1' ' HB3' ' A' ' 10' ' ' ASN . 0.0 OUTLIER -90.47 19.41 5.29 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.826 -0.624 . . . . 0.0 109.982 175.412 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 1.4 mptm? 62.56 26.81 15.91 Favored 'General case' 0 N--CA 1.466 0.336 0 CA-C-N 114.747 -1.115 . . . . 0.0 112.026 177.867 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . 0.543 ' HB3' ' HE1' ' A' ' 8' ' ' MET . 0.2 OUTLIER -85.12 66.44 9.74 Favored 'General case' 0 C--N 1.324 -0.53 0 N-CA-C 108.586 -0.894 . . . . 0.0 108.586 175.411 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 25.2 t -64.61 121.44 73.04 Favored Pre-proline 0 C--N 1.322 -0.594 0 CA-C-N 115.082 -0.963 . . . . 0.0 110.027 178.848 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . 0.405 ' HG2' ' HB2' ' A' ' 39' ' ' PHE . 16.9 Cg_exo -62.6 -30.84 79.59 Favored 'Trans proline' 0 C--O 1.233 0.253 0 C-N-CA 123.109 2.54 . . . . 0.0 112.095 -177.659 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.773 HG12 HD11 ' A' ' 36' ' ' ILE . 31.0 m -107.49 149.84 10.55 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 CA-C-N 115.267 -0.878 . . . . 0.0 110.465 -176.715 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -124.35 136.71 54.3 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-O 120.862 0.363 . . . . 0.0 110.393 177.905 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -70.54 106.59 3.51 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.996 -178.217 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 120.68 -13.1 10.02 Favored Glycine 0 N--CA 1.446 -0.653 0 C-N-CA 120.924 -0.655 . . . . 0.0 112.329 -179.719 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . 0.451 ' HB3' ' HZ3' ' A' ' 17' ' ' LYS . 8.1 mtpm? -102.56 156.74 17.41 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.724 0.297 . . . . 0.0 110.907 -178.87 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . 0.543 ' HA ' ' O ' ' A' ' 54' ' ' VAL . 0.0 OUTLIER -112.16 142.01 45.14 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 121.166 0.508 . . . . 0.0 111.375 -179.074 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' TYR . . . . . 0.537 ' O ' ' HA ' ' A' ' 53' ' ' ASN . 81.4 m-85 -130.64 141.74 50.43 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 116.051 -0.522 . . . . 0.0 111.121 -176.085 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 37.7 mt-10 -79.79 98.85 7.21 Favored 'General case' 0 C--N 1.326 -0.456 0 N-CA-C 109.3 -0.63 . . . . 0.0 109.3 174.835 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.473 ' HB ' ' HB3' ' A' ' 34' ' ' ALA . 35.8 m -110.3 156.2 11.36 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.81 0 CA-C-N 115.787 -0.642 . . . . 0.0 111.526 -174.275 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 24.2 m -105.09 148.73 26.51 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 115.407 -0.815 . . . . 0.0 109.77 176.07 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.514 HG13 ' HB2' ' A' ' 46' ' ' ALA . 33.6 mm -114.45 65.91 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.783 0 N-CA-C 108.053 -1.091 . . . . 0.0 108.053 -174.662 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 -62.25 -24.89 67.52 Favored 'General case' 0 C--N 1.312 -1.025 0 CA-C-N 113.621 -1.627 . . . . 0.0 111.552 178.974 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.522 ' HB3' ' HB ' ' A' ' 33' ' ' ILE . 5.9 t70 -133.7 152.03 51.78 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.521 -0.309 . . . . 0.0 111.125 -170.166 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' MET . . . . . 0.503 ' SD ' ' HB2' ' A' ' 48' ' ' LYS . 18.0 mtp -129.84 161.7 30.18 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 121.018 0.437 . . . . 0.0 110.73 176.341 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -104.99 -117.38 4.34 Favored Glycine 0 N--CA 1.448 -0.52 0 CA-C-N 115.74 -0.664 . . . . 0.0 111.957 177.282 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 63.6 mmtt -76.47 19.75 0.25 Allowed 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 112.769 0.655 . . . . 0.0 112.769 -179.613 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 102.6 -42.51 1.88 Allowed Glycine 0 C--N 1.313 -0.739 0 C-N-CA 120.926 -0.654 . . . . 0.0 112.664 178.109 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -100.76 19.74 51.02 Favored Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 120.783 -0.722 . . . . 0.0 111.678 178.593 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 16.2 m-20 -124.64 114.21 19.05 Favored 'General case' 0 C--N 1.324 -0.52 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 179.011 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -96.53 122.35 7.34 Favored Glycine 0 N--CA 1.444 -0.815 0 N-CA-C 110.563 -1.015 . . . . 0.0 110.563 174.468 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.522 ' HB ' ' HB3' ' A' ' 25' ' ' ASP . 1.9 mp -95.84 100.67 11.32 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.698 0 CA-C-O 121.426 0.631 . . . . 0.0 110.462 -176.798 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . 0.473 ' HB3' ' HB ' ' A' ' 21' ' ' VAL . . . -99.4 162.04 13.27 Favored 'General case' 0 CA--C 1.495 -1.16 0 CA-C-N 115.265 -0.879 . . . . 0.0 108.947 168.563 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 29.0 ptt180 -156.65 119.64 4.12 Favored 'General case' 0 N--CA 1.43 -1.47 0 CA-C-O 121.423 0.63 . . . . 0.0 110.859 -177.379 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.773 HD11 HG12 ' A' ' 13' ' ' VAL . 43.9 mt -96.67 111.21 26.25 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.829 0 CA-C-N 115.186 -0.915 . . . . 0.0 110.349 -175.175 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 25.9 t0 57.97 29.18 17.3 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 114.685 -1.143 . . . . 0.0 110.836 -177.871 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 103.63 -22.69 34.98 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.957 -0.639 . . . . 0.0 112.347 179.401 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . 0.405 ' HB2' ' HG2' ' A' ' 12' ' ' PRO . 63.3 t80 -74.86 112.54 11.19 Favored 'General case' 0 C--N 1.324 -0.519 0 N-CA-C 109.959 -0.386 . . . . 0.0 109.959 -178.299 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 41.2 t -69.14 123.9 23.71 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 CA-C-O 121.42 0.628 . . . . 0.0 111.84 -174.791 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 25.5 t -121.8 109.23 24.0 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.691 0 CA-C-N 115.233 -0.894 . . . . 0.0 109.18 -179.884 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 87.9 m-85 -77.11 124.47 27.85 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.176 -176.39 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.431 ' CG1' ' HB1' ' A' ' 46' ' ' ALA . 2.7 t -122.01 98.96 44.37 Favored Pre-proline 0 C--N 1.325 -0.48 0 CA-C-N 115.753 -0.658 . . . . 0.0 110.534 -179.377 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -74.11 -0.16 9.2 Favored 'Trans proline' 0 CA--C 1.53 0.312 0 C-N-CA 122.704 2.269 . . . . 0.0 113.458 -175.752 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' ASN . . . . . 0.405 ' HB2' ' HB3' ' A' ' 68' ' ' ARG . 12.6 m120 -125.57 8.25 7.66 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 121.099 0.476 . . . . 0.0 110.91 -175.132 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.514 ' HB2' HG13 ' A' ' 23' ' ' ILE . . . -91.03 153.25 20.27 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 112.069 0.396 . . . . 0.0 112.069 -176.176 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 5.4 mm-40 -105.04 135.9 45.52 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.444 -0.798 . . . . 0.0 110.433 176.426 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . 0.503 ' HB2' ' SD ' ' A' ' 26' ' ' MET . 14.3 tmtt? -65.14 136.65 56.95 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.494 -179.895 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 70.64 23.44 77.73 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.993 -0.622 . . . . 0.0 112.522 179.069 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 23.3 t -122.36 145.89 47.83 Favored 'General case' 0 C--N 1.321 -0.654 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 179.518 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 52.8 t -90.44 101.62 12.51 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 N-CA-C 109.53 -0.545 . . . . 0.0 109.53 177.839 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.506 HD11 ' HB2' ' A' ' 68' ' ' ARG . 0.9 OUTLIER -119.29 140.96 41.48 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.749 0 CA-C-N 115.768 -0.651 . . . . 0.0 111.034 -175.29 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . 0.537 ' HA ' ' O ' ' A' ' 19' ' ' TYR . 7.1 p-10 -97.81 118.06 33.5 Favored 'General case' 0 C--N 1.313 -0.99 0 CA-C-N 115.128 -0.942 . . . . 0.0 109.016 176.288 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . 0.543 ' O ' ' HA ' ' A' ' 18' ' ' GLU . 35.3 m -111.67 140.96 28.66 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.765 0 CA-C-N 115.304 -0.862 . . . . 0.0 111.731 -173.481 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 25.6 ttmt -94.96 109.22 21.26 Favored 'General case' 0 C--N 1.319 -0.724 0 N-CA-C 109.212 -0.662 . . . . 0.0 109.212 177.389 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.433 HG21 ' HB ' ' A' ' 13' ' ' VAL . 60.5 t -70.56 113.26 6.37 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 N-CA-C 109.53 -0.544 . . . . 0.0 109.53 179.516 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.9 p -111.42 -14.97 13.66 Favored 'General case' 0 C--N 1.323 -0.587 0 N-CA-C 112.32 0.489 . . . . 0.0 112.32 -173.077 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . 0.415 ' HB2' ' HB2' ' A' ' 65' ' ' PHE . . . -145.82 93.38 2.33 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.947 0.403 . . . . 0.0 111.048 -176.214 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 21.9 t -87.6 122.93 39.93 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 CA-C-N 116.061 -0.518 . . . . 0.0 109.919 176.085 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 32.3 mmtp -109.15 -165.26 1.0 Allowed 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.668 -0.242 . . . . 0.0 110.375 179.832 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . 0.406 ' H ' ' CD ' ' A' ' 61' ' ' GLU . 4.1 mp0 -64.25 -54.05 39.44 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.752 -175.925 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 88.9 mttt -108.82 -19.78 13.29 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.838 -171.533 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 23.9 p90 -150.13 175.02 12.13 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.589 -175.111 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -137.29 167.45 21.56 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-O 120.808 0.337 . . . . 0.0 111.024 179.378 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . 0.415 ' HB2' ' HB2' ' A' ' 58' ' ' ALA . 90.8 m-85 -119.63 135.17 54.92 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.753 -0.658 . . . . 0.0 109.822 177.211 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' ALA . . . . . 0.462 ' HB2' ' HB ' ' A' ' 54' ' ' VAL . . . -132.38 154.99 49.24 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.321 -0.399 . . . . 0.0 111.043 -178.926 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 13.7 pt-20 -111.81 143.49 42.67 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 121.088 0.471 . . . . 0.0 111.11 -179.408 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . 0.506 ' HB2' HD11 ' A' ' 52' ' ' ILE . 27.3 ttt180 -66.69 114.18 5.4 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.469 -0.787 . . . . 0.0 111.135 174.255 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.48 ' HB ' ' ND2' ' A' ' 53' ' ' ASN . 3.7 t -83.14 5.85 1.9 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 121.7 0.762 . . . . 0.0 110.915 176.761 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 68.7 mt . . . . . 0 C--N 1.315 -0.935 0 CA-C-N 115.305 -0.861 . . . . 0.0 110.588 -177.602 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 2.2 mpt? . . . . . 0 N--CA 1.482 1.131 0 N-CA-C 109.843 -0.429 . . . . 0.0 109.843 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . 0.64 ' HA ' ' O ' ' A' ' 6' ' ' PRO . . . 62.99 27.16 15.82 Favored 'General case' 0 N--CA 1.464 0.269 0 O-C-N 123.785 0.678 . . . . 0.0 112.017 174.941 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 26.7 t80 -85.98 68.82 10.44 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-O 121.339 0.59 . . . . 0.0 110.576 -177.621 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 98.25 -70.63 0.64 Allowed Glycine 0 N--CA 1.449 -0.442 0 C-N-CA 120.978 -0.629 . . . . 0.0 113.423 174.305 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.627 ' HB3' ' HZ2' ' A' ' 5' ' ' LYS . 8.0 ttpm? -94.35 -50.7 0.26 Allowed Pre-proline 0 CA--C 1.538 0.497 0 N-CA-C 112.933 0.716 . . . . 0.0 112.933 -173.775 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.64 ' O ' ' HA ' ' A' ' 2' ' ' ALA . 8.5 Cg_exo -74.51 152.52 43.46 Favored 'Trans proline' 0 C--N 1.348 0.55 0 C-N-CA 122.038 1.826 . . . . 0.0 112.184 -179.48 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . 59.9 77.57 0.31 Allowed 'General case' 0 N--CA 1.463 0.198 0 O-C-N 123.832 0.707 . . . . 0.0 111.279 -179.387 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' MET . . . . . . . . . . . . . 34.9 tpp -97.43 26.82 4.62 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-O 121.584 0.707 . . . . 0.0 109.97 -179.621 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -77.26 102.14 6.56 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.558 -0.747 . . . . 0.0 110.987 -177.653 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 4.1 p-10 -82.42 36.56 0.48 Allowed 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.614 -0.721 . . . . 0.0 111.124 178.745 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.418 ' HA ' ' HD3' ' A' ' 12' ' ' PRO . 77.7 t -158.52 108.34 1.66 Allowed Pre-proline 0 C--N 1.332 -0.16 0 N-CA-C 109.398 -0.593 . . . . 0.0 109.398 -174.193 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . 0.418 ' HD3' ' HA ' ' A' ' 11' ' ' VAL . 6.0 Cg_exo -76.33 -39.13 0.87 Allowed 'Trans proline' 0 C--N 1.343 0.251 0 C-N-CA 123.253 2.635 . . . . 0.0 112.51 -178.458 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.562 HG13 HD11 ' A' ' 36' ' ' ILE . 6.0 m -73.51 130.9 35.61 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.718 0 CA-C-N 115.06 -0.973 . . . . 0.0 111.932 -173.525 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -102.45 119.09 38.22 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.754 -0.657 . . . . 0.0 109.372 177.858 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -68.17 108.69 3.24 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 120.975 0.417 . . . . 0.0 110.752 -178.565 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 127.54 -23.87 5.33 Favored Glycine 0 N--CA 1.443 -0.854 0 C-N-CA 120.814 -0.708 . . . . 0.0 112.409 -179.695 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . 0.42 ' HE3' ' HB3' ' A' ' 17' ' ' LYS . 24.0 mtpp -104.19 165.95 10.72 Favored 'General case' 0 C--O 1.235 0.336 0 CA-C-O 121.019 0.438 . . . . 0.0 111.28 179.613 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . 0.524 ' HA ' ' HA ' ' A' ' 55' ' ' LYS . 0.2 OUTLIER -117.8 151.06 38.09 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.719 -0.673 . . . . 0.0 111.067 -177.584 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 72.6 m-85 -139.01 145.68 39.94 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.694 -0.684 . . . . 0.0 109.504 179.245 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . 0.547 ' HA ' ' HA ' ' A' ' 53' ' ' ASN . 42.6 tt0 -85.32 108.18 17.68 Favored 'General case' 0 C--N 1.32 -0.692 0 N-CA-C 109.529 -0.545 . . . . 0.0 109.529 176.756 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 34.4 m -122.8 165.66 18.56 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.968 -172.61 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 9.0 m -102.31 148.01 25.99 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-O 120.965 0.412 . . . . 0.0 110.543 179.801 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.441 HG13 ' HB3' ' A' ' 46' ' ' ALA . 29.3 mm -112.97 61.59 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 N-CA-C 107.916 -1.142 . . . . 0.0 107.916 -177.471 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 13.1 tp10 -64.12 -17.07 63.09 Favored 'General case' 0 C--N 1.317 -0.843 0 CA-C-N 113.283 -1.78 . . . . 0.0 111.67 -177.29 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 33.3 t70 -145.41 152.21 39.47 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 116.483 -0.326 . . . . 0.0 110.196 -173.236 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' MET . . . . . 0.626 ' HA ' ' HA2' ' A' ' 32' ' ' GLY . 33.3 mtp -128.25 157.18 41.61 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 121.171 0.51 . . . . 0.0 110.974 177.866 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.501 ' HA3' ' OD2' ' A' ' 31' ' ' ASP . . . -83.53 -48.42 5.3 Favored Glycine 0 N--CA 1.445 -0.732 0 CA-C-N 115.66 -0.7 . . . . 0.0 112.724 -176.564 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 79.5 tttt -161.55 21.9 0.12 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 121.513 0.673 . . . . 0.0 111.413 -177.863 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 123.19 -47.58 1.01 Allowed Glycine 0 C--N 1.315 -0.602 0 C-N-CA 120.3 -0.952 . . . . 0.0 113.8 172.387 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -103.23 -35.66 3.58 Favored Glycine 0 C--O 1.228 -0.268 0 C-N-CA 120.524 -0.846 . . . . 0.0 111.919 -179.325 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . 0.501 ' OD2' ' HA3' ' A' ' 27' ' ' GLY . 12.1 p-10 -85.84 133.27 33.98 Favored 'General case' 0 C--N 1.318 -0.768 0 N-CA-C 109.611 -0.514 . . . . 0.0 109.611 177.435 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . 0.626 ' HA2' ' HA ' ' A' ' 26' ' ' MET . . . -117.78 158.79 14.46 Favored Glycine 0 N--CA 1.445 -0.709 0 C-N-CA 121.032 -0.604 . . . . 0.0 112.154 -179.154 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 2.2 mp -108.88 106.89 21.56 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.5 0 CA-C-O 121.175 0.512 . . . . 0.0 110.103 178.682 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . 0.439 ' HB3' ' HB ' ' A' ' 41' ' ' VAL . . . -90.84 152.92 20.57 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.6 -0.727 . . . . 0.0 109.842 172.278 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -122.14 113.46 19.53 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.556 -178.274 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.562 HD11 HG13 ' A' ' 13' ' ' VAL . 38.7 mt -110.39 105.81 19.53 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.758 0 CA-C-O 121.085 0.469 . . . . 0.0 109.985 175.2 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 26.9 t0 55.18 36.69 27.55 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 114.852 -1.067 . . . . 0.0 110.663 -178.528 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 94.27 -19.93 50.68 Favored Glycine 0 C--N 1.333 0.394 0 C-N-CA 120.976 -0.63 . . . . 0.0 112.787 -179.807 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 78.3 t80 -77.13 142.54 39.66 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 110.098 -0.334 . . . . 0.0 110.098 -175.258 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 11.1 t -88.25 114.64 27.12 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 CA-C-N 115.888 -0.596 . . . . 0.0 111.113 -175.7 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.439 ' HB ' ' HB3' ' A' ' 34' ' ' ALA . 54.6 t -109.8 108.14 24.64 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.649 0 CA-C-N 116.033 -0.531 . . . . 0.0 109.913 177.265 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 67.6 m-85 -76.84 119.03 20.04 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 121.351 0.596 . . . . 0.0 110.256 178.822 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.576 ' HB ' ' HB2' ' A' ' 46' ' ' ALA . 17.5 t -117.9 100.49 52.17 Favored Pre-proline 0 C--N 1.315 -0.93 0 CA-C-N 115.474 -0.784 . . . . 0.0 110.512 -175.769 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 33.7 Cg_exo -64.62 -9.32 20.22 Favored 'Trans proline' 0 N--CA 1.476 0.476 0 C-N-CA 123.799 2.999 . . . . 0.0 114.412 -175.563 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' ASN . . . . . 0.401 ' HB2' ' HB3' ' A' ' 68' ' ' ARG . 0.9 OUTLIER -128.35 17.77 6.49 Favored 'General case' 0 C--N 1.324 -0.511 0 C-N-CA 120.907 -0.317 . . . . 0.0 110.7 -175.192 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.576 ' HB2' ' HB ' ' A' ' 43' ' ' VAL . . . -67.75 154.32 41.77 Favored 'General case' 0 C--N 1.32 -0.696 0 N-CA-C 113.334 0.864 . . . . 0.0 113.334 -175.655 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 10.9 mm-40 -105.76 121.33 43.8 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 114.695 -1.139 . . . . 0.0 109.64 174.522 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . 0.621 ' HB2' ' SD ' ' A' ' 26' ' ' MET . 63.2 tttm -60.84 123.99 19.14 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 120.947 0.404 . . . . 0.0 110.918 -177.119 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 89.06 -33.62 4.2 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 121.006 -0.616 . . . . 0.0 112.853 178.122 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 17.7 m -71.08 155.62 40.58 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 120.906 0.384 . . . . 0.0 110.627 -179.05 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.507 HG11 ' HG2' ' A' ' 20' ' ' GLU . 21.8 t -102.82 87.95 1.25 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 177.498 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.551 HD13 HG11 ' A' ' 43' ' ' VAL . 0.1 OUTLIER -92.49 144.98 8.18 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-N 115.622 -0.717 . . . . 0.0 110.688 -171.002 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . 0.547 ' HA ' ' HA ' ' A' ' 20' ' ' GLU . 8.5 t30 -83.36 112.52 19.99 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-N 115.691 -0.686 . . . . 0.0 109.794 175.229 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . 0.454 ' O ' ' HA ' ' A' ' 18' ' ' GLU . 33.9 m -104.44 137.38 33.71 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.264 -176.72 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . 0.524 ' HA ' ' HA ' ' A' ' 18' ' ' GLU . 35.9 ttpt -103.49 110.93 23.15 Favored 'General case' 0 C--N 1.318 -0.8 0 N-CA-C 108.958 -0.756 . . . . 0.0 108.958 172.644 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 60.4 t -65.21 118.08 7.0 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 CA-C-N 116.45 -0.341 . . . . 0.0 110.157 -179.294 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 12.3 p -104.35 -24.53 13.08 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 116.248 -0.433 . . . . 0.0 112.001 -174.992 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -154.75 102.31 2.36 Favored 'General case' 0 N--CA 1.451 -0.422 0 CA-C-O 121.097 0.475 . . . . 0.0 111.007 -175.131 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 17.9 t -88.22 122.72 40.12 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.705 0 CA-C-N 115.676 -0.693 . . . . 0.0 110.2 174.755 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . 0.424 ' HD2' ' N ' ' A' ' 60' ' ' LYS . 0.6 OUTLIER -101.35 -171.23 1.95 Allowed 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 176.634 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 39.4 mm-40 -59.51 -48.81 80.19 Favored 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 112.667 0.618 . . . . 0.0 112.667 -174.466 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 64.4 mttm -116.03 -5.45 11.96 Favored 'General case' 0 C--N 1.328 -0.326 0 N-CA-C 112.346 0.499 . . . . 0.0 112.346 -171.811 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 16.1 p90 -162.63 156.11 20.28 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 120.682 0.277 . . . . 0.0 110.761 -176.059 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -121.39 159.0 27.07 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.698 -178.65 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 96.2 m-85 -116.39 137.15 52.39 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.269 -0.423 . . . . 0.0 109.926 176.374 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' ALA . . . . . 0.417 ' HB2' ' HB ' ' A' ' 54' ' ' VAL . . . -137.48 152.89 50.02 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 116.443 -0.344 . . . . 0.0 111.161 -177.962 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' GLU . . . . . 0.419 ' O ' ' HA ' ' A' ' 54' ' ' VAL . 9.6 pt-20 -102.84 144.07 31.63 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.932 -179.11 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . 0.503 ' HB2' HD12 ' A' ' 52' ' ' ILE . 9.2 ttp180 -70.95 109.29 4.98 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.341 172.793 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.497 ' HB ' HD21 ' A' ' 53' ' ' ASN . 3.8 t -81.95 28.34 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.468 0 CA-C-O 121.506 0.67 . . . . 0.0 110.856 -179.587 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.424 HD22 ' N ' ' A' ' 70' ' ' LEU . 1.3 pt? . . . . . 0 C--O 1.243 0.744 0 CA-C-N 116.136 -0.484 . . . . 0.0 109.748 178.75 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.482 1.128 0 N-CA-C 109.549 -0.537 . . . . 0.0 109.549 . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -82.3 118.22 22.98 Favored 'General case' 0 N--CA 1.45 -0.445 0 N-CA-C 109.209 -0.663 . . . . 0.0 109.209 172.614 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 57.1 m-85 -83.97 -25.67 29.86 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-O 120.907 0.384 . . . . 0.0 110.915 -174.112 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 96.91 -21.82 44.01 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.645 -0.788 . . . . 0.0 111.633 -178.446 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.549 ' HB2' ' HD3' ' A' ' 6' ' ' PRO . 53.5 mtmt -73.79 -50.69 5.52 Favored Pre-proline 0 C--N 1.326 -0.428 0 CA-C-N 115.485 -0.357 . . . . 0.0 111.957 177.826 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.549 ' HD3' ' HB2' ' A' ' 5' ' ' LYS . 25.5 Cg_exo -66.2 151.28 83.93 Favored 'Trans proline' 0 C--N 1.354 0.854 0 C-N-CA 122.185 1.924 . . . . 0.0 112.064 -179.475 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . 0.405 ' C ' ' H ' ' A' ' 9' ' ' LYS . . . 72.19 -30.59 0.21 Allowed 'General case' 0 N--CA 1.469 0.501 0 C-N-CA 123.87 0.868 . . . . 0.0 112.21 -178.771 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' MET . . . . . 0.443 ' H ' ' C ' ' A' ' 6' ' ' PRO . 14.0 tpt -83.35 21.64 1.13 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 121.925 0.869 . . . . 0.0 110.178 179.443 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . 0.632 ' HA ' ' HE3' ' A' ' 9' ' ' LYS . 0.9 OUTLIER -134.67 24.04 3.68 Favored 'General case' 0 C--N 1.319 -0.719 0 N-CA-C 108.64 -0.874 . . . . 0.0 108.64 176.94 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 18.3 m120 -139.45 104.23 4.91 Favored 'General case' 0 N--CA 1.444 -0.73 0 CA-C-N 114.975 -1.011 . . . . 0.0 109.25 -174.243 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.416 HG11 ' O ' ' A' ' 13' ' ' VAL . 86.6 t -33.09 107.59 0.28 Allowed Pre-proline 0 N--CA 1.471 0.585 0 O-C-N 124.825 1.328 . . . . 0.0 111.42 175.195 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -75.47 -2.47 12.61 Favored 'Trans proline' 0 C--N 1.346 0.43 0 C-N-CA 122.972 2.448 . . . . 0.0 112.379 -176.954 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.416 ' O ' HG11 ' A' ' 11' ' ' VAL . 9.4 m -121.8 -175.61 1.04 Allowed 'Isoleucine or valine' 0 C--N 1.314 -0.94 0 CA-C-N 115.16 -0.927 . . . . 0.0 109.722 179.806 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . 0.537 ' HG3' ' HD2' ' A' ' 17' ' ' LYS . 74.5 mm-40 -116.82 -159.46 0.73 Allowed 'General case' 0 C--N 1.314 -0.94 0 N-CA-C 109.587 -0.523 . . . . 0.0 109.587 177.21 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . 0.444 ' HA ' ' O ' ' A' ' 56' ' ' VAL . . . -162.56 101.11 1.04 Allowed 'General case' 0 C--N 1.317 -0.837 0 CA-C-N 115.591 -0.732 . . . . 0.0 109.315 174.862 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 124.81 -18.41 7.12 Favored Glycine 0 N--CA 1.446 -0.65 0 CA-C-N 114.82 -1.082 . . . . 0.0 111.571 -173.623 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . 0.537 ' HD2' ' HG3' ' A' ' 14' ' ' GLU . 61.6 mttm -102.31 164.11 11.86 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 120.597 0.237 . . . . 0.0 110.663 -178.76 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . 0.497 ' HA ' ' O ' ' A' ' 54' ' ' VAL . 2.1 mp0 -111.15 144.22 40.63 Favored 'General case' 0 N--CA 1.455 -0.179 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.072 -179.383 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 98.0 m-85 -132.58 -179.66 5.59 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.69 -0.686 . . . . 0.0 109.492 173.775 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 6.5 pt-20 -124.8 113.32 17.76 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-O 121.583 0.706 . . . . 0.0 109.495 175.07 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.434 ' O ' ' HA ' ' A' ' 51' ' ' VAL . 30.2 m -116.82 173.9 3.88 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.91 0 CA-C-N 115.26 -0.882 . . . . 0.0 111.202 -173.031 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 5.8 m -112.82 152.19 29.49 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.028 179.431 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.531 HG13 ' HB1' ' A' ' 46' ' ' ALA . 19.9 mm -115.23 61.22 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.678 0 N-CA-C 108.355 -0.98 . . . . 0.0 108.355 -176.064 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 6.9 mm-40 -66.12 -18.18 65.18 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 114.006 -1.452 . . . . 0.0 111.405 -179.259 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.508 ' HB3' ' HB ' ' A' ' 33' ' ' ILE . 26.0 t0 -138.53 137.01 36.66 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.472 -172.397 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' MET . . . . . 0.41 ' HE3' HG23 ' A' ' 23' ' ' ILE . 10.8 mmt -114.89 144.03 44.19 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.886 174.929 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -70.46 -86.53 0.13 Allowed Glycine 0 N--CA 1.447 -0.607 0 N-CA-C 110.809 -0.916 . . . . 0.0 110.809 172.934 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 9.4 ptpp? -164.07 -29.01 0.04 OUTLIER 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 112.346 0.499 . . . . 0.0 112.346 172.179 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -105.38 38.25 3.39 Favored Glycine 0 C--N 1.308 -0.992 0 CA-C-N 115.636 -0.711 . . . . 0.0 113.358 -176.673 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 83.12 -5.84 74.49 Favored Glycine 0 C--N 1.329 0.139 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.909 177.888 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . 0.407 ' HA ' ' HA ' ' A' ' 44' ' ' PRO . 4.7 t70 -82.76 117.96 23.03 Favored 'General case' 0 C--N 1.325 -0.472 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 178.392 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -98.67 154.18 19.98 Favored Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.924 -173.732 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.508 ' HB ' ' HB3' ' A' ' 25' ' ' ASP . 2.5 mp -105.94 113.53 42.96 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.582 0 CA-C-O 121.136 0.493 . . . . 0.0 110.451 179.258 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . 0.41 ' HB1' ' HB ' ' A' ' 21' ' ' VAL . . . -106.37 160.62 15.24 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.775 -0.648 . . . . 0.0 109.9 175.902 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' ARG . . . . . 0.402 HH11 ' HD3' ' A' ' 35' ' ' ARG . 0.1 OUTLIER -130.05 128.02 41.1 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-O 120.652 0.263 . . . . 0.0 111.062 -175.027 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 54.7 mt -127.25 110.1 21.95 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 172.145 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 57.95 23.48 9.92 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 115.319 -0.855 . . . . 0.0 111.539 -175.946 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 99.88 -12.94 60.89 Favored Glycine 0 C--N 1.333 0.393 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.008 -178.605 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 52.6 t80 -76.18 139.28 41.16 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 109.652 -0.499 . . . . 0.0 109.652 -178.202 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 26.0 t -89.44 114.84 28.07 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 CA-C-O 121.097 0.475 . . . . 0.0 111.029 -175.475 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 37.1 t -115.24 118.23 58.13 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.661 0 CA-C-N 115.924 -0.58 . . . . 0.0 109.828 179.28 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 94.6 m-85 -87.09 142.31 28.02 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.773 -177.535 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.434 HG13 HD12 ' A' ' 52' ' ' ILE . 1.4 m -138.55 102.8 7.84 Favored Pre-proline 0 C--N 1.325 -0.496 0 CA-C-N 115.762 -0.654 . . . . 0.0 110.79 -179.115 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . 0.407 ' HA ' ' HA ' ' A' ' 31' ' ' ASP . 4.9 Cg_exo -77.23 3.39 6.75 Favored 'Trans proline' 0 CA--C 1.531 0.354 0 C-N-CA 123.564 2.842 . . . . 0.0 113.956 -170.943 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' ASN . . . . . 0.447 ' O ' ' HD3' ' A' ' 68' ' ' ARG . 57.2 m-80 -136.53 25.49 3.15 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 121.263 0.554 . . . . 0.0 110.489 -179.431 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.531 ' HB1' HG13 ' A' ' 23' ' ' ILE . . . -86.01 163.8 17.75 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 115.98 -0.554 . . . . 0.0 111.741 -179.682 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 42.9 mt-10 -116.93 134.4 54.8 Favored 'General case' 0 N--CA 1.446 -0.647 0 CA-C-N 115.472 -0.785 . . . . 0.0 109.297 172.224 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 27.0 ttpp -65.56 140.07 58.51 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-O 120.967 0.413 . . . . 0.0 111.493 -174.207 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 70.52 35.79 68.27 Favored Glycine 0 N--CA 1.448 -0.504 0 CA-C-N 115.525 -0.761 . . . . 0.0 112.704 177.367 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 50.8 m -142.18 162.23 35.99 Favored 'General case' 0 C--N 1.321 -0.663 0 O-C-N 122.772 -0.252 . . . . 0.0 110.747 179.07 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.434 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 88.9 t -98.86 122.9 51.1 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 N-CA-C 108.994 -0.743 . . . . 0.0 108.994 174.327 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.554 HD11 ' HB2' ' A' ' 68' ' ' ARG . 3.4 pt -121.62 142.97 35.67 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.703 0 C-N-CA 120.615 -0.434 . . . . 0.0 110.371 -178.8 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . 0.4 ' O ' ' HA ' ' A' ' 68' ' ' ARG . 16.5 t-20 -76.71 129.48 36.4 Favored 'General case' 0 C--N 1.323 -0.556 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 174.053 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . 0.54 ' HB ' ' HB1' ' A' ' 66' ' ' ALA . 25.0 m -128.24 128.49 68.61 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 CA-C-O 121.163 0.506 . . . . 0.0 112.032 -176.202 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . 0.414 ' HB2' ' HG3' ' A' ' 18' ' ' GLU . 22.8 ttmm -98.95 102.14 13.77 Favored 'General case' 0 C--N 1.314 -0.945 0 N-CA-C 108.611 -0.885 . . . . 0.0 108.611 170.044 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.448 HG22 ' HB3' ' A' ' 66' ' ' ALA . 68.1 t -66.27 108.21 0.96 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 N-CA-C 109.459 -0.571 . . . . 0.0 109.459 178.368 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 12.9 p -109.87 -13.81 14.39 Favored 'General case' 0 C--N 1.321 -0.634 0 N-CA-C 112.304 0.483 . . . . 0.0 112.304 -174.405 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . 0.418 ' HB2' ' HB2' ' A' ' 65' ' ' PHE . . . -143.13 92.24 2.36 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.134 0.493 . . . . 0.0 111.256 -176.608 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 20.3 t -84.58 142.8 12.84 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.768 0 CA-C-N 115.95 -0.568 . . . . 0.0 109.7 177.645 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 42.5 mmtm -127.72 -162.33 1.16 Allowed 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 116.716 -0.22 . . . . 0.0 110.779 -179.364 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 6.5 mm-40 -47.34 -64.09 0.87 Allowed 'General case' 0 N--CA 1.468 0.435 0 C-N-CA 123.699 0.799 . . . . 0.0 112.761 -172.302 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 59.9 pttt -138.31 20.59 2.77 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 121.666 0.746 . . . . 0.0 110.198 -178.926 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 28.9 p90 -153.12 153.19 32.3 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 114.939 -1.028 . . . . 0.0 108.906 -179.745 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -127.41 155.66 43.29 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-O 120.825 0.345 . . . . 0.0 111.112 -177.69 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . 0.418 ' HB2' ' HB2' ' A' ' 58' ' ' ALA . 99.0 m-85 -108.97 124.69 51.09 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 115.836 -0.62 . . . . 0.0 109.476 176.412 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' ALA . . . . . 0.54 ' HB1' ' HB ' ' A' ' 54' ' ' VAL . . . -125.12 151.24 46.0 Favored 'General case' 0 C--N 1.318 -0.793 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.707 -179.001 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 5.3 pt-20 -110.27 128.51 55.56 Favored 'General case' 0 C--N 1.316 -0.882 0 CA-C-O 121.263 0.554 . . . . 0.0 111.117 -178.888 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . 0.554 ' HB2' HD11 ' A' ' 52' ' ' ILE . 22.4 ttt180 -61.74 115.4 3.95 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.008 -0.996 . . . . 0.0 111.515 178.262 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.481 ' O ' HG13 ' A' ' 69' ' ' VAL . 22.0 t -82.07 12.29 0.64 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-N 114.922 -1.036 . . . . 0.0 110.876 179.32 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.438 ' HB2' ' HE ' ' A' ' 68' ' ' ARG . 60.4 mt . . . . . 0 C--O 1.249 1.045 0 CA-C-O 118.317 -0.849 . . . . 0.0 110.692 -178.447 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 16.2 Cg_endo . . . . . 0 N--CA 1.475 0.435 0 N-CA-C 113.212 0.428 . . . . 0.0 113.212 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.528 HG12 HD12 ' A' ' 36' ' ' ILE . 16.1 m -114.72 121.0 65.93 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.356 179.846 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 49.0 mt-10 -99.29 118.33 35.73 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.782 -177.686 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' ALA . . . . . 0.428 ' HB2' HG23 ' A' ' 59' ' ' VAL . . . -63.84 125.06 23.16 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.674 -0.694 . . . . 0.0 111.028 179.934 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 112.45 -4.44 26.48 Favored Glycine 0 N--CA 1.449 -0.44 0 C-N-CA 120.891 -0.671 . . . . 0.0 111.814 -177.852 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 97.1 mttt -118.59 158.52 25.28 Favored 'General case' 0 C--N 1.324 -0.542 0 N-CA-C 110.289 -0.263 . . . . 0.0 110.289 178.997 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' GLU . . . . . 0.506 ' HA ' ' O ' ' A' ' 54' ' ' VAL . 0.0 OUTLIER -120.61 130.7 54.28 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-O 121.606 0.717 . . . . 0.0 111.29 179.878 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 45.8 m-85 -122.66 149.63 43.77 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.257 -0.883 . . . . 0.0 110.179 -174.912 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 2.3 mp0 -84.8 119.13 24.96 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 121.138 0.494 . . . . 0.0 109.693 173.857 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 36.0 m -130.43 165.04 31.74 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.879 0 CA-C-N 115.599 -0.728 . . . . 0.0 110.865 -175.097 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 11.7 m -108.35 149.64 28.42 Favored 'General case' 0 C--N 1.316 -0.87 0 CA-C-N 115.999 -0.546 . . . . 0.0 109.935 175.911 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.621 HG13 ' HB1' ' A' ' 46' ' ' ALA . 36.0 mm -110.67 61.6 0.16 Allowed 'Isoleucine or valine' 0 CA--C 1.509 -0.609 0 N-CA-C 107.652 -1.24 . . . . 0.0 107.652 -176.995 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 31.4 tt0 -62.57 -24.79 67.73 Favored 'General case' 0 C--N 1.311 -1.084 0 CA-C-N 113.062 -1.881 . . . . 0.0 111.207 -179.583 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.566 ' HB2' ' HB ' ' A' ' 33' ' ' ILE . 15.3 m-20 -124.33 149.15 46.91 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.33 -0.396 . . . . 0.0 111.18 -175.213 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 26' ' ' MET . . . . . . . . . . . . . 96.0 mmm -123.19 147.85 46.42 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.092 -0.504 . . . . 0.0 109.932 173.975 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.448 -0.544 0 C-N-CA 121.091 -0.576 . . . . 0.0 112.792 -178.02 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 31' ' ' ASP . . . . . 0.419 ' OD1' ' HA ' ' A' ' 44' ' ' PRO . 27.5 t70 . . . . . 0 N--CA 1.454 -0.251 0 N-CA-C 109.56 -0.533 . . . . 0.0 109.56 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -98.66 132.53 10.97 Favored Glycine 0 N--CA 1.447 -0.615 0 C-N-CA 120.602 -0.808 . . . . 0.0 111.897 -177.293 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.566 ' HB ' ' HB2' ' A' ' 25' ' ' ASP . 1.9 mp -101.83 104.1 15.9 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.737 0 CA-C-O 121.492 0.663 . . . . 0.0 110.625 -178.248 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -84.17 157.19 21.75 Favored 'General case' 0 C--N 1.317 -0.809 0 CA-C-N 115.406 -0.816 . . . . 0.0 109.167 169.036 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 35' ' ' ARG . . . . . 0.403 HH11 ' HD2' ' A' ' 35' ' ' ARG . 6.0 ttm180 -142.18 107.87 5.11 Favored 'General case' 0 C--N 1.313 -0.982 0 C-N-CA 120.644 -0.422 . . . . 0.0 110.819 -176.769 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.528 HD12 HG12 ' A' ' 13' ' ' VAL . 37.2 mt -99.43 108.68 22.96 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 CA-C-N 115.733 -0.667 . . . . 0.0 110.11 178.093 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 58.2 16.46 3.95 Favored 'General case' 0 N--CA 1.468 0.473 0 CA-C-N 115.26 -0.882 . . . . 0.0 112.079 -176.539 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 110.28 -16.99 29.36 Favored Glycine 0 N--CA 1.449 -0.447 0 C-N-CA 120.856 -0.688 . . . . 0.0 111.764 -178.057 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 34.0 t80 -71.68 117.59 13.44 Favored 'General case' 0 C--N 1.328 -0.362 0 N-CA-C 109.576 -0.527 . . . . 0.0 109.576 179.334 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.448 HG13 HG23 ' A' ' 33' ' ' ILE . 29.1 t -70.61 117.59 13.9 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 CA-C-N 115.824 -0.625 . . . . 0.0 111.301 -178.43 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 49.1 t -119.34 108.39 23.65 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 CA-C-N 115.481 -0.781 . . . . 0.0 109.594 -179.812 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 93.7 m-85 -78.58 129.55 34.92 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.086 -175.411 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 5.6 t -125.73 105.57 26.65 Favored Pre-proline 0 C--N 1.321 -0.659 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.246 -177.948 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 44' ' ' PRO . . . . . 0.419 ' HA ' ' OD1' ' A' ' 31' ' ' ASP . 34.9 Cg_endo -65.75 -8.26 19.01 Favored 'Trans proline' 0 N--CA 1.477 0.538 0 C-N-CA 123.537 2.825 . . . . 0.0 114.476 -172.561 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 1.2 p30 -142.54 20.35 2.03 Favored 'General case' 0 C--N 1.321 -0.65 0 N-CA-C 112.264 0.468 . . . . 0.0 112.264 -167.603 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.621 ' HB1' HG13 ' A' ' 23' ' ' ILE . . . -97.18 155.89 16.64 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.082 176.126 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 48.9 mt-10 -106.38 144.9 32.39 Favored 'General case' 0 N--CA 1.451 -0.421 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.093 178.54 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 60.8 tttm -66.2 137.36 56.93 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.457 -0.338 . . . . 0.0 111.352 -175.676 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 82.86 -2.24 86.84 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 121.017 -0.611 . . . . 0.0 113.121 175.943 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 29.7 m -93.56 152.08 19.27 Favored 'General case' 0 C--N 1.324 -0.538 0 O-C-N 122.654 -0.321 . . . . 0.0 111.085 -179.529 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 46.6 t -98.46 101.65 12.42 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 N-CA-C 108.456 -0.942 . . . . 0.0 108.456 172.897 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.571 HD11 ' HB2' ' A' ' 68' ' ' ARG . 0.8 OUTLIER -115.2 145.23 21.22 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.851 0 CA-C-N 115.789 -0.641 . . . . 0.0 112.018 -170.281 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 58.1 t30 -88.3 112.86 23.31 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 114.923 -1.035 . . . . 0.0 109.005 176.306 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 54' ' ' VAL . . . . . 0.555 ' HB ' ' HB1' ' A' ' 66' ' ' ALA . 35.2 m -115.01 134.56 57.69 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.724 0 CA-C-O 121.115 0.483 . . . . 0.0 111.609 -175.259 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 2.3 ttmp? -93.42 111.06 22.63 Favored 'General case' 0 C--N 1.32 -0.709 0 N-CA-C 109.124 -0.695 . . . . 0.0 109.124 175.52 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.467 HG21 ' HB ' ' A' ' 13' ' ' VAL . 87.6 t -67.88 113.08 3.41 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 N-CA-C 109.189 -0.671 . . . . 0.0 109.189 177.693 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.7 p -109.36 -26.02 10.24 Favored 'General case' 0 C--N 1.324 -0.53 0 N-CA-C 112.455 0.539 . . . . 0.0 112.455 -173.104 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 58' ' ' ALA . . . . . 0.434 ' HB3' ' HB2' ' A' ' 65' ' ' PHE . . . -143.38 92.17 2.34 Favored 'General case' 0 C--N 1.325 -0.476 0 C-N-CA 120.679 -0.408 . . . . 0.0 111.738 -175.301 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.428 HG23 ' HB2' ' A' ' 15' ' ' ALA . 15.6 t -79.9 125.89 39.07 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.735 0 CA-C-N 116.109 -0.496 . . . . 0.0 109.781 174.079 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 46.0 mmtm -106.01 -164.17 0.99 Allowed 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.439 -179.559 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 61' ' ' GLU . . . . . 0.41 ' OE1' ' HE3' ' A' ' 62' ' ' LYS . 40.8 tt0 -66.03 -48.84 69.77 Favored 'General case' 0 CA--C 1.533 0.297 0 N-CA-C 112.623 0.601 . . . . 0.0 112.623 -175.3 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 62' ' ' LYS . . . . . 0.41 ' HE3' ' OE1' ' A' ' 61' ' ' GLU . 93.1 mttt -120.6 3.89 10.66 Favored 'General case' 0 C--N 1.328 -0.332 0 N-CA-C 111.934 0.346 . . . . 0.0 111.934 -172.982 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 15.1 p90 -166.6 169.01 14.06 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 116.42 -0.355 . . . . 0.0 110.21 -174.273 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -129.42 158.76 38.26 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-O 120.878 0.37 . . . . 0.0 111.095 -179.95 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 65' ' ' PHE . . . . . 0.434 ' HB2' ' HB3' ' A' ' 58' ' ' ALA . 95.3 m-85 -114.47 136.14 53.34 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.579 -0.737 . . . . 0.0 109.824 176.827 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 66' ' ' ALA . . . . . 0.555 ' HB1' ' HB ' ' A' ' 54' ' ' VAL . . . -127.35 -179.3 4.82 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.571 -179.155 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 67' ' ' GLU . . . . . 0.43 ' O ' ' HA ' ' A' ' 54' ' ' VAL . 8.1 pt-20 -141.67 143.82 33.79 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 120.861 0.362 . . . . 0.0 111.212 178.85 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 68' ' ' ARG . . . . . 0.571 ' HB2' HD11 ' A' ' 52' ' ' ILE . 31.2 ttt180 -67.73 106.16 2.15 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.405 -0.816 . . . . 0.0 111.707 178.185 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 2.6 t -83.54 21.66 0.19 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.361 0 CA-C-O 121.501 0.667 . . . . 0.0 110.405 175.286 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.551 HD11 ' HA ' ' A' ' 52' ' ' ILE . 64.2 mt . . . . . 0 C--O 1.249 1.074 0 CA-C-O 118.351 -0.833 . . . . 0.0 110.064 -179.255 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 10.9 Cg_endo . . . . . 0 N--CA 1.473 0.315 0 N-CA-C 113.125 0.394 . . . . 0.0 113.125 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.504 ' HB ' HG21 ' A' ' 56' ' ' VAL . 15.6 m -103.64 126.8 58.09 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-N 116.09 -0.504 . . . . 0.0 111.214 -178.311 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 14' ' ' GLU . . . . . 0.423 ' CB ' ' HD3' ' A' ' 17' ' ' LYS . 37.6 mt-10 -101.06 123.96 46.05 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.058 176.398 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 15' ' ' ALA . . . . . 0.483 ' HA ' ' O ' ' A' ' 56' ' ' VAL . . . -60.94 110.16 1.27 Allowed 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.355 177.227 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 123.64 -18.76 7.6 Favored Glycine 0 N--CA 1.447 -0.613 0 C-N-CA 121.029 -0.605 . . . . 0.0 112.436 -178.29 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 17' ' ' LYS . . . . . 0.423 ' HD3' ' CB ' ' A' ' 14' ' ' GLU . 2.4 mptm? -94.1 162.97 13.66 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.935 0.398 . . . . 0.0 111.393 -179.99 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 18' ' ' GLU . . . . . 0.563 ' HG2' ' HB2' ' A' ' 55' ' ' LYS . 31.4 mt-10 -118.84 128.41 54.43 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.538 -0.755 . . . . 0.0 110.036 179.611 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 19' ' ' TYR . . . . . 0.421 ' O ' HG22 ' A' ' 54' ' ' VAL . 62.0 m-85 -127.87 127.17 42.94 Favored 'General case' 0 C--N 1.322 -0.627 0 N-CA-C 110.065 -0.346 . . . . 0.0 110.065 179.412 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 20' ' ' GLU . . . . . 0.628 ' HA ' ' HA ' ' A' ' 53' ' ' ASN . 34.8 tt0 -78.24 119.12 21.16 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 121.149 0.5 . . . . 0.0 109.764 177.03 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 23.3 m -129.82 162.81 36.77 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-N 115.499 -0.773 . . . . 0.0 111.702 -170.116 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 9.7 m -97.33 149.12 22.44 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.021 177.215 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.493 ' CD1' ' HB2' ' A' ' 34' ' ' ALA . 24.0 mm -121.33 65.94 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 108.572 -0.899 . . . . 0.0 108.572 -175.546 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 35.5 tt0 -86.98 -5.34 59.12 Favored 'General case' 0 C--N 1.31 -1.116 0 CA-C-N 114.445 -1.252 . . . . 0.0 110.465 -178.209 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.543 ' HB2' ' HB ' ' A' ' 33' ' ' ILE . 25.1 m-20 -118.59 134.42 55.11 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 115.526 -0.761 . . . . 0.0 109.396 -178.874 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 26' ' ' MET . . . . . . . . . . . . . 98.1 mmm -124.82 147.03 48.95 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-O 120.697 0.284 . . . . 0.0 110.91 -179.842 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.445 -0.757 0 N-CA-C 110.71 -0.956 . . . . 0.0 110.71 175.667 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 4.4 p-10 . . . . . 0 N--CA 1.445 -0.696 0 N-CA-C 109.203 -0.666 . . . . 0.0 109.203 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -109.38 160.87 13.28 Favored Glycine 0 N--CA 1.443 -0.863 0 CA-C-N 115.526 -0.761 . . . . 0.0 112.588 -175.347 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.546 HG23 HG13 ' A' ' 40' ' ' VAL . 2.5 mp -114.1 110.08 30.81 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.836 0 N-CA-C 109.962 -0.385 . . . . 0.0 109.962 -179.973 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 34' ' ' ALA . . . . . 0.493 ' HB2' ' CD1' ' A' ' 23' ' ' ILE . . . -94.03 155.17 17.26 Favored 'General case' 0 C--N 1.318 -0.761 0 CA-C-O 121.732 0.777 . . . . 0.0 111.098 173.868 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 29.1 mmt180 -121.4 103.11 8.71 Favored 'General case' 0 N--CA 1.437 -1.114 0 CA-C-N 114.552 -1.204 . . . . 0.0 110.629 -172.52 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.413 HD12 ' CG1' ' A' ' 13' ' ' VAL . 26.1 mt -100.61 101.4 12.04 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.601 0 CA-C-O 121.1 0.476 . . . . 0.0 109.917 175.623 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 33.2 t70 67.06 -4.14 0.86 Allowed 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 114.669 -1.151 . . . . 0.0 111.006 -173.522 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 122.61 -19.28 8.01 Favored Glycine 0 N--CA 1.446 -0.673 0 N-CA-C 110.845 -0.902 . . . . 0.0 110.845 -172.207 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 51.7 t80 -65.84 126.08 27.38 Favored 'General case' 0 C--O 1.237 0.399 0 N-CA-C 109.126 -0.694 . . . . 0.0 109.126 176.702 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.546 HG13 HG23 ' A' ' 33' ' ' ILE . 39.9 t -76.77 113.45 15.84 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.757 0 CA-C-N 115.78 -0.646 . . . . 0.0 111.292 -175.344 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 68.0 t -109.31 111.65 37.03 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 CA-C-N 115.48 -0.782 . . . . 0.0 109.885 177.347 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 60.6 m-85 -77.95 120.12 22.37 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.376 -179.625 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.533 ' HB ' ' HB2' ' A' ' 46' ' ' ALA . 8.7 t -120.81 104.56 41.83 Favored Pre-proline 0 C--N 1.319 -0.725 0 CA-C-N 115.587 -0.733 . . . . 0.0 110.398 -177.304 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -77.32 16.84 0.96 Allowed 'Trans proline' 0 CA--C 1.53 0.324 0 C-N-CA 123.379 2.719 . . . . 0.0 113.584 -174.187 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -152.04 21.43 0.67 Allowed 'General case' 0 C--N 1.321 -0.65 0 CA-C-O 121.523 0.678 . . . . 0.0 110.266 -178.042 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.533 ' HB2' ' HB ' ' A' ' 43' ' ' VAL . . . -78.63 168.86 19.14 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 115.224 -0.898 . . . . 0.0 111.488 177.923 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 47' ' ' GLU . . . . . 0.466 ' O ' ' HB ' ' A' ' 23' ' ' ILE . 0.0 OUTLIER -126.16 134.76 51.2 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.549 -0.75 . . . . 0.0 109.594 178.21 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 1.8 tmtp? -63.37 120.84 12.39 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.891 -176.15 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 81.96 5.91 89.36 Favored Glycine 0 N--CA 1.45 -0.412 0 CA-C-N 115.776 -0.647 . . . . 0.0 112.821 177.097 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 20.0 t -101.78 163.34 12.3 Favored 'General case' 0 C--N 1.324 -0.538 0 N-CA-C 110.123 -0.325 . . . . 0.0 110.123 -178.478 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.52 HG12 ' HG2' ' A' ' 20' ' ' GLU . 32.2 t -114.35 101.46 12.46 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.463 0 N-CA-C 109.106 -0.702 . . . . 0.0 109.106 179.269 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.591 HD12 ' HB2' ' A' ' 68' ' ' ARG . 6.4 pt -108.58 145.47 15.5 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-O 121.054 0.454 . . . . 0.0 110.934 -173.131 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 53' ' ' ASN . . . . . 0.628 ' HA ' ' HA ' ' A' ' 20' ' ' GLU . 39.6 t30 -82.55 115.81 21.69 Favored 'General case' 0 C--N 1.318 -0.765 0 N-CA-C 109.328 -0.619 . . . . 0.0 109.328 172.157 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 54' ' ' VAL . . . . . 0.54 HG13 HG13 ' A' ' 52' ' ' ILE . 28.8 m -107.97 130.81 59.81 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-O 121.358 0.599 . . . . 0.0 111.816 -177.198 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 55' ' ' LYS . . . . . 0.563 ' HB2' ' HG2' ' A' ' 18' ' ' GLU . 39.8 ttmt -97.98 106.65 18.98 Favored 'General case' 0 C--N 1.318 -0.772 0 N-CA-C 108.959 -0.756 . . . . 0.0 108.959 172.304 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.504 HG21 ' HB ' ' A' ' 13' ' ' VAL . 47.1 t -68.12 112.88 3.44 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.079 179.559 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 21.0 p -109.41 -17.94 13.67 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 112.071 0.397 . . . . 0.0 112.071 -174.86 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -143.58 92.58 2.37 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.063 0.458 . . . . 0.0 110.984 -177.607 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 13.4 t -85.24 129.61 37.55 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.638 0 CA-C-N 115.854 -0.612 . . . . 0.0 109.913 175.868 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 74.8 mmtt -106.76 -173.07 2.21 Favored 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 109.979 -0.378 . . . . 0.0 109.979 178.437 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -72.42 -41.22 66.45 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.35 -0.386 . . . . 0.0 111.859 179.648 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 56.3 mttp -92.13 -45.3 8.35 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 121.036 0.446 . . . . 0.0 111.295 -178.269 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 10.4 p90 -142.84 -171.3 3.42 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.969 -0.559 . . . . 0.0 110.492 -172.538 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -138.91 158.51 44.07 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-O 120.814 0.34 . . . . 0.0 111.113 -179.462 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 93.2 m-85 -113.85 138.72 49.91 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.694 -0.684 . . . . 0.0 109.43 175.492 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 66' ' ' ALA . . . . . 0.524 ' HB1' ' HB ' ' A' ' 54' ' ' VAL . . . -142.6 159.14 42.82 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 116.553 -0.294 . . . . 0.0 110.906 -178.668 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 67' ' ' GLU . . . . . 0.411 ' O ' ' HA ' ' A' ' 54' ' ' VAL . 10.8 pt-20 -113.72 137.75 51.19 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 121.303 0.573 . . . . 0.0 111.254 179.142 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 68' ' ' ARG . . . . . 0.591 ' HB2' HD12 ' A' ' 52' ' ' ILE . 25.0 ttt180 -66.41 109.86 2.89 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 115.237 -0.892 . . . . 0.0 109.98 172.458 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 2.8 t -81.92 25.13 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.536 0.41 0 CA-C-O 121.526 0.679 . . . . 0.0 111.867 -174.767 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.463 ' CD2' ' HG3' ' A' ' 68' ' ' ARG . 0.8 OUTLIER . . . . . 0 C--O 1.245 0.838 0 CA-C-O 118.759 -0.639 . . . . 0.0 110.329 179.218 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo . . . . . 0 CA--C 1.516 -0.403 0 CA-C-O 121.621 0.592 . . . . 0.0 112.507 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.604 HG12 HD12 ' A' ' 36' ' ' ILE . 16.1 m -80.5 163.03 3.53 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.896 0 CA-C-N 115.175 -0.921 . . . . 0.0 110.906 -177.989 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 9.8 tp10 -147.14 119.72 8.53 Favored 'General case' 0 C--N 1.322 -0.588 0 N-CA-C 108.918 -0.771 . . . . 0.0 108.918 178.471 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' ALA . . . . . 0.456 ' HA ' ' O ' ' A' ' 56' ' ' VAL . . . -58.91 117.55 4.78 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-O 121.111 0.482 . . . . 0.0 111.377 -177.207 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 119.09 -24.84 8.1 Favored Glycine 0 N--CA 1.447 -0.625 0 CA-C-N 115.653 -0.703 . . . . 0.0 112.218 -179.246 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' LYS . . . . . 0.408 ' HE2' ' HB3' ' A' ' 17' ' ' LYS . 53.1 mtpt -90.55 156.37 18.21 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.871 0.367 . . . . 0.0 110.734 179.077 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 18' ' ' GLU . . . . . 0.484 ' HA ' ' O ' ' A' ' 54' ' ' VAL . 46.0 mt-10 -113.96 128.34 56.35 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.824 -0.625 . . . . 0.0 109.858 -179.864 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 81.5 m-85 -122.58 143.42 49.75 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 121.173 0.511 . . . . 0.0 111.583 -175.887 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 32.7 tt0 -82.98 111.06 18.49 Favored 'General case' 0 C--N 1.317 -0.808 0 CA-C-N 115.548 -0.751 . . . . 0.0 109.475 175.069 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.486 ' HB ' ' HB1' ' A' ' 34' ' ' ALA . 32.7 m -121.81 151.32 25.28 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-O 121.053 0.454 . . . . 0.0 112.023 -172.714 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 17.0 m -97.62 152.44 19.06 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.658 -0.701 . . . . 0.0 109.721 176.474 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.491 HD13 ' HB2' ' A' ' 34' ' ' ALA . 18.9 mm -121.89 64.5 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-O 121.791 0.805 . . . . 0.0 108.908 -174.423 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 26.1 mm-40 -69.02 -19.15 64.11 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-N 114.782 -1.099 . . . . 0.0 111.835 -179.663 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.56 ' HB2' ' HB ' ' A' ' 33' ' ' ILE . 5.6 m-20 -126.34 138.7 53.6 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 116.392 -0.367 . . . . 0.0 111.277 -176.093 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 26' ' ' MET . . . . . . . . . . . . . 92.9 mmm -120.28 142.09 49.39 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 115.814 -0.63 . . . . 0.0 109.917 175.655 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.444 -0.773 0 N-CA-C 111.559 -0.616 . . . . 0.0 111.559 179.537 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 30.3 t70 . . . . . 0 CA--C 1.514 -0.432 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 32' ' ' GLY . . . . . 0.55 ' HA3' ' HB3' ' A' ' 46' ' ' ALA . . . -114.42 141.71 17.15 Favored Glycine 0 N--CA 1.441 -1.022 0 N-CA-C 111.178 -0.769 . . . . 0.0 111.178 177.994 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.56 ' HB ' ' HB2' ' A' ' 25' ' ' ASP . 2.6 mp -97.93 98.19 7.03 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.767 0 CA-C-O 121.329 0.585 . . . . 0.0 110.276 -178.09 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 34' ' ' ALA . . . . . 0.491 ' HB2' HD13 ' A' ' 23' ' ' ILE . . . -99.85 123.01 43.65 Favored 'General case' 0 CA--C 1.497 -1.065 0 CA-C-N 115.747 -0.661 . . . . 0.0 109.398 171.706 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 35' ' ' ARG . . . . . 0.525 ' HA ' ' O ' ' A' ' 39' ' ' PHE . 0.0 OUTLIER -118.56 108.66 15.23 Favored 'General case' 0 C--N 1.303 -1.453 0 CA-C-N 115.6 -0.727 . . . . 0.0 111.363 -174.11 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.604 HD12 HG12 ' A' ' 13' ' ' VAL . 53.1 mt -84.43 112.62 21.9 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.702 0 CA-C-N 115.208 -0.905 . . . . 0.0 109.604 177.649 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 36.7 t70 60.43 19.07 8.76 Favored 'General case' 0 CA--C 1.539 0.523 0 CA-C-N 115.495 -0.775 . . . . 0.0 110.702 -175.451 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 100.78 -9.26 58.41 Favored Glycine 0 C--N 1.329 0.189 0 C-N-CA 120.583 -0.818 . . . . 0.0 112.143 -178.794 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 39' ' ' PHE . . . . . 0.525 ' O ' ' HA ' ' A' ' 35' ' ' ARG . 60.8 t80 -77.43 114.76 16.59 Favored 'General case' 0 C--N 1.323 -0.576 0 N-CA-C 109.708 -0.479 . . . . 0.0 109.708 178.779 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.521 HG13 HG23 ' A' ' 33' ' ' ILE . 21.5 t -68.98 110.09 2.3 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 CA-C-O 121.6 0.714 . . . . 0.0 111.968 -175.347 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 17.6 t -108.26 110.42 31.91 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.824 0 CA-C-N 115.092 -0.958 . . . . 0.0 108.896 175.503 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 65.9 m-85 -74.3 134.7 42.57 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-O 121.126 0.489 . . . . 0.0 111.284 -176.653 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.695 HG11 HD11 ' A' ' 52' ' ' ILE . 8.1 t -131.56 113.93 15.55 Favored Pre-proline 0 N--CA 1.449 -0.524 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.794 -174.943 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 59.8 Cg_endo -74.71 -9.41 21.17 Favored 'Trans proline' 0 CA--C 1.531 0.359 0 C-N-CA 122.692 2.262 . . . . 0.0 113.681 -176.943 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 45' ' ' ASN . . . . . 0.564 ' HB2' ' HB3' ' A' ' 68' ' ' ARG . 72.0 m-20 -124.64 9.78 8.37 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.008 0.432 . . . . 0.0 111.34 -175.163 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.55 ' HB3' ' HA3' ' A' ' 32' ' ' GLY . . . -71.43 150.63 44.76 Favored 'General case' 0 C--N 1.319 -0.755 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.878 -179.542 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 48.8 mt-10 -123.6 141.77 51.68 Favored 'General case' 0 N--CA 1.448 -0.567 0 CA-C-N 115.669 -0.696 . . . . 0.0 109.972 178.335 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 33.1 ttpt -55.19 129.52 38.54 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.8 -176.818 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 67.08 22.46 72.47 Favored Glycine 0 C--N 1.33 0.218 0 CA-C-N 115.947 -0.57 . . . . 0.0 112.902 174.327 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 18.4 m -113.78 158.89 20.38 Favored 'General case' 0 C--N 1.319 -0.731 0 O-C-N 122.609 -0.348 . . . . 0.0 110.179 179.651 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 51.1 t -118.39 99.87 8.86 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 N-CA-C 109.444 -0.576 . . . . 0.0 109.444 -178.69 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.695 HD11 HG11 ' A' ' 43' ' ' VAL . 0.5 OUTLIER -110.0 152.98 11.89 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.695 0 CA-C-N 116.044 -0.525 . . . . 0.0 109.861 -174.831 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 28.9 t-20 -92.56 120.5 33.08 Favored 'General case' 0 C--N 1.317 -0.826 0 N-CA-C 108.926 -0.768 . . . . 0.0 108.926 178.018 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 54' ' ' VAL . . . . . 0.666 ' HB ' ' HB1' ' A' ' 66' ' ' ALA . 34.9 m -114.67 139.83 38.74 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 N-CA-C 112.405 0.52 . . . . 0.0 112.405 -174.561 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 55' ' ' LYS . . . . . 0.434 ' HB2' ' HG2' ' A' ' 18' ' ' GLU . 3.2 ttmp? -98.54 109.21 22.0 Favored 'General case' 0 C--N 1.319 -0.758 0 N-CA-C 109.026 -0.731 . . . . 0.0 109.026 171.339 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.456 ' O ' ' HA ' ' A' ' 15' ' ' ALA . 90.7 t -69.39 113.16 4.82 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 178.554 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 17.5 p -101.97 -28.92 12.1 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 116.216 -0.447 . . . . 0.0 112.009 -175.096 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -140.58 94.09 2.69 Favored 'General case' 0 N--CA 1.452 -0.365 0 CA-C-O 121.121 0.486 . . . . 0.0 111.343 -173.536 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 39.5 t -81.34 133.08 30.05 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.833 0 CA-C-N 115.595 -0.73 . . . . 0.0 109.865 174.426 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 72.9 mmtt -112.82 -164.74 0.94 Allowed 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.397 -0.365 . . . . 0.0 110.368 178.555 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 8.9 mm-40 -67.56 -47.21 70.49 Favored 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 112.17 0.433 . . . . 0.0 112.17 -171.873 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 66.6 mttm -124.1 -2.45 8.15 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-O 120.625 0.25 . . . . 0.0 111.636 -176.574 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 9.9 p90 -153.73 174.73 14.14 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 116.26 -0.427 . . . . 0.0 109.871 -174.45 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -142.22 166.76 23.8 Favored 'General case' 0 C--N 1.322 -0.59 0 C-N-CA 120.876 -0.33 . . . . 0.0 111.465 -179.177 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 89.4 m-85 -117.14 131.86 56.79 Favored 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 175.033 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 66' ' ' ALA . . . . . 0.666 ' HB1' ' HB ' ' A' ' 54' ' ' VAL . . . -124.68 155.58 38.99 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-O 121.463 0.649 . . . . 0.0 112.433 -175.926 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 10.8 tt0 -104.71 120.28 40.98 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 114.946 -1.024 . . . . 0.0 110.324 178.557 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 68' ' ' ARG . . . . . 0.564 ' HB3' ' HB2' ' A' ' 45' ' ' ASN . 41.0 ttt180 -66.19 107.71 2.04 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 121.624 0.726 . . . . 0.0 111.18 174.573 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.566 ' O ' ' HB3' ' A' ' 70' ' ' LEU . 2.6 t -80.57 -177.52 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.759 0 N-CA-C 106.241 -1.762 . . . . 0.0 106.241 167.005 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.578 HD23 ' OXT' ' A' ' 70' ' ' LEU . 0.0 OUTLIER . . . . . 0 C--O 1.247 0.935 0 CA-C-O 118.257 -0.878 . . . . 0.0 110.85 179.614 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 42.0 Cg_endo . . . . . 0 C--O 1.232 0.204 0 N-CA-C 113.584 0.571 . . . . 0.0 113.584 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.468 HG12 HD12 ' A' ' 36' ' ' ILE . 13.9 m -119.97 120.72 63.99 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.819 0 CA-C-O 121.106 0.479 . . . . 0.0 111.017 -176.808 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 15.6 mm-40 -92.15 122.09 34.31 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.035 -177.678 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' ALA . . . . . 0.406 ' HA ' ' O ' ' A' ' 56' ' ' VAL . . . -67.09 96.74 0.47 Allowed 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.711 -0.677 . . . . 0.0 110.705 179.261 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 142.76 -30.15 2.07 Favored Glycine 0 N--CA 1.443 -0.887 0 C-N-CA 120.977 -0.63 . . . . 0.0 112.278 -178.298 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 8.8 mtpm? -95.7 168.79 10.45 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 121.64 0.733 . . . . 0.0 111.562 -179.478 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 18' ' ' GLU . . . . . 0.515 ' HB2' ' OD1' ' A' ' 53' ' ' ASN . 0.0 OUTLIER -115.5 149.63 37.82 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 114.557 -1.201 . . . . 0.0 110.621 -179.176 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 80.0 m-85 -137.67 141.21 41.12 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.259 178.125 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 8.1 tt0 -79.05 107.55 11.89 Favored 'General case' 0 C--N 1.325 -0.458 0 N-CA-C 109.408 -0.59 . . . . 0.0 109.408 174.356 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 35.2 m -118.08 164.13 14.64 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 CA-C-O 120.969 0.414 . . . . 0.0 110.756 -176.186 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 6.1 m -112.0 140.12 46.94 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-O 121.207 0.527 . . . . 0.0 110.202 177.833 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.57 HG13 ' HB1' ' A' ' 46' ' ' ALA . 30.7 mm -104.39 59.59 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.804 0 N-CA-C 108.188 -1.041 . . . . 0.0 108.188 -177.487 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 36.8 tt0 -65.69 -7.89 17.84 Favored 'General case' 0 C--N 1.315 -0.902 0 CA-C-N 113.724 -1.58 . . . . 0.0 110.873 -179.089 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.523 ' HB3' ' HB ' ' A' ' 33' ' ' ILE . 28.5 t70 -138.7 138.51 37.81 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 120.849 0.357 . . . . 0.0 110.86 -176.869 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 26' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -120.85 114.01 20.97 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.952 -0.567 . . . . 0.0 109.863 178.024 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.446 -0.649 0 C-N-CA 120.981 -0.628 . . . . 0.0 111.848 -178.439 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 31' ' ' ASP . . . . . 0.487 ' OD1' ' HA ' ' A' ' 44' ' ' PRO . 24.2 t70 . . . . . 0 C--O 1.232 0.144 0 N-CA-C 108.908 -0.775 . . . . 0.0 108.908 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -88.06 129.22 9.45 Favored Glycine 0 N--CA 1.449 -0.476 0 C-N-CA 120.627 -0.797 . . . . 0.0 112.381 -176.461 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.523 ' HB ' ' HB3' ' A' ' 25' ' ' ASP . 1.8 mp -100.16 101.74 12.5 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.46 0 CA-C-O 121.403 0.621 . . . . 0.0 110.423 178.864 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -95.47 151.71 19.06 Favored 'General case' 0 C--N 1.321 -0.66 0 N-CA-C 108.71 -0.848 . . . . 0.0 108.71 167.328 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 11.9 ttp-105 -139.95 104.28 4.83 Favored 'General case' 0 C--N 1.319 -0.726 0 C-N-CA 120.15 -0.62 . . . . 0.0 110.431 -178.883 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.468 HD12 HG12 ' A' ' 13' ' ' VAL . 29.8 mt -86.95 103.5 13.24 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-N 115.594 -0.73 . . . . 0.0 110.765 -175.938 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 13.7 t70 61.41 12.54 4.4 Favored 'General case' 0 N--CA 1.469 0.49 0 CA-C-N 114.372 -1.286 . . . . 0.0 111.737 179.323 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 120.12 -17.61 9.83 Favored Glycine 0 N--CA 1.448 -0.514 0 C-N-CA 120.472 -0.871 . . . . 0.0 112.007 -177.482 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 56.6 t80 -82.58 118.89 23.62 Favored 'General case' 0 C--N 1.326 -0.425 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 178.473 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 19.4 t -73.63 116.75 16.43 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-O 121.205 0.526 . . . . 0.0 111.057 -175.695 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 47.9 t -112.09 107.16 22.27 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 CA-C-N 115.586 -0.734 . . . . 0.0 109.322 178.038 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 94.3 m-85 -77.92 128.29 33.7 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.156 -178.28 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.446 HG11 ' HB2' ' A' ' 46' ' ' ALA . 3.3 t -115.82 98.38 50.9 Favored Pre-proline 0 C--N 1.317 -0.822 0 CA-C-N 115.883 -0.599 . . . . 0.0 109.905 -177.946 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 44' ' ' PRO . . . . . 0.487 ' HA ' ' OD1' ' A' ' 31' ' ' ASP . 48.6 Cg_exo -59.51 -17.73 42.92 Favored 'Trans proline' 0 N--CA 1.476 0.451 0 C-N-CA 124.07 3.18 . . . . 0.0 114.277 -173.486 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -131.62 8.36 4.55 Favored 'General case' 0 C--N 1.317 -0.817 0 N-CA-C 112.707 0.632 . . . . 0.0 112.707 -167.8 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.57 ' HB1' HG13 ' A' ' 23' ' ' ILE . . . -81.93 159.74 23.54 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-O 120.705 0.288 . . . . 0.0 110.892 175.272 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 46.0 mt-10 -108.16 159.48 16.57 Favored 'General case' 0 N--CA 1.448 -0.575 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.505 178.724 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -65.12 123.34 19.25 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.624 -175.211 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 74.49 22.71 76.97 Favored Glycine 0 C--N 1.331 0.29 0 CA-C-N 115.79 -0.641 . . . . 0.0 113.476 175.003 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 68.8 p -96.86 153.51 17.84 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-O 121.089 0.471 . . . . 0.0 111.101 -178.578 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 59.2 t -99.37 106.81 19.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 N-CA-C 108.195 -1.039 . . . . 0.0 108.195 172.562 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.563 HD11 ' HA ' ' A' ' 68' ' ' ARG . 0.8 OUTLIER -128.45 145.81 34.89 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.761 0 CA-C-O 121.772 0.796 . . . . 0.0 112.591 -166.647 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 53' ' ' ASN . . . . . 0.515 ' OD1' ' HB2' ' A' ' 18' ' ' GLU . 49.3 t30 -94.29 111.2 22.92 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 114.598 -1.183 . . . . 0.0 108.759 175.384 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 54' ' ' VAL . . . . . 0.562 ' HB ' ' HB1' ' A' ' 66' ' ' ALA . 34.6 m -108.69 128.52 64.34 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 CA-C-O 121.169 0.509 . . . . 0.0 111.399 -175.957 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 55' ' ' LYS . . . . . 0.505 ' HA ' ' HA ' ' A' ' 18' ' ' GLU . 2.7 ttpm? -96.34 106.43 18.65 Favored 'General case' 0 C--N 1.319 -0.757 0 N-CA-C 109.173 -0.677 . . . . 0.0 109.173 175.027 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.466 HG22 ' HB2' ' A' ' 66' ' ' ALA . 55.6 t -70.11 112.82 5.26 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 N-CA-C 109.875 -0.417 . . . . 0.0 109.875 -178.812 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 19.1 p -113.88 -9.6 13.05 Favored 'General case' 0 C--N 1.324 -0.516 0 N-CA-C 111.994 0.368 . . . . 0.0 111.994 -176.518 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -142.04 92.03 2.4 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.129 0.49 . . . . 0.0 111.064 -176.954 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 29.4 t -90.9 131.94 36.76 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.818 0 CA-C-N 115.917 -0.583 . . . . 0.0 109.89 177.363 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 32.2 mmtp -113.56 -178.18 3.31 Favored 'General case' 0 C--N 1.326 -0.452 0 N-CA-C 109.316 -0.624 . . . . 0.0 109.316 177.427 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 35.3 mt-10 -70.98 -26.42 63.14 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 113.054 0.761 . . . . 0.0 113.054 -172.179 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 62' ' ' LYS . . . . . 0.636 ' HB2' ' CD2' ' A' ' 63' ' ' PHE . 68.9 mmtt -114.97 -28.31 7.06 Favored 'General case' 0 N--CA 1.468 0.444 0 CA-C-O 121.162 0.506 . . . . 0.0 111.313 -177.03 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 63' ' ' PHE . . . . . 0.636 ' CD2' ' HB2' ' A' ' 62' ' ' LYS . 10.7 p90 -153.15 170.44 20.52 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.737 -0.665 . . . . 0.0 109.664 -172.074 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -131.57 160.18 36.04 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-O 120.769 0.318 . . . . 0.0 111.235 -179.01 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 97.8 m-85 -117.45 134.66 54.59 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 115.661 -0.699 . . . . 0.0 109.635 176.152 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 66' ' ' ALA . . . . . 0.562 ' HB1' ' HB ' ' A' ' 54' ' ' VAL . . . -124.73 177.21 6.1 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.806 -178.917 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 67' ' ' GLU . . . . . 0.557 ' O ' ' HA ' ' A' ' 54' ' ' VAL . 11.6 pt-20 -127.05 141.13 51.85 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 121.015 0.436 . . . . 0.0 111.103 -179.129 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 68' ' ' ARG . . . . . 0.563 ' HA ' HD11 ' A' ' 52' ' ' ILE . 74.5 ttt-85 -71.07 98.21 1.61 Allowed 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.979 176.211 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.41 ' O ' HD23 ' A' ' 70' ' ' LEU . 3.1 t -82.34 64.82 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-N 116.469 -0.332 . . . . 0.0 110.275 177.4 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.506 HD12 ' NE ' ' A' ' 68' ' ' ARG . 73.7 mt . . . . . 0 C--O 1.248 0.982 0 CA-C-O 118.212 -0.899 . . . . 0.0 110.092 -178.245 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 12.3 Cg_endo . . . . . 0 CA--C 1.529 0.271 0 N-CA-C 113.264 0.448 . . . . 0.0 113.264 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 12.3 m -103.07 125.97 57.43 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.602 0 CA-C-O 121.062 0.458 . . . . 0.0 111.097 -178.275 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 47.3 mt-10 -95.3 113.59 25.29 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.511 178.896 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -58.25 121.45 10.8 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.95 -0.568 . . . . 0.0 111.469 -179.016 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 115.26 -31.39 6.24 Favored Glycine 0 N--CA 1.448 -0.534 0 CA-C-N 115.895 -0.593 . . . . 0.0 112.057 -179.328 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -89.04 150.47 22.76 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 121.096 0.474 . . . . 0.0 111.02 -178.126 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 18' ' ' GLU . . . . . 0.588 ' HA ' ' HA ' ' A' ' 55' ' ' LYS . 0.7 OUTLIER -107.72 142.17 38.13 Favored 'General case' 0 C--N 1.317 -0.823 0 CA-C-N 115.546 -0.752 . . . . 0.0 110.518 179.192 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 67.1 m-85 -128.37 145.51 51.05 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.695 -176.032 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 6.2 tp10 -80.03 105.1 11.05 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 108.534 -0.913 . . . . 0.0 108.534 172.725 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 32.2 m -118.14 170.58 7.37 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-O 121.246 0.546 . . . . 0.0 112.176 -172.614 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 20.7 m -114.56 155.71 25.99 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.214 -0.903 . . . . 0.0 109.539 176.328 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.64 HG13 ' HB1' ' A' ' 46' ' ' ALA . 36.5 mm -118.62 64.66 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-O 122.127 0.965 . . . . 0.0 108.641 -175.239 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 -72.65 -8.51 55.65 Favored 'General case' 0 C--N 1.314 -0.944 0 CA-C-N 113.84 -1.527 . . . . 0.0 112.189 179.759 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.434 ' HB2' ' HB ' ' A' ' 33' ' ' ILE . 5.5 m-20 -134.61 153.93 51.74 Favored 'General case' 0 N--CA 1.465 0.288 0 N-CA-C 109.976 -0.379 . . . . 0.0 109.976 176.401 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 26' ' ' MET . . . . . 0.583 ' SD ' ' HB2' ' A' ' 48' ' ' LYS . 59.1 mtp -138.06 155.33 48.9 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.744 0.307 . . . . 0.0 110.777 174.226 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.35 0 C-N-CA 120.944 -0.646 . . . . 0.0 111.779 177.206 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 7.6 t70 . . . . . 0 C--O 1.236 0.367 0 CA-C-O 120.779 0.323 . . . . 0.0 110.68 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 32' ' ' GLY . . . . . 0.552 ' HA2' ' HA ' ' A' ' 26' ' ' MET . . . -118.06 156.6 15.57 Favored Glycine 0 N--CA 1.447 -0.613 0 N-CA-C 111.515 -0.634 . . . . 0.0 111.515 178.008 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.461 HG23 HG13 ' A' ' 40' ' ' VAL . 2.3 mp -111.5 110.21 31.37 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 CA-C-O 121.326 0.584 . . . . 0.0 110.859 -177.598 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -83.59 161.21 21.23 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.582 -0.735 . . . . 0.0 110.176 170.627 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -133.84 103.7 5.97 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.431 -179.232 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 65.5 mt -103.32 112.24 36.05 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.714 0 N-CA-C 110.006 -0.368 . . . . 0.0 110.006 177.338 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 28.9 t70 67.35 5.59 4.35 Favored 'General case' 0 N--CA 1.47 0.558 0 O-C-N 123.969 0.793 . . . . 0.0 110.899 -178.565 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 105.42 -6.26 41.9 Favored Glycine 0 C--N 1.333 0.37 0 C-N-CA 120.762 -0.732 . . . . 0.0 111.308 -173.913 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 46.6 t80 -81.57 135.56 35.57 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 109.067 -0.716 . . . . 0.0 109.067 178.09 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.461 HG13 HG23 ' A' ' 33' ' ' ILE . 43.4 t -81.98 120.79 34.18 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.196 -175.348 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 52.3 t -122.63 110.66 27.38 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.612 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.679 -179.397 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 73.9 m-85 -76.87 130.3 37.4 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.095 -178.174 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.479 ' HA ' ' HD3' ' A' ' 44' ' ' PRO . 11.7 t -123.41 110.55 30.42 Favored Pre-proline 0 C--N 1.323 -0.579 0 CA-C-N 115.644 -0.707 . . . . 0.0 109.886 -179.378 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 44' ' ' PRO . . . . . 0.479 ' HD3' ' HA ' ' A' ' 43' ' ' VAL . 32.0 Cg_exo -58.53 -30.94 93.28 Favored 'Trans proline' 0 CA--C 1.531 0.375 0 C-N-CA 123.805 3.004 . . . . 0.0 115.427 -168.154 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 34.1 m-80 -132.63 22.11 4.29 Favored 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 112.687 0.625 . . . . 0.0 112.687 -173.413 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.64 ' HB1' HG13 ' A' ' 23' ' ' ILE . . . -87.03 134.09 33.53 Favored 'General case' 0 C--N 1.318 -0.801 0 CA-C-O 120.721 0.296 . . . . 0.0 111.637 176.104 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 70.4 mm-40 -86.91 156.18 19.93 Favored 'General case' 0 C--O 1.235 0.314 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.806 178.081 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 48' ' ' LYS . . . . . 0.583 ' HB2' ' SD ' ' A' ' 26' ' ' MET . 49.7 tttm -65.44 123.68 20.26 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.864 0.364 . . . . 0.0 110.462 -179.411 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 90.93 0.05 75.39 Favored Glycine 0 N--CA 1.446 -0.67 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.784 178.097 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 69.3 m -78.82 138.52 38.21 Favored 'General case' 0 C--N 1.322 -0.601 0 C-N-CA 120.784 -0.367 . . . . 0.0 110.82 177.967 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 44.5 t -92.16 100.7 11.65 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 N-CA-C 107.859 -1.163 . . . . 0.0 107.859 173.149 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.612 HD11 ' HB2' ' A' ' 68' ' ' ARG . 2.9 tt -123.27 140.17 47.71 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.824 0 CA-C-O 121.969 0.89 . . . . 0.0 112.636 -168.455 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 48.4 t30 -86.93 114.88 23.93 Favored 'General case' 0 C--N 1.313 -0.999 0 CA-C-N 113.801 -1.545 . . . . 0.0 108.588 175.389 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 54' ' ' VAL . . . . . 0.583 ' HB ' ' HB1' ' A' ' 66' ' ' ALA . 35.7 m -118.87 132.15 69.58 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.723 0 CA-C-O 120.763 0.316 . . . . 0.0 111.329 -176.287 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 55' ' ' LYS . . . . . 0.588 ' HA ' ' HA ' ' A' ' 18' ' ' GLU . 22.5 ttmm -96.78 106.92 19.3 Favored 'General case' 0 C--N 1.324 -0.519 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 177.071 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.466 ' HA ' ' HA ' ' A' ' 66' ' ' ALA . 48.5 t -70.83 107.12 2.0 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 N-CA-C 109.901 -0.407 . . . . 0.0 109.901 -177.985 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 8.9 p -103.22 -21.86 13.81 Favored 'General case' 0 C--N 1.323 -0.578 0 N-CA-C 112.13 0.419 . . . . 0.0 112.13 -174.293 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -135.41 92.15 2.81 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 121.225 0.536 . . . . 0.0 110.781 -175.882 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 45.3 t -88.49 117.16 31.53 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.735 0 CA-C-N 115.583 -0.735 . . . . 0.0 110.591 177.509 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 60' ' ' LYS . . . . . 0.527 ' HB2' ' O ' ' A' ' 63' ' ' PHE . 4.9 mptp? -97.59 -168.84 1.74 Allowed 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 109.61 -0.515 . . . . 0.0 109.61 174.894 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 34.6 mt-10 -70.54 -53.77 14.79 Favored 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 111.979 0.362 . . . . 0.0 111.979 -176.903 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -93.46 -29.35 15.6 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 120.976 0.417 . . . . 0.0 112.113 -174.293 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 63' ' ' PHE . . . . . 0.527 ' O ' ' HB2' ' A' ' 60' ' ' LYS . 16.2 p90 -151.75 164.65 36.53 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.735 -174.66 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -125.45 163.91 21.6 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-O 120.749 0.309 . . . . 0.0 110.958 -178.648 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 98.4 m-85 -116.06 130.17 56.68 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-N 115.783 -0.644 . . . . 0.0 109.286 176.214 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 66' ' ' ALA . . . . . 0.583 ' HB1' ' HB ' ' A' ' 54' ' ' VAL . . . -121.4 154.64 36.24 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-O 121.195 0.521 . . . . 0.0 111.778 -175.504 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 30.1 tt0 -101.87 116.41 32.64 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-N 115.243 -0.89 . . . . 0.0 111.531 -177.294 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 68' ' ' ARG . . . . . 0.612 ' HB2' HD11 ' A' ' 52' ' ' ILE . 15.5 ttt-85 -54.03 108.06 0.33 Allowed 'General case' 0 CA--C 1.536 0.405 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.678 172.159 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.428 ' O ' HG12 ' A' ' 69' ' ' VAL . 12.2 t -82.01 12.26 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.328 0 CA-C-O 122.211 1.005 . . . . 0.0 110.324 179.707 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 54.9 mt . . . . . 0 C--N 1.316 -0.877 0 CA-C-N 114.932 -1.031 . . . . 0.0 109.148 176.773 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo . . . . . 0 N--CA 1.473 0.267 0 N-CA-C 113.143 0.401 . . . . 0.0 113.143 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 24.0 m -130.51 134.78 61.73 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.584 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.09 -178.577 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 14' ' ' GLU . . . . . 0.657 ' HB2' ' HG3' ' A' ' 17' ' ' LYS . 2.9 mp0 -110.24 136.33 49.62 Favored 'General case' 0 C--N 1.318 -0.798 0 CA-C-O 120.827 0.346 . . . . 0.0 110.671 179.191 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 15' ' ' ALA . . . . . 0.463 ' HA ' ' O ' ' A' ' 56' ' ' VAL . . . -64.12 117.77 7.58 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 115.795 -0.638 . . . . 0.0 110.551 176.578 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 112.23 -7.49 26.9 Favored Glycine 0 N--CA 1.446 -0.652 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.633 179.753 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 17' ' ' LYS . . . . . 0.657 ' HG3' ' HB2' ' A' ' 14' ' ' GLU . 12.8 mmmm -93.08 155.69 17.34 Favored 'General case' 0 C--N 1.326 -0.448 0 O-C-N 122.604 -0.35 . . . . 0.0 110.448 -179.867 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 18' ' ' GLU . . . . . 0.486 ' HB3' ' OD1' ' A' ' 53' ' ' ASN . 0.7 OUTLIER -113.85 118.49 34.37 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 109.065 -0.717 . . . . 0.0 109.065 172.71 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 19' ' ' TYR . . . . . 0.408 ' CE2' ' HB2' ' A' ' 17' ' ' LYS . 64.7 m-85 -112.37 140.77 46.82 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-O 121.142 0.496 . . . . 0.0 111.614 -177.334 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 36.2 tt0 -84.42 99.21 10.52 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.09 -0.959 . . . . 0.0 109.193 176.727 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 35.8 m -114.58 171.25 4.45 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.57 0 CA-C-O 121.21 0.529 . . . . 0.0 112.168 -170.986 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 23.4 m -115.36 153.37 31.13 Favored 'General case' 0 N--CA 1.45 -0.445 0 CA-C-N 115.244 -0.889 . . . . 0.0 109.749 175.917 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.615 HG13 ' HB1' ' A' ' 46' ' ' ALA . 37.5 mm -119.1 65.33 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-O 122.056 0.931 . . . . 0.0 108.927 -173.984 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -64.46 -17.43 63.83 Favored 'General case' 0 C--N 1.318 -0.796 0 CA-C-N 113.977 -1.465 . . . . 0.0 111.816 177.737 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.529 ' HB3' ' HB ' ' A' ' 33' ' ' ILE . 27.0 t0 -136.02 151.46 49.9 Favored 'General case' 0 C--N 1.324 -0.517 0 C-N-CA 121.064 -0.254 . . . . 0.0 110.824 -176.539 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 26' ' ' MET . . . . . 0.668 ' SD ' ' HB2' ' A' ' 48' ' ' LYS . 70.1 mtp -137.33 152.75 50.07 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.724 0.297 . . . . 0.0 110.22 175.521 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.448 -0.507 0 C-N-CA 120.969 -0.634 . . . . 0.0 111.56 177.726 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 31' ' ' ASP . . . . . 0.625 ' HA ' ' HA ' ' A' ' 44' ' ' PRO . 27.6 m-20 . . . . . 0 CA--C 1.522 -0.103 0 CA-C-O 121.021 0.439 . . . . 0.0 111.331 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -106.62 143.24 15.76 Favored Glycine 0 N--CA 1.444 -0.778 0 N-CA-C 110.2 -1.16 . . . . 0.0 110.2 171.614 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.529 ' HB ' ' HB3' ' A' ' 25' ' ' ASP . 2.1 mp -103.49 105.36 18.19 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.752 0 CA-C-O 121.354 0.597 . . . . 0.0 111.123 -173.761 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -86.99 155.77 20.04 Favored 'General case' 0 N--CA 1.444 -0.733 0 N-CA-C 108.134 -1.061 . . . . 0.0 108.134 166.572 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 37.0 ttt180 -141.93 118.36 10.88 Favored 'General case' 0 C--N 1.314 -0.956 0 C-N-CA 120.031 -0.668 . . . . 0.0 110.376 179.278 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 27.0 mt -109.27 108.7 26.0 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.664 0 CA-C-N 115.458 -0.792 . . . . 0.0 110.397 -179.37 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 31.7 t70 65.29 19.55 11.7 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.121 -0.945 . . . . 0.0 110.932 179.006 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 99.81 -9.39 60.16 Favored Glycine 0 N--CA 1.449 -0.445 0 C-N-CA 120.207 -0.997 . . . . 0.0 111.788 -177.43 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 54.1 t80 -82.75 118.84 23.66 Favored 'General case' 0 C--N 1.322 -0.62 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 177.672 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 17.0 t -75.08 122.93 29.74 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-O 120.993 0.425 . . . . 0.0 111.193 -174.961 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 45.3 t -115.86 109.29 27.69 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-N 116.202 -0.454 . . . . 0.0 109.863 179.646 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 85.6 m-85 -80.35 119.22 22.78 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 121.039 0.447 . . . . 0.0 110.752 -178.327 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.464 HG11 HD13 ' A' ' 52' ' ' ILE . 3.2 t -115.13 101.41 54.47 Favored Pre-proline 0 C--N 1.32 -0.706 0 CA-C-N 115.677 -0.692 . . . . 0.0 109.379 178.567 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 44' ' ' PRO . . . . . 0.625 ' HA ' ' HA ' ' A' ' 31' ' ' ASP . 16.9 Cg_exo -68.12 5.27 1.19 Allowed 'Trans proline' 0 CA--C 1.531 0.374 0 C-N-CA 123.383 2.722 . . . . 0.0 114.818 -168.721 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 47.5 m-80 -143.43 14.61 1.81 Allowed 'General case' 0 N--CA 1.464 0.225 0 CA-C-O 120.632 0.253 . . . . 0.0 111.609 179.553 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.615 ' HB1' HG13 ' A' ' 23' ' ' ILE . . . -86.43 134.1 33.72 Favored 'General case' 0 C--N 1.32 -0.713 0 N-CA-C 112.018 0.377 . . . . 0.0 112.018 -178.86 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 44.2 mt-10 -92.83 146.18 23.83 Favored 'General case' 0 N--CA 1.454 -0.266 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.976 177.281 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 48' ' ' LYS . . . . . 0.668 ' HB2' ' SD ' ' A' ' 26' ' ' MET . 46.8 tttp -65.43 129.93 41.51 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.051 -0.522 . . . . 0.0 111.136 -177.916 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 88.17 -5.42 84.83 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.827 -0.702 . . . . 0.0 113.397 176.005 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 51.1 m -95.14 147.78 23.08 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.872 0.336 . . . . 0.0 110.796 -179.329 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 46.0 t -91.91 109.59 21.54 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 N-CA-C 109.23 -0.656 . . . . 0.0 109.23 178.14 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.842 HG13 HD21 ' A' ' 70' ' ' LEU . 2.5 tt -119.57 143.41 31.13 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.819 0 CA-C-O 121.853 0.835 . . . . 0.0 112.403 -170.568 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 53' ' ' ASN . . . . . 0.486 ' OD1' ' HB3' ' A' ' 18' ' ' GLU . 23.5 t-20 -89.56 114.19 25.72 Favored 'General case' 0 C--N 1.316 -0.869 0 CA-C-N 114.051 -1.432 . . . . 0.0 108.543 175.406 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 54' ' ' VAL . . . . . 0.533 ' HB ' ' HB1' ' A' ' 66' ' ' ALA . 32.6 m -114.67 128.26 71.84 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 CA-C-O 121.264 0.554 . . . . 0.0 111.856 -175.601 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 55' ' ' LYS . . . . . 0.589 ' HA ' ' O ' ' A' ' 17' ' ' LYS . 38.2 ttmt -95.13 104.44 16.32 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 115.912 -0.585 . . . . 0.0 109.496 173.976 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.463 ' O ' ' HA ' ' A' ' 15' ' ' ALA . 66.0 t -66.09 110.48 1.35 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 N-CA-C 109.681 -0.489 . . . . 0.0 109.681 179.575 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 11.5 p -105.83 -28.86 10.39 Favored 'General case' 0 C--N 1.324 -0.54 0 N-CA-C 112.247 0.462 . . . . 0.0 112.247 -174.449 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -136.99 92.42 2.73 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 121.12 0.486 . . . . 0.0 110.978 -175.47 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 22.4 t -81.62 125.1 39.58 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.667 0 CA-C-N 115.623 -0.717 . . . . 0.0 110.017 176.225 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 32.2 mmtp -109.47 -150.21 0.45 Allowed 'General case' 0 C--N 1.325 -0.458 0 N-CA-C 109.951 -0.389 . . . . 0.0 109.951 178.484 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 20.2 mm-40 -70.78 -76.89 0.09 Allowed 'General case' 0 C--N 1.331 -0.239 0 N-CA-C 112.18 0.437 . . . . 0.0 112.18 -176.105 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 63.7 mttm -98.22 -2.57 39.39 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 121.182 0.515 . . . . 0.0 110.821 -175.652 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 35.7 p90 -151.37 164.97 35.5 Favored 'General case' 0 C--N 1.318 -0.761 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.725 -173.138 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -137.91 171.02 15.04 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.603 178.182 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 96.8 m-85 -118.92 133.81 55.59 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 109.493 -0.558 . . . . 0.0 109.493 176.702 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 66' ' ' ALA . . . . . 0.533 ' HB1' ' HB ' ' A' ' 54' ' ' VAL . . . -133.95 145.11 49.24 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.464 -179.001 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 67' ' ' GLU . . . . . 0.504 ' HG2' ' HB3' ' A' ' 55' ' ' LYS . 9.6 pt-20 -93.67 142.22 27.6 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-O 121.179 0.514 . . . . 0.0 111.408 -177.83 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 68' ' ' ARG . . . . . 0.567 ' HB2' HD11 ' A' ' 52' ' ' ILE . 17.8 ttt180 -71.17 109.96 5.54 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.341 -0.845 . . . . 0.0 110.043 173.721 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.489 ' O ' HG12 ' A' ' 69' ' ' VAL . 40.7 t -81.66 12.75 0.58 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.518 0 CA-C-O 122.076 0.941 . . . . 0.0 111.505 -176.415 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.842 HD21 HG13 ' A' ' 52' ' ' ILE . 1.0 OUTLIER . . . . . 0 C--N 1.314 -0.952 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.397 -179.333 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 94.8 Cg_endo . . . . . 0 N--CA 1.47 0.134 0 N-CA-C 113.18 0.415 . . . . 0.0 113.18 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.539 ' HB ' HG21 ' A' ' 56' ' ' VAL . 17.0 m -97.34 124.36 50.2 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.724 0 CA-C-N 115.857 -0.611 . . . . 0.0 110.779 -175.714 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 14' ' ' GLU . . . . . 0.475 ' OE2' ' HE2' ' A' ' 17' ' ' LYS . 31.7 tt0 -104.04 129.04 51.65 Favored 'General case' 0 C--N 1.322 -0.613 0 C-N-CA 120.85 -0.34 . . . . 0.0 110.105 -179.734 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -54.42 118.49 4.18 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.79 -0.641 . . . . 0.0 111.155 -178.477 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.31 -25.75 10.98 Favored Glycine 0 N--CA 1.444 -0.826 0 C-N-CA 120.671 -0.776 . . . . 0.0 112.448 179.941 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 17' ' ' LYS . . . . . 0.475 ' HE2' ' OE2' ' A' ' 14' ' ' GLU . 68.6 mttm -85.55 160.48 19.64 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 120.938 0.399 . . . . 0.0 110.457 179.034 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 18' ' ' GLU . . . . . 0.51 ' HA ' ' HA ' ' A' ' 55' ' ' LYS . 0.0 OUTLIER -126.87 133.32 50.74 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.449 179.052 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 19' ' ' TYR . . . . . 0.416 ' CE2' ' HA ' ' A' ' 13' ' ' VAL . 64.4 m-85 -123.14 162.6 22.19 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.331 -176.589 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 45.4 tt0 -96.58 122.39 39.44 Favored 'General case' 0 C--N 1.321 -0.665 0 N-CA-C 109.398 -0.593 . . . . 0.0 109.398 176.323 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.527 ' HB ' ' HB1' ' A' ' 34' ' ' ALA . 28.0 m -128.84 168.88 21.21 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-O 121.131 0.491 . . . . 0.0 111.587 -174.62 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 26.2 m -118.88 143.22 47.11 Favored 'General case' 0 N--CA 1.446 -0.65 0 CA-C-N 115.755 -0.657 . . . . 0.0 109.359 175.313 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.559 HG13 ' HB1' ' A' ' 46' ' ' ALA . 19.9 mm -111.77 59.53 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.664 0 CA-C-O 121.997 0.903 . . . . 0.0 108.755 -173.284 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -78.17 9.69 3.57 Favored 'General case' 0 C--N 1.315 -0.921 0 CA-C-N 114.573 -1.194 . . . . 0.0 112.229 -177.555 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.445 ' HB3' ' HB ' ' A' ' 33' ' ' ILE . 29.1 t0 -150.11 148.31 28.82 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.444 -0.344 . . . . 0.0 110.119 176.91 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 26' ' ' MET . . . . . 0.652 ' HA ' ' HA2' ' A' ' 32' ' ' GLY . 39.4 mtp -123.99 151.93 43.13 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.999 0.428 . . . . 0.0 111.157 178.649 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.445 -0.758 0 CA-C-N 115.554 -0.748 . . . . 0.0 112.709 -177.421 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.7 p30 . . . . . 0 N--CA 1.452 -0.333 0 CA-C-O 120.882 0.372 . . . . 0.0 110.013 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 32' ' ' GLY . . . . . 0.652 ' HA2' ' HA ' ' A' ' 26' ' ' MET . . . -128.57 172.78 19.33 Favored Glycine 0 N--CA 1.442 -0.95 0 C-N-CA 120.824 -0.703 . . . . 0.0 112.46 -177.384 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.445 ' HB ' ' HB3' ' A' ' 25' ' ' ASP . 2.2 mp -114.03 121.93 67.14 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.71 0 CA-C-O 120.947 0.403 . . . . 0.0 110.34 -179.949 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 34' ' ' ALA . . . . . 0.527 ' HB1' ' HB ' ' A' ' 21' ' ' VAL . . . -116.92 117.18 28.98 Favored 'General case' 0 C--N 1.317 -0.805 0 N-CA-C 108.804 -0.813 . . . . 0.0 108.804 172.663 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 35' ' ' ARG . . . . . 0.404 HH11 ' HD3' ' A' ' 35' ' ' ARG . 28.2 ttp180 -104.25 110.67 22.97 Favored 'General case' 0 C--N 1.318 -0.795 0 CA-C-O 121.143 0.497 . . . . 0.0 111.224 -172.735 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 43.7 mt -99.75 110.11 26.19 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-N 115.443 -0.799 . . . . 0.0 110.385 178.992 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 56.6 27.71 12.87 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.217 -0.902 . . . . 0.0 112.081 -179.837 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 100.17 -14.61 59.71 Favored Glycine 0 C--N 1.33 0.207 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.014 -179.627 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 65.9 t80 -85.04 135.44 34.01 Favored 'General case' 0 C--N 1.321 -0.65 0 N-CA-C 109.554 -0.536 . . . . 0.0 109.554 -178.585 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 34.0 t -88.2 117.06 31.17 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-O 121.162 0.506 . . . . 0.0 111.239 -175.424 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 40.8 t -112.51 118.78 58.7 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.686 0 CA-C-N 115.695 -0.684 . . . . 0.0 109.273 174.952 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 76.3 m-85 -87.07 132.04 33.94 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-O 121.194 0.521 . . . . 0.0 111.47 -177.474 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.554 HG21 HD12 ' A' ' 23' ' ' ILE . 15.5 m -111.54 124.2 33.09 Favored Pre-proline 0 C--N 1.324 -0.513 0 CA-C-N 115.461 -0.79 . . . . 0.0 110.336 178.377 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 44' ' ' PRO . . . . . 0.494 ' HD3' ' HA ' ' A' ' 43' ' ' VAL . 13.5 Cg_exo -71.42 -34.54 9.47 Favored 'Trans proline' 0 CA--C 1.527 0.175 0 C-N-CA 123.05 2.5 . . . . 0.0 113.667 -175.495 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 4.5 p30 -136.12 34.36 2.82 Favored 'General case' 0 C--N 1.325 -0.46 0 N-CA-C 112.887 0.699 . . . . 0.0 112.887 -167.092 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.559 ' HB1' HG13 ' A' ' 23' ' ' ILE . . . -90.41 161.33 15.62 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 120.991 0.424 . . . . 0.0 112.125 175.562 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 47' ' ' GLU . . . . . 0.526 ' CD ' HH12 ' A' ' 68' ' ' ARG . 2.1 mp0 -102.61 147.16 27.14 Favored 'General case' 0 C--O 1.235 0.302 0 CA-C-N 115.871 -0.604 . . . . 0.0 109.741 170.867 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 48' ' ' LYS . . . . . 0.505 ' HE3' ' SD ' ' A' ' 26' ' ' MET . 9.3 ptpp? -66.54 139.98 57.95 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.15 0.5 . . . . 0.0 111.061 -179.859 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 73.33 13.94 79.53 Favored Glycine 0 N--CA 1.45 -0.375 0 CA-C-N 115.861 -0.609 . . . . 0.0 112.764 177.513 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 8.5 t -107.46 151.2 25.87 Favored 'General case' 0 C--N 1.323 -0.57 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 178.647 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 57.9 t -104.1 104.92 17.52 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 N-CA-C 109.554 -0.535 . . . . 0.0 109.554 179.266 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.552 HD12 ' HB2' ' A' ' 68' ' ' ARG . 0.9 OUTLIER -113.97 154.94 15.27 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.512 -174.556 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 28.6 t-20 -95.29 119.95 34.68 Favored 'General case' 0 C--N 1.321 -0.665 0 N-CA-C 109.001 -0.741 . . . . 0.0 109.001 174.508 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 54' ' ' VAL . . . . . 0.492 ' HB ' ' HB1' ' A' ' 66' ' ' ALA . 27.8 m -112.08 131.92 62.18 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.664 0 CA-C-O 121.08 0.467 . . . . 0.0 111.738 -175.43 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 55' ' ' LYS . . . . . 0.51 ' HA ' ' HA ' ' A' ' 18' ' ' GLU . 6.3 ttpm? -100.06 109.54 21.85 Favored 'General case' 0 C--N 1.318 -0.786 0 N-CA-C 108.74 -0.837 . . . . 0.0 108.74 173.321 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.539 HG21 ' HB ' ' A' ' 13' ' ' VAL . 39.1 t -72.28 114.02 10.45 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.551 -176.321 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 7.9 p -108.15 -18.14 13.85 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 116.196 -0.456 . . . . 0.0 112.004 -177.523 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 58' ' ' ALA . . . . . 0.407 ' HB3' ' HB2' ' A' ' 65' ' ' PHE . . . -134.57 91.1 2.74 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 121.217 0.532 . . . . 0.0 110.591 -177.85 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 19.0 t -90.25 134.61 28.67 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.781 0 CA-C-N 115.298 -0.865 . . . . 0.0 110.801 179.156 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 60' ' ' LYS . . . . . 0.509 ' HB2' ' O ' ' A' ' 63' ' ' PHE . 75.4 mmtt -119.03 172.52 7.49 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 121.172 0.51 . . . . 0.0 110.563 174.351 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 42.2 tt0 -69.75 -29.34 66.68 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.072 -0.967 . . . . 0.0 109.428 173.691 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 62' ' ' LYS . . . . . 0.465 ' O ' ' CG ' ' A' ' 63' ' ' PHE . 38.6 mtmt -129.11 87.26 2.54 Favored 'General case' 0 N--CA 1.416 -2.154 0 N-CA-C 105.314 -2.106 . . . . 0.0 105.314 177.587 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 63' ' ' PHE . . . . . 0.509 ' O ' ' HB2' ' A' ' 60' ' ' LYS . 20.5 p90 78.89 142.25 0.08 Allowed 'General case' 0 N--CA 1.488 1.462 0 CA-C-N 112.903 -1.953 . . . . 0.0 112.17 164.658 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -117.1 169.58 9.32 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.452 -0.795 . . . . 0.0 111.894 -170.322 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 65' ' ' PHE . . . . . 0.407 ' HB2' ' HB3' ' A' ' 58' ' ' ALA . 79.5 m-85 -120.26 133.55 55.45 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 115.359 -0.837 . . . . 0.0 109.396 177.949 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 66' ' ' ALA . . . . . 0.537 ' HB2' HG22 ' A' ' 56' ' ' VAL . . . -134.81 148.04 50.09 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 120.922 0.391 . . . . 0.0 111.23 -177.271 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 11.1 pt-20 -94.27 132.63 38.65 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.914 -178.826 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 68' ' ' ARG . . . . . 0.926 ' HE ' HD12 ' A' ' 70' ' ' LEU . 31.0 ttt180 -67.02 106.39 1.93 Allowed 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.449 -0.796 . . . . 0.0 110.728 175.717 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 18.9 t -80.53 66.45 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.535 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.015 179.55 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.926 HD12 ' HE ' ' A' ' 68' ' ' ARG . 70.8 mt . . . . . 0 C--O 1.246 0.896 0 CA-C-N 115.687 -0.688 . . . . 0.0 109.466 178.266 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 12' ' ' PRO . . . . . 0.436 ' HG2' ' HB2' ' A' ' 39' ' ' PHE . 16.9 Cg_exo . . . . . 0 C--O 1.233 0.253 0 CA-C-O 121.364 0.485 . . . . 0.0 112.095 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.793 HG12 HD12 ' A' ' 36' ' ' ILE . 31.0 m -107.49 149.84 10.55 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 CA-C-N 115.267 -0.878 . . . . 0.0 110.465 -176.715 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -124.35 136.71 54.3 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-O 120.862 0.363 . . . . 0.0 110.393 177.905 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -70.54 106.59 3.51 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.996 -178.217 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 120.68 -13.1 10.02 Favored Glycine 0 N--CA 1.446 -0.653 0 C-N-CA 120.924 -0.655 . . . . 0.0 112.329 -179.719 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 8.1 mtpm? -102.56 156.74 17.41 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.724 0.297 . . . . 0.0 110.907 -178.87 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 18' ' ' GLU . . . . . 0.563 ' HA ' ' O ' ' A' ' 54' ' ' VAL . 0.0 OUTLIER -112.16 142.01 45.14 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 121.166 0.508 . . . . 0.0 111.375 -179.074 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 19' ' ' TYR . . . . . 0.563 ' O ' ' HA ' ' A' ' 53' ' ' ASN . 81.4 m-85 -130.64 141.74 50.43 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 116.051 -0.522 . . . . 0.0 111.121 -176.085 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 37.7 mt-10 -79.79 98.85 7.21 Favored 'General case' 0 C--N 1.326 -0.456 0 N-CA-C 109.3 -0.63 . . . . 0.0 109.3 174.835 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.488 ' HB ' ' HB1' ' A' ' 34' ' ' ALA . 35.8 m -110.3 156.2 11.36 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.81 0 CA-C-N 115.787 -0.642 . . . . 0.0 111.526 -174.275 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 24.2 m -105.09 148.73 26.51 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 115.407 -0.815 . . . . 0.0 109.77 176.07 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.534 HG13 ' HB1' ' A' ' 46' ' ' ALA . 33.6 mm -114.45 65.91 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.783 0 N-CA-C 108.053 -1.091 . . . . 0.0 108.053 -174.662 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 -62.25 -24.89 67.52 Favored 'General case' 0 C--N 1.312 -1.025 0 CA-C-N 113.621 -1.627 . . . . 0.0 111.552 178.974 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.529 ' HB3' ' HB ' ' A' ' 33' ' ' ILE . 5.9 t70 -133.7 152.03 51.78 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.521 -0.309 . . . . 0.0 111.125 -170.166 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 26' ' ' MET . . . . . 0.522 ' SD ' ' HB2' ' A' ' 48' ' ' LYS . 18.0 mtp -129.84 161.7 30.18 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 121.018 0.437 . . . . 0.0 110.73 176.341 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.448 -0.52 0 CA-C-N 115.74 -0.664 . . . . 0.0 111.957 177.282 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 16.2 m-20 . . . . . 0 CA--C 1.514 -0.442 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -96.53 122.35 7.34 Favored Glycine 0 N--CA 1.444 -0.815 0 N-CA-C 110.563 -1.015 . . . . 0.0 110.563 174.468 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.529 ' HB ' ' HB3' ' A' ' 25' ' ' ASP . 1.9 mp -95.84 100.67 11.32 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.698 0 CA-C-O 121.426 0.631 . . . . 0.0 110.462 -176.798 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 34' ' ' ALA . . . . . 0.488 ' HB1' ' HB ' ' A' ' 21' ' ' VAL . . . -99.4 162.04 13.27 Favored 'General case' 0 CA--C 1.495 -1.16 0 CA-C-N 115.265 -0.879 . . . . 0.0 108.947 168.563 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 35' ' ' ARG . . . . . 0.4 ' HA ' ' O ' ' A' ' 39' ' ' PHE . 29.0 ptt180 -156.65 119.64 4.12 Favored 'General case' 0 N--CA 1.43 -1.47 0 CA-C-O 121.423 0.63 . . . . 0.0 110.859 -177.379 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.793 HD12 HG12 ' A' ' 13' ' ' VAL . 43.9 mt -96.67 111.21 26.25 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.829 0 CA-C-N 115.186 -0.915 . . . . 0.0 110.349 -175.175 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 25.9 t0 57.97 29.18 17.3 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 114.685 -1.143 . . . . 0.0 110.836 -177.871 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 103.63 -22.69 34.98 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.957 -0.639 . . . . 0.0 112.347 179.401 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 39' ' ' PHE . . . . . 0.436 ' HB2' ' HG2' ' A' ' 12' ' ' PRO . 63.3 t80 -74.86 112.54 11.19 Favored 'General case' 0 C--N 1.324 -0.519 0 N-CA-C 109.959 -0.386 . . . . 0.0 109.959 -178.299 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 41.2 t -69.14 123.9 23.71 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 CA-C-O 121.42 0.628 . . . . 0.0 111.84 -174.791 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 25.5 t -121.8 109.23 24.0 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.691 0 CA-C-N 115.233 -0.894 . . . . 0.0 109.18 -179.884 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 87.9 m-85 -77.11 124.47 27.85 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.176 -176.39 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.42 ' CG1' ' HB2' ' A' ' 46' ' ' ALA . 2.7 t -122.01 98.96 44.37 Favored Pre-proline 0 C--N 1.325 -0.48 0 CA-C-N 115.753 -0.658 . . . . 0.0 110.534 -179.377 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -74.11 -0.16 9.2 Favored 'Trans proline' 0 CA--C 1.53 0.312 0 C-N-CA 122.704 2.269 . . . . 0.0 113.458 -175.752 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 45' ' ' ASN . . . . . 0.441 ' HB2' ' HB3' ' A' ' 68' ' ' ARG . 70.3 m-20 -125.57 8.25 7.66 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 121.099 0.476 . . . . 0.0 110.91 -175.132 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.534 ' HB1' HG13 ' A' ' 23' ' ' ILE . . . -91.03 153.25 20.27 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 112.069 0.396 . . . . 0.0 112.069 -176.176 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 5.4 mm-40 -105.04 135.9 45.52 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.444 -0.798 . . . . 0.0 110.433 176.426 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 48' ' ' LYS . . . . . 0.522 ' HB2' ' SD ' ' A' ' 26' ' ' MET . 14.3 tmtt? -65.14 136.65 56.95 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.494 -179.895 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 70.64 23.44 77.73 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.993 -0.622 . . . . 0.0 112.522 179.069 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 23.3 t -122.36 145.89 47.83 Favored 'General case' 0 C--N 1.321 -0.654 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 179.518 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 52.8 t -90.44 101.62 12.51 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 N-CA-C 109.53 -0.545 . . . . 0.0 109.53 177.839 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.561 HD11 ' HB2' ' A' ' 68' ' ' ARG . 0.9 OUTLIER -119.29 140.96 41.48 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.749 0 CA-C-N 115.768 -0.651 . . . . 0.0 111.034 -175.29 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 53' ' ' ASN . . . . . 0.563 ' HA ' ' O ' ' A' ' 19' ' ' TYR . 3.9 p30 -97.81 118.06 33.5 Favored 'General case' 0 C--N 1.313 -0.99 0 CA-C-N 115.128 -0.942 . . . . 0.0 109.016 176.288 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 54' ' ' VAL . . . . . 0.563 ' O ' ' HA ' ' A' ' 18' ' ' GLU . 35.3 m -111.67 140.96 28.66 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.765 0 CA-C-N 115.304 -0.862 . . . . 0.0 111.731 -173.481 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 25.6 ttmt -94.96 109.22 21.26 Favored 'General case' 0 C--N 1.319 -0.724 0 N-CA-C 109.212 -0.662 . . . . 0.0 109.212 177.389 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.456 HG21 ' HB ' ' A' ' 13' ' ' VAL . 60.5 t -70.56 113.26 6.37 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 N-CA-C 109.53 -0.544 . . . . 0.0 109.53 179.516 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.9 p -111.42 -14.97 13.66 Favored 'General case' 0 C--N 1.323 -0.587 0 N-CA-C 112.32 0.489 . . . . 0.0 112.32 -173.077 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 58' ' ' ALA . . . . . 0.433 ' HB3' ' HB2' ' A' ' 65' ' ' PHE . . . -145.82 93.38 2.33 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.947 0.403 . . . . 0.0 111.048 -176.214 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 21.9 t -87.6 122.93 39.93 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 CA-C-N 116.061 -0.518 . . . . 0.0 109.919 176.085 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 32.3 mmtp -109.15 -165.26 1.0 Allowed 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.668 -0.242 . . . . 0.0 110.375 179.832 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 61' ' ' GLU . . . . . 0.471 ' CD ' ' H ' ' A' ' 61' ' ' GLU . 4.1 mp0 -64.25 -54.05 39.44 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.752 -175.925 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 88.9 mttt -108.82 -19.78 13.29 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.838 -171.533 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 23.9 p90 -150.13 175.02 12.13 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.589 -175.111 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -137.29 167.45 21.56 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-O 120.808 0.337 . . . . 0.0 111.024 179.378 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 65' ' ' PHE . . . . . 0.433 ' HB2' ' HB3' ' A' ' 58' ' ' ALA . 90.8 m-85 -119.63 135.17 54.92 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.753 -0.658 . . . . 0.0 109.822 177.211 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 66' ' ' ALA . . . . . 0.513 ' HB1' ' HB ' ' A' ' 54' ' ' VAL . . . -132.38 154.99 49.24 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.321 -0.399 . . . . 0.0 111.043 -178.926 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 13.7 pt-20 -111.81 143.49 42.67 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 121.088 0.471 . . . . 0.0 111.11 -179.408 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 68' ' ' ARG . . . . . 0.561 ' HB2' HD11 ' A' ' 52' ' ' ILE . 27.3 ttt180 -66.69 114.18 5.4 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.469 -0.787 . . . . 0.0 111.135 174.255 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 3.7 t -83.14 5.85 1.9 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 121.7 0.762 . . . . 0.0 110.915 176.761 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.408 ' HB2' ' HG3' ' A' ' 68' ' ' ARG . 68.7 mt . . . . . 0 C--N 1.315 -0.935 0 CA-C-N 115.305 -0.861 . . . . 0.0 110.588 -177.602 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo . . . . . 0 C--O 1.231 0.173 0 CA-C-O 121.342 0.476 . . . . 0.0 112.51 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.583 HG12 HD12 ' A' ' 36' ' ' ILE . 6.0 m -73.51 130.9 35.61 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.718 0 CA-C-N 115.06 -0.973 . . . . 0.0 111.932 -173.525 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -102.45 119.09 38.22 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.754 -0.657 . . . . 0.0 109.372 177.858 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -68.17 108.69 3.24 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 120.975 0.417 . . . . 0.0 110.752 -178.565 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 127.54 -23.87 5.33 Favored Glycine 0 N--CA 1.443 -0.854 0 C-N-CA 120.814 -0.708 . . . . 0.0 112.409 -179.695 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 17' ' ' LYS . . . . . 0.407 ' HE3' ' HB3' ' A' ' 17' ' ' LYS . 24.0 mtpp -104.19 165.95 10.72 Favored 'General case' 0 C--O 1.235 0.336 0 CA-C-O 121.019 0.438 . . . . 0.0 111.28 179.613 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 18' ' ' GLU . . . . . 0.536 ' HA ' ' HA ' ' A' ' 55' ' ' LYS . 0.2 OUTLIER -117.8 151.06 38.09 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.719 -0.673 . . . . 0.0 111.067 -177.584 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 72.6 m-85 -139.01 145.68 39.94 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.694 -0.684 . . . . 0.0 109.504 179.245 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 20' ' ' GLU . . . . . 0.551 ' HG2' HG12 ' A' ' 51' ' ' VAL . 42.6 tt0 -85.32 108.18 17.68 Favored 'General case' 0 C--N 1.32 -0.692 0 N-CA-C 109.529 -0.545 . . . . 0.0 109.529 176.756 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 34.4 m -122.8 165.66 18.56 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.968 -172.61 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 9.0 m -102.31 148.01 25.99 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-O 120.965 0.412 . . . . 0.0 110.543 179.801 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.455 HG13 ' HB1' ' A' ' 46' ' ' ALA . 29.3 mm -112.97 61.59 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 N-CA-C 107.916 -1.142 . . . . 0.0 107.916 -177.471 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 13.1 tp10 -64.12 -17.07 63.09 Favored 'General case' 0 C--N 1.317 -0.843 0 CA-C-N 113.283 -1.78 . . . . 0.0 111.67 -177.29 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 33.3 t70 -145.41 152.21 39.47 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 116.483 -0.326 . . . . 0.0 110.196 -173.236 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 26' ' ' MET . . . . . 0.655 ' HA ' ' HA2' ' A' ' 32' ' ' GLY . 33.3 mtp -128.25 157.18 41.61 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 121.171 0.51 . . . . 0.0 110.974 177.866 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.503 ' HA3' ' OD2' ' A' ' 31' ' ' ASP . . . . . . . . 0 N--CA 1.445 -0.732 0 CA-C-N 115.66 -0.7 . . . . 0.0 112.724 -176.564 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 31' ' ' ASP . . . . . 0.503 ' OD2' ' HA3' ' A' ' 27' ' ' GLY . 12.1 p-10 . . . . . 0 N--CA 1.453 -0.311 0 N-CA-C 109.611 -0.514 . . . . 0.0 109.611 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 32' ' ' GLY . . . . . 0.655 ' HA2' ' HA ' ' A' ' 26' ' ' MET . . . -117.78 158.79 14.46 Favored Glycine 0 N--CA 1.445 -0.709 0 C-N-CA 121.032 -0.604 . . . . 0.0 112.154 -179.154 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 2.2 mp -108.88 106.89 21.56 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.5 0 CA-C-O 121.175 0.512 . . . . 0.0 110.103 178.682 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 34' ' ' ALA . . . . . 0.445 ' HB3' ' HB ' ' A' ' 41' ' ' VAL . . . -90.84 152.92 20.57 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.6 -0.727 . . . . 0.0 109.842 172.278 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -122.14 113.46 19.53 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.556 -178.274 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.583 HD12 HG12 ' A' ' 13' ' ' VAL . 38.7 mt -110.39 105.81 19.53 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.758 0 CA-C-O 121.085 0.469 . . . . 0.0 109.985 175.2 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 26.9 t0 55.18 36.69 27.55 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 114.852 -1.067 . . . . 0.0 110.663 -178.528 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 94.27 -19.93 50.68 Favored Glycine 0 C--N 1.333 0.394 0 C-N-CA 120.976 -0.63 . . . . 0.0 112.787 -179.807 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 78.3 t80 -77.13 142.54 39.66 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 110.098 -0.334 . . . . 0.0 110.098 -175.258 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 11.1 t -88.25 114.64 27.12 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 CA-C-N 115.888 -0.596 . . . . 0.0 111.113 -175.7 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.445 ' HB ' ' HB3' ' A' ' 34' ' ' ALA . 54.6 t -109.8 108.14 24.64 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.649 0 CA-C-N 116.033 -0.531 . . . . 0.0 109.913 177.265 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 67.6 m-85 -76.84 119.03 20.04 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 121.351 0.596 . . . . 0.0 110.256 178.822 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.731 HG11 HD11 ' A' ' 52' ' ' ILE . 17.5 t -117.9 100.49 52.17 Favored Pre-proline 0 C--N 1.315 -0.93 0 CA-C-N 115.474 -0.784 . . . . 0.0 110.512 -175.769 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 33.7 Cg_exo -64.62 -9.32 20.22 Favored 'Trans proline' 0 N--CA 1.476 0.476 0 C-N-CA 123.799 2.999 . . . . 0.0 114.412 -175.563 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 45' ' ' ASN . . . . . 0.43 ' HB2' ' HB3' ' A' ' 68' ' ' ARG . 0.9 OUTLIER -128.35 17.77 6.49 Favored 'General case' 0 C--N 1.324 -0.511 0 C-N-CA 120.907 -0.317 . . . . 0.0 110.7 -175.192 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.601 ' HB2' ' HB ' ' A' ' 43' ' ' VAL . . . -67.75 154.32 41.77 Favored 'General case' 0 C--N 1.32 -0.696 0 N-CA-C 113.334 0.864 . . . . 0.0 113.334 -175.655 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 10.9 mm-40 -105.76 121.33 43.8 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 114.695 -1.139 . . . . 0.0 109.64 174.522 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 48' ' ' LYS . . . . . 0.622 ' HB2' ' SD ' ' A' ' 26' ' ' MET . 63.2 tttm -60.84 123.99 19.14 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 120.947 0.404 . . . . 0.0 110.918 -177.119 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 89.06 -33.62 4.2 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 121.006 -0.616 . . . . 0.0 112.853 178.122 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 17.7 m -71.08 155.62 40.58 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 120.906 0.384 . . . . 0.0 110.627 -179.05 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.551 HG12 ' HG2' ' A' ' 20' ' ' GLU . 21.8 t -102.82 87.95 1.25 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 177.498 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.731 HD11 HG11 ' A' ' 43' ' ' VAL . 0.1 OUTLIER -92.49 144.98 8.18 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-N 115.622 -0.717 . . . . 0.0 110.688 -171.002 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 53' ' ' ASN . . . . . 0.549 ' HA ' ' HA ' ' A' ' 20' ' ' GLU . 28.2 t-20 -83.36 112.52 19.99 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-N 115.691 -0.686 . . . . 0.0 109.794 175.229 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 54' ' ' VAL . . . . . 0.513 ' HB ' ' HB1' ' A' ' 66' ' ' ALA . 33.9 m -104.44 137.38 33.71 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.264 -176.72 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 55' ' ' LYS . . . . . 0.536 ' HA ' ' HA ' ' A' ' 18' ' ' GLU . 35.9 ttpt -103.49 110.93 23.15 Favored 'General case' 0 C--N 1.318 -0.8 0 N-CA-C 108.958 -0.756 . . . . 0.0 108.958 172.644 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 60.4 t -65.21 118.08 7.0 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 CA-C-N 116.45 -0.341 . . . . 0.0 110.157 -179.294 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 12.3 p -104.35 -24.53 13.08 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 116.248 -0.433 . . . . 0.0 112.001 -174.992 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -154.75 102.31 2.36 Favored 'General case' 0 N--CA 1.451 -0.422 0 CA-C-O 121.097 0.475 . . . . 0.0 111.007 -175.131 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.412 HG13 ' HB2' ' A' ' 64' ' ' ALA . 17.9 t -88.22 122.72 40.12 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.705 0 CA-C-N 115.676 -0.693 . . . . 0.0 110.2 174.755 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 60' ' ' LYS . . . . . 0.433 ' HD2' ' N ' ' A' ' 60' ' ' LYS . 0.6 OUTLIER -101.35 -171.23 1.95 Allowed 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 176.634 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 39.4 mm-40 -59.51 -48.81 80.19 Favored 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 112.667 0.618 . . . . 0.0 112.667 -174.466 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 64.4 mttm -116.03 -5.45 11.96 Favored 'General case' 0 C--N 1.328 -0.326 0 N-CA-C 112.346 0.499 . . . . 0.0 112.346 -171.811 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 16.1 p90 -162.63 156.11 20.28 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 120.682 0.277 . . . . 0.0 110.761 -176.059 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.412 ' HB2' HG13 ' A' ' 59' ' ' VAL . . . -121.39 159.0 27.07 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.698 -178.65 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 96.2 m-85 -116.39 137.15 52.39 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.269 -0.423 . . . . 0.0 109.926 176.374 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 66' ' ' ALA . . . . . 0.513 ' HB1' ' HB ' ' A' ' 54' ' ' VAL . . . -137.48 152.89 50.02 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 116.443 -0.344 . . . . 0.0 111.161 -177.962 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 67' ' ' GLU . . . . . 0.4 ' O ' ' HA ' ' A' ' 54' ' ' VAL . 9.6 pt-20 -102.84 144.07 31.63 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.932 -179.11 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 68' ' ' ARG . . . . . 0.672 ' HB2' HD12 ' A' ' 52' ' ' ILE . 9.2 ttp180 -70.95 109.29 4.98 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.341 172.793 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 3.8 t -81.95 28.34 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.468 0 CA-C-O 121.506 0.67 . . . . 0.0 110.856 -179.587 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.441 ' N ' HD23 ' A' ' 70' ' ' LEU . 1.3 pt? . . . . . 0 C--O 1.243 0.744 0 CA-C-N 116.136 -0.484 . . . . 0.0 109.748 178.75 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo . . . . . 0 CA--C 1.519 -0.254 0 CA-C-O 121.449 0.52 . . . . 0.0 112.379 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 9.4 m -121.8 -175.61 1.04 Allowed 'Isoleucine or valine' 0 C--N 1.314 -0.94 0 CA-C-N 115.16 -0.927 . . . . 0.0 109.722 179.806 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 14' ' ' GLU . . . . . 0.539 ' HG3' ' HD2' ' A' ' 17' ' ' LYS . 74.5 mm-40 -116.82 -159.46 0.73 Allowed 'General case' 0 C--N 1.314 -0.94 0 N-CA-C 109.587 -0.523 . . . . 0.0 109.587 177.21 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 15' ' ' ALA . . . . . 0.454 ' HA ' ' O ' ' A' ' 56' ' ' VAL . . . -162.56 101.11 1.04 Allowed 'General case' 0 C--N 1.317 -0.837 0 CA-C-N 115.591 -0.732 . . . . 0.0 109.315 174.862 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 124.81 -18.41 7.12 Favored Glycine 0 N--CA 1.446 -0.65 0 CA-C-N 114.82 -1.082 . . . . 0.0 111.571 -173.623 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 17' ' ' LYS . . . . . 0.539 ' HD2' ' HG3' ' A' ' 14' ' ' GLU . 61.6 mttm -102.31 164.11 11.86 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 120.597 0.237 . . . . 0.0 110.663 -178.76 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 18' ' ' GLU . . . . . 0.493 ' HA ' ' O ' ' A' ' 54' ' ' VAL . 2.1 mp0 -111.15 144.22 40.63 Favored 'General case' 0 N--CA 1.455 -0.179 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.072 -179.383 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 98.0 m-85 -132.58 -179.66 5.59 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.69 -0.686 . . . . 0.0 109.492 173.775 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 6.5 pt-20 -124.8 113.32 17.76 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-O 121.583 0.706 . . . . 0.0 109.495 175.07 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.436 ' O ' ' HA ' ' A' ' 51' ' ' VAL . 30.2 m -116.82 173.9 3.88 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.91 0 CA-C-N 115.26 -0.882 . . . . 0.0 111.202 -173.031 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 5.8 m -112.82 152.19 29.49 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.028 179.431 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.533 HG13 ' HB1' ' A' ' 46' ' ' ALA . 19.9 mm -115.23 61.22 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.678 0 N-CA-C 108.355 -0.98 . . . . 0.0 108.355 -176.064 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 6.9 mm-40 -66.12 -18.18 65.18 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 114.006 -1.452 . . . . 0.0 111.405 -179.259 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.498 ' HB3' ' HB ' ' A' ' 33' ' ' ILE . 26.0 t0 -138.53 137.01 36.66 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.472 -172.397 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 26' ' ' MET . . . . . . . . . . . . . 10.8 mmt -114.89 144.03 44.19 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.886 174.929 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.447 -0.607 0 N-CA-C 110.809 -0.916 . . . . 0.0 110.809 172.934 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 31' ' ' ASP . . . . . 0.468 ' HA ' ' HA ' ' A' ' 44' ' ' PRO . 4.7 t70 . . . . . 0 C--O 1.236 0.358 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -98.67 154.18 19.98 Favored Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.924 -173.732 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.498 ' HB ' ' HB3' ' A' ' 25' ' ' ASP . 2.5 mp -105.94 113.53 42.96 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.582 0 CA-C-O 121.136 0.493 . . . . 0.0 110.451 179.258 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 34' ' ' ALA . . . . . 0.429 ' HB1' ' HB ' ' A' ' 21' ' ' VAL . . . -106.37 160.62 15.24 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.775 -0.648 . . . . 0.0 109.9 175.902 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 35' ' ' ARG . . . . . 0.418 HH11 ' HD3' ' A' ' 35' ' ' ARG . 0.1 OUTLIER -130.05 128.02 41.1 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-O 120.652 0.263 . . . . 0.0 111.062 -175.027 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 54.7 mt -127.25 110.1 21.95 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 172.145 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 57.95 23.48 9.92 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 115.319 -0.855 . . . . 0.0 111.539 -175.946 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 99.88 -12.94 60.89 Favored Glycine 0 C--N 1.333 0.393 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.008 -178.605 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 52.6 t80 -76.18 139.28 41.16 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 109.652 -0.499 . . . . 0.0 109.652 -178.202 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 26.0 t -89.44 114.84 28.07 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 CA-C-O 121.097 0.475 . . . . 0.0 111.029 -175.475 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 37.1 t -115.24 118.23 58.13 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.661 0 CA-C-N 115.924 -0.58 . . . . 0.0 109.828 179.28 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 94.6 m-85 -87.09 142.31 28.02 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.773 -177.535 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.467 ' HA ' ' HD3' ' A' ' 44' ' ' PRO . 1.4 m -138.55 102.8 7.84 Favored Pre-proline 0 C--N 1.325 -0.496 0 CA-C-N 115.762 -0.654 . . . . 0.0 110.79 -179.115 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 44' ' ' PRO . . . . . 0.468 ' HA ' ' HA ' ' A' ' 31' ' ' ASP . 4.9 Cg_exo -77.23 3.39 6.75 Favored 'Trans proline' 0 CA--C 1.531 0.354 0 C-N-CA 123.564 2.842 . . . . 0.0 113.956 -170.943 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 45' ' ' ASN . . . . . 0.461 ' O ' ' HD3' ' A' ' 68' ' ' ARG . 57.2 m-80 -136.53 25.49 3.15 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 121.263 0.554 . . . . 0.0 110.489 -179.431 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.533 ' HB1' HG13 ' A' ' 23' ' ' ILE . . . -86.01 163.8 17.75 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 115.98 -0.554 . . . . 0.0 111.741 -179.682 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 42.9 mt-10 -116.93 134.4 54.8 Favored 'General case' 0 N--CA 1.446 -0.647 0 CA-C-N 115.472 -0.785 . . . . 0.0 109.297 172.224 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 27.0 ttpp -65.56 140.07 58.51 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-O 120.967 0.413 . . . . 0.0 111.493 -174.207 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 70.52 35.79 68.27 Favored Glycine 0 N--CA 1.448 -0.504 0 CA-C-N 115.525 -0.761 . . . . 0.0 112.704 177.367 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 50.8 m -142.18 162.23 35.99 Favored 'General case' 0 C--N 1.321 -0.663 0 O-C-N 122.772 -0.252 . . . . 0.0 110.747 179.07 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.436 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 88.9 t -98.86 122.9 51.1 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 N-CA-C 108.994 -0.743 . . . . 0.0 108.994 174.327 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.587 HD12 ' HB2' ' A' ' 68' ' ' ARG . 3.4 pt -121.62 142.97 35.67 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.703 0 C-N-CA 120.615 -0.434 . . . . 0.0 110.371 -178.8 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 53' ' ' ASN . . . . . 0.425 ' O ' ' HA ' ' A' ' 68' ' ' ARG . 16.5 t-20 -76.71 129.48 36.4 Favored 'General case' 0 C--N 1.323 -0.556 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 174.053 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 54' ' ' VAL . . . . . 0.683 ' HB ' ' HB1' ' A' ' 66' ' ' ALA . 25.0 m -128.24 128.49 68.61 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 CA-C-O 121.163 0.506 . . . . 0.0 112.032 -176.202 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 55' ' ' LYS . . . . . 0.426 ' HB2' ' HG3' ' A' ' 18' ' ' GLU . 22.8 ttmm -98.95 102.14 13.77 Favored 'General case' 0 C--N 1.314 -0.945 0 N-CA-C 108.611 -0.885 . . . . 0.0 108.611 170.044 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.556 HG22 ' HB2' ' A' ' 66' ' ' ALA . 68.1 t -66.27 108.21 0.96 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 N-CA-C 109.459 -0.571 . . . . 0.0 109.459 178.368 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 12.9 p -109.87 -13.81 14.39 Favored 'General case' 0 C--N 1.321 -0.634 0 N-CA-C 112.304 0.483 . . . . 0.0 112.304 -174.405 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 58' ' ' ALA . . . . . 0.429 ' HB3' ' HB2' ' A' ' 65' ' ' PHE . . . -143.13 92.24 2.36 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.134 0.493 . . . . 0.0 111.256 -176.608 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 20.3 t -84.58 142.8 12.84 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.768 0 CA-C-N 115.95 -0.568 . . . . 0.0 109.7 177.645 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 42.5 mmtm -127.72 -162.33 1.16 Allowed 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 116.716 -0.22 . . . . 0.0 110.779 -179.364 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 6.5 mm-40 -47.34 -64.09 0.87 Allowed 'General case' 0 N--CA 1.468 0.435 0 C-N-CA 123.699 0.799 . . . . 0.0 112.761 -172.302 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 59.9 pttt -138.31 20.59 2.77 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 121.666 0.746 . . . . 0.0 110.198 -178.926 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 28.9 p90 -153.12 153.19 32.3 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 114.939 -1.028 . . . . 0.0 108.906 -179.745 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -127.41 155.66 43.29 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-O 120.825 0.345 . . . . 0.0 111.112 -177.69 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 65' ' ' PHE . . . . . 0.429 ' HB2' ' HB3' ' A' ' 58' ' ' ALA . 99.0 m-85 -108.97 124.69 51.09 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 115.836 -0.62 . . . . 0.0 109.476 176.412 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 66' ' ' ALA . . . . . 0.683 ' HB1' ' HB ' ' A' ' 54' ' ' VAL . . . -125.12 151.24 46.0 Favored 'General case' 0 C--N 1.318 -0.793 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.707 -179.001 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 5.3 pt-20 -110.27 128.51 55.56 Favored 'General case' 0 C--N 1.316 -0.882 0 CA-C-O 121.263 0.554 . . . . 0.0 111.117 -178.888 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 68' ' ' ARG . . . . . 0.587 ' HB2' HD12 ' A' ' 52' ' ' ILE . 22.4 ttt180 -61.74 115.4 3.95 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.008 -0.996 . . . . 0.0 111.515 178.262 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.452 ' O ' HG12 ' A' ' 69' ' ' VAL . 22.0 t -82.07 12.29 0.64 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-N 114.922 -1.036 . . . . 0.0 110.876 179.32 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.456 ' HB2' ' HE ' ' A' ' 68' ' ' ARG . 60.4 mt . . . . . 0 C--O 1.249 1.045 0 CA-C-O 118.317 -0.849 . . . . 0.0 110.692 -178.447 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 15.5 tpt . . . . . 0 N--CA 1.479 1.003 0 CA-C-O 120.877 0.37 . . . . 0.0 110.196 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -156.31 126.27 6.45 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.727 -178.734 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 3.2 p90 -95.22 65.26 2.8 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 121.456 0.646 . . . . 0.0 109.986 176.773 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 96.99 -64.9 0.97 Allowed Glycine 0 N--CA 1.447 -0.601 0 N-CA-C 110.769 -0.932 . . . . 0.0 110.769 -173.379 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.416 ' HA ' ' HD3' ' A' ' 6' ' ' PRO . 98.7 mttt -142.09 150.69 56.65 Favored Pre-proline 0 C--N 1.328 -0.335 0 N-CA-C 109.276 -0.639 . . . . 0.0 109.276 175.422 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.416 ' HD3' ' HA ' ' A' ' 5' ' ' LYS . 5.7 Cg_exo -76.49 94.66 1.04 Allowed 'Trans proline' 0 N--CA 1.459 -0.552 0 C-N-CA 122.553 2.169 . . . . 0.0 111.671 177.72 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . 63.55 -165.14 0.24 Allowed 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.676 -0.693 . . . . 0.0 111.139 178.454 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' MET . . . . . . . . . . . . . 26.4 ttt -99.26 39.8 1.26 Allowed 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 121.327 0.584 . . . . 0.0 109.786 179.579 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 10.5 ttpp 66.7 22.79 10.33 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-N 115.165 -0.925 . . . . 0.0 110.932 177.442 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 2.4 m120 60.52 99.1 0.03 OUTLIER 'General case' 0 N--CA 1.467 0.424 0 CA-C-N 115.707 -0.679 . . . . 0.0 112.126 -178.221 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.513 HG11 HG11 ' A' ' 59' ' ' VAL . 21.2 t -76.02 126.86 86.31 Favored Pre-proline 0 C--N 1.321 -0.641 0 CA-C-N 115.719 -0.673 . . . . 0.0 109.251 175.22 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 16.2 Cg_endo -58.54 -22.15 58.27 Favored 'Trans proline' 0 N--CA 1.475 0.435 0 C-N-CA 123.281 2.654 . . . . 0.0 113.212 -178.562 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.528 HG12 HD12 ' A' ' 36' ' ' ILE . 16.1 m -114.72 121.0 65.93 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.356 179.846 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 49.0 mt-10 -99.29 118.33 35.73 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.782 -177.686 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' ALA . . . . . 0.428 ' HB2' HG23 ' A' ' 59' ' ' VAL . . . -63.84 125.06 23.16 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.674 -0.694 . . . . 0.0 111.028 179.934 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 112.45 -4.44 26.48 Favored Glycine 0 N--CA 1.449 -0.44 0 C-N-CA 120.891 -0.671 . . . . 0.0 111.814 -177.852 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 97.1 mttt -118.59 158.52 25.28 Favored 'General case' 0 C--N 1.324 -0.542 0 N-CA-C 110.289 -0.263 . . . . 0.0 110.289 178.997 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' GLU . . . . . 0.506 ' HA ' ' O ' ' A' ' 54' ' ' VAL . 0.0 OUTLIER -120.61 130.7 54.28 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-O 121.606 0.717 . . . . 0.0 111.29 179.878 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 45.8 m-85 -122.66 149.63 43.77 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.257 -0.883 . . . . 0.0 110.179 -174.912 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 2.3 mp0 -84.8 119.13 24.96 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 121.138 0.494 . . . . 0.0 109.693 173.857 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 36.0 m -130.43 165.04 31.74 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.879 0 CA-C-N 115.599 -0.728 . . . . 0.0 110.865 -175.097 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 11.7 m -108.35 149.64 28.42 Favored 'General case' 0 C--N 1.316 -0.87 0 CA-C-N 115.999 -0.546 . . . . 0.0 109.935 175.911 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.621 HG13 ' HB1' ' A' ' 46' ' ' ALA . 36.0 mm -110.67 61.6 0.16 Allowed 'Isoleucine or valine' 0 CA--C 1.509 -0.609 0 N-CA-C 107.652 -1.24 . . . . 0.0 107.652 -176.995 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 31.4 tt0 -62.57 -24.79 67.73 Favored 'General case' 0 C--N 1.311 -1.084 0 CA-C-N 113.062 -1.881 . . . . 0.0 111.207 -179.583 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.566 ' HB2' ' HB ' ' A' ' 33' ' ' ILE . 15.3 m-20 -124.33 149.15 46.91 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.33 -0.396 . . . . 0.0 111.18 -175.213 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 26' ' ' MET . . . . . . . . . . . . . 96.0 mmm -123.19 147.85 46.42 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.092 -0.504 . . . . 0.0 109.932 173.975 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -96.46 173.42 29.86 Favored Glycine 0 N--CA 1.448 -0.544 0 C-N-CA 121.091 -0.576 . . . . 0.0 112.792 -178.02 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 61.4 mttm -75.99 18.29 0.28 Allowed 'General case' 0 N--CA 1.465 0.303 0 N-CA-C 112.484 0.55 . . . . 0.0 112.484 -175.281 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -144.1 28.24 1.98 Allowed Glycine 0 C--N 1.312 -0.754 0 C-N-CA 120.872 -0.68 . . . . 0.0 112.488 -178.898 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 68.47 20.12 73.34 Favored Glycine 0 CA--C 1.518 0.277 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.6 -179.276 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 31' ' ' ASP . . . . . 0.419 ' OD1' ' HA ' ' A' ' 44' ' ' PRO . 27.5 t70 -97.13 144.53 26.89 Favored 'General case' 0 C--N 1.32 -0.694 0 N-CA-C 109.56 -0.533 . . . . 0.0 109.56 -179.413 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -98.66 132.53 10.97 Favored Glycine 0 N--CA 1.447 -0.615 0 C-N-CA 120.602 -0.808 . . . . 0.0 111.897 -177.293 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.566 ' HB ' ' HB2' ' A' ' 25' ' ' ASP . 1.9 mp -101.83 104.1 15.9 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.737 0 CA-C-O 121.492 0.663 . . . . 0.0 110.625 -178.248 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -84.17 157.19 21.75 Favored 'General case' 0 C--N 1.317 -0.809 0 CA-C-N 115.406 -0.816 . . . . 0.0 109.167 169.036 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' ARG . . . . . 0.403 HH11 ' HD2' ' A' ' 35' ' ' ARG . 6.0 ttm180 -142.18 107.87 5.11 Favored 'General case' 0 C--N 1.313 -0.982 0 C-N-CA 120.644 -0.422 . . . . 0.0 110.819 -176.769 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.528 HD12 HG12 ' A' ' 13' ' ' VAL . 37.2 mt -99.43 108.68 22.96 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 CA-C-N 115.733 -0.667 . . . . 0.0 110.11 178.093 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 58.2 16.46 3.95 Favored 'General case' 0 N--CA 1.468 0.473 0 CA-C-N 115.26 -0.882 . . . . 0.0 112.079 -176.539 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 110.28 -16.99 29.36 Favored Glycine 0 N--CA 1.449 -0.447 0 C-N-CA 120.856 -0.688 . . . . 0.0 111.764 -178.057 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 34.0 t80 -71.68 117.59 13.44 Favored 'General case' 0 C--N 1.328 -0.362 0 N-CA-C 109.576 -0.527 . . . . 0.0 109.576 179.334 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.448 HG13 HG23 ' A' ' 33' ' ' ILE . 29.1 t -70.61 117.59 13.9 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 CA-C-N 115.824 -0.625 . . . . 0.0 111.301 -178.43 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 49.1 t -119.34 108.39 23.65 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 CA-C-N 115.481 -0.781 . . . . 0.0 109.594 -179.812 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 93.7 m-85 -78.58 129.55 34.92 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.086 -175.411 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 5.6 t -125.73 105.57 26.65 Favored Pre-proline 0 C--N 1.321 -0.659 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.246 -177.948 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 44' ' ' PRO . . . . . 0.419 ' HA ' ' OD1' ' A' ' 31' ' ' ASP . 34.9 Cg_endo -65.75 -8.26 19.01 Favored 'Trans proline' 0 N--CA 1.477 0.538 0 C-N-CA 123.537 2.825 . . . . 0.0 114.476 -172.561 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 1.2 p30 -142.54 20.35 2.03 Favored 'General case' 0 C--N 1.321 -0.65 0 N-CA-C 112.264 0.468 . . . . 0.0 112.264 -167.603 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.621 ' HB1' HG13 ' A' ' 23' ' ' ILE . . . -97.18 155.89 16.64 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.082 176.126 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 48.9 mt-10 -106.38 144.9 32.39 Favored 'General case' 0 N--CA 1.451 -0.421 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.093 178.54 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 60.8 tttm -66.2 137.36 56.93 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.457 -0.338 . . . . 0.0 111.352 -175.676 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 82.86 -2.24 86.84 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 121.017 -0.611 . . . . 0.0 113.121 175.943 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 29.7 m -93.56 152.08 19.27 Favored 'General case' 0 C--N 1.324 -0.538 0 O-C-N 122.654 -0.321 . . . . 0.0 111.085 -179.529 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 46.6 t -98.46 101.65 12.42 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 N-CA-C 108.456 -0.942 . . . . 0.0 108.456 172.897 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.571 HD11 ' HB2' ' A' ' 68' ' ' ARG . 0.8 OUTLIER -115.2 145.23 21.22 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.851 0 CA-C-N 115.789 -0.641 . . . . 0.0 112.018 -170.281 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 58.1 t30 -88.3 112.86 23.31 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 114.923 -1.035 . . . . 0.0 109.005 176.306 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 54' ' ' VAL . . . . . 0.555 ' HB ' ' HB1' ' A' ' 66' ' ' ALA . 35.2 m -115.01 134.56 57.69 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.724 0 CA-C-O 121.115 0.483 . . . . 0.0 111.609 -175.259 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 2.3 ttmp? -93.42 111.06 22.63 Favored 'General case' 0 C--N 1.32 -0.709 0 N-CA-C 109.124 -0.695 . . . . 0.0 109.124 175.52 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.467 HG21 ' HB ' ' A' ' 13' ' ' VAL . 87.6 t -67.88 113.08 3.41 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 N-CA-C 109.189 -0.671 . . . . 0.0 109.189 177.693 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.7 p -109.36 -26.02 10.24 Favored 'General case' 0 C--N 1.324 -0.53 0 N-CA-C 112.455 0.539 . . . . 0.0 112.455 -173.104 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 58' ' ' ALA . . . . . 0.434 ' HB3' ' HB2' ' A' ' 65' ' ' PHE . . . -143.38 92.17 2.34 Favored 'General case' 0 C--N 1.325 -0.476 0 C-N-CA 120.679 -0.408 . . . . 0.0 111.738 -175.301 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.513 HG11 HG11 ' A' ' 11' ' ' VAL . 15.6 t -79.9 125.89 39.07 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.735 0 CA-C-N 116.109 -0.496 . . . . 0.0 109.781 174.079 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 46.0 mmtm -106.01 -164.17 0.99 Allowed 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.439 -179.559 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 61' ' ' GLU . . . . . 0.41 ' OE1' ' HE3' ' A' ' 62' ' ' LYS . 40.8 tt0 -66.03 -48.84 69.77 Favored 'General case' 0 CA--C 1.533 0.297 0 N-CA-C 112.623 0.601 . . . . 0.0 112.623 -175.3 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 62' ' ' LYS . . . . . 0.41 ' HE3' ' OE1' ' A' ' 61' ' ' GLU . 93.1 mttt -120.6 3.89 10.66 Favored 'General case' 0 C--N 1.328 -0.332 0 N-CA-C 111.934 0.346 . . . . 0.0 111.934 -172.982 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 15.1 p90 -166.6 169.01 14.06 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 116.42 -0.355 . . . . 0.0 110.21 -174.273 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -129.42 158.76 38.26 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-O 120.878 0.37 . . . . 0.0 111.095 -179.95 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 65' ' ' PHE . . . . . 0.434 ' HB2' ' HB3' ' A' ' 58' ' ' ALA . 95.3 m-85 -114.47 136.14 53.34 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.579 -0.737 . . . . 0.0 109.824 176.827 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 66' ' ' ALA . . . . . 0.555 ' HB1' ' HB ' ' A' ' 54' ' ' VAL . . . -127.35 -179.3 4.82 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.571 -179.155 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 67' ' ' GLU . . . . . 0.43 ' O ' ' HA ' ' A' ' 54' ' ' VAL . 8.1 pt-20 -141.67 143.82 33.79 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 120.861 0.362 . . . . 0.0 111.212 178.85 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.571 ' HB2' HD11 ' A' ' 52' ' ' ILE . 31.2 ttt180 -67.73 106.16 2.15 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.405 -0.816 . . . . 0.0 111.707 178.185 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 2.6 t -83.54 21.66 0.19 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.361 0 CA-C-O 121.501 0.667 . . . . 0.0 110.405 175.286 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.551 HD11 ' HA ' ' A' ' 52' ' ' ILE . 64.2 mt . . . . . 0 C--O 1.249 1.074 0 CA-C-O 118.351 -0.833 . . . . 0.0 110.064 -179.255 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.479 1.015 0 CA-C-O 120.616 0.246 . . . . 0.0 110.573 . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -106.68 -80.86 0.56 Allowed 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.529 -179.96 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' PHE . . . . . 0.602 ' HA ' ' HD2' ' A' ' 6' ' ' PRO . 34.6 m-85 -124.1 -174.11 2.92 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 120.951 0.405 . . . . 0.0 111.49 -173.004 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 123.39 -24.68 6.48 Favored Glycine 0 N--CA 1.451 -0.358 0 N-CA-C 109.807 -1.317 . . . . 0.0 109.807 -171.579 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.541 ' HB2' ' HD3' ' A' ' 6' ' ' PRO . 32.4 mmmt -121.94 -47.18 0.04 OUTLIER Pre-proline 0 C--N 1.325 -0.49 0 CA-C-N 114.201 -1.0 . . . . 0.0 110.274 172.802 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.602 ' HD2' ' HA ' ' A' ' 3' ' ' PHE . 6.7 Cg_endo -92.84 164.98 2.68 Favored 'Trans proline' 0 C--N 1.355 0.88 0 C-N-CA 122.649 2.233 . . . . 0.0 111.923 174.46 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . 62.68 14.28 7.07 Favored 'General case' 0 N--CA 1.47 0.553 0 C-N-CA 123.446 0.698 . . . . 0.0 112.677 175.956 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' MET . . . . . . . . . . . . . 23.6 ttt -100.13 32.83 2.82 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 121.573 0.701 . . . . 0.0 109.907 -179.821 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' LYS . . . . . 0.438 ' H ' ' HD3' ' A' ' 9' ' ' LYS . 0.0 OUTLIER -107.67 27.77 8.84 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.604 179.56 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 20.3 p-10 -79.25 53.98 1.59 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.449 178.289 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.526 HG11 HG11 ' A' ' 59' ' ' VAL . 69.6 t -159.28 124.79 2.3 Favored Pre-proline 0 C--N 1.328 -0.352 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 -172.713 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 10.9 Cg_endo -55.11 -31.49 75.51 Favored 'Trans proline' 0 C--N 1.345 0.393 0 C-N-CA 123.518 2.812 . . . . 0.0 113.125 -176.625 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.504 ' HB ' HG21 ' A' ' 56' ' ' VAL . 15.6 m -103.64 126.8 58.09 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-N 116.09 -0.504 . . . . 0.0 111.214 -178.311 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 14' ' ' GLU . . . . . 0.423 ' CB ' ' HD3' ' A' ' 17' ' ' LYS . 37.6 mt-10 -101.06 123.96 46.05 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.058 176.398 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 15' ' ' ALA . . . . . 0.483 ' HA ' ' O ' ' A' ' 56' ' ' VAL . . . -60.94 110.16 1.27 Allowed 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.355 177.227 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 123.64 -18.76 7.6 Favored Glycine 0 N--CA 1.447 -0.613 0 C-N-CA 121.029 -0.605 . . . . 0.0 112.436 -178.29 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' LYS . . . . . 0.423 ' HD3' ' CB ' ' A' ' 14' ' ' GLU . 2.4 mptm? -94.1 162.97 13.66 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.935 0.398 . . . . 0.0 111.393 -179.99 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 18' ' ' GLU . . . . . 0.563 ' HG2' ' HB2' ' A' ' 55' ' ' LYS . 31.4 mt-10 -118.84 128.41 54.43 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.538 -0.755 . . . . 0.0 110.036 179.611 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 19' ' ' TYR . . . . . 0.421 ' O ' HG22 ' A' ' 54' ' ' VAL . 62.0 m-85 -127.87 127.17 42.94 Favored 'General case' 0 C--N 1.322 -0.627 0 N-CA-C 110.065 -0.346 . . . . 0.0 110.065 179.412 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 20' ' ' GLU . . . . . 0.628 ' HA ' ' HA ' ' A' ' 53' ' ' ASN . 34.8 tt0 -78.24 119.12 21.16 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 121.149 0.5 . . . . 0.0 109.764 177.03 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 23.3 m -129.82 162.81 36.77 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-N 115.499 -0.773 . . . . 0.0 111.702 -170.116 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 9.7 m -97.33 149.12 22.44 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.021 177.215 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.493 ' CD1' ' HB2' ' A' ' 34' ' ' ALA . 24.0 mm -121.33 65.94 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 108.572 -0.899 . . . . 0.0 108.572 -175.546 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 35.5 tt0 -86.98 -5.34 59.12 Favored 'General case' 0 C--N 1.31 -1.116 0 CA-C-N 114.445 -1.252 . . . . 0.0 110.465 -178.209 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.543 ' HB2' ' HB ' ' A' ' 33' ' ' ILE . 25.1 m-20 -118.59 134.42 55.11 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 115.526 -0.761 . . . . 0.0 109.396 -178.874 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 26' ' ' MET . . . . . . . . . . . . . 98.1 mmm -124.82 147.03 48.95 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-O 120.697 0.284 . . . . 0.0 110.91 -179.842 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -87.64 -50.92 3.4 Favored Glycine 0 N--CA 1.445 -0.757 0 N-CA-C 110.71 -0.956 . . . . 0.0 110.71 175.667 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 51.5 tptt -164.76 -79.27 0.03 OUTLIER 'General case' 0 CA--C 1.514 -0.431 0 CA-C-O 121.243 0.544 . . . . 0.0 111.411 173.439 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -124.85 73.42 0.42 Allowed Glycine 0 C--N 1.306 -1.118 0 CA-C-N 115.338 -0.846 . . . . 0.0 113.588 -171.906 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 107.0 -29.9 10.1 Favored Glycine 0 CA--C 1.507 -0.449 0 C-N-CA 120.906 -0.664 . . . . 0.0 111.586 174.783 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 4.4 p-10 -73.54 105.62 4.97 Favored 'General case' 0 C--N 1.317 -0.814 0 N-CA-C 109.203 -0.666 . . . . 0.0 109.203 173.394 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -109.38 160.87 13.28 Favored Glycine 0 N--CA 1.443 -0.863 0 CA-C-N 115.526 -0.761 . . . . 0.0 112.588 -175.347 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.546 HG23 HG13 ' A' ' 40' ' ' VAL . 2.5 mp -114.1 110.08 30.81 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.836 0 N-CA-C 109.962 -0.385 . . . . 0.0 109.962 -179.973 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 34' ' ' ALA . . . . . 0.493 ' HB2' ' CD1' ' A' ' 23' ' ' ILE . . . -94.03 155.17 17.26 Favored 'General case' 0 C--N 1.318 -0.761 0 CA-C-O 121.732 0.777 . . . . 0.0 111.098 173.868 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 29.1 mmt180 -121.4 103.11 8.71 Favored 'General case' 0 N--CA 1.437 -1.114 0 CA-C-N 114.552 -1.204 . . . . 0.0 110.629 -172.52 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.413 HD12 ' CG1' ' A' ' 13' ' ' VAL . 26.1 mt -100.61 101.4 12.04 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.601 0 CA-C-O 121.1 0.476 . . . . 0.0 109.917 175.623 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 33.2 t70 67.06 -4.14 0.86 Allowed 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 114.669 -1.151 . . . . 0.0 111.006 -173.522 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 122.61 -19.28 8.01 Favored Glycine 0 N--CA 1.446 -0.673 0 N-CA-C 110.845 -0.902 . . . . 0.0 110.845 -172.207 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 51.7 t80 -65.84 126.08 27.38 Favored 'General case' 0 C--O 1.237 0.399 0 N-CA-C 109.126 -0.694 . . . . 0.0 109.126 176.702 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.546 HG13 HG23 ' A' ' 33' ' ' ILE . 39.9 t -76.77 113.45 15.84 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.757 0 CA-C-N 115.78 -0.646 . . . . 0.0 111.292 -175.344 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 68.0 t -109.31 111.65 37.03 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 CA-C-N 115.48 -0.782 . . . . 0.0 109.885 177.347 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 60.6 m-85 -77.95 120.12 22.37 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.376 -179.625 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.533 ' HB ' ' HB2' ' A' ' 46' ' ' ALA . 8.7 t -120.81 104.56 41.83 Favored Pre-proline 0 C--N 1.319 -0.725 0 CA-C-N 115.587 -0.733 . . . . 0.0 110.398 -177.304 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -77.32 16.84 0.96 Allowed 'Trans proline' 0 CA--C 1.53 0.324 0 C-N-CA 123.379 2.719 . . . . 0.0 113.584 -174.187 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -152.04 21.43 0.67 Allowed 'General case' 0 C--N 1.321 -0.65 0 CA-C-O 121.523 0.678 . . . . 0.0 110.266 -178.042 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.533 ' HB2' ' HB ' ' A' ' 43' ' ' VAL . . . -78.63 168.86 19.14 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 115.224 -0.898 . . . . 0.0 111.488 177.923 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 47' ' ' GLU . . . . . 0.466 ' O ' ' HB ' ' A' ' 23' ' ' ILE . 0.0 OUTLIER -126.16 134.76 51.2 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.549 -0.75 . . . . 0.0 109.594 178.21 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 1.8 tmtp? -63.37 120.84 12.39 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.891 -176.15 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 81.96 5.91 89.36 Favored Glycine 0 N--CA 1.45 -0.412 0 CA-C-N 115.776 -0.647 . . . . 0.0 112.821 177.097 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 20.0 t -101.78 163.34 12.3 Favored 'General case' 0 C--N 1.324 -0.538 0 N-CA-C 110.123 -0.325 . . . . 0.0 110.123 -178.478 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.52 HG12 ' HG2' ' A' ' 20' ' ' GLU . 32.2 t -114.35 101.46 12.46 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.463 0 N-CA-C 109.106 -0.702 . . . . 0.0 109.106 179.269 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.591 HD12 ' HB2' ' A' ' 68' ' ' ARG . 6.4 pt -108.58 145.47 15.5 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-O 121.054 0.454 . . . . 0.0 110.934 -173.131 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 53' ' ' ASN . . . . . 0.628 ' HA ' ' HA ' ' A' ' 20' ' ' GLU . 39.6 t30 -82.55 115.81 21.69 Favored 'General case' 0 C--N 1.318 -0.765 0 N-CA-C 109.328 -0.619 . . . . 0.0 109.328 172.157 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 54' ' ' VAL . . . . . 0.54 HG13 HG13 ' A' ' 52' ' ' ILE . 28.8 m -107.97 130.81 59.81 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-O 121.358 0.599 . . . . 0.0 111.816 -177.198 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 55' ' ' LYS . . . . . 0.563 ' HB2' ' HG2' ' A' ' 18' ' ' GLU . 39.8 ttmt -97.98 106.65 18.98 Favored 'General case' 0 C--N 1.318 -0.772 0 N-CA-C 108.959 -0.756 . . . . 0.0 108.959 172.304 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.504 HG21 ' HB ' ' A' ' 13' ' ' VAL . 47.1 t -68.12 112.88 3.44 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.079 179.559 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 21.0 p -109.41 -17.94 13.67 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 112.071 0.397 . . . . 0.0 112.071 -174.86 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -143.58 92.58 2.37 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.063 0.458 . . . . 0.0 110.984 -177.607 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.526 HG11 HG11 ' A' ' 11' ' ' VAL . 13.4 t -85.24 129.61 37.55 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.638 0 CA-C-N 115.854 -0.612 . . . . 0.0 109.913 175.868 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 74.8 mmtt -106.76 -173.07 2.21 Favored 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 109.979 -0.378 . . . . 0.0 109.979 178.437 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -72.42 -41.22 66.45 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.35 -0.386 . . . . 0.0 111.859 179.648 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 56.3 mttp -92.13 -45.3 8.35 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 121.036 0.446 . . . . 0.0 111.295 -178.269 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 10.4 p90 -142.84 -171.3 3.42 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.969 -0.559 . . . . 0.0 110.492 -172.538 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -138.91 158.51 44.07 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-O 120.814 0.34 . . . . 0.0 111.113 -179.462 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 93.2 m-85 -113.85 138.72 49.91 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.694 -0.684 . . . . 0.0 109.43 175.492 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 66' ' ' ALA . . . . . 0.524 ' HB1' ' HB ' ' A' ' 54' ' ' VAL . . . -142.6 159.14 42.82 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 116.553 -0.294 . . . . 0.0 110.906 -178.668 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 67' ' ' GLU . . . . . 0.411 ' O ' ' HA ' ' A' ' 54' ' ' VAL . 10.8 pt-20 -113.72 137.75 51.19 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 121.303 0.573 . . . . 0.0 111.254 179.142 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.591 ' HB2' HD12 ' A' ' 52' ' ' ILE . 25.0 ttt180 -66.41 109.86 2.89 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 115.237 -0.892 . . . . 0.0 109.98 172.458 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 2.8 t -81.92 25.13 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.536 0.41 0 CA-C-O 121.526 0.679 . . . . 0.0 111.867 -174.767 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.463 ' CD2' ' HG3' ' A' ' 68' ' ' ARG . 0.8 OUTLIER . . . . . 0 C--O 1.245 0.838 0 CA-C-O 118.759 -0.639 . . . . 0.0 110.329 179.218 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 25.4 ttt . . . . . 0 N--CA 1.478 0.93 0 CA-C-O 120.705 0.288 . . . . 0.0 110.624 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -146.04 -168.06 2.89 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.902 0.382 . . . . 0.0 110.985 -179.51 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 17.6 p90 -84.13 50.75 1.91 Allowed 'General case' 0 C--N 1.324 -0.505 0 CA-C-O 121.467 0.651 . . . . 0.0 110.754 -179.441 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 97.65 -64.47 0.9 Allowed Glycine 0 N--CA 1.446 -0.687 0 CA-C-N 115.752 -0.658 . . . . 0.0 111.711 -178.56 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 64.0 tttp -124.16 116.82 27.08 Favored Pre-proline 0 C--N 1.321 -0.653 0 N-CA-C 110.026 -0.361 . . . . 0.0 110.026 179.164 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.432 ' HD2' ' OD1' ' A' ' 10' ' ' ASN . 18.9 Cg_endo -90.34 -162.55 0.12 Allowed 'Trans proline' 0 N--CA 1.453 -0.905 0 C-N-CA 122.987 2.458 . . . . 0.0 112.717 178.533 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -98.26 -144.1 0.31 Allowed 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.322 -0.854 . . . . 0.0 110.71 -178.656 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' MET . . . . . . . . . . . . . 60.5 mtt 69.65 18.98 7.49 Favored 'General case' 0 N--CA 1.468 0.433 0 C-N-CA 122.838 0.455 . . . . 0.0 111.028 177.564 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' LYS . . . . . 0.439 ' C ' ' H ' ' A' ' 11' ' ' VAL . 12.5 mmmm 54.5 85.23 0.06 Allowed 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.328 -0.851 . . . . 0.0 112.028 -177.782 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 10' ' ' ASN . . . . . 0.432 ' OD1' ' HD2' ' A' ' 6' ' ' PRO . 5.8 m120 -81.55 40.84 0.6 Allowed 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 121.543 0.687 . . . . 0.0 109.175 171.158 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.439 ' H ' ' C ' ' A' ' 9' ' ' LYS . 47.2 t -160.58 106.25 1.33 Allowed Pre-proline 0 C--N 1.327 -0.397 0 N-CA-C 107.276 -1.379 . . . . 0.0 107.276 -174.587 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -68.08 -31.44 30.04 Favored 'Trans proline' 0 CA--C 1.516 -0.403 0 C-N-CA 123.218 2.612 . . . . 0.0 112.507 -173.625 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.604 HG12 HD12 ' A' ' 36' ' ' ILE . 16.1 m -80.5 163.03 3.53 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.896 0 CA-C-N 115.175 -0.921 . . . . 0.0 110.906 -177.989 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 9.8 tp10 -147.14 119.72 8.53 Favored 'General case' 0 C--N 1.322 -0.588 0 N-CA-C 108.918 -0.771 . . . . 0.0 108.918 178.471 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' ALA . . . . . 0.456 ' HA ' ' O ' ' A' ' 56' ' ' VAL . . . -58.91 117.55 4.78 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-O 121.111 0.482 . . . . 0.0 111.377 -177.207 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 119.09 -24.84 8.1 Favored Glycine 0 N--CA 1.447 -0.625 0 CA-C-N 115.653 -0.703 . . . . 0.0 112.218 -179.246 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' LYS . . . . . 0.408 ' HE2' ' HB3' ' A' ' 17' ' ' LYS . 53.1 mtpt -90.55 156.37 18.21 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.871 0.367 . . . . 0.0 110.734 179.077 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 18' ' ' GLU . . . . . 0.484 ' HA ' ' O ' ' A' ' 54' ' ' VAL . 46.0 mt-10 -113.96 128.34 56.35 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.824 -0.625 . . . . 0.0 109.858 -179.864 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 81.5 m-85 -122.58 143.42 49.75 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 121.173 0.511 . . . . 0.0 111.583 -175.887 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 32.7 tt0 -82.98 111.06 18.49 Favored 'General case' 0 C--N 1.317 -0.808 0 CA-C-N 115.548 -0.751 . . . . 0.0 109.475 175.069 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.486 ' HB ' ' HB1' ' A' ' 34' ' ' ALA . 32.7 m -121.81 151.32 25.28 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-O 121.053 0.454 . . . . 0.0 112.023 -172.714 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 17.0 m -97.62 152.44 19.06 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.658 -0.701 . . . . 0.0 109.721 176.474 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.491 HD13 ' HB2' ' A' ' 34' ' ' ALA . 18.9 mm -121.89 64.5 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-O 121.791 0.805 . . . . 0.0 108.908 -174.423 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 26.1 mm-40 -69.02 -19.15 64.11 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-N 114.782 -1.099 . . . . 0.0 111.835 -179.663 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.56 ' HB2' ' HB ' ' A' ' 33' ' ' ILE . 5.6 m-20 -126.34 138.7 53.6 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 116.392 -0.367 . . . . 0.0 111.277 -176.093 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 26' ' ' MET . . . . . . . . . . . . . 92.9 mmm -120.28 142.09 49.39 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 115.814 -0.63 . . . . 0.0 109.917 175.655 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -81.19 -67.07 1.56 Allowed Glycine 0 N--CA 1.444 -0.773 0 N-CA-C 111.559 -0.616 . . . . 0.0 111.559 179.537 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 37.2 ttmt -170.2 78.57 0.09 Allowed 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 121.972 0.891 . . . . 0.0 110.571 178.591 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 82.54 -64.85 4.21 Favored Glycine 0 C--N 1.304 -1.205 0 CA-C-N 114.194 -1.366 . . . . 0.0 113.304 173.741 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -111.47 38.19 3.38 Favored Glycine 0 C--N 1.321 -0.294 0 C-N-CA 120.896 -0.669 . . . . 0.0 112.642 -173.96 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 30.3 t70 -156.64 117.84 3.77 Favored 'General case' 0 C--N 1.319 -0.74 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 179.069 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 32' ' ' GLY . . . . . 0.55 ' HA3' ' HB3' ' A' ' 46' ' ' ALA . . . -114.42 141.71 17.15 Favored Glycine 0 N--CA 1.441 -1.022 0 N-CA-C 111.178 -0.769 . . . . 0.0 111.178 177.994 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.56 ' HB ' ' HB2' ' A' ' 25' ' ' ASP . 2.6 mp -97.93 98.19 7.03 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.767 0 CA-C-O 121.329 0.585 . . . . 0.0 110.276 -178.09 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 34' ' ' ALA . . . . . 0.491 ' HB2' HD13 ' A' ' 23' ' ' ILE . . . -99.85 123.01 43.65 Favored 'General case' 0 CA--C 1.497 -1.065 0 CA-C-N 115.747 -0.661 . . . . 0.0 109.398 171.706 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 35' ' ' ARG . . . . . 0.525 ' HA ' ' O ' ' A' ' 39' ' ' PHE . 0.0 OUTLIER -118.56 108.66 15.23 Favored 'General case' 0 C--N 1.303 -1.453 0 CA-C-N 115.6 -0.727 . . . . 0.0 111.363 -174.11 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.604 HD12 HG12 ' A' ' 13' ' ' VAL . 53.1 mt -84.43 112.62 21.9 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.702 0 CA-C-N 115.208 -0.905 . . . . 0.0 109.604 177.649 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 36.7 t70 60.43 19.07 8.76 Favored 'General case' 0 CA--C 1.539 0.523 0 CA-C-N 115.495 -0.775 . . . . 0.0 110.702 -175.451 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 100.78 -9.26 58.41 Favored Glycine 0 C--N 1.329 0.189 0 C-N-CA 120.583 -0.818 . . . . 0.0 112.143 -178.794 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 39' ' ' PHE . . . . . 0.525 ' O ' ' HA ' ' A' ' 35' ' ' ARG . 60.8 t80 -77.43 114.76 16.59 Favored 'General case' 0 C--N 1.323 -0.576 0 N-CA-C 109.708 -0.479 . . . . 0.0 109.708 178.779 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.521 HG13 HG23 ' A' ' 33' ' ' ILE . 21.5 t -68.98 110.09 2.3 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 CA-C-O 121.6 0.714 . . . . 0.0 111.968 -175.347 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 17.6 t -108.26 110.42 31.91 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.824 0 CA-C-N 115.092 -0.958 . . . . 0.0 108.896 175.503 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 65.9 m-85 -74.3 134.7 42.57 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-O 121.126 0.489 . . . . 0.0 111.284 -176.653 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.695 HG11 HD11 ' A' ' 52' ' ' ILE . 8.1 t -131.56 113.93 15.55 Favored Pre-proline 0 N--CA 1.449 -0.524 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.794 -174.943 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 59.8 Cg_endo -74.71 -9.41 21.17 Favored 'Trans proline' 0 CA--C 1.531 0.359 0 C-N-CA 122.692 2.262 . . . . 0.0 113.681 -176.943 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 45' ' ' ASN . . . . . 0.564 ' HB2' ' HB3' ' A' ' 68' ' ' ARG . 72.0 m-20 -124.64 9.78 8.37 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.008 0.432 . . . . 0.0 111.34 -175.163 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.55 ' HB3' ' HA3' ' A' ' 32' ' ' GLY . . . -71.43 150.63 44.76 Favored 'General case' 0 C--N 1.319 -0.755 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.878 -179.542 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 48.8 mt-10 -123.6 141.77 51.68 Favored 'General case' 0 N--CA 1.448 -0.567 0 CA-C-N 115.669 -0.696 . . . . 0.0 109.972 178.335 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 33.1 ttpt -55.19 129.52 38.54 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.8 -176.818 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 67.08 22.46 72.47 Favored Glycine 0 C--N 1.33 0.218 0 CA-C-N 115.947 -0.57 . . . . 0.0 112.902 174.327 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 18.4 m -113.78 158.89 20.38 Favored 'General case' 0 C--N 1.319 -0.731 0 O-C-N 122.609 -0.348 . . . . 0.0 110.179 179.651 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 51.1 t -118.39 99.87 8.86 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 N-CA-C 109.444 -0.576 . . . . 0.0 109.444 -178.69 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.695 HD11 HG11 ' A' ' 43' ' ' VAL . 0.5 OUTLIER -110.0 152.98 11.89 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.695 0 CA-C-N 116.044 -0.525 . . . . 0.0 109.861 -174.831 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 28.9 t-20 -92.56 120.5 33.08 Favored 'General case' 0 C--N 1.317 -0.826 0 N-CA-C 108.926 -0.768 . . . . 0.0 108.926 178.018 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 54' ' ' VAL . . . . . 0.666 ' HB ' ' HB1' ' A' ' 66' ' ' ALA . 34.9 m -114.67 139.83 38.74 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 N-CA-C 112.405 0.52 . . . . 0.0 112.405 -174.561 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 55' ' ' LYS . . . . . 0.434 ' HB2' ' HG2' ' A' ' 18' ' ' GLU . 3.2 ttmp? -98.54 109.21 22.0 Favored 'General case' 0 C--N 1.319 -0.758 0 N-CA-C 109.026 -0.731 . . . . 0.0 109.026 171.339 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.456 ' O ' ' HA ' ' A' ' 15' ' ' ALA . 90.7 t -69.39 113.16 4.82 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 178.554 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 17.5 p -101.97 -28.92 12.1 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 116.216 -0.447 . . . . 0.0 112.009 -175.096 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -140.58 94.09 2.69 Favored 'General case' 0 N--CA 1.452 -0.365 0 CA-C-O 121.121 0.486 . . . . 0.0 111.343 -173.536 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 39.5 t -81.34 133.08 30.05 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.833 0 CA-C-N 115.595 -0.73 . . . . 0.0 109.865 174.426 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 72.9 mmtt -112.82 -164.74 0.94 Allowed 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.397 -0.365 . . . . 0.0 110.368 178.555 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 8.9 mm-40 -67.56 -47.21 70.49 Favored 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 112.17 0.433 . . . . 0.0 112.17 -171.873 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 66.6 mttm -124.1 -2.45 8.15 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-O 120.625 0.25 . . . . 0.0 111.636 -176.574 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 9.9 p90 -153.73 174.73 14.14 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 116.26 -0.427 . . . . 0.0 109.871 -174.45 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -142.22 166.76 23.8 Favored 'General case' 0 C--N 1.322 -0.59 0 C-N-CA 120.876 -0.33 . . . . 0.0 111.465 -179.177 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 89.4 m-85 -117.14 131.86 56.79 Favored 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 175.033 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 66' ' ' ALA . . . . . 0.666 ' HB1' ' HB ' ' A' ' 54' ' ' VAL . . . -124.68 155.58 38.99 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-O 121.463 0.649 . . . . 0.0 112.433 -175.926 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 10.8 tt0 -104.71 120.28 40.98 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 114.946 -1.024 . . . . 0.0 110.324 178.557 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.564 ' HB3' ' HB2' ' A' ' 45' ' ' ASN . 41.0 ttt180 -66.19 107.71 2.04 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 121.624 0.726 . . . . 0.0 111.18 174.573 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.566 ' O ' ' HB3' ' A' ' 70' ' ' LEU . 2.6 t -80.57 -177.52 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.759 0 N-CA-C 106.241 -1.762 . . . . 0.0 106.241 167.005 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.578 HD23 ' OXT' ' A' ' 70' ' ' LEU . 0.0 OUTLIER . . . . . 0 C--O 1.247 0.935 0 CA-C-O 118.257 -0.878 . . . . 0.0 110.85 179.614 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 85.5 mtp . . . . . 0 N--CA 1.482 1.14 0 CA-C-O 120.888 0.375 . . . . 0.0 110.393 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -90.18 162.09 15.42 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.318 -0.401 . . . . 0.0 109.974 178.811 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 77.4 t80 -155.64 -37.63 0.09 Allowed 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 121.017 0.437 . . . . 0.0 110.814 -177.411 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 124.5 -15.03 7.65 Favored Glycine 0 N--CA 1.449 -0.483 0 N-CA-C 110.669 -0.972 . . . . 0.0 110.669 -175.411 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.569 ' HB3' ' HD3' ' A' ' 6' ' ' PRO . 31.7 ttmt -71.09 -45.14 14.47 Favored Pre-proline 0 CA--C 1.537 0.472 0 CA-C-N 114.848 -0.676 . . . . 0.0 111.063 176.15 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.569 ' HD3' ' HB3' ' A' ' 5' ' ' LYS . 6.4 Cg_exo -78.21 171.32 17.22 Favored 'Trans proline' 0 C--N 1.353 0.786 0 C-N-CA 122.26 1.973 . . . . 0.0 111.199 171.297 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . 65.69 -177.09 0.18 Allowed 'General case' 0 N--CA 1.467 0.4 0 O-C-N 123.627 0.579 . . . . 0.0 110.572 -174.19 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' MET . . . . . . . . . . . . . 15.7 tpt 56.55 52.51 9.71 Favored 'General case' 0 N--CA 1.465 0.31 0 CA-C-O 121.439 0.638 . . . . 0.0 109.823 -178.175 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' LYS . . . . . 0.45 ' NZ ' ' HB3' ' A' ' 9' ' ' LYS . 3.0 mmmp? 64.67 8.39 4.43 Favored 'General case' 0 N--CA 1.471 0.615 0 CA-C-N 115.402 -0.817 . . . . 0.0 111.539 -177.876 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 15.7 t-20 61.39 13.02 4.68 Favored 'General case' 0 N--CA 1.468 0.469 0 CA-C-N 115.363 -0.835 . . . . 0.0 110.233 -176.523 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.408 HG12 ' H ' ' A' ' 13' ' ' VAL . 96.8 t -160.87 111.84 1.3 Allowed Pre-proline 0 C--N 1.326 -0.427 0 CA-C-N 114.755 -1.111 . . . . 0.0 108.423 -173.388 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 42.0 Cg_endo -68.5 -10.22 28.38 Favored 'Trans proline' 0 C--O 1.232 0.204 0 C-N-CA 122.92 2.414 . . . . 0.0 113.584 -174.34 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.468 HG12 HD12 ' A' ' 36' ' ' ILE . 13.9 m -119.97 120.72 63.99 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.819 0 CA-C-O 121.106 0.479 . . . . 0.0 111.017 -176.808 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 15.6 mm-40 -92.15 122.09 34.31 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.035 -177.678 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' ALA . . . . . 0.406 ' HA ' ' O ' ' A' ' 56' ' ' VAL . . . -67.09 96.74 0.47 Allowed 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.711 -0.677 . . . . 0.0 110.705 179.261 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 142.76 -30.15 2.07 Favored Glycine 0 N--CA 1.443 -0.887 0 C-N-CA 120.977 -0.63 . . . . 0.0 112.278 -178.298 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 8.8 mtpm? -95.7 168.79 10.45 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 121.64 0.733 . . . . 0.0 111.562 -179.478 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' GLU . . . . . 0.515 ' HB2' ' OD1' ' A' ' 53' ' ' ASN . 0.0 OUTLIER -115.5 149.63 37.82 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 114.557 -1.201 . . . . 0.0 110.621 -179.176 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 80.0 m-85 -137.67 141.21 41.12 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.259 178.125 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 8.1 tt0 -79.05 107.55 11.89 Favored 'General case' 0 C--N 1.325 -0.458 0 N-CA-C 109.408 -0.59 . . . . 0.0 109.408 174.356 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 35.2 m -118.08 164.13 14.64 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 CA-C-O 120.969 0.414 . . . . 0.0 110.756 -176.186 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 6.1 m -112.0 140.12 46.94 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-O 121.207 0.527 . . . . 0.0 110.202 177.833 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.57 HG13 ' HB1' ' A' ' 46' ' ' ALA . 30.7 mm -104.39 59.59 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.804 0 N-CA-C 108.188 -1.041 . . . . 0.0 108.188 -177.487 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 36.8 tt0 -65.69 -7.89 17.84 Favored 'General case' 0 C--N 1.315 -0.902 0 CA-C-N 113.724 -1.58 . . . . 0.0 110.873 -179.089 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.523 ' HB3' ' HB ' ' A' ' 33' ' ' ILE . 28.5 t70 -138.7 138.51 37.81 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 120.849 0.357 . . . . 0.0 110.86 -176.869 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 26' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -120.85 114.01 20.97 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.952 -0.567 . . . . 0.0 109.863 178.024 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -112.51 173.09 15.06 Favored Glycine 0 N--CA 1.446 -0.649 0 C-N-CA 120.981 -0.628 . . . . 0.0 111.848 -178.439 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.465 ' HD2' ' CB ' ' A' ' 31' ' ' ASP . 77.5 mttt 57.2 14.57 2.11 Favored 'General case' 0 N--CA 1.462 0.153 0 N-CA-C 112.894 0.702 . . . . 0.0 112.894 175.685 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 83.08 -16.92 25.66 Favored Glycine 0 C--N 1.317 -0.504 0 C-N-CA 121.172 -0.537 . . . . 0.0 113.527 -179.768 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -170.31 31.75 0.15 Allowed Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.111 -1.042 . . . . 0.0 113.173 -178.406 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 31' ' ' ASP . . . . . 0.487 ' OD1' ' HA ' ' A' ' 44' ' ' PRO . 24.2 t70 -120.65 132.01 54.89 Favored 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 108.908 -0.775 . . . . 0.0 108.908 178.459 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -88.06 129.22 9.45 Favored Glycine 0 N--CA 1.449 -0.476 0 C-N-CA 120.627 -0.797 . . . . 0.0 112.381 -176.461 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.523 ' HB ' ' HB3' ' A' ' 25' ' ' ASP . 1.8 mp -100.16 101.74 12.5 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.46 0 CA-C-O 121.403 0.621 . . . . 0.0 110.423 178.864 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -95.47 151.71 19.06 Favored 'General case' 0 C--N 1.321 -0.66 0 N-CA-C 108.71 -0.848 . . . . 0.0 108.71 167.328 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 11.9 ttp-105 -139.95 104.28 4.83 Favored 'General case' 0 C--N 1.319 -0.726 0 C-N-CA 120.15 -0.62 . . . . 0.0 110.431 -178.883 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.468 HD12 HG12 ' A' ' 13' ' ' VAL . 29.8 mt -86.95 103.5 13.24 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-N 115.594 -0.73 . . . . 0.0 110.765 -175.938 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 13.7 t70 61.41 12.54 4.4 Favored 'General case' 0 N--CA 1.469 0.49 0 CA-C-N 114.372 -1.286 . . . . 0.0 111.737 179.323 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 120.12 -17.61 9.83 Favored Glycine 0 N--CA 1.448 -0.514 0 C-N-CA 120.472 -0.871 . . . . 0.0 112.007 -177.482 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 56.6 t80 -82.58 118.89 23.62 Favored 'General case' 0 C--N 1.326 -0.425 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 178.473 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 19.4 t -73.63 116.75 16.43 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-O 121.205 0.526 . . . . 0.0 111.057 -175.695 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 47.9 t -112.09 107.16 22.27 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 CA-C-N 115.586 -0.734 . . . . 0.0 109.322 178.038 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 94.3 m-85 -77.92 128.29 33.7 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.156 -178.28 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.446 HG11 ' HB2' ' A' ' 46' ' ' ALA . 3.3 t -115.82 98.38 50.9 Favored Pre-proline 0 C--N 1.317 -0.822 0 CA-C-N 115.883 -0.599 . . . . 0.0 109.905 -177.946 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 44' ' ' PRO . . . . . 0.487 ' HA ' ' OD1' ' A' ' 31' ' ' ASP . 48.6 Cg_exo -59.51 -17.73 42.92 Favored 'Trans proline' 0 N--CA 1.476 0.451 0 C-N-CA 124.07 3.18 . . . . 0.0 114.277 -173.486 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -131.62 8.36 4.55 Favored 'General case' 0 C--N 1.317 -0.817 0 N-CA-C 112.707 0.632 . . . . 0.0 112.707 -167.8 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.57 ' HB1' HG13 ' A' ' 23' ' ' ILE . . . -81.93 159.74 23.54 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-O 120.705 0.288 . . . . 0.0 110.892 175.272 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 46.0 mt-10 -108.16 159.48 16.57 Favored 'General case' 0 N--CA 1.448 -0.575 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.505 178.724 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -65.12 123.34 19.25 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.624 -175.211 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 74.49 22.71 76.97 Favored Glycine 0 C--N 1.331 0.29 0 CA-C-N 115.79 -0.641 . . . . 0.0 113.476 175.003 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 68.8 p -96.86 153.51 17.84 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-O 121.089 0.471 . . . . 0.0 111.101 -178.578 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 59.2 t -99.37 106.81 19.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 N-CA-C 108.195 -1.039 . . . . 0.0 108.195 172.562 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.563 HD11 ' HA ' ' A' ' 68' ' ' ARG . 0.8 OUTLIER -128.45 145.81 34.89 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.761 0 CA-C-O 121.772 0.796 . . . . 0.0 112.591 -166.647 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 53' ' ' ASN . . . . . 0.515 ' OD1' ' HB2' ' A' ' 18' ' ' GLU . 49.3 t30 -94.29 111.2 22.92 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 114.598 -1.183 . . . . 0.0 108.759 175.384 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 54' ' ' VAL . . . . . 0.562 ' HB ' ' HB1' ' A' ' 66' ' ' ALA . 34.6 m -108.69 128.52 64.34 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 CA-C-O 121.169 0.509 . . . . 0.0 111.399 -175.957 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 55' ' ' LYS . . . . . 0.505 ' HA ' ' HA ' ' A' ' 18' ' ' GLU . 2.7 ttpm? -96.34 106.43 18.65 Favored 'General case' 0 C--N 1.319 -0.757 0 N-CA-C 109.173 -0.677 . . . . 0.0 109.173 175.027 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.466 HG22 ' HB2' ' A' ' 66' ' ' ALA . 55.6 t -70.11 112.82 5.26 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 N-CA-C 109.875 -0.417 . . . . 0.0 109.875 -178.812 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 19.1 p -113.88 -9.6 13.05 Favored 'General case' 0 C--N 1.324 -0.516 0 N-CA-C 111.994 0.368 . . . . 0.0 111.994 -176.518 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -142.04 92.03 2.4 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.129 0.49 . . . . 0.0 111.064 -176.954 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 29.4 t -90.9 131.94 36.76 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.818 0 CA-C-N 115.917 -0.583 . . . . 0.0 109.89 177.363 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 32.2 mmtp -113.56 -178.18 3.31 Favored 'General case' 0 C--N 1.326 -0.452 0 N-CA-C 109.316 -0.624 . . . . 0.0 109.316 177.427 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 35.3 mt-10 -70.98 -26.42 63.14 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 113.054 0.761 . . . . 0.0 113.054 -172.179 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 62' ' ' LYS . . . . . 0.636 ' HB2' ' CD2' ' A' ' 63' ' ' PHE . 68.9 mmtt -114.97 -28.31 7.06 Favored 'General case' 0 N--CA 1.468 0.444 0 CA-C-O 121.162 0.506 . . . . 0.0 111.313 -177.03 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 63' ' ' PHE . . . . . 0.636 ' CD2' ' HB2' ' A' ' 62' ' ' LYS . 10.7 p90 -153.15 170.44 20.52 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.737 -0.665 . . . . 0.0 109.664 -172.074 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -131.57 160.18 36.04 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-O 120.769 0.318 . . . . 0.0 111.235 -179.01 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 97.8 m-85 -117.45 134.66 54.59 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 115.661 -0.699 . . . . 0.0 109.635 176.152 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 66' ' ' ALA . . . . . 0.562 ' HB1' ' HB ' ' A' ' 54' ' ' VAL . . . -124.73 177.21 6.1 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.806 -178.917 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 67' ' ' GLU . . . . . 0.557 ' O ' ' HA ' ' A' ' 54' ' ' VAL . 11.6 pt-20 -127.05 141.13 51.85 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 121.015 0.436 . . . . 0.0 111.103 -179.129 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.563 ' HA ' HD11 ' A' ' 52' ' ' ILE . 74.5 ttt-85 -71.07 98.21 1.61 Allowed 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.979 176.211 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.41 ' O ' HD23 ' A' ' 70' ' ' LEU . 3.1 t -82.34 64.82 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-N 116.469 -0.332 . . . . 0.0 110.275 177.4 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.506 HD12 ' NE ' ' A' ' 68' ' ' ARG . 73.7 mt . . . . . 0 C--O 1.248 0.982 0 CA-C-O 118.212 -0.899 . . . . 0.0 110.092 -178.245 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 22.9 mmt . . . . . 0 N--CA 1.482 1.171 0 CA-C-O 120.91 0.386 . . . . 0.0 110.96 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -97.18 4.25 51.2 Favored 'General case' 0 C--N 1.33 -0.27 0 N-CA-C 112.908 0.707 . . . . 0.0 112.908 -171.233 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 56.7 t80 -83.31 108.64 16.65 Favored 'General case' 0 C--N 1.326 -0.437 0 C-N-CA 120.091 -0.644 . . . . 0.0 110.246 -178.793 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 136.27 -42.73 1.3 Allowed Glycine 0 N--CA 1.444 -0.809 0 N-CA-C 110.009 -1.236 . . . . 0.0 110.009 -174.531 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.529 ' HG3' ' O ' ' A' ' 5' ' ' LYS . 1.8 pttp -166.13 90.96 0.84 Allowed Pre-proline 0 C--N 1.328 -0.355 0 CA-C-O 121.434 0.635 . . . . 0.0 109.928 173.96 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 5.6 Cg_exo -78.58 29.08 0.46 Allowed 'Trans proline' 0 N--CA 1.463 -0.316 0 C-N-CA 123.06 2.507 . . . . 0.0 111.705 178.468 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -157.59 -153.37 0.4 Allowed 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.582 -0.735 . . . . 0.0 110.162 -175.395 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' MET . . . . . . . . . . . . . 18.7 ttt 81.48 21.13 0.35 Allowed 'General case' 0 N--CA 1.468 0.446 0 O-C-N 124.332 1.02 . . . . 0.0 110.762 179.251 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 56.8 mtpt 54.31 49.74 17.85 Favored 'General case' 0 N--CA 1.464 0.236 0 CA-C-N 115.113 -0.949 . . . . 0.0 112.146 171.256 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 3.8 p-10 -81.63 60.67 4.7 Favored 'General case' 0 C--O 1.235 0.334 0 CA-C-O 121.687 0.756 . . . . 0.0 111.355 -178.259 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.517 HG11 HG11 ' A' ' 59' ' ' VAL . 60.9 t -65.38 128.52 93.87 Favored Pre-proline 0 C--N 1.326 -0.43 0 CA-C-N 115.503 -0.772 . . . . 0.0 109.658 175.424 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 12.3 Cg_endo -56.9 -31.35 88.97 Favored 'Trans proline' 0 CA--C 1.529 0.271 0 C-N-CA 123.052 2.501 . . . . 0.0 113.264 -176.484 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 12.3 m -103.07 125.97 57.43 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.602 0 CA-C-O 121.062 0.458 . . . . 0.0 111.097 -178.275 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 47.3 mt-10 -95.3 113.59 25.29 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.511 178.896 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -58.25 121.45 10.8 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.95 -0.568 . . . . 0.0 111.469 -179.016 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 115.26 -31.39 6.24 Favored Glycine 0 N--CA 1.448 -0.534 0 CA-C-N 115.895 -0.593 . . . . 0.0 112.057 -179.328 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -89.04 150.47 22.76 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 121.096 0.474 . . . . 0.0 111.02 -178.126 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' GLU . . . . . 0.588 ' HA ' ' HA ' ' A' ' 55' ' ' LYS . 0.7 OUTLIER -107.72 142.17 38.13 Favored 'General case' 0 C--N 1.317 -0.823 0 CA-C-N 115.546 -0.752 . . . . 0.0 110.518 179.192 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 67.1 m-85 -128.37 145.51 51.05 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.695 -176.032 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 6.2 tp10 -80.03 105.1 11.05 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 108.534 -0.913 . . . . 0.0 108.534 172.725 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 32.2 m -118.14 170.58 7.37 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-O 121.246 0.546 . . . . 0.0 112.176 -172.614 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 20.7 m -114.56 155.71 25.99 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.214 -0.903 . . . . 0.0 109.539 176.328 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.64 HG13 ' HB1' ' A' ' 46' ' ' ALA . 36.5 mm -118.62 64.66 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-O 122.127 0.965 . . . . 0.0 108.641 -175.239 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 -72.65 -8.51 55.65 Favored 'General case' 0 C--N 1.314 -0.944 0 CA-C-N 113.84 -1.527 . . . . 0.0 112.189 179.759 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.434 ' HB2' ' HB ' ' A' ' 33' ' ' ILE . 5.5 m-20 -134.61 153.93 51.74 Favored 'General case' 0 N--CA 1.465 0.288 0 N-CA-C 109.976 -0.379 . . . . 0.0 109.976 176.401 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 26' ' ' MET . . . . . 0.583 ' SD ' ' HB2' ' A' ' 48' ' ' LYS . 59.1 mtp -138.06 155.33 48.9 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.744 0.307 . . . . 0.0 110.777 174.226 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -86.31 0.19 87.06 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.944 -0.646 . . . . 0.0 111.779 177.206 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 55.5 tttp 68.75 14.13 8.94 Favored 'General case' 0 N--CA 1.466 0.359 0 CA-C-O 121.783 0.802 . . . . 0.0 111.578 175.674 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -127.2 24.05 5.4 Favored Glycine 0 C--N 1.314 -0.642 0 CA-C-N 115.451 -0.795 . . . . 0.0 111.903 178.815 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 98.21 -35.84 4.34 Favored Glycine 0 N--CA 1.451 -0.351 0 N-CA-C 110.946 -0.862 . . . . 0.0 110.946 -175.722 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 7.6 t70 -70.13 137.57 51.2 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.405 -0.397 . . . . 0.0 110.68 175.926 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 32' ' ' GLY . . . . . 0.552 ' HA2' ' HA ' ' A' ' 26' ' ' MET . . . -118.06 156.6 15.57 Favored Glycine 0 N--CA 1.447 -0.613 0 N-CA-C 111.515 -0.634 . . . . 0.0 111.515 178.008 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.461 HG23 HG13 ' A' ' 40' ' ' VAL . 2.3 mp -111.5 110.21 31.37 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 CA-C-O 121.326 0.584 . . . . 0.0 110.859 -177.598 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -83.59 161.21 21.23 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.582 -0.735 . . . . 0.0 110.176 170.627 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -133.84 103.7 5.97 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.431 -179.232 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 65.5 mt -103.32 112.24 36.05 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.714 0 N-CA-C 110.006 -0.368 . . . . 0.0 110.006 177.338 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 28.9 t70 67.35 5.59 4.35 Favored 'General case' 0 N--CA 1.47 0.558 0 O-C-N 123.969 0.793 . . . . 0.0 110.899 -178.565 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 105.42 -6.26 41.9 Favored Glycine 0 C--N 1.333 0.37 0 C-N-CA 120.762 -0.732 . . . . 0.0 111.308 -173.913 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 46.6 t80 -81.57 135.56 35.57 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 109.067 -0.716 . . . . 0.0 109.067 178.09 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.461 HG13 HG23 ' A' ' 33' ' ' ILE . 43.4 t -81.98 120.79 34.18 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.196 -175.348 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 52.3 t -122.63 110.66 27.38 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.612 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.679 -179.397 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 73.9 m-85 -76.87 130.3 37.4 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.095 -178.174 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.479 ' HA ' ' HD3' ' A' ' 44' ' ' PRO . 11.7 t -123.41 110.55 30.42 Favored Pre-proline 0 C--N 1.323 -0.579 0 CA-C-N 115.644 -0.707 . . . . 0.0 109.886 -179.378 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 44' ' ' PRO . . . . . 0.479 ' HD3' ' HA ' ' A' ' 43' ' ' VAL . 32.0 Cg_exo -58.53 -30.94 93.28 Favored 'Trans proline' 0 CA--C 1.531 0.375 0 C-N-CA 123.805 3.004 . . . . 0.0 115.427 -168.154 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 34.1 m-80 -132.63 22.11 4.29 Favored 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 112.687 0.625 . . . . 0.0 112.687 -173.413 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.64 ' HB1' HG13 ' A' ' 23' ' ' ILE . . . -87.03 134.09 33.53 Favored 'General case' 0 C--N 1.318 -0.801 0 CA-C-O 120.721 0.296 . . . . 0.0 111.637 176.104 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 70.4 mm-40 -86.91 156.18 19.93 Favored 'General case' 0 C--O 1.235 0.314 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.806 178.081 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 48' ' ' LYS . . . . . 0.583 ' HB2' ' SD ' ' A' ' 26' ' ' MET . 49.7 tttm -65.44 123.68 20.26 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.864 0.364 . . . . 0.0 110.462 -179.411 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 90.93 0.05 75.39 Favored Glycine 0 N--CA 1.446 -0.67 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.784 178.097 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 69.3 m -78.82 138.52 38.21 Favored 'General case' 0 C--N 1.322 -0.601 0 C-N-CA 120.784 -0.367 . . . . 0.0 110.82 177.967 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 44.5 t -92.16 100.7 11.65 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 N-CA-C 107.859 -1.163 . . . . 0.0 107.859 173.149 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.612 HD11 ' HB2' ' A' ' 68' ' ' ARG . 2.9 tt -123.27 140.17 47.71 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.824 0 CA-C-O 121.969 0.89 . . . . 0.0 112.636 -168.455 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 48.4 t30 -86.93 114.88 23.93 Favored 'General case' 0 C--N 1.313 -0.999 0 CA-C-N 113.801 -1.545 . . . . 0.0 108.588 175.389 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 54' ' ' VAL . . . . . 0.583 ' HB ' ' HB1' ' A' ' 66' ' ' ALA . 35.7 m -118.87 132.15 69.58 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.723 0 CA-C-O 120.763 0.316 . . . . 0.0 111.329 -176.287 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 55' ' ' LYS . . . . . 0.588 ' HA ' ' HA ' ' A' ' 18' ' ' GLU . 22.5 ttmm -96.78 106.92 19.3 Favored 'General case' 0 C--N 1.324 -0.519 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 177.071 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.466 ' HA ' ' HA ' ' A' ' 66' ' ' ALA . 48.5 t -70.83 107.12 2.0 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 N-CA-C 109.901 -0.407 . . . . 0.0 109.901 -177.985 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 8.9 p -103.22 -21.86 13.81 Favored 'General case' 0 C--N 1.323 -0.578 0 N-CA-C 112.13 0.419 . . . . 0.0 112.13 -174.293 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -135.41 92.15 2.81 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 121.225 0.536 . . . . 0.0 110.781 -175.882 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.517 HG11 HG11 ' A' ' 11' ' ' VAL . 45.3 t -88.49 117.16 31.53 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.735 0 CA-C-N 115.583 -0.735 . . . . 0.0 110.591 177.509 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 60' ' ' LYS . . . . . 0.527 ' HB2' ' O ' ' A' ' 63' ' ' PHE . 4.9 mptp? -97.59 -168.84 1.74 Allowed 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 109.61 -0.515 . . . . 0.0 109.61 174.894 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 34.6 mt-10 -70.54 -53.77 14.79 Favored 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 111.979 0.362 . . . . 0.0 111.979 -176.903 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -93.46 -29.35 15.6 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 120.976 0.417 . . . . 0.0 112.113 -174.293 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 63' ' ' PHE . . . . . 0.527 ' O ' ' HB2' ' A' ' 60' ' ' LYS . 16.2 p90 -151.75 164.65 36.53 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.735 -174.66 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -125.45 163.91 21.6 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-O 120.749 0.309 . . . . 0.0 110.958 -178.648 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 98.4 m-85 -116.06 130.17 56.68 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-N 115.783 -0.644 . . . . 0.0 109.286 176.214 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 66' ' ' ALA . . . . . 0.583 ' HB1' ' HB ' ' A' ' 54' ' ' VAL . . . -121.4 154.64 36.24 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-O 121.195 0.521 . . . . 0.0 111.778 -175.504 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 30.1 tt0 -101.87 116.41 32.64 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-N 115.243 -0.89 . . . . 0.0 111.531 -177.294 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.612 ' HB2' HD11 ' A' ' 52' ' ' ILE . 15.5 ttt-85 -54.03 108.06 0.33 Allowed 'General case' 0 CA--C 1.536 0.405 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.678 172.159 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.428 ' O ' HG12 ' A' ' 69' ' ' VAL . 12.2 t -82.01 12.26 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.328 0 CA-C-O 122.211 1.005 . . . . 0.0 110.324 179.707 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 54.9 mt . . . . . 0 C--N 1.316 -0.877 0 CA-C-N 114.932 -1.031 . . . . 0.0 109.148 176.773 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 52.5 mtt . . . . . 0 N--CA 1.483 1.197 0 CA-C-O 121.133 0.492 . . . . 0.0 111.434 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -110.54 99.5 8.47 Favored 'General case' 0 C--N 1.321 -0.661 0 N-CA-C 109.253 -0.647 . . . . 0.0 109.253 174.851 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 71.1 m-85 -85.34 39.95 0.81 Allowed 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.894 -0.594 . . . . 0.0 111.093 -174.627 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 96.54 -48.63 1.67 Allowed Glycine 0 N--CA 1.449 -0.481 0 N-CA-C 110.96 -0.856 . . . . 0.0 110.96 -177.802 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 18.2 ptpt -115.2 124.66 29.88 Favored Pre-proline 0 C--N 1.321 -0.666 0 CA-C-N 115.089 -0.556 . . . . 0.0 110.004 177.6 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 25.8 Cg_exo -65.0 139.37 61.2 Favored 'Trans proline' 0 C--O 1.239 0.534 0 C-N-CA 122.394 2.063 . . . . 0.0 110.907 173.279 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . 61.97 -147.68 0.39 Allowed 'General case' 0 CA--C 1.533 0.3 0 O-C-N 123.685 0.616 . . . . 0.0 110.757 -176.639 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' MET . . . . . . . . . . . . . 25.7 mmt 62.81 43.46 7.06 Favored 'General case' 0 C--O 1.234 0.26 0 CA-C-O 121.234 0.54 . . . . 0.0 111.168 178.817 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 16.2 pttp -115.09 71.42 0.76 Allowed 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 121.447 0.641 . . . . 0.0 110.556 178.936 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 3.3 t30 72.98 110.32 0.07 Allowed 'General case' 0 C--O 1.232 0.158 0 CA-C-N 114.741 -1.118 . . . . 0.0 110.731 179.58 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.508 HG12 ' H ' ' A' ' 13' ' ' VAL . 39.0 t -57.88 126.16 75.78 Favored Pre-proline 0 C--N 1.326 -0.432 0 CA-C-N 115.493 -0.776 . . . . 0.0 110.29 178.213 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -69.86 -9.82 26.99 Favored 'Trans proline' 0 C--N 1.345 0.374 0 C-N-CA 123.072 2.515 . . . . 0.0 113.143 -175.406 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.508 ' H ' HG12 ' A' ' 11' ' ' VAL . 24.0 m -130.51 134.78 61.73 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.584 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.09 -178.577 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 14' ' ' GLU . . . . . 0.657 ' HB2' ' HG3' ' A' ' 17' ' ' LYS . 2.9 mp0 -110.24 136.33 49.62 Favored 'General case' 0 C--N 1.318 -0.798 0 CA-C-O 120.827 0.346 . . . . 0.0 110.671 179.191 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 15' ' ' ALA . . . . . 0.463 ' HA ' ' O ' ' A' ' 56' ' ' VAL . . . -64.12 117.77 7.58 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 115.795 -0.638 . . . . 0.0 110.551 176.578 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 112.23 -7.49 26.9 Favored Glycine 0 N--CA 1.446 -0.652 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.633 179.753 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' LYS . . . . . 0.657 ' HG3' ' HB2' ' A' ' 14' ' ' GLU . 12.8 mmmm -93.08 155.69 17.34 Favored 'General case' 0 C--N 1.326 -0.448 0 O-C-N 122.604 -0.35 . . . . 0.0 110.448 -179.867 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 18' ' ' GLU . . . . . 0.486 ' HB3' ' OD1' ' A' ' 53' ' ' ASN . 0.7 OUTLIER -113.85 118.49 34.37 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 109.065 -0.717 . . . . 0.0 109.065 172.71 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 19' ' ' TYR . . . . . 0.408 ' CE2' ' HB2' ' A' ' 17' ' ' LYS . 64.7 m-85 -112.37 140.77 46.82 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-O 121.142 0.496 . . . . 0.0 111.614 -177.334 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 36.2 tt0 -84.42 99.21 10.52 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.09 -0.959 . . . . 0.0 109.193 176.727 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 35.8 m -114.58 171.25 4.45 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.57 0 CA-C-O 121.21 0.529 . . . . 0.0 112.168 -170.986 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 23.4 m -115.36 153.37 31.13 Favored 'General case' 0 N--CA 1.45 -0.445 0 CA-C-N 115.244 -0.889 . . . . 0.0 109.749 175.917 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.615 HG13 ' HB1' ' A' ' 46' ' ' ALA . 37.5 mm -119.1 65.33 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-O 122.056 0.931 . . . . 0.0 108.927 -173.984 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -64.46 -17.43 63.83 Favored 'General case' 0 C--N 1.318 -0.796 0 CA-C-N 113.977 -1.465 . . . . 0.0 111.816 177.737 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.529 ' HB3' ' HB ' ' A' ' 33' ' ' ILE . 27.0 t0 -136.02 151.46 49.9 Favored 'General case' 0 C--N 1.324 -0.517 0 C-N-CA 121.064 -0.254 . . . . 0.0 110.824 -176.539 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 26' ' ' MET . . . . . 0.668 ' SD ' ' HB2' ' A' ' 48' ' ' LYS . 70.1 mtp -137.33 152.75 50.07 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.724 0.297 . . . . 0.0 110.22 175.521 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -86.75 -1.33 85.35 Favored Glycine 0 N--CA 1.448 -0.507 0 C-N-CA 120.969 -0.634 . . . . 0.0 111.56 177.726 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 97.7 mttt 58.64 23.51 11.06 Favored 'General case' 0 CA--C 1.523 -0.073 0 CA-C-O 121.712 0.768 . . . . 0.0 111.938 178.89 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -138.65 35.28 2.02 Favored Glycine 0 N--CA 1.445 -0.736 0 CA-C-N 114.884 -1.053 . . . . 0.0 111.026 175.894 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 98.02 -41.52 2.26 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 121.06 -0.59 . . . . 0.0 111.975 -178.252 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 31' ' ' ASP . . . . . 0.625 ' HA ' ' HA ' ' A' ' 44' ' ' PRO . 27.6 m-20 -73.53 127.68 33.41 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 121.021 0.439 . . . . 0.0 111.331 -179.216 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -106.62 143.24 15.76 Favored Glycine 0 N--CA 1.444 -0.778 0 N-CA-C 110.2 -1.16 . . . . 0.0 110.2 171.614 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.529 ' HB ' ' HB3' ' A' ' 25' ' ' ASP . 2.1 mp -103.49 105.36 18.19 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.752 0 CA-C-O 121.354 0.597 . . . . 0.0 111.123 -173.761 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -86.99 155.77 20.04 Favored 'General case' 0 N--CA 1.444 -0.733 0 N-CA-C 108.134 -1.061 . . . . 0.0 108.134 166.572 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 37.0 ttt180 -141.93 118.36 10.88 Favored 'General case' 0 C--N 1.314 -0.956 0 C-N-CA 120.031 -0.668 . . . . 0.0 110.376 179.278 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 27.0 mt -109.27 108.7 26.0 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.664 0 CA-C-N 115.458 -0.792 . . . . 0.0 110.397 -179.37 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 31.7 t70 65.29 19.55 11.7 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.121 -0.945 . . . . 0.0 110.932 179.006 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 99.81 -9.39 60.16 Favored Glycine 0 N--CA 1.449 -0.445 0 C-N-CA 120.207 -0.997 . . . . 0.0 111.788 -177.43 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 54.1 t80 -82.75 118.84 23.66 Favored 'General case' 0 C--N 1.322 -0.62 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 177.672 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 17.0 t -75.08 122.93 29.74 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-O 120.993 0.425 . . . . 0.0 111.193 -174.961 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 45.3 t -115.86 109.29 27.69 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-N 116.202 -0.454 . . . . 0.0 109.863 179.646 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 85.6 m-85 -80.35 119.22 22.78 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 121.039 0.447 . . . . 0.0 110.752 -178.327 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.464 HG11 HD13 ' A' ' 52' ' ' ILE . 3.2 t -115.13 101.41 54.47 Favored Pre-proline 0 C--N 1.32 -0.706 0 CA-C-N 115.677 -0.692 . . . . 0.0 109.379 178.567 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 44' ' ' PRO . . . . . 0.625 ' HA ' ' HA ' ' A' ' 31' ' ' ASP . 16.9 Cg_exo -68.12 5.27 1.19 Allowed 'Trans proline' 0 CA--C 1.531 0.374 0 C-N-CA 123.383 2.722 . . . . 0.0 114.818 -168.721 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 47.5 m-80 -143.43 14.61 1.81 Allowed 'General case' 0 N--CA 1.464 0.225 0 CA-C-O 120.632 0.253 . . . . 0.0 111.609 179.553 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.615 ' HB1' HG13 ' A' ' 23' ' ' ILE . . . -86.43 134.1 33.72 Favored 'General case' 0 C--N 1.32 -0.713 0 N-CA-C 112.018 0.377 . . . . 0.0 112.018 -178.86 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 44.2 mt-10 -92.83 146.18 23.83 Favored 'General case' 0 N--CA 1.454 -0.266 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.976 177.281 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 48' ' ' LYS . . . . . 0.668 ' HB2' ' SD ' ' A' ' 26' ' ' MET . 46.8 tttp -65.43 129.93 41.51 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.051 -0.522 . . . . 0.0 111.136 -177.916 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 88.17 -5.42 84.83 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.827 -0.702 . . . . 0.0 113.397 176.005 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 51.1 m -95.14 147.78 23.08 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.872 0.336 . . . . 0.0 110.796 -179.329 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 46.0 t -91.91 109.59 21.54 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 N-CA-C 109.23 -0.656 . . . . 0.0 109.23 178.14 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.842 HG13 HD21 ' A' ' 70' ' ' LEU . 2.5 tt -119.57 143.41 31.13 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.819 0 CA-C-O 121.853 0.835 . . . . 0.0 112.403 -170.568 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 53' ' ' ASN . . . . . 0.486 ' OD1' ' HB3' ' A' ' 18' ' ' GLU . 23.5 t-20 -89.56 114.19 25.72 Favored 'General case' 0 C--N 1.316 -0.869 0 CA-C-N 114.051 -1.432 . . . . 0.0 108.543 175.406 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 54' ' ' VAL . . . . . 0.533 ' HB ' ' HB1' ' A' ' 66' ' ' ALA . 32.6 m -114.67 128.26 71.84 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 CA-C-O 121.264 0.554 . . . . 0.0 111.856 -175.601 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 55' ' ' LYS . . . . . 0.589 ' HA ' ' O ' ' A' ' 17' ' ' LYS . 38.2 ttmt -95.13 104.44 16.32 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 115.912 -0.585 . . . . 0.0 109.496 173.976 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.463 ' O ' ' HA ' ' A' ' 15' ' ' ALA . 66.0 t -66.09 110.48 1.35 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 N-CA-C 109.681 -0.489 . . . . 0.0 109.681 179.575 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 11.5 p -105.83 -28.86 10.39 Favored 'General case' 0 C--N 1.324 -0.54 0 N-CA-C 112.247 0.462 . . . . 0.0 112.247 -174.449 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -136.99 92.42 2.73 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 121.12 0.486 . . . . 0.0 110.978 -175.47 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 22.4 t -81.62 125.1 39.58 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.667 0 CA-C-N 115.623 -0.717 . . . . 0.0 110.017 176.225 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 32.2 mmtp -109.47 -150.21 0.45 Allowed 'General case' 0 C--N 1.325 -0.458 0 N-CA-C 109.951 -0.389 . . . . 0.0 109.951 178.484 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 20.2 mm-40 -70.78 -76.89 0.09 Allowed 'General case' 0 C--N 1.331 -0.239 0 N-CA-C 112.18 0.437 . . . . 0.0 112.18 -176.105 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 63.7 mttm -98.22 -2.57 39.39 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 121.182 0.515 . . . . 0.0 110.821 -175.652 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 35.7 p90 -151.37 164.97 35.5 Favored 'General case' 0 C--N 1.318 -0.761 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.725 -173.138 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -137.91 171.02 15.04 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.603 178.182 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 96.8 m-85 -118.92 133.81 55.59 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 109.493 -0.558 . . . . 0.0 109.493 176.702 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 66' ' ' ALA . . . . . 0.533 ' HB1' ' HB ' ' A' ' 54' ' ' VAL . . . -133.95 145.11 49.24 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.464 -179.001 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 67' ' ' GLU . . . . . 0.504 ' HG2' ' HB3' ' A' ' 55' ' ' LYS . 9.6 pt-20 -93.67 142.22 27.6 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-O 121.179 0.514 . . . . 0.0 111.408 -177.83 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.567 ' HB2' HD11 ' A' ' 52' ' ' ILE . 17.8 ttt180 -71.17 109.96 5.54 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.341 -0.845 . . . . 0.0 110.043 173.721 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.489 ' O ' HG12 ' A' ' 69' ' ' VAL . 40.7 t -81.66 12.75 0.58 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.518 0 CA-C-O 122.076 0.941 . . . . 0.0 111.505 -176.415 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.842 HD21 HG13 ' A' ' 52' ' ' ILE . 1.0 OUTLIER . . . . . 0 C--N 1.314 -0.952 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.397 -179.333 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 25.9 ttt . . . . . 0 N--CA 1.479 1.01 0 CA-C-O 120.924 0.393 . . . . 0.0 110.479 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -85.85 137.97 32.38 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.397 178.998 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 79.9 m-85 -83.98 121.67 27.7 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.756 -172.853 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 97.38 -15.92 61.45 Favored Glycine 0 N--CA 1.448 -0.524 0 C-N-CA 120.875 -0.679 . . . . 0.0 111.785 -179.657 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 22.6 tptm 61.51 95.34 0.05 OUTLIER Pre-proline 0 C--O 1.234 0.241 0 C-N-CA 123.071 0.548 . . . . 0.0 110.97 -178.277 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.533 ' HG2' ' HG3' ' A' ' 8' ' ' MET . 92.3 Cg_endo -79.88 -162.84 0.2 Allowed 'Trans proline' 0 N--CA 1.46 -0.48 0 C-N-CA 122.671 2.247 . . . . 0.0 111.549 177.753 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -80.45 -65.17 1.04 Allowed 'General case' 0 C--N 1.322 -0.626 0 CA-C-O 120.562 0.22 . . . . 0.0 110.473 -179.756 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' MET . . . . . 0.533 ' HG3' ' HG2' ' A' ' 6' ' ' PRO . 84.0 mtp 58.92 24.6 12.73 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.632 -179.368 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 26.5 mtpp 63.9 -90.8 0.03 OUTLIER 'General case' 0 CA--C 1.516 -0.341 0 CA-C-N 115.389 -0.823 . . . . 0.0 110.188 -171.998 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 7.1 t30 62.39 11.01 4.28 Favored 'General case' 0 C--N 1.316 -0.859 0 CA-C-N 115.016 -0.993 . . . . 0.0 111.066 176.649 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 54.9 t -159.69 123.91 2.1 Favored Pre-proline 0 C--N 1.32 -0.677 0 CA-C-N 115.034 -0.985 . . . . 0.0 109.185 -171.107 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 94.8 Cg_endo -78.65 -21.37 9.98 Favored 'Trans proline' 0 C--N 1.343 0.246 0 C-N-CA 123.272 2.648 . . . . 0.0 113.18 -177.677 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.539 ' HB ' HG21 ' A' ' 56' ' ' VAL . 17.0 m -97.34 124.36 50.2 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.724 0 CA-C-N 115.857 -0.611 . . . . 0.0 110.779 -175.714 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 14' ' ' GLU . . . . . 0.475 ' OE2' ' HE2' ' A' ' 17' ' ' LYS . 31.7 tt0 -104.04 129.04 51.65 Favored 'General case' 0 C--N 1.322 -0.613 0 C-N-CA 120.85 -0.34 . . . . 0.0 110.105 -179.734 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -54.42 118.49 4.18 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.79 -0.641 . . . . 0.0 111.155 -178.477 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.31 -25.75 10.98 Favored Glycine 0 N--CA 1.444 -0.826 0 C-N-CA 120.671 -0.776 . . . . 0.0 112.448 179.941 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' LYS . . . . . 0.475 ' HE2' ' OE2' ' A' ' 14' ' ' GLU . 68.6 mttm -85.55 160.48 19.64 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 120.938 0.399 . . . . 0.0 110.457 179.034 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 18' ' ' GLU . . . . . 0.51 ' HA ' ' HA ' ' A' ' 55' ' ' LYS . 0.0 OUTLIER -126.87 133.32 50.74 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.449 179.052 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 19' ' ' TYR . . . . . 0.416 ' CE2' ' HA ' ' A' ' 13' ' ' VAL . 64.4 m-85 -123.14 162.6 22.19 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.331 -176.589 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 45.4 tt0 -96.58 122.39 39.44 Favored 'General case' 0 C--N 1.321 -0.665 0 N-CA-C 109.398 -0.593 . . . . 0.0 109.398 176.323 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.527 ' HB ' ' HB1' ' A' ' 34' ' ' ALA . 28.0 m -128.84 168.88 21.21 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-O 121.131 0.491 . . . . 0.0 111.587 -174.62 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 26.2 m -118.88 143.22 47.11 Favored 'General case' 0 N--CA 1.446 -0.65 0 CA-C-N 115.755 -0.657 . . . . 0.0 109.359 175.313 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.559 HG13 ' HB1' ' A' ' 46' ' ' ALA . 19.9 mm -111.77 59.53 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.664 0 CA-C-O 121.997 0.903 . . . . 0.0 108.755 -173.284 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -78.17 9.69 3.57 Favored 'General case' 0 C--N 1.315 -0.921 0 CA-C-N 114.573 -1.194 . . . . 0.0 112.229 -177.555 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.445 ' HB3' ' HB ' ' A' ' 33' ' ' ILE . 29.1 t0 -150.11 148.31 28.82 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.444 -0.344 . . . . 0.0 110.119 176.91 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 26' ' ' MET . . . . . 0.652 ' HA ' ' HA2' ' A' ' 32' ' ' GLY . 39.4 mtp -123.99 151.93 43.13 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.999 0.428 . . . . 0.0 111.157 178.649 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -87.49 -63.25 1.43 Allowed Glycine 0 N--CA 1.445 -0.758 0 CA-C-N 115.554 -0.748 . . . . 0.0 112.709 -177.421 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.455 ' HG3' ' OD2' ' A' ' 31' ' ' ASP . 16.7 pttp -163.71 79.88 0.43 Allowed 'General case' 0 N--CA 1.443 -0.782 0 CA-C-O 121.842 0.83 . . . . 0.0 112.876 -175.828 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 64.6 40.53 97.63 Favored Glycine 0 C--N 1.307 -1.054 0 CA-C-N 114.626 -1.17 . . . . 0.0 114.591 169.021 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 158.94 -47.91 0.42 Allowed Glycine 0 CA--C 1.505 -0.541 0 C-N-CA 120.268 -0.968 . . . . 0.0 111.76 173.88 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 31' ' ' ASP . . . . . 0.455 ' OD2' ' HG3' ' A' ' 28' ' ' LYS . 1.7 p30 -80.91 146.77 30.64 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-O 120.882 0.372 . . . . 0.0 110.013 177.13 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 32' ' ' GLY . . . . . 0.652 ' HA2' ' HA ' ' A' ' 26' ' ' MET . . . -128.57 172.78 19.33 Favored Glycine 0 N--CA 1.442 -0.95 0 C-N-CA 120.824 -0.703 . . . . 0.0 112.46 -177.384 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.445 ' HB ' ' HB3' ' A' ' 25' ' ' ASP . 2.2 mp -114.03 121.93 67.14 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.71 0 CA-C-O 120.947 0.403 . . . . 0.0 110.34 -179.949 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 34' ' ' ALA . . . . . 0.527 ' HB1' ' HB ' ' A' ' 21' ' ' VAL . . . -116.92 117.18 28.98 Favored 'General case' 0 C--N 1.317 -0.805 0 N-CA-C 108.804 -0.813 . . . . 0.0 108.804 172.663 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 35' ' ' ARG . . . . . 0.404 HH11 ' HD3' ' A' ' 35' ' ' ARG . 28.2 ttp180 -104.25 110.67 22.97 Favored 'General case' 0 C--N 1.318 -0.795 0 CA-C-O 121.143 0.497 . . . . 0.0 111.224 -172.735 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 43.7 mt -99.75 110.11 26.19 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-N 115.443 -0.799 . . . . 0.0 110.385 178.992 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 56.6 27.71 12.87 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.217 -0.902 . . . . 0.0 112.081 -179.837 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 100.17 -14.61 59.71 Favored Glycine 0 C--N 1.33 0.207 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.014 -179.627 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 65.9 t80 -85.04 135.44 34.01 Favored 'General case' 0 C--N 1.321 -0.65 0 N-CA-C 109.554 -0.536 . . . . 0.0 109.554 -178.585 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 34.0 t -88.2 117.06 31.17 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-O 121.162 0.506 . . . . 0.0 111.239 -175.424 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 40.8 t -112.51 118.78 58.7 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.686 0 CA-C-N 115.695 -0.684 . . . . 0.0 109.273 174.952 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 76.3 m-85 -87.07 132.04 33.94 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-O 121.194 0.521 . . . . 0.0 111.47 -177.474 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.554 HG21 HD12 ' A' ' 23' ' ' ILE . 15.5 m -111.54 124.2 33.09 Favored Pre-proline 0 C--N 1.324 -0.513 0 CA-C-N 115.461 -0.79 . . . . 0.0 110.336 178.377 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 44' ' ' PRO . . . . . 0.494 ' HD3' ' HA ' ' A' ' 43' ' ' VAL . 13.5 Cg_exo -71.42 -34.54 9.47 Favored 'Trans proline' 0 CA--C 1.527 0.175 0 C-N-CA 123.05 2.5 . . . . 0.0 113.667 -175.495 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 4.5 p30 -136.12 34.36 2.82 Favored 'General case' 0 C--N 1.325 -0.46 0 N-CA-C 112.887 0.699 . . . . 0.0 112.887 -167.092 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.559 ' HB1' HG13 ' A' ' 23' ' ' ILE . . . -90.41 161.33 15.62 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 120.991 0.424 . . . . 0.0 112.125 175.562 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 47' ' ' GLU . . . . . 0.526 ' CD ' HH12 ' A' ' 68' ' ' ARG . 2.1 mp0 -102.61 147.16 27.14 Favored 'General case' 0 C--O 1.235 0.302 0 CA-C-N 115.871 -0.604 . . . . 0.0 109.741 170.867 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 48' ' ' LYS . . . . . 0.505 ' HE3' ' SD ' ' A' ' 26' ' ' MET . 9.3 ptpp? -66.54 139.98 57.95 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.15 0.5 . . . . 0.0 111.061 -179.859 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 73.33 13.94 79.53 Favored Glycine 0 N--CA 1.45 -0.375 0 CA-C-N 115.861 -0.609 . . . . 0.0 112.764 177.513 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 8.5 t -107.46 151.2 25.87 Favored 'General case' 0 C--N 1.323 -0.57 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 178.647 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 57.9 t -104.1 104.92 17.52 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 N-CA-C 109.554 -0.535 . . . . 0.0 109.554 179.266 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.552 HD12 ' HB2' ' A' ' 68' ' ' ARG . 0.9 OUTLIER -113.97 154.94 15.27 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.512 -174.556 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 28.6 t-20 -95.29 119.95 34.68 Favored 'General case' 0 C--N 1.321 -0.665 0 N-CA-C 109.001 -0.741 . . . . 0.0 109.001 174.508 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 54' ' ' VAL . . . . . 0.492 ' HB ' ' HB1' ' A' ' 66' ' ' ALA . 27.8 m -112.08 131.92 62.18 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.664 0 CA-C-O 121.08 0.467 . . . . 0.0 111.738 -175.43 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 55' ' ' LYS . . . . . 0.51 ' HA ' ' HA ' ' A' ' 18' ' ' GLU . 6.3 ttpm? -100.06 109.54 21.85 Favored 'General case' 0 C--N 1.318 -0.786 0 N-CA-C 108.74 -0.837 . . . . 0.0 108.74 173.321 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.539 HG21 ' HB ' ' A' ' 13' ' ' VAL . 39.1 t -72.28 114.02 10.45 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.551 -176.321 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 7.9 p -108.15 -18.14 13.85 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 116.196 -0.456 . . . . 0.0 112.004 -177.523 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 58' ' ' ALA . . . . . 0.407 ' HB3' ' HB2' ' A' ' 65' ' ' PHE . . . -134.57 91.1 2.74 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 121.217 0.532 . . . . 0.0 110.591 -177.85 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 19.0 t -90.25 134.61 28.67 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.781 0 CA-C-N 115.298 -0.865 . . . . 0.0 110.801 179.156 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 60' ' ' LYS . . . . . 0.509 ' HB2' ' O ' ' A' ' 63' ' ' PHE . 75.4 mmtt -119.03 172.52 7.49 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 121.172 0.51 . . . . 0.0 110.563 174.351 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 42.2 tt0 -69.75 -29.34 66.68 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.072 -0.967 . . . . 0.0 109.428 173.691 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 62' ' ' LYS . . . . . 0.465 ' O ' ' CG ' ' A' ' 63' ' ' PHE . 38.6 mtmt -129.11 87.26 2.54 Favored 'General case' 0 N--CA 1.416 -2.154 0 N-CA-C 105.314 -2.106 . . . . 0.0 105.314 177.587 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 63' ' ' PHE . . . . . 0.509 ' O ' ' HB2' ' A' ' 60' ' ' LYS . 20.5 p90 78.89 142.25 0.08 Allowed 'General case' 0 N--CA 1.488 1.462 0 CA-C-N 112.903 -1.953 . . . . 0.0 112.17 164.658 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -117.1 169.58 9.32 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.452 -0.795 . . . . 0.0 111.894 -170.322 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 65' ' ' PHE . . . . . 0.407 ' HB2' ' HB3' ' A' ' 58' ' ' ALA . 79.5 m-85 -120.26 133.55 55.45 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 115.359 -0.837 . . . . 0.0 109.396 177.949 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 66' ' ' ALA . . . . . 0.537 ' HB2' HG22 ' A' ' 56' ' ' VAL . . . -134.81 148.04 50.09 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 120.922 0.391 . . . . 0.0 111.23 -177.271 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 11.1 pt-20 -94.27 132.63 38.65 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.914 -178.826 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.926 ' HE ' HD12 ' A' ' 70' ' ' LEU . 31.0 ttt180 -67.02 106.39 1.93 Allowed 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.449 -0.796 . . . . 0.0 110.728 175.717 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 18.9 t -80.53 66.45 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.535 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.015 179.55 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.926 HD12 ' HE ' ' A' ' 68' ' ' ARG . 70.8 mt . . . . . 0 C--O 1.246 0.896 0 CA-C-N 115.687 -0.688 . . . . 0.0 109.466 178.266 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 15.5 tpt . . . . . 0 N--CA 1.478 0.935 0 N-CA-C 110.378 -0.23 . . . . 0.0 110.378 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -153.32 98.18 2.23 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.867 0.365 . . . . 0.0 111.063 -179.384 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 85.4 m-85 -106.92 120.81 43.05 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.715 178.225 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 95.77 -5.02 66.44 Favored Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 120.576 -0.821 . . . . 0.0 112.512 175.905 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 49.3 mtpt 57.92 74.66 0.61 Allowed Pre-proline 0 C--O 1.234 0.253 0 CA-C-O 121.194 0.521 . . . . 0.0 109.98 -173.724 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 98.3 Cg_endo -93.41 166.81 2.32 Favored 'Trans proline' 0 N--CA 1.454 -0.85 0 C-N-CA 122.988 2.459 . . . . 0.0 113.774 -171.94 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . 70.7 127.61 0.03 OUTLIER 'General case' 0 N--CA 1.464 0.264 0 CA-C-N 114.956 -1.02 . . . . 0.0 112.854 173.731 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -90.47 19.41 5.29 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.826 -0.624 . . . . 0.0 109.982 175.412 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 1.4 mptm? 62.56 26.81 15.91 Favored 'General case' 0 N--CA 1.466 0.336 0 CA-C-N 114.747 -1.115 . . . . 0.0 112.026 177.867 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 35.2 t-20 -85.12 66.44 9.74 Favored 'General case' 0 C--N 1.324 -0.53 0 N-CA-C 108.586 -0.894 . . . . 0.0 108.586 175.411 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 25.2 t -64.61 121.44 73.04 Favored Pre-proline 0 C--N 1.322 -0.594 0 CA-C-N 115.082 -0.963 . . . . 0.0 110.027 178.848 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' PRO . . . . . 0.436 ' HG2' ' HB2' ' A' ' 39' ' ' PHE . 16.9 Cg_exo -62.6 -30.84 79.59 Favored 'Trans proline' 0 C--O 1.233 0.253 0 C-N-CA 123.109 2.54 . . . . 0.0 112.095 -177.659 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.793 HG12 HD12 ' A' ' 36' ' ' ILE . 31.0 m -107.49 149.84 10.55 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 CA-C-N 115.267 -0.878 . . . . 0.0 110.465 -176.715 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -124.35 136.71 54.3 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-O 120.862 0.363 . . . . 0.0 110.393 177.905 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -70.54 106.59 3.51 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.996 -178.217 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 120.68 -13.1 10.02 Favored Glycine 0 N--CA 1.446 -0.653 0 C-N-CA 120.924 -0.655 . . . . 0.0 112.329 -179.719 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 8.1 mtpm? -102.56 156.74 17.41 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.724 0.297 . . . . 0.0 110.907 -178.87 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' GLU . . . . . 0.563 ' HA ' ' O ' ' A' ' 54' ' ' VAL . 0.0 OUTLIER -112.16 142.01 45.14 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 121.166 0.508 . . . . 0.0 111.375 -179.074 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 19' ' ' TYR . . . . . 0.563 ' O ' ' HA ' ' A' ' 53' ' ' ASN . 81.4 m-85 -130.64 141.74 50.43 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 116.051 -0.522 . . . . 0.0 111.121 -176.085 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 37.7 mt-10 -79.79 98.85 7.21 Favored 'General case' 0 C--N 1.326 -0.456 0 N-CA-C 109.3 -0.63 . . . . 0.0 109.3 174.835 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.488 ' HB ' ' HB1' ' A' ' 34' ' ' ALA . 35.8 m -110.3 156.2 11.36 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.81 0 CA-C-N 115.787 -0.642 . . . . 0.0 111.526 -174.275 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 24.2 m -105.09 148.73 26.51 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 115.407 -0.815 . . . . 0.0 109.77 176.07 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.534 HG13 ' HB1' ' A' ' 46' ' ' ALA . 33.6 mm -114.45 65.91 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.783 0 N-CA-C 108.053 -1.091 . . . . 0.0 108.053 -174.662 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 -62.25 -24.89 67.52 Favored 'General case' 0 C--N 1.312 -1.025 0 CA-C-N 113.621 -1.627 . . . . 0.0 111.552 178.974 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.529 ' HB3' ' HB ' ' A' ' 33' ' ' ILE . 5.9 t70 -133.7 152.03 51.78 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.521 -0.309 . . . . 0.0 111.125 -170.166 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 26' ' ' MET . . . . . 0.522 ' SD ' ' HB2' ' A' ' 48' ' ' LYS . 18.0 mtp -129.84 161.7 30.18 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 121.018 0.437 . . . . 0.0 110.73 176.341 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -104.99 -117.38 4.34 Favored Glycine 0 N--CA 1.448 -0.52 0 CA-C-N 115.74 -0.664 . . . . 0.0 111.957 177.282 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 63.6 mmtt -76.47 19.75 0.25 Allowed 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 112.769 0.655 . . . . 0.0 112.769 -179.613 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 102.6 -42.51 1.88 Allowed Glycine 0 C--N 1.313 -0.739 0 C-N-CA 120.926 -0.654 . . . . 0.0 112.664 178.109 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -100.76 19.74 51.02 Favored Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 120.783 -0.722 . . . . 0.0 111.678 178.593 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 16.2 m-20 -124.64 114.21 19.05 Favored 'General case' 0 C--N 1.324 -0.52 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 179.011 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -96.53 122.35 7.34 Favored Glycine 0 N--CA 1.444 -0.815 0 N-CA-C 110.563 -1.015 . . . . 0.0 110.563 174.468 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.529 ' HB ' ' HB3' ' A' ' 25' ' ' ASP . 1.9 mp -95.84 100.67 11.32 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.698 0 CA-C-O 121.426 0.631 . . . . 0.0 110.462 -176.798 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 34' ' ' ALA . . . . . 0.488 ' HB1' ' HB ' ' A' ' 21' ' ' VAL . . . -99.4 162.04 13.27 Favored 'General case' 0 CA--C 1.495 -1.16 0 CA-C-N 115.265 -0.879 . . . . 0.0 108.947 168.563 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 35' ' ' ARG . . . . . 0.4 ' HA ' ' O ' ' A' ' 39' ' ' PHE . 29.0 ptt180 -156.65 119.64 4.12 Favored 'General case' 0 N--CA 1.43 -1.47 0 CA-C-O 121.423 0.63 . . . . 0.0 110.859 -177.379 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.793 HD12 HG12 ' A' ' 13' ' ' VAL . 43.9 mt -96.67 111.21 26.25 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.829 0 CA-C-N 115.186 -0.915 . . . . 0.0 110.349 -175.175 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 25.9 t0 57.97 29.18 17.3 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 114.685 -1.143 . . . . 0.0 110.836 -177.871 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 103.63 -22.69 34.98 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.957 -0.639 . . . . 0.0 112.347 179.401 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 39' ' ' PHE . . . . . 0.436 ' HB2' ' HG2' ' A' ' 12' ' ' PRO . 63.3 t80 -74.86 112.54 11.19 Favored 'General case' 0 C--N 1.324 -0.519 0 N-CA-C 109.959 -0.386 . . . . 0.0 109.959 -178.299 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 41.2 t -69.14 123.9 23.71 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 CA-C-O 121.42 0.628 . . . . 0.0 111.84 -174.791 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 25.5 t -121.8 109.23 24.0 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.691 0 CA-C-N 115.233 -0.894 . . . . 0.0 109.18 -179.884 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 87.9 m-85 -77.11 124.47 27.85 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.176 -176.39 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.42 ' CG1' ' HB2' ' A' ' 46' ' ' ALA . 2.7 t -122.01 98.96 44.37 Favored Pre-proline 0 C--N 1.325 -0.48 0 CA-C-N 115.753 -0.658 . . . . 0.0 110.534 -179.377 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -74.11 -0.16 9.2 Favored 'Trans proline' 0 CA--C 1.53 0.312 0 C-N-CA 122.704 2.269 . . . . 0.0 113.458 -175.752 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 45' ' ' ASN . . . . . 0.441 ' HB2' ' HB3' ' A' ' 68' ' ' ARG . 70.3 m-20 -125.57 8.25 7.66 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 121.099 0.476 . . . . 0.0 110.91 -175.132 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.534 ' HB1' HG13 ' A' ' 23' ' ' ILE . . . -91.03 153.25 20.27 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 112.069 0.396 . . . . 0.0 112.069 -176.176 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 5.4 mm-40 -105.04 135.9 45.52 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.444 -0.798 . . . . 0.0 110.433 176.426 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 48' ' ' LYS . . . . . 0.522 ' HB2' ' SD ' ' A' ' 26' ' ' MET . 14.3 tmtt? -65.14 136.65 56.95 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.494 -179.895 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 70.64 23.44 77.73 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.993 -0.622 . . . . 0.0 112.522 179.069 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 23.3 t -122.36 145.89 47.83 Favored 'General case' 0 C--N 1.321 -0.654 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 179.518 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 52.8 t -90.44 101.62 12.51 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 N-CA-C 109.53 -0.545 . . . . 0.0 109.53 177.839 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.561 HD11 ' HB2' ' A' ' 68' ' ' ARG . 0.9 OUTLIER -119.29 140.96 41.48 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.749 0 CA-C-N 115.768 -0.651 . . . . 0.0 111.034 -175.29 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 53' ' ' ASN . . . . . 0.563 ' HA ' ' O ' ' A' ' 19' ' ' TYR . 3.9 p30 -97.81 118.06 33.5 Favored 'General case' 0 C--N 1.313 -0.99 0 CA-C-N 115.128 -0.942 . . . . 0.0 109.016 176.288 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 54' ' ' VAL . . . . . 0.563 ' O ' ' HA ' ' A' ' 18' ' ' GLU . 35.3 m -111.67 140.96 28.66 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.765 0 CA-C-N 115.304 -0.862 . . . . 0.0 111.731 -173.481 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 25.6 ttmt -94.96 109.22 21.26 Favored 'General case' 0 C--N 1.319 -0.724 0 N-CA-C 109.212 -0.662 . . . . 0.0 109.212 177.389 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.456 HG21 ' HB ' ' A' ' 13' ' ' VAL . 60.5 t -70.56 113.26 6.37 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 N-CA-C 109.53 -0.544 . . . . 0.0 109.53 179.516 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.9 p -111.42 -14.97 13.66 Favored 'General case' 0 C--N 1.323 -0.587 0 N-CA-C 112.32 0.489 . . . . 0.0 112.32 -173.077 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 58' ' ' ALA . . . . . 0.433 ' HB3' ' HB2' ' A' ' 65' ' ' PHE . . . -145.82 93.38 2.33 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.947 0.403 . . . . 0.0 111.048 -176.214 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 21.9 t -87.6 122.93 39.93 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 CA-C-N 116.061 -0.518 . . . . 0.0 109.919 176.085 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 32.3 mmtp -109.15 -165.26 1.0 Allowed 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.668 -0.242 . . . . 0.0 110.375 179.832 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 61' ' ' GLU . . . . . 0.471 ' CD ' ' H ' ' A' ' 61' ' ' GLU . 4.1 mp0 -64.25 -54.05 39.44 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.752 -175.925 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 88.9 mttt -108.82 -19.78 13.29 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.838 -171.533 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 23.9 p90 -150.13 175.02 12.13 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.589 -175.111 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -137.29 167.45 21.56 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-O 120.808 0.337 . . . . 0.0 111.024 179.378 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 65' ' ' PHE . . . . . 0.433 ' HB2' ' HB3' ' A' ' 58' ' ' ALA . 90.8 m-85 -119.63 135.17 54.92 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.753 -0.658 . . . . 0.0 109.822 177.211 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 66' ' ' ALA . . . . . 0.513 ' HB1' ' HB ' ' A' ' 54' ' ' VAL . . . -132.38 154.99 49.24 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.321 -0.399 . . . . 0.0 111.043 -178.926 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 13.7 pt-20 -111.81 143.49 42.67 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 121.088 0.471 . . . . 0.0 111.11 -179.408 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.561 ' HB2' HD11 ' A' ' 52' ' ' ILE . 27.3 ttt180 -66.69 114.18 5.4 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.469 -0.787 . . . . 0.0 111.135 174.255 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 3.7 t -83.14 5.85 1.9 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 121.7 0.762 . . . . 0.0 110.915 176.761 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.408 ' HB2' ' HG3' ' A' ' 68' ' ' ARG . 68.7 mt . . . . . 0 C--N 1.315 -0.935 0 CA-C-N 115.305 -0.861 . . . . 0.0 110.588 -177.602 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 2.2 mpt? . . . . . 0 N--CA 1.482 1.131 0 N-CA-C 109.843 -0.429 . . . . 0.0 109.843 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 0.651 ' HA ' ' O ' ' A' ' 6' ' ' PRO . . . 62.99 27.16 15.82 Favored 'General case' 0 N--CA 1.464 0.269 0 O-C-N 123.785 0.678 . . . . 0.0 112.017 174.941 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 26.7 t80 -85.98 68.82 10.44 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-O 121.339 0.59 . . . . 0.0 110.576 -177.621 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 98.25 -70.63 0.64 Allowed Glycine 0 N--CA 1.449 -0.442 0 C-N-CA 120.978 -0.629 . . . . 0.0 113.423 174.305 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.548 ' HB3' ' HD3' ' A' ' 6' ' ' PRO . 8.0 ttpm? -94.35 -50.7 0.26 Allowed Pre-proline 0 CA--C 1.538 0.497 0 N-CA-C 112.933 0.716 . . . . 0.0 112.933 -173.775 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.651 ' O ' ' HA ' ' A' ' 2' ' ' ALA . 8.5 Cg_exo -74.51 152.52 43.46 Favored 'Trans proline' 0 C--N 1.348 0.55 0 C-N-CA 122.038 1.826 . . . . 0.0 112.184 -179.48 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . 59.9 77.57 0.31 Allowed 'General case' 0 N--CA 1.463 0.198 0 O-C-N 123.832 0.707 . . . . 0.0 111.279 -179.387 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' MET . . . . . . . . . . . . . 34.9 tpp -97.43 26.82 4.62 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-O 121.584 0.707 . . . . 0.0 109.97 -179.621 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -77.26 102.14 6.56 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.558 -0.747 . . . . 0.0 110.987 -177.653 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 4.1 p-10 -82.42 36.56 0.48 Allowed 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.614 -0.721 . . . . 0.0 111.124 178.745 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.418 ' HA ' ' HD3' ' A' ' 12' ' ' PRO . 77.7 t -158.52 108.34 1.66 Allowed Pre-proline 0 C--N 1.332 -0.16 0 N-CA-C 109.398 -0.593 . . . . 0.0 109.398 -174.193 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 12' ' ' PRO . . . . . 0.418 ' HD3' ' HA ' ' A' ' 11' ' ' VAL . 6.0 Cg_exo -76.33 -39.13 0.87 Allowed 'Trans proline' 0 C--N 1.343 0.251 0 C-N-CA 123.253 2.635 . . . . 0.0 112.51 -178.458 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.583 HG12 HD12 ' A' ' 36' ' ' ILE . 6.0 m -73.51 130.9 35.61 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.718 0 CA-C-N 115.06 -0.973 . . . . 0.0 111.932 -173.525 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -102.45 119.09 38.22 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.754 -0.657 . . . . 0.0 109.372 177.858 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -68.17 108.69 3.24 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 120.975 0.417 . . . . 0.0 110.752 -178.565 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 127.54 -23.87 5.33 Favored Glycine 0 N--CA 1.443 -0.854 0 C-N-CA 120.814 -0.708 . . . . 0.0 112.409 -179.695 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' LYS . . . . . 0.407 ' HE3' ' HB3' ' A' ' 17' ' ' LYS . 24.0 mtpp -104.19 165.95 10.72 Favored 'General case' 0 C--O 1.235 0.336 0 CA-C-O 121.019 0.438 . . . . 0.0 111.28 179.613 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 18' ' ' GLU . . . . . 0.536 ' HA ' ' HA ' ' A' ' 55' ' ' LYS . 0.2 OUTLIER -117.8 151.06 38.09 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.719 -0.673 . . . . 0.0 111.067 -177.584 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 72.6 m-85 -139.01 145.68 39.94 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.694 -0.684 . . . . 0.0 109.504 179.245 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 20' ' ' GLU . . . . . 0.551 ' HG2' HG12 ' A' ' 51' ' ' VAL . 42.6 tt0 -85.32 108.18 17.68 Favored 'General case' 0 C--N 1.32 -0.692 0 N-CA-C 109.529 -0.545 . . . . 0.0 109.529 176.756 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 34.4 m -122.8 165.66 18.56 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.968 -172.61 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 9.0 m -102.31 148.01 25.99 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-O 120.965 0.412 . . . . 0.0 110.543 179.801 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.455 HG13 ' HB1' ' A' ' 46' ' ' ALA . 29.3 mm -112.97 61.59 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 N-CA-C 107.916 -1.142 . . . . 0.0 107.916 -177.471 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 13.1 tp10 -64.12 -17.07 63.09 Favored 'General case' 0 C--N 1.317 -0.843 0 CA-C-N 113.283 -1.78 . . . . 0.0 111.67 -177.29 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 33.3 t70 -145.41 152.21 39.47 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 116.483 -0.326 . . . . 0.0 110.196 -173.236 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' MET . . . . . 0.655 ' HA ' ' HA2' ' A' ' 32' ' ' GLY . 33.3 mtp -128.25 157.18 41.61 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 121.171 0.51 . . . . 0.0 110.974 177.866 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.503 ' HA3' ' OD2' ' A' ' 31' ' ' ASP . . . -83.53 -48.42 5.3 Favored Glycine 0 N--CA 1.445 -0.732 0 CA-C-N 115.66 -0.7 . . . . 0.0 112.724 -176.564 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 79.5 tttt -161.55 21.9 0.12 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 121.513 0.673 . . . . 0.0 111.413 -177.863 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 123.19 -47.58 1.01 Allowed Glycine 0 C--N 1.315 -0.602 0 C-N-CA 120.3 -0.952 . . . . 0.0 113.8 172.387 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -103.23 -35.66 3.58 Favored Glycine 0 C--O 1.228 -0.268 0 C-N-CA 120.524 -0.846 . . . . 0.0 111.919 -179.325 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 31' ' ' ASP . . . . . 0.503 ' OD2' ' HA3' ' A' ' 27' ' ' GLY . 12.1 p-10 -85.84 133.27 33.98 Favored 'General case' 0 C--N 1.318 -0.768 0 N-CA-C 109.611 -0.514 . . . . 0.0 109.611 177.435 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 32' ' ' GLY . . . . . 0.655 ' HA2' ' HA ' ' A' ' 26' ' ' MET . . . -117.78 158.79 14.46 Favored Glycine 0 N--CA 1.445 -0.709 0 C-N-CA 121.032 -0.604 . . . . 0.0 112.154 -179.154 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 2.2 mp -108.88 106.89 21.56 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.5 0 CA-C-O 121.175 0.512 . . . . 0.0 110.103 178.682 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 34' ' ' ALA . . . . . 0.445 ' HB3' ' HB ' ' A' ' 41' ' ' VAL . . . -90.84 152.92 20.57 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.6 -0.727 . . . . 0.0 109.842 172.278 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -122.14 113.46 19.53 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.556 -178.274 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.583 HD12 HG12 ' A' ' 13' ' ' VAL . 38.7 mt -110.39 105.81 19.53 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.758 0 CA-C-O 121.085 0.469 . . . . 0.0 109.985 175.2 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 26.9 t0 55.18 36.69 27.55 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 114.852 -1.067 . . . . 0.0 110.663 -178.528 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 94.27 -19.93 50.68 Favored Glycine 0 C--N 1.333 0.394 0 C-N-CA 120.976 -0.63 . . . . 0.0 112.787 -179.807 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 78.3 t80 -77.13 142.54 39.66 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 110.098 -0.334 . . . . 0.0 110.098 -175.258 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 11.1 t -88.25 114.64 27.12 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 CA-C-N 115.888 -0.596 . . . . 0.0 111.113 -175.7 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.445 ' HB ' ' HB3' ' A' ' 34' ' ' ALA . 54.6 t -109.8 108.14 24.64 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.649 0 CA-C-N 116.033 -0.531 . . . . 0.0 109.913 177.265 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 67.6 m-85 -76.84 119.03 20.04 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 121.351 0.596 . . . . 0.0 110.256 178.822 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.731 HG11 HD11 ' A' ' 52' ' ' ILE . 17.5 t -117.9 100.49 52.17 Favored Pre-proline 0 C--N 1.315 -0.93 0 CA-C-N 115.474 -0.784 . . . . 0.0 110.512 -175.769 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 33.7 Cg_exo -64.62 -9.32 20.22 Favored 'Trans proline' 0 N--CA 1.476 0.476 0 C-N-CA 123.799 2.999 . . . . 0.0 114.412 -175.563 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 45' ' ' ASN . . . . . 0.43 ' HB2' ' HB3' ' A' ' 68' ' ' ARG . 0.9 OUTLIER -128.35 17.77 6.49 Favored 'General case' 0 C--N 1.324 -0.511 0 C-N-CA 120.907 -0.317 . . . . 0.0 110.7 -175.192 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.601 ' HB2' ' HB ' ' A' ' 43' ' ' VAL . . . -67.75 154.32 41.77 Favored 'General case' 0 C--N 1.32 -0.696 0 N-CA-C 113.334 0.864 . . . . 0.0 113.334 -175.655 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 10.9 mm-40 -105.76 121.33 43.8 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 114.695 -1.139 . . . . 0.0 109.64 174.522 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 48' ' ' LYS . . . . . 0.622 ' HB2' ' SD ' ' A' ' 26' ' ' MET . 63.2 tttm -60.84 123.99 19.14 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 120.947 0.404 . . . . 0.0 110.918 -177.119 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 89.06 -33.62 4.2 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 121.006 -0.616 . . . . 0.0 112.853 178.122 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 17.7 m -71.08 155.62 40.58 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 120.906 0.384 . . . . 0.0 110.627 -179.05 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.551 HG12 ' HG2' ' A' ' 20' ' ' GLU . 21.8 t -102.82 87.95 1.25 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 177.498 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.731 HD11 HG11 ' A' ' 43' ' ' VAL . 0.1 OUTLIER -92.49 144.98 8.18 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-N 115.622 -0.717 . . . . 0.0 110.688 -171.002 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 53' ' ' ASN . . . . . 0.549 ' HA ' ' HA ' ' A' ' 20' ' ' GLU . 28.2 t-20 -83.36 112.52 19.99 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-N 115.691 -0.686 . . . . 0.0 109.794 175.229 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 54' ' ' VAL . . . . . 0.513 ' HB ' ' HB1' ' A' ' 66' ' ' ALA . 33.9 m -104.44 137.38 33.71 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.264 -176.72 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 55' ' ' LYS . . . . . 0.536 ' HA ' ' HA ' ' A' ' 18' ' ' GLU . 35.9 ttpt -103.49 110.93 23.15 Favored 'General case' 0 C--N 1.318 -0.8 0 N-CA-C 108.958 -0.756 . . . . 0.0 108.958 172.644 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 60.4 t -65.21 118.08 7.0 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 CA-C-N 116.45 -0.341 . . . . 0.0 110.157 -179.294 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 12.3 p -104.35 -24.53 13.08 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 116.248 -0.433 . . . . 0.0 112.001 -174.992 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -154.75 102.31 2.36 Favored 'General case' 0 N--CA 1.451 -0.422 0 CA-C-O 121.097 0.475 . . . . 0.0 111.007 -175.131 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.412 HG13 ' HB2' ' A' ' 64' ' ' ALA . 17.9 t -88.22 122.72 40.12 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.705 0 CA-C-N 115.676 -0.693 . . . . 0.0 110.2 174.755 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 60' ' ' LYS . . . . . 0.433 ' HD2' ' N ' ' A' ' 60' ' ' LYS . 0.6 OUTLIER -101.35 -171.23 1.95 Allowed 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 176.634 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 39.4 mm-40 -59.51 -48.81 80.19 Favored 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 112.667 0.618 . . . . 0.0 112.667 -174.466 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 64.4 mttm -116.03 -5.45 11.96 Favored 'General case' 0 C--N 1.328 -0.326 0 N-CA-C 112.346 0.499 . . . . 0.0 112.346 -171.811 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 16.1 p90 -162.63 156.11 20.28 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 120.682 0.277 . . . . 0.0 110.761 -176.059 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.412 ' HB2' HG13 ' A' ' 59' ' ' VAL . . . -121.39 159.0 27.07 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.698 -178.65 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 96.2 m-85 -116.39 137.15 52.39 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.269 -0.423 . . . . 0.0 109.926 176.374 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 66' ' ' ALA . . . . . 0.513 ' HB1' ' HB ' ' A' ' 54' ' ' VAL . . . -137.48 152.89 50.02 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 116.443 -0.344 . . . . 0.0 111.161 -177.962 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 67' ' ' GLU . . . . . 0.4 ' O ' ' HA ' ' A' ' 54' ' ' VAL . 9.6 pt-20 -102.84 144.07 31.63 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.932 -179.11 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.672 ' HB2' HD12 ' A' ' 52' ' ' ILE . 9.2 ttp180 -70.95 109.29 4.98 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.341 172.793 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 3.8 t -81.95 28.34 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.468 0 CA-C-O 121.506 0.67 . . . . 0.0 110.856 -179.587 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.441 ' N ' HD23 ' A' ' 70' ' ' LEU . 1.3 pt? . . . . . 0 C--O 1.243 0.744 0 CA-C-N 116.136 -0.484 . . . . 0.0 109.748 178.75 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.482 1.128 0 N-CA-C 109.549 -0.537 . . . . 0.0 109.549 . . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -82.3 118.22 22.98 Favored 'General case' 0 N--CA 1.45 -0.445 0 N-CA-C 109.209 -0.663 . . . . 0.0 109.209 172.614 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 57.1 m-85 -83.97 -25.67 29.86 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-O 120.907 0.384 . . . . 0.0 110.915 -174.112 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 96.91 -21.82 44.01 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.645 -0.788 . . . . 0.0 111.633 -178.446 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.558 ' HB2' ' HD3' ' A' ' 6' ' ' PRO . 53.5 mtmt -73.79 -50.69 5.52 Favored Pre-proline 0 C--N 1.326 -0.428 0 CA-C-N 115.485 -0.357 . . . . 0.0 111.957 177.826 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.558 ' HD3' ' HB2' ' A' ' 5' ' ' LYS . 25.5 Cg_exo -66.2 151.28 83.93 Favored 'Trans proline' 0 C--N 1.354 0.854 0 C-N-CA 122.185 1.924 . . . . 0.0 112.064 -179.475 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . 72.19 -30.59 0.21 Allowed 'General case' 0 N--CA 1.469 0.501 0 C-N-CA 123.87 0.868 . . . . 0.0 112.21 -178.771 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' MET . . . . . 0.41 ' H ' ' C ' ' A' ' 6' ' ' PRO . 14.0 tpt -83.35 21.64 1.13 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 121.925 0.869 . . . . 0.0 110.178 179.443 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 9' ' ' LYS . . . . . 0.679 ' HA ' ' HE3' ' A' ' 9' ' ' LYS . 0.9 OUTLIER -134.67 24.04 3.68 Favored 'General case' 0 C--N 1.319 -0.719 0 N-CA-C 108.64 -0.874 . . . . 0.0 108.64 176.94 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 18.3 m120 -139.45 104.23 4.91 Favored 'General case' 0 N--CA 1.444 -0.73 0 CA-C-N 114.975 -1.011 . . . . 0.0 109.25 -174.243 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.468 HG12 ' O ' ' A' ' 13' ' ' VAL . 86.6 t -33.09 107.59 0.28 Allowed Pre-proline 0 N--CA 1.471 0.585 0 O-C-N 124.825 1.328 . . . . 0.0 111.42 175.195 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -75.47 -2.47 12.61 Favored 'Trans proline' 0 C--N 1.346 0.43 0 C-N-CA 122.972 2.448 . . . . 0.0 112.379 -176.954 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.468 ' O ' HG12 ' A' ' 11' ' ' VAL . 9.4 m -121.8 -175.61 1.04 Allowed 'Isoleucine or valine' 0 C--N 1.314 -0.94 0 CA-C-N 115.16 -0.927 . . . . 0.0 109.722 179.806 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 14' ' ' GLU . . . . . 0.539 ' HG3' ' HD2' ' A' ' 17' ' ' LYS . 74.5 mm-40 -116.82 -159.46 0.73 Allowed 'General case' 0 C--N 1.314 -0.94 0 N-CA-C 109.587 -0.523 . . . . 0.0 109.587 177.21 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 15' ' ' ALA . . . . . 0.454 ' HA ' ' O ' ' A' ' 56' ' ' VAL . . . -162.56 101.11 1.04 Allowed 'General case' 0 C--N 1.317 -0.837 0 CA-C-N 115.591 -0.732 . . . . 0.0 109.315 174.862 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 124.81 -18.41 7.12 Favored Glycine 0 N--CA 1.446 -0.65 0 CA-C-N 114.82 -1.082 . . . . 0.0 111.571 -173.623 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' LYS . . . . . 0.539 ' HD2' ' HG3' ' A' ' 14' ' ' GLU . 61.6 mttm -102.31 164.11 11.86 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 120.597 0.237 . . . . 0.0 110.663 -178.76 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 18' ' ' GLU . . . . . 0.493 ' HA ' ' O ' ' A' ' 54' ' ' VAL . 2.1 mp0 -111.15 144.22 40.63 Favored 'General case' 0 N--CA 1.455 -0.179 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.072 -179.383 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 98.0 m-85 -132.58 -179.66 5.59 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.69 -0.686 . . . . 0.0 109.492 173.775 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 6.5 pt-20 -124.8 113.32 17.76 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-O 121.583 0.706 . . . . 0.0 109.495 175.07 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.436 ' O ' ' HA ' ' A' ' 51' ' ' VAL . 30.2 m -116.82 173.9 3.88 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.91 0 CA-C-N 115.26 -0.882 . . . . 0.0 111.202 -173.031 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 5.8 m -112.82 152.19 29.49 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.028 179.431 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.533 HG13 ' HB1' ' A' ' 46' ' ' ALA . 19.9 mm -115.23 61.22 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.678 0 N-CA-C 108.355 -0.98 . . . . 0.0 108.355 -176.064 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 6.9 mm-40 -66.12 -18.18 65.18 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 114.006 -1.452 . . . . 0.0 111.405 -179.259 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.498 ' HB3' ' HB ' ' A' ' 33' ' ' ILE . 26.0 t0 -138.53 137.01 36.66 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.472 -172.397 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 26' ' ' MET . . . . . . . . . . . . . 10.8 mmt -114.89 144.03 44.19 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.886 174.929 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -70.46 -86.53 0.13 Allowed Glycine 0 N--CA 1.447 -0.607 0 N-CA-C 110.809 -0.916 . . . . 0.0 110.809 172.934 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 9.4 ptpp? -164.07 -29.01 0.04 OUTLIER 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 112.346 0.499 . . . . 0.0 112.346 172.179 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -105.38 38.25 3.39 Favored Glycine 0 C--N 1.308 -0.992 0 CA-C-N 115.636 -0.711 . . . . 0.0 113.358 -176.673 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 83.12 -5.84 74.49 Favored Glycine 0 C--N 1.329 0.139 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.909 177.888 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 31' ' ' ASP . . . . . 0.468 ' HA ' ' HA ' ' A' ' 44' ' ' PRO . 4.7 t70 -82.76 117.96 23.03 Favored 'General case' 0 C--N 1.325 -0.472 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 178.392 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -98.67 154.18 19.98 Favored Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.924 -173.732 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.498 ' HB ' ' HB3' ' A' ' 25' ' ' ASP . 2.5 mp -105.94 113.53 42.96 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.582 0 CA-C-O 121.136 0.493 . . . . 0.0 110.451 179.258 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 34' ' ' ALA . . . . . 0.429 ' HB1' ' HB ' ' A' ' 21' ' ' VAL . . . -106.37 160.62 15.24 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.775 -0.648 . . . . 0.0 109.9 175.902 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 35' ' ' ARG . . . . . 0.418 HH11 ' HD3' ' A' ' 35' ' ' ARG . 0.1 OUTLIER -130.05 128.02 41.1 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-O 120.652 0.263 . . . . 0.0 111.062 -175.027 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 54.7 mt -127.25 110.1 21.95 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 172.145 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 57.95 23.48 9.92 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 115.319 -0.855 . . . . 0.0 111.539 -175.946 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 99.88 -12.94 60.89 Favored Glycine 0 C--N 1.333 0.393 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.008 -178.605 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 52.6 t80 -76.18 139.28 41.16 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 109.652 -0.499 . . . . 0.0 109.652 -178.202 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 26.0 t -89.44 114.84 28.07 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 CA-C-O 121.097 0.475 . . . . 0.0 111.029 -175.475 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 37.1 t -115.24 118.23 58.13 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.661 0 CA-C-N 115.924 -0.58 . . . . 0.0 109.828 179.28 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 94.6 m-85 -87.09 142.31 28.02 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.773 -177.535 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.467 ' HA ' ' HD3' ' A' ' 44' ' ' PRO . 1.4 m -138.55 102.8 7.84 Favored Pre-proline 0 C--N 1.325 -0.496 0 CA-C-N 115.762 -0.654 . . . . 0.0 110.79 -179.115 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 44' ' ' PRO . . . . . 0.468 ' HA ' ' HA ' ' A' ' 31' ' ' ASP . 4.9 Cg_exo -77.23 3.39 6.75 Favored 'Trans proline' 0 CA--C 1.531 0.354 0 C-N-CA 123.564 2.842 . . . . 0.0 113.956 -170.943 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 45' ' ' ASN . . . . . 0.461 ' O ' ' HD3' ' A' ' 68' ' ' ARG . 57.2 m-80 -136.53 25.49 3.15 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 121.263 0.554 . . . . 0.0 110.489 -179.431 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.533 ' HB1' HG13 ' A' ' 23' ' ' ILE . . . -86.01 163.8 17.75 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 115.98 -0.554 . . . . 0.0 111.741 -179.682 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 42.9 mt-10 -116.93 134.4 54.8 Favored 'General case' 0 N--CA 1.446 -0.647 0 CA-C-N 115.472 -0.785 . . . . 0.0 109.297 172.224 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 27.0 ttpp -65.56 140.07 58.51 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-O 120.967 0.413 . . . . 0.0 111.493 -174.207 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 70.52 35.79 68.27 Favored Glycine 0 N--CA 1.448 -0.504 0 CA-C-N 115.525 -0.761 . . . . 0.0 112.704 177.367 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 50.8 m -142.18 162.23 35.99 Favored 'General case' 0 C--N 1.321 -0.663 0 O-C-N 122.772 -0.252 . . . . 0.0 110.747 179.07 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.436 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 88.9 t -98.86 122.9 51.1 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 N-CA-C 108.994 -0.743 . . . . 0.0 108.994 174.327 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.587 HD12 ' HB2' ' A' ' 68' ' ' ARG . 3.4 pt -121.62 142.97 35.67 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.703 0 C-N-CA 120.615 -0.434 . . . . 0.0 110.371 -178.8 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 53' ' ' ASN . . . . . 0.425 ' O ' ' HA ' ' A' ' 68' ' ' ARG . 16.5 t-20 -76.71 129.48 36.4 Favored 'General case' 0 C--N 1.323 -0.556 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 174.053 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 54' ' ' VAL . . . . . 0.683 ' HB ' ' HB1' ' A' ' 66' ' ' ALA . 25.0 m -128.24 128.49 68.61 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 CA-C-O 121.163 0.506 . . . . 0.0 112.032 -176.202 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 55' ' ' LYS . . . . . 0.426 ' HB2' ' HG3' ' A' ' 18' ' ' GLU . 22.8 ttmm -98.95 102.14 13.77 Favored 'General case' 0 C--N 1.314 -0.945 0 N-CA-C 108.611 -0.885 . . . . 0.0 108.611 170.044 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.556 HG22 ' HB2' ' A' ' 66' ' ' ALA . 68.1 t -66.27 108.21 0.96 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 N-CA-C 109.459 -0.571 . . . . 0.0 109.459 178.368 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 12.9 p -109.87 -13.81 14.39 Favored 'General case' 0 C--N 1.321 -0.634 0 N-CA-C 112.304 0.483 . . . . 0.0 112.304 -174.405 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 58' ' ' ALA . . . . . 0.429 ' HB3' ' HB2' ' A' ' 65' ' ' PHE . . . -143.13 92.24 2.36 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.134 0.493 . . . . 0.0 111.256 -176.608 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 20.3 t -84.58 142.8 12.84 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.768 0 CA-C-N 115.95 -0.568 . . . . 0.0 109.7 177.645 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 42.5 mmtm -127.72 -162.33 1.16 Allowed 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 116.716 -0.22 . . . . 0.0 110.779 -179.364 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 6.5 mm-40 -47.34 -64.09 0.87 Allowed 'General case' 0 N--CA 1.468 0.435 0 C-N-CA 123.699 0.799 . . . . 0.0 112.761 -172.302 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 59.9 pttt -138.31 20.59 2.77 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 121.666 0.746 . . . . 0.0 110.198 -178.926 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 28.9 p90 -153.12 153.19 32.3 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 114.939 -1.028 . . . . 0.0 108.906 -179.745 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -127.41 155.66 43.29 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-O 120.825 0.345 . . . . 0.0 111.112 -177.69 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 65' ' ' PHE . . . . . 0.429 ' HB2' ' HB3' ' A' ' 58' ' ' ALA . 99.0 m-85 -108.97 124.69 51.09 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 115.836 -0.62 . . . . 0.0 109.476 176.412 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 66' ' ' ALA . . . . . 0.683 ' HB1' ' HB ' ' A' ' 54' ' ' VAL . . . -125.12 151.24 46.0 Favored 'General case' 0 C--N 1.318 -0.793 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.707 -179.001 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 5.3 pt-20 -110.27 128.51 55.56 Favored 'General case' 0 C--N 1.316 -0.882 0 CA-C-O 121.263 0.554 . . . . 0.0 111.117 -178.888 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.587 ' HB2' HD12 ' A' ' 52' ' ' ILE . 22.4 ttt180 -61.74 115.4 3.95 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.008 -0.996 . . . . 0.0 111.515 178.262 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.452 ' O ' HG12 ' A' ' 69' ' ' VAL . 22.0 t -82.07 12.29 0.64 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-N 114.922 -1.036 . . . . 0.0 110.876 179.32 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.456 ' HB2' ' HE ' ' A' ' 68' ' ' ARG . 60.4 mt . . . . . 0 C--O 1.249 1.045 0 CA-C-O 118.317 -0.849 . . . . 0.0 110.692 -178.447 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 16.2 Cg_endo . . . . . 0 N--CA 1.475 0.435 0 N-CA-C 113.212 0.428 . . . . 0.0 113.212 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.528 HG12 HD12 ' A' ' 36' ' ' ILE . 16.1 m -114.72 121.0 65.93 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.356 179.846 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 49.0 mt-10 -99.29 118.33 35.73 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.782 -177.686 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . 0.428 ' HB2' HG23 ' A' ' 59' ' ' VAL . . . -63.84 125.06 23.16 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.674 -0.694 . . . . 0.0 111.028 179.934 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 112.45 -4.44 26.48 Favored Glycine 0 N--CA 1.449 -0.44 0 C-N-CA 120.891 -0.671 . . . . 0.0 111.814 -177.852 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 97.1 mttt -118.59 158.52 25.28 Favored 'General case' 0 C--N 1.324 -0.542 0 N-CA-C 110.289 -0.263 . . . . 0.0 110.289 178.997 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . 0.506 ' HA ' ' O ' ' A' ' 54' ' ' VAL . 0.0 OUTLIER -120.61 130.7 54.28 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-O 121.606 0.717 . . . . 0.0 111.29 179.878 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 45.8 m-85 -122.66 149.63 43.77 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.257 -0.883 . . . . 0.0 110.179 -174.912 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 2.3 mp0 -84.8 119.13 24.96 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 121.138 0.494 . . . . 0.0 109.693 173.857 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 36.0 m -130.43 165.04 31.74 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.879 0 CA-C-N 115.599 -0.728 . . . . 0.0 110.865 -175.097 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 11.7 m -108.35 149.64 28.42 Favored 'General case' 0 C--N 1.316 -0.87 0 CA-C-N 115.999 -0.546 . . . . 0.0 109.935 175.911 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.621 HG13 ' HB1' ' A' ' 46' ' ' ALA . 36.0 mm -110.67 61.6 0.16 Allowed 'Isoleucine or valine' 0 CA--C 1.509 -0.609 0 N-CA-C 107.652 -1.24 . . . . 0.0 107.652 -176.995 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 31.4 tt0 -62.57 -24.79 67.73 Favored 'General case' 0 C--N 1.311 -1.084 0 CA-C-N 113.062 -1.881 . . . . 0.0 111.207 -179.583 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.566 ' HB2' ' HB ' ' A' ' 33' ' ' ILE . 15.3 m-20 -124.33 149.15 46.91 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.33 -0.396 . . . . 0.0 111.18 -175.213 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' MET . . . . . . . . . . . . . 96.0 mmm -123.19 147.85 46.42 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.092 -0.504 . . . . 0.0 109.932 173.975 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.448 -0.544 0 C-N-CA 121.091 -0.576 . . . . 0.0 112.792 -178.02 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . 0.419 ' OD1' ' HA ' ' A' ' 44' ' ' PRO . 27.5 t70 . . . . . 0 N--CA 1.454 -0.251 0 N-CA-C 109.56 -0.533 . . . . 0.0 109.56 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -98.66 132.53 10.97 Favored Glycine 0 N--CA 1.447 -0.615 0 C-N-CA 120.602 -0.808 . . . . 0.0 111.897 -177.293 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.566 ' HB ' ' HB2' ' A' ' 25' ' ' ASP . 1.9 mp -101.83 104.1 15.9 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.737 0 CA-C-O 121.492 0.663 . . . . 0.0 110.625 -178.248 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -84.17 157.19 21.75 Favored 'General case' 0 C--N 1.317 -0.809 0 CA-C-N 115.406 -0.816 . . . . 0.0 109.167 169.036 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' ARG . . . . . 0.403 HH11 ' HD2' ' A' ' 35' ' ' ARG . 6.0 ttm180 -142.18 107.87 5.11 Favored 'General case' 0 C--N 1.313 -0.982 0 C-N-CA 120.644 -0.422 . . . . 0.0 110.819 -176.769 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.528 HD12 HG12 ' A' ' 13' ' ' VAL . 37.2 mt -99.43 108.68 22.96 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 CA-C-N 115.733 -0.667 . . . . 0.0 110.11 178.093 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 58.2 16.46 3.95 Favored 'General case' 0 N--CA 1.468 0.473 0 CA-C-N 115.26 -0.882 . . . . 0.0 112.079 -176.539 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 110.28 -16.99 29.36 Favored Glycine 0 N--CA 1.449 -0.447 0 C-N-CA 120.856 -0.688 . . . . 0.0 111.764 -178.057 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 34.0 t80 -71.68 117.59 13.44 Favored 'General case' 0 C--N 1.328 -0.362 0 N-CA-C 109.576 -0.527 . . . . 0.0 109.576 179.334 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.448 HG13 HG23 ' A' ' 33' ' ' ILE . 29.1 t -70.61 117.59 13.9 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 CA-C-N 115.824 -0.625 . . . . 0.0 111.301 -178.43 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 49.1 t -119.34 108.39 23.65 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 CA-C-N 115.481 -0.781 . . . . 0.0 109.594 -179.812 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 93.7 m-85 -78.58 129.55 34.92 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.086 -175.411 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 5.6 t -125.73 105.57 26.65 Favored Pre-proline 0 C--N 1.321 -0.659 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.246 -177.948 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . 0.419 ' HA ' ' OD1' ' A' ' 31' ' ' ASP . 34.9 Cg_endo -65.75 -8.26 19.01 Favored 'Trans proline' 0 N--CA 1.477 0.538 0 C-N-CA 123.537 2.825 . . . . 0.0 114.476 -172.561 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 1.2 p30 -142.54 20.35 2.03 Favored 'General case' 0 C--N 1.321 -0.65 0 N-CA-C 112.264 0.468 . . . . 0.0 112.264 -167.603 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.621 ' HB1' HG13 ' A' ' 23' ' ' ILE . . . -97.18 155.89 16.64 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.082 176.126 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 48.9 mt-10 -106.38 144.9 32.39 Favored 'General case' 0 N--CA 1.451 -0.421 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.093 178.54 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 60.8 tttm -66.2 137.36 56.93 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.457 -0.338 . . . . 0.0 111.352 -175.676 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 82.86 -2.24 86.84 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 121.017 -0.611 . . . . 0.0 113.121 175.943 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 29.7 m -93.56 152.08 19.27 Favored 'General case' 0 C--N 1.324 -0.538 0 O-C-N 122.654 -0.321 . . . . 0.0 111.085 -179.529 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 46.6 t -98.46 101.65 12.42 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 N-CA-C 108.456 -0.942 . . . . 0.0 108.456 172.897 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.571 HD11 ' HB2' ' A' ' 68' ' ' ARG . 0.8 OUTLIER -115.2 145.23 21.22 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.851 0 CA-C-N 115.789 -0.641 . . . . 0.0 112.018 -170.281 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 58.1 t30 -88.3 112.86 23.31 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 114.923 -1.035 . . . . 0.0 109.005 176.306 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . 0.555 ' HB ' ' HB1' ' A' ' 66' ' ' ALA . 35.2 m -115.01 134.56 57.69 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.724 0 CA-C-O 121.115 0.483 . . . . 0.0 111.609 -175.259 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 2.3 ttmp? -93.42 111.06 22.63 Favored 'General case' 0 C--N 1.32 -0.709 0 N-CA-C 109.124 -0.695 . . . . 0.0 109.124 175.52 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.467 HG21 ' HB ' ' A' ' 13' ' ' VAL . 87.6 t -67.88 113.08 3.41 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 N-CA-C 109.189 -0.671 . . . . 0.0 109.189 177.693 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.7 p -109.36 -26.02 10.24 Favored 'General case' 0 C--N 1.324 -0.53 0 N-CA-C 112.455 0.539 . . . . 0.0 112.455 -173.104 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . 0.434 ' HB3' ' HB2' ' A' ' 65' ' ' PHE . . . -143.38 92.17 2.34 Favored 'General case' 0 C--N 1.325 -0.476 0 C-N-CA 120.679 -0.408 . . . . 0.0 111.738 -175.301 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.428 HG23 ' HB2' ' A' ' 15' ' ' ALA . 15.6 t -79.9 125.89 39.07 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.735 0 CA-C-N 116.109 -0.496 . . . . 0.0 109.781 174.079 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 46.0 mmtm -106.01 -164.17 0.99 Allowed 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.439 -179.559 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . 0.41 ' OE1' ' HE3' ' A' ' 62' ' ' LYS . 40.8 tt0 -66.03 -48.84 69.77 Favored 'General case' 0 CA--C 1.533 0.297 0 N-CA-C 112.623 0.601 . . . . 0.0 112.623 -175.3 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . 0.41 ' HE3' ' OE1' ' A' ' 61' ' ' GLU . 93.1 mttt -120.6 3.89 10.66 Favored 'General case' 0 C--N 1.328 -0.332 0 N-CA-C 111.934 0.346 . . . . 0.0 111.934 -172.982 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 15.1 p90 -166.6 169.01 14.06 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 116.42 -0.355 . . . . 0.0 110.21 -174.273 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -129.42 158.76 38.26 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-O 120.878 0.37 . . . . 0.0 111.095 -179.95 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' PHE . . . . . 0.434 ' HB2' ' HB3' ' A' ' 58' ' ' ALA . 95.3 m-85 -114.47 136.14 53.34 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.579 -0.737 . . . . 0.0 109.824 176.827 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' ALA . . . . . 0.555 ' HB1' ' HB ' ' A' ' 54' ' ' VAL . . . -127.35 -179.3 4.82 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.571 -179.155 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' GLU . . . . . 0.43 ' O ' ' HA ' ' A' ' 54' ' ' VAL . 8.1 pt-20 -141.67 143.82 33.79 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 120.861 0.362 . . . . 0.0 111.212 178.85 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . 0.571 ' HB2' HD11 ' A' ' 52' ' ' ILE . 31.2 ttt180 -67.73 106.16 2.15 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.405 -0.816 . . . . 0.0 111.707 178.185 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 2.6 t -83.54 21.66 0.19 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.361 0 CA-C-O 121.501 0.667 . . . . 0.0 110.405 175.286 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.551 HD11 ' HA ' ' A' ' 52' ' ' ILE . 64.2 mt . . . . . 0 C--O 1.249 1.074 0 CA-C-O 118.351 -0.833 . . . . 0.0 110.064 -179.255 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 10.9 Cg_endo . . . . . 0 N--CA 1.473 0.315 0 N-CA-C 113.125 0.394 . . . . 0.0 113.125 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.504 ' HB ' HG21 ' A' ' 56' ' ' VAL . 15.6 m -103.64 126.8 58.09 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-N 116.09 -0.504 . . . . 0.0 111.214 -178.311 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . 0.423 ' CB ' ' HD3' ' A' ' 17' ' ' LYS . 37.6 mt-10 -101.06 123.96 46.05 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.058 176.398 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . 0.483 ' HA ' ' O ' ' A' ' 56' ' ' VAL . . . -60.94 110.16 1.27 Allowed 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.355 177.227 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 123.64 -18.76 7.6 Favored Glycine 0 N--CA 1.447 -0.613 0 C-N-CA 121.029 -0.605 . . . . 0.0 112.436 -178.29 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' LYS . . . . . 0.423 ' HD3' ' CB ' ' A' ' 14' ' ' GLU . 2.4 mptm? -94.1 162.97 13.66 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.935 0.398 . . . . 0.0 111.393 -179.99 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . 0.563 ' HG2' ' HB2' ' A' ' 55' ' ' LYS . 31.4 mt-10 -118.84 128.41 54.43 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.538 -0.755 . . . . 0.0 110.036 179.611 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' TYR . . . . . 0.421 ' O ' HG22 ' A' ' 54' ' ' VAL . 62.0 m-85 -127.87 127.17 42.94 Favored 'General case' 0 C--N 1.322 -0.627 0 N-CA-C 110.065 -0.346 . . . . 0.0 110.065 179.412 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . 0.628 ' HA ' ' HA ' ' A' ' 53' ' ' ASN . 34.8 tt0 -78.24 119.12 21.16 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 121.149 0.5 . . . . 0.0 109.764 177.03 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 23.3 m -129.82 162.81 36.77 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-N 115.499 -0.773 . . . . 0.0 111.702 -170.116 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 9.7 m -97.33 149.12 22.44 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.021 177.215 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.493 ' CD1' ' HB2' ' A' ' 34' ' ' ALA . 24.0 mm -121.33 65.94 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 108.572 -0.899 . . . . 0.0 108.572 -175.546 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 35.5 tt0 -86.98 -5.34 59.12 Favored 'General case' 0 C--N 1.31 -1.116 0 CA-C-N 114.445 -1.252 . . . . 0.0 110.465 -178.209 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.543 ' HB2' ' HB ' ' A' ' 33' ' ' ILE . 25.1 m-20 -118.59 134.42 55.11 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 115.526 -0.761 . . . . 0.0 109.396 -178.874 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' MET . . . . . . . . . . . . . 98.1 mmm -124.82 147.03 48.95 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-O 120.697 0.284 . . . . 0.0 110.91 -179.842 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.445 -0.757 0 N-CA-C 110.71 -0.956 . . . . 0.0 110.71 175.667 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 4.4 p-10 . . . . . 0 N--CA 1.445 -0.696 0 N-CA-C 109.203 -0.666 . . . . 0.0 109.203 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -109.38 160.87 13.28 Favored Glycine 0 N--CA 1.443 -0.863 0 CA-C-N 115.526 -0.761 . . . . 0.0 112.588 -175.347 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.546 HG23 HG13 ' A' ' 40' ' ' VAL . 2.5 mp -114.1 110.08 30.81 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.836 0 N-CA-C 109.962 -0.385 . . . . 0.0 109.962 -179.973 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . 0.493 ' HB2' ' CD1' ' A' ' 23' ' ' ILE . . . -94.03 155.17 17.26 Favored 'General case' 0 C--N 1.318 -0.761 0 CA-C-O 121.732 0.777 . . . . 0.0 111.098 173.868 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 29.1 mmt180 -121.4 103.11 8.71 Favored 'General case' 0 N--CA 1.437 -1.114 0 CA-C-N 114.552 -1.204 . . . . 0.0 110.629 -172.52 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.413 HD12 ' CG1' ' A' ' 13' ' ' VAL . 26.1 mt -100.61 101.4 12.04 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.601 0 CA-C-O 121.1 0.476 . . . . 0.0 109.917 175.623 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 33.2 t70 67.06 -4.14 0.86 Allowed 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 114.669 -1.151 . . . . 0.0 111.006 -173.522 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 122.61 -19.28 8.01 Favored Glycine 0 N--CA 1.446 -0.673 0 N-CA-C 110.845 -0.902 . . . . 0.0 110.845 -172.207 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 51.7 t80 -65.84 126.08 27.38 Favored 'General case' 0 C--O 1.237 0.399 0 N-CA-C 109.126 -0.694 . . . . 0.0 109.126 176.702 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.546 HG13 HG23 ' A' ' 33' ' ' ILE . 39.9 t -76.77 113.45 15.84 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.757 0 CA-C-N 115.78 -0.646 . . . . 0.0 111.292 -175.344 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 68.0 t -109.31 111.65 37.03 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 CA-C-N 115.48 -0.782 . . . . 0.0 109.885 177.347 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 60.6 m-85 -77.95 120.12 22.37 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.376 -179.625 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.533 ' HB ' ' HB2' ' A' ' 46' ' ' ALA . 8.7 t -120.81 104.56 41.83 Favored Pre-proline 0 C--N 1.319 -0.725 0 CA-C-N 115.587 -0.733 . . . . 0.0 110.398 -177.304 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -77.32 16.84 0.96 Allowed 'Trans proline' 0 CA--C 1.53 0.324 0 C-N-CA 123.379 2.719 . . . . 0.0 113.584 -174.187 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -152.04 21.43 0.67 Allowed 'General case' 0 C--N 1.321 -0.65 0 CA-C-O 121.523 0.678 . . . . 0.0 110.266 -178.042 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.533 ' HB2' ' HB ' ' A' ' 43' ' ' VAL . . . -78.63 168.86 19.14 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 115.224 -0.898 . . . . 0.0 111.488 177.923 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' GLU . . . . . 0.466 ' O ' ' HB ' ' A' ' 23' ' ' ILE . 0.0 OUTLIER -126.16 134.76 51.2 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.549 -0.75 . . . . 0.0 109.594 178.21 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 1.8 tmtp? -63.37 120.84 12.39 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.891 -176.15 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 81.96 5.91 89.36 Favored Glycine 0 N--CA 1.45 -0.412 0 CA-C-N 115.776 -0.647 . . . . 0.0 112.821 177.097 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 20.0 t -101.78 163.34 12.3 Favored 'General case' 0 C--N 1.324 -0.538 0 N-CA-C 110.123 -0.325 . . . . 0.0 110.123 -178.478 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.52 HG12 ' HG2' ' A' ' 20' ' ' GLU . 32.2 t -114.35 101.46 12.46 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.463 0 N-CA-C 109.106 -0.702 . . . . 0.0 109.106 179.269 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.591 HD12 ' HB2' ' A' ' 68' ' ' ARG . 6.4 pt -108.58 145.47 15.5 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-O 121.054 0.454 . . . . 0.0 110.934 -173.131 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . 0.628 ' HA ' ' HA ' ' A' ' 20' ' ' GLU . 39.6 t30 -82.55 115.81 21.69 Favored 'General case' 0 C--N 1.318 -0.765 0 N-CA-C 109.328 -0.619 . . . . 0.0 109.328 172.157 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . 0.54 HG13 HG13 ' A' ' 52' ' ' ILE . 28.8 m -107.97 130.81 59.81 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-O 121.358 0.599 . . . . 0.0 111.816 -177.198 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . 0.563 ' HB2' ' HG2' ' A' ' 18' ' ' GLU . 39.8 ttmt -97.98 106.65 18.98 Favored 'General case' 0 C--N 1.318 -0.772 0 N-CA-C 108.959 -0.756 . . . . 0.0 108.959 172.304 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.504 HG21 ' HB ' ' A' ' 13' ' ' VAL . 47.1 t -68.12 112.88 3.44 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.079 179.559 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 21.0 p -109.41 -17.94 13.67 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 112.071 0.397 . . . . 0.0 112.071 -174.86 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -143.58 92.58 2.37 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.063 0.458 . . . . 0.0 110.984 -177.607 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 13.4 t -85.24 129.61 37.55 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.638 0 CA-C-N 115.854 -0.612 . . . . 0.0 109.913 175.868 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 74.8 mmtt -106.76 -173.07 2.21 Favored 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 109.979 -0.378 . . . . 0.0 109.979 178.437 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -72.42 -41.22 66.45 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.35 -0.386 . . . . 0.0 111.859 179.648 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 56.3 mttp -92.13 -45.3 8.35 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 121.036 0.446 . . . . 0.0 111.295 -178.269 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 10.4 p90 -142.84 -171.3 3.42 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.969 -0.559 . . . . 0.0 110.492 -172.538 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -138.91 158.51 44.07 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-O 120.814 0.34 . . . . 0.0 111.113 -179.462 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 93.2 m-85 -113.85 138.72 49.91 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.694 -0.684 . . . . 0.0 109.43 175.492 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' ALA . . . . . 0.524 ' HB1' ' HB ' ' A' ' 54' ' ' VAL . . . -142.6 159.14 42.82 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 116.553 -0.294 . . . . 0.0 110.906 -178.668 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' GLU . . . . . 0.411 ' O ' ' HA ' ' A' ' 54' ' ' VAL . 10.8 pt-20 -113.72 137.75 51.19 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 121.303 0.573 . . . . 0.0 111.254 179.142 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . 0.591 ' HB2' HD12 ' A' ' 52' ' ' ILE . 25.0 ttt180 -66.41 109.86 2.89 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 115.237 -0.892 . . . . 0.0 109.98 172.458 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 2.8 t -81.92 25.13 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.536 0.41 0 CA-C-O 121.526 0.679 . . . . 0.0 111.867 -174.767 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.463 ' CD2' ' HG3' ' A' ' 68' ' ' ARG . 0.8 OUTLIER . . . . . 0 C--O 1.245 0.838 0 CA-C-O 118.759 -0.639 . . . . 0.0 110.329 179.218 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo . . . . . 0 CA--C 1.516 -0.403 0 CA-C-O 121.621 0.592 . . . . 0.0 112.507 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.604 HG12 HD12 ' A' ' 36' ' ' ILE . 16.1 m -80.5 163.03 3.53 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.896 0 CA-C-N 115.175 -0.921 . . . . 0.0 110.906 -177.989 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 9.8 tp10 -147.14 119.72 8.53 Favored 'General case' 0 C--N 1.322 -0.588 0 N-CA-C 108.918 -0.771 . . . . 0.0 108.918 178.471 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . 0.456 ' HA ' ' O ' ' A' ' 56' ' ' VAL . . . -58.91 117.55 4.78 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-O 121.111 0.482 . . . . 0.0 111.377 -177.207 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 119.09 -24.84 8.1 Favored Glycine 0 N--CA 1.447 -0.625 0 CA-C-N 115.653 -0.703 . . . . 0.0 112.218 -179.246 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' LYS . . . . . 0.408 ' HE2' ' HB3' ' A' ' 17' ' ' LYS . 53.1 mtpt -90.55 156.37 18.21 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.871 0.367 . . . . 0.0 110.734 179.077 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . 0.484 ' HA ' ' O ' ' A' ' 54' ' ' VAL . 46.0 mt-10 -113.96 128.34 56.35 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.824 -0.625 . . . . 0.0 109.858 -179.864 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 81.5 m-85 -122.58 143.42 49.75 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 121.173 0.511 . . . . 0.0 111.583 -175.887 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 32.7 tt0 -82.98 111.06 18.49 Favored 'General case' 0 C--N 1.317 -0.808 0 CA-C-N 115.548 -0.751 . . . . 0.0 109.475 175.069 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.486 ' HB ' ' HB1' ' A' ' 34' ' ' ALA . 32.7 m -121.81 151.32 25.28 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-O 121.053 0.454 . . . . 0.0 112.023 -172.714 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 17.0 m -97.62 152.44 19.06 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.658 -0.701 . . . . 0.0 109.721 176.474 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.491 HD13 ' HB2' ' A' ' 34' ' ' ALA . 18.9 mm -121.89 64.5 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-O 121.791 0.805 . . . . 0.0 108.908 -174.423 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 26.1 mm-40 -69.02 -19.15 64.11 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-N 114.782 -1.099 . . . . 0.0 111.835 -179.663 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.56 ' HB2' ' HB ' ' A' ' 33' ' ' ILE . 5.6 m-20 -126.34 138.7 53.6 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 116.392 -0.367 . . . . 0.0 111.277 -176.093 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' MET . . . . . . . . . . . . . 92.9 mmm -120.28 142.09 49.39 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 115.814 -0.63 . . . . 0.0 109.917 175.655 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.444 -0.773 0 N-CA-C 111.559 -0.616 . . . . 0.0 111.559 179.537 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 30.3 t70 . . . . . 0 CA--C 1.514 -0.432 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . 0.55 ' HA3' ' HB3' ' A' ' 46' ' ' ALA . . . -114.42 141.71 17.15 Favored Glycine 0 N--CA 1.441 -1.022 0 N-CA-C 111.178 -0.769 . . . . 0.0 111.178 177.994 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.56 ' HB ' ' HB2' ' A' ' 25' ' ' ASP . 2.6 mp -97.93 98.19 7.03 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.767 0 CA-C-O 121.329 0.585 . . . . 0.0 110.276 -178.09 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . 0.491 ' HB2' HD13 ' A' ' 23' ' ' ILE . . . -99.85 123.01 43.65 Favored 'General case' 0 CA--C 1.497 -1.065 0 CA-C-N 115.747 -0.661 . . . . 0.0 109.398 171.706 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' ARG . . . . . 0.525 ' HA ' ' O ' ' A' ' 39' ' ' PHE . 0.0 OUTLIER -118.56 108.66 15.23 Favored 'General case' 0 C--N 1.303 -1.453 0 CA-C-N 115.6 -0.727 . . . . 0.0 111.363 -174.11 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.604 HD12 HG12 ' A' ' 13' ' ' VAL . 53.1 mt -84.43 112.62 21.9 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.702 0 CA-C-N 115.208 -0.905 . . . . 0.0 109.604 177.649 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 36.7 t70 60.43 19.07 8.76 Favored 'General case' 0 CA--C 1.539 0.523 0 CA-C-N 115.495 -0.775 . . . . 0.0 110.702 -175.451 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 100.78 -9.26 58.41 Favored Glycine 0 C--N 1.329 0.189 0 C-N-CA 120.583 -0.818 . . . . 0.0 112.143 -178.794 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' PHE . . . . . 0.525 ' O ' ' HA ' ' A' ' 35' ' ' ARG . 60.8 t80 -77.43 114.76 16.59 Favored 'General case' 0 C--N 1.323 -0.576 0 N-CA-C 109.708 -0.479 . . . . 0.0 109.708 178.779 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.521 HG13 HG23 ' A' ' 33' ' ' ILE . 21.5 t -68.98 110.09 2.3 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 CA-C-O 121.6 0.714 . . . . 0.0 111.968 -175.347 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 17.6 t -108.26 110.42 31.91 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.824 0 CA-C-N 115.092 -0.958 . . . . 0.0 108.896 175.503 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 65.9 m-85 -74.3 134.7 42.57 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-O 121.126 0.489 . . . . 0.0 111.284 -176.653 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.695 HG11 HD11 ' A' ' 52' ' ' ILE . 8.1 t -131.56 113.93 15.55 Favored Pre-proline 0 N--CA 1.449 -0.524 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.794 -174.943 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 59.8 Cg_endo -74.71 -9.41 21.17 Favored 'Trans proline' 0 CA--C 1.531 0.359 0 C-N-CA 122.692 2.262 . . . . 0.0 113.681 -176.943 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' ASN . . . . . 0.564 ' HB2' ' HB3' ' A' ' 68' ' ' ARG . 12.5 m120 -124.64 9.78 8.37 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.008 0.432 . . . . 0.0 111.34 -175.163 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.55 ' HB3' ' HA3' ' A' ' 32' ' ' GLY . . . -71.43 150.63 44.76 Favored 'General case' 0 C--N 1.319 -0.755 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.878 -179.542 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 48.8 mt-10 -123.6 141.77 51.68 Favored 'General case' 0 N--CA 1.448 -0.567 0 CA-C-N 115.669 -0.696 . . . . 0.0 109.972 178.335 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 33.1 ttpt -55.19 129.52 38.54 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.8 -176.818 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 67.08 22.46 72.47 Favored Glycine 0 C--N 1.33 0.218 0 CA-C-N 115.947 -0.57 . . . . 0.0 112.902 174.327 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 18.4 m -113.78 158.89 20.38 Favored 'General case' 0 C--N 1.319 -0.731 0 O-C-N 122.609 -0.348 . . . . 0.0 110.179 179.651 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 51.1 t -118.39 99.87 8.86 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 N-CA-C 109.444 -0.576 . . . . 0.0 109.444 -178.69 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.695 HD11 HG11 ' A' ' 43' ' ' VAL . 0.5 OUTLIER -110.0 152.98 11.89 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.695 0 CA-C-N 116.044 -0.525 . . . . 0.0 109.861 -174.831 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . 0.54 HD22 ' HB ' ' A' ' 69' ' ' VAL . 12.4 t30 -92.56 120.5 33.08 Favored 'General case' 0 C--N 1.317 -0.826 0 N-CA-C 108.926 -0.768 . . . . 0.0 108.926 178.018 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . 0.666 ' HB ' ' HB1' ' A' ' 66' ' ' ALA . 34.9 m -114.67 139.83 38.74 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 N-CA-C 112.405 0.52 . . . . 0.0 112.405 -174.561 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . 0.434 ' HB2' ' HG2' ' A' ' 18' ' ' GLU . 3.2 ttmp? -98.54 109.21 22.0 Favored 'General case' 0 C--N 1.319 -0.758 0 N-CA-C 109.026 -0.731 . . . . 0.0 109.026 171.339 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.456 ' O ' ' HA ' ' A' ' 15' ' ' ALA . 90.7 t -69.39 113.16 4.82 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 178.554 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 17.5 p -101.97 -28.92 12.1 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 116.216 -0.447 . . . . 0.0 112.009 -175.096 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -140.58 94.09 2.69 Favored 'General case' 0 N--CA 1.452 -0.365 0 CA-C-O 121.121 0.486 . . . . 0.0 111.343 -173.536 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 39.5 t -81.34 133.08 30.05 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.833 0 CA-C-N 115.595 -0.73 . . . . 0.0 109.865 174.426 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 72.9 mmtt -112.82 -164.74 0.94 Allowed 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.397 -0.365 . . . . 0.0 110.368 178.555 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 8.9 mm-40 -67.56 -47.21 70.49 Favored 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 112.17 0.433 . . . . 0.0 112.17 -171.873 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 66.6 mttm -124.1 -2.45 8.15 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-O 120.625 0.25 . . . . 0.0 111.636 -176.574 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 9.9 p90 -153.73 174.73 14.14 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 116.26 -0.427 . . . . 0.0 109.871 -174.45 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -142.22 166.76 23.8 Favored 'General case' 0 C--N 1.322 -0.59 0 C-N-CA 120.876 -0.33 . . . . 0.0 111.465 -179.177 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 89.4 m-85 -117.14 131.86 56.79 Favored 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 175.033 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' ALA . . . . . 0.666 ' HB1' ' HB ' ' A' ' 54' ' ' VAL . . . -124.68 155.58 38.99 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-O 121.463 0.649 . . . . 0.0 112.433 -175.926 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 10.8 tt0 -104.71 120.28 40.98 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 114.946 -1.024 . . . . 0.0 110.324 178.557 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . 0.564 ' HB3' ' HB2' ' A' ' 45' ' ' ASN . 41.0 ttt180 -66.19 107.71 2.04 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 121.624 0.726 . . . . 0.0 111.18 174.573 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.566 ' O ' ' HB3' ' A' ' 70' ' ' LEU . 2.6 t -80.57 -177.52 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.759 0 N-CA-C 106.241 -1.762 . . . . 0.0 106.241 167.005 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.578 HD23 ' OXT' ' A' ' 70' ' ' LEU . 0.0 OUTLIER . . . . . 0 C--O 1.247 0.935 0 CA-C-O 118.257 -0.878 . . . . 0.0 110.85 179.614 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 42.0 Cg_endo . . . . . 0 C--O 1.232 0.204 0 N-CA-C 113.584 0.571 . . . . 0.0 113.584 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.468 HG12 HD12 ' A' ' 36' ' ' ILE . 13.9 m -119.97 120.72 63.99 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.819 0 CA-C-O 121.106 0.479 . . . . 0.0 111.017 -176.808 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 15.6 mm-40 -92.15 122.09 34.31 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.035 -177.678 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . 0.406 ' HA ' ' O ' ' A' ' 56' ' ' VAL . . . -67.09 96.74 0.47 Allowed 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.711 -0.677 . . . . 0.0 110.705 179.261 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 142.76 -30.15 2.07 Favored Glycine 0 N--CA 1.443 -0.887 0 C-N-CA 120.977 -0.63 . . . . 0.0 112.278 -178.298 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 8.8 mtpm? -95.7 168.79 10.45 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 121.64 0.733 . . . . 0.0 111.562 -179.478 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . 0.515 ' HB2' ' OD1' ' A' ' 53' ' ' ASN . 0.0 OUTLIER -115.5 149.63 37.82 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 114.557 -1.201 . . . . 0.0 110.621 -179.176 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 80.0 m-85 -137.67 141.21 41.12 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.259 178.125 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 8.1 tt0 -79.05 107.55 11.89 Favored 'General case' 0 C--N 1.325 -0.458 0 N-CA-C 109.408 -0.59 . . . . 0.0 109.408 174.356 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 35.2 m -118.08 164.13 14.64 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 CA-C-O 120.969 0.414 . . . . 0.0 110.756 -176.186 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 6.1 m -112.0 140.12 46.94 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-O 121.207 0.527 . . . . 0.0 110.202 177.833 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.57 HG13 ' HB1' ' A' ' 46' ' ' ALA . 30.7 mm -104.39 59.59 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.804 0 N-CA-C 108.188 -1.041 . . . . 0.0 108.188 -177.487 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 36.8 tt0 -65.69 -7.89 17.84 Favored 'General case' 0 C--N 1.315 -0.902 0 CA-C-N 113.724 -1.58 . . . . 0.0 110.873 -179.089 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.523 ' HB3' ' HB ' ' A' ' 33' ' ' ILE . 28.5 t70 -138.7 138.51 37.81 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 120.849 0.357 . . . . 0.0 110.86 -176.869 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -120.85 114.01 20.97 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.952 -0.567 . . . . 0.0 109.863 178.024 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.446 -0.649 0 C-N-CA 120.981 -0.628 . . . . 0.0 111.848 -178.439 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . 0.487 ' OD1' ' HA ' ' A' ' 44' ' ' PRO . 24.2 t70 . . . . . 0 C--O 1.232 0.144 0 N-CA-C 108.908 -0.775 . . . . 0.0 108.908 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -88.06 129.22 9.45 Favored Glycine 0 N--CA 1.449 -0.476 0 C-N-CA 120.627 -0.797 . . . . 0.0 112.381 -176.461 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.523 ' HB ' ' HB3' ' A' ' 25' ' ' ASP . 1.8 mp -100.16 101.74 12.5 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.46 0 CA-C-O 121.403 0.621 . . . . 0.0 110.423 178.864 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -95.47 151.71 19.06 Favored 'General case' 0 C--N 1.321 -0.66 0 N-CA-C 108.71 -0.848 . . . . 0.0 108.71 167.328 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 11.9 ttp-105 -139.95 104.28 4.83 Favored 'General case' 0 C--N 1.319 -0.726 0 C-N-CA 120.15 -0.62 . . . . 0.0 110.431 -178.883 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.468 HD12 HG12 ' A' ' 13' ' ' VAL . 29.8 mt -86.95 103.5 13.24 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-N 115.594 -0.73 . . . . 0.0 110.765 -175.938 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 13.7 t70 61.41 12.54 4.4 Favored 'General case' 0 N--CA 1.469 0.49 0 CA-C-N 114.372 -1.286 . . . . 0.0 111.737 179.323 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 120.12 -17.61 9.83 Favored Glycine 0 N--CA 1.448 -0.514 0 C-N-CA 120.472 -0.871 . . . . 0.0 112.007 -177.482 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 56.6 t80 -82.58 118.89 23.62 Favored 'General case' 0 C--N 1.326 -0.425 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 178.473 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 19.4 t -73.63 116.75 16.43 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-O 121.205 0.526 . . . . 0.0 111.057 -175.695 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 47.9 t -112.09 107.16 22.27 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 CA-C-N 115.586 -0.734 . . . . 0.0 109.322 178.038 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 94.3 m-85 -77.92 128.29 33.7 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.156 -178.28 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.446 HG11 ' HB2' ' A' ' 46' ' ' ALA . 3.3 t -115.82 98.38 50.9 Favored Pre-proline 0 C--N 1.317 -0.822 0 CA-C-N 115.883 -0.599 . . . . 0.0 109.905 -177.946 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . 0.487 ' HA ' ' OD1' ' A' ' 31' ' ' ASP . 48.6 Cg_exo -59.51 -17.73 42.92 Favored 'Trans proline' 0 N--CA 1.476 0.451 0 C-N-CA 124.07 3.18 . . . . 0.0 114.277 -173.486 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -131.62 8.36 4.55 Favored 'General case' 0 C--N 1.317 -0.817 0 N-CA-C 112.707 0.632 . . . . 0.0 112.707 -167.8 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.57 ' HB1' HG13 ' A' ' 23' ' ' ILE . . . -81.93 159.74 23.54 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-O 120.705 0.288 . . . . 0.0 110.892 175.272 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 46.0 mt-10 -108.16 159.48 16.57 Favored 'General case' 0 N--CA 1.448 -0.575 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.505 178.724 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -65.12 123.34 19.25 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.624 -175.211 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 74.49 22.71 76.97 Favored Glycine 0 C--N 1.331 0.29 0 CA-C-N 115.79 -0.641 . . . . 0.0 113.476 175.003 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 68.8 p -96.86 153.51 17.84 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-O 121.089 0.471 . . . . 0.0 111.101 -178.578 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 59.2 t -99.37 106.81 19.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 N-CA-C 108.195 -1.039 . . . . 0.0 108.195 172.562 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.563 HD11 ' HA ' ' A' ' 68' ' ' ARG . 0.8 OUTLIER -128.45 145.81 34.89 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.761 0 CA-C-O 121.772 0.796 . . . . 0.0 112.591 -166.647 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . 0.515 ' OD1' ' HB2' ' A' ' 18' ' ' GLU . 49.3 t30 -94.29 111.2 22.92 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 114.598 -1.183 . . . . 0.0 108.759 175.384 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . 0.562 ' HB ' ' HB1' ' A' ' 66' ' ' ALA . 34.6 m -108.69 128.52 64.34 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 CA-C-O 121.169 0.509 . . . . 0.0 111.399 -175.957 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . 0.505 ' HA ' ' HA ' ' A' ' 18' ' ' GLU . 2.7 ttpm? -96.34 106.43 18.65 Favored 'General case' 0 C--N 1.319 -0.757 0 N-CA-C 109.173 -0.677 . . . . 0.0 109.173 175.027 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.466 HG22 ' HB2' ' A' ' 66' ' ' ALA . 55.6 t -70.11 112.82 5.26 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 N-CA-C 109.875 -0.417 . . . . 0.0 109.875 -178.812 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 19.1 p -113.88 -9.6 13.05 Favored 'General case' 0 C--N 1.324 -0.516 0 N-CA-C 111.994 0.368 . . . . 0.0 111.994 -176.518 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -142.04 92.03 2.4 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.129 0.49 . . . . 0.0 111.064 -176.954 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 29.4 t -90.9 131.94 36.76 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.818 0 CA-C-N 115.917 -0.583 . . . . 0.0 109.89 177.363 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 32.2 mmtp -113.56 -178.18 3.31 Favored 'General case' 0 C--N 1.326 -0.452 0 N-CA-C 109.316 -0.624 . . . . 0.0 109.316 177.427 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 35.3 mt-10 -70.98 -26.42 63.14 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 113.054 0.761 . . . . 0.0 113.054 -172.179 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . 0.636 ' HB2' ' CD2' ' A' ' 63' ' ' PHE . 68.9 mmtt -114.97 -28.31 7.06 Favored 'General case' 0 N--CA 1.468 0.444 0 CA-C-O 121.162 0.506 . . . . 0.0 111.313 -177.03 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' PHE . . . . . 0.636 ' CD2' ' HB2' ' A' ' 62' ' ' LYS . 10.7 p90 -153.15 170.44 20.52 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.737 -0.665 . . . . 0.0 109.664 -172.074 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -131.57 160.18 36.04 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-O 120.769 0.318 . . . . 0.0 111.235 -179.01 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 97.8 m-85 -117.45 134.66 54.59 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 115.661 -0.699 . . . . 0.0 109.635 176.152 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' ALA . . . . . 0.562 ' HB1' ' HB ' ' A' ' 54' ' ' VAL . . . -124.73 177.21 6.1 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.806 -178.917 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' GLU . . . . . 0.557 ' O ' ' HA ' ' A' ' 54' ' ' VAL . 11.6 pt-20 -127.05 141.13 51.85 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 121.015 0.436 . . . . 0.0 111.103 -179.129 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . 0.563 ' HA ' HD11 ' A' ' 52' ' ' ILE . 74.5 ttt-85 -71.07 98.21 1.61 Allowed 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.979 176.211 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.41 ' O ' HD23 ' A' ' 70' ' ' LEU . 3.1 t -82.34 64.82 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-N 116.469 -0.332 . . . . 0.0 110.275 177.4 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.506 HD12 ' NE ' ' A' ' 68' ' ' ARG . 73.7 mt . . . . . 0 C--O 1.248 0.982 0 CA-C-O 118.212 -0.899 . . . . 0.0 110.092 -178.245 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 12.3 Cg_endo . . . . . 0 CA--C 1.529 0.271 0 N-CA-C 113.264 0.448 . . . . 0.0 113.264 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 12.3 m -103.07 125.97 57.43 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.602 0 CA-C-O 121.062 0.458 . . . . 0.0 111.097 -178.275 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 47.3 mt-10 -95.3 113.59 25.29 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.511 178.896 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -58.25 121.45 10.8 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.95 -0.568 . . . . 0.0 111.469 -179.016 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 115.26 -31.39 6.24 Favored Glycine 0 N--CA 1.448 -0.534 0 CA-C-N 115.895 -0.593 . . . . 0.0 112.057 -179.328 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -89.04 150.47 22.76 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 121.096 0.474 . . . . 0.0 111.02 -178.126 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . 0.588 ' HA ' ' HA ' ' A' ' 55' ' ' LYS . 0.7 OUTLIER -107.72 142.17 38.13 Favored 'General case' 0 C--N 1.317 -0.823 0 CA-C-N 115.546 -0.752 . . . . 0.0 110.518 179.192 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 67.1 m-85 -128.37 145.51 51.05 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.695 -176.032 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 6.2 tp10 -80.03 105.1 11.05 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 108.534 -0.913 . . . . 0.0 108.534 172.725 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 32.2 m -118.14 170.58 7.37 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-O 121.246 0.546 . . . . 0.0 112.176 -172.614 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 20.7 m -114.56 155.71 25.99 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.214 -0.903 . . . . 0.0 109.539 176.328 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.64 HG13 ' HB1' ' A' ' 46' ' ' ALA . 36.5 mm -118.62 64.66 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-O 122.127 0.965 . . . . 0.0 108.641 -175.239 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 -72.65 -8.51 55.65 Favored 'General case' 0 C--N 1.314 -0.944 0 CA-C-N 113.84 -1.527 . . . . 0.0 112.189 179.759 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.434 ' HB2' ' HB ' ' A' ' 33' ' ' ILE . 5.5 m-20 -134.61 153.93 51.74 Favored 'General case' 0 N--CA 1.465 0.288 0 N-CA-C 109.976 -0.379 . . . . 0.0 109.976 176.401 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' MET . . . . . 0.583 ' SD ' ' HB2' ' A' ' 48' ' ' LYS . 59.1 mtp -138.06 155.33 48.9 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.744 0.307 . . . . 0.0 110.777 174.226 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.35 0 C-N-CA 120.944 -0.646 . . . . 0.0 111.779 177.206 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 7.6 t70 . . . . . 0 C--O 1.236 0.367 0 CA-C-O 120.779 0.323 . . . . 0.0 110.68 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . 0.552 ' HA2' ' HA ' ' A' ' 26' ' ' MET . . . -118.06 156.6 15.57 Favored Glycine 0 N--CA 1.447 -0.613 0 N-CA-C 111.515 -0.634 . . . . 0.0 111.515 178.008 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.461 HG23 HG13 ' A' ' 40' ' ' VAL . 2.3 mp -111.5 110.21 31.37 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 CA-C-O 121.326 0.584 . . . . 0.0 110.859 -177.598 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -83.59 161.21 21.23 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.582 -0.735 . . . . 0.0 110.176 170.627 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -133.84 103.7 5.97 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.431 -179.232 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 65.5 mt -103.32 112.24 36.05 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.714 0 N-CA-C 110.006 -0.368 . . . . 0.0 110.006 177.338 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 28.9 t70 67.35 5.59 4.35 Favored 'General case' 0 N--CA 1.47 0.558 0 O-C-N 123.969 0.793 . . . . 0.0 110.899 -178.565 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 105.42 -6.26 41.9 Favored Glycine 0 C--N 1.333 0.37 0 C-N-CA 120.762 -0.732 . . . . 0.0 111.308 -173.913 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 46.6 t80 -81.57 135.56 35.57 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 109.067 -0.716 . . . . 0.0 109.067 178.09 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.461 HG13 HG23 ' A' ' 33' ' ' ILE . 43.4 t -81.98 120.79 34.18 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.196 -175.348 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 52.3 t -122.63 110.66 27.38 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.612 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.679 -179.397 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 73.9 m-85 -76.87 130.3 37.4 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.095 -178.174 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.479 ' HA ' ' HD3' ' A' ' 44' ' ' PRO . 11.7 t -123.41 110.55 30.42 Favored Pre-proline 0 C--N 1.323 -0.579 0 CA-C-N 115.644 -0.707 . . . . 0.0 109.886 -179.378 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . 0.479 ' HD3' ' HA ' ' A' ' 43' ' ' VAL . 32.0 Cg_exo -58.53 -30.94 93.28 Favored 'Trans proline' 0 CA--C 1.531 0.375 0 C-N-CA 123.805 3.004 . . . . 0.0 115.427 -168.154 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 34.1 m-80 -132.63 22.11 4.29 Favored 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 112.687 0.625 . . . . 0.0 112.687 -173.413 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.64 ' HB1' HG13 ' A' ' 23' ' ' ILE . . . -87.03 134.09 33.53 Favored 'General case' 0 C--N 1.318 -0.801 0 CA-C-O 120.721 0.296 . . . . 0.0 111.637 176.104 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 70.4 mm-40 -86.91 156.18 19.93 Favored 'General case' 0 C--O 1.235 0.314 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.806 178.081 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . 0.583 ' HB2' ' SD ' ' A' ' 26' ' ' MET . 49.7 tttm -65.44 123.68 20.26 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.864 0.364 . . . . 0.0 110.462 -179.411 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 90.93 0.05 75.39 Favored Glycine 0 N--CA 1.446 -0.67 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.784 178.097 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 69.3 m -78.82 138.52 38.21 Favored 'General case' 0 C--N 1.322 -0.601 0 C-N-CA 120.784 -0.367 . . . . 0.0 110.82 177.967 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 44.5 t -92.16 100.7 11.65 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 N-CA-C 107.859 -1.163 . . . . 0.0 107.859 173.149 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.612 HD11 ' HB2' ' A' ' 68' ' ' ARG . 2.9 tt -123.27 140.17 47.71 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.824 0 CA-C-O 121.969 0.89 . . . . 0.0 112.636 -168.455 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 48.4 t30 -86.93 114.88 23.93 Favored 'General case' 0 C--N 1.313 -0.999 0 CA-C-N 113.801 -1.545 . . . . 0.0 108.588 175.389 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . 0.583 ' HB ' ' HB1' ' A' ' 66' ' ' ALA . 35.7 m -118.87 132.15 69.58 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.723 0 CA-C-O 120.763 0.316 . . . . 0.0 111.329 -176.287 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . 0.588 ' HA ' ' HA ' ' A' ' 18' ' ' GLU . 22.5 ttmm -96.78 106.92 19.3 Favored 'General case' 0 C--N 1.324 -0.519 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 177.071 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.466 ' HA ' ' HA ' ' A' ' 66' ' ' ALA . 48.5 t -70.83 107.12 2.0 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 N-CA-C 109.901 -0.407 . . . . 0.0 109.901 -177.985 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 8.9 p -103.22 -21.86 13.81 Favored 'General case' 0 C--N 1.323 -0.578 0 N-CA-C 112.13 0.419 . . . . 0.0 112.13 -174.293 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -135.41 92.15 2.81 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 121.225 0.536 . . . . 0.0 110.781 -175.882 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 45.3 t -88.49 117.16 31.53 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.735 0 CA-C-N 115.583 -0.735 . . . . 0.0 110.591 177.509 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . 0.527 ' HB2' ' O ' ' A' ' 63' ' ' PHE . 4.9 mptp? -97.59 -168.84 1.74 Allowed 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 109.61 -0.515 . . . . 0.0 109.61 174.894 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 34.6 mt-10 -70.54 -53.77 14.79 Favored 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 111.979 0.362 . . . . 0.0 111.979 -176.903 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -93.46 -29.35 15.6 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 120.976 0.417 . . . . 0.0 112.113 -174.293 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' PHE . . . . . 0.527 ' O ' ' HB2' ' A' ' 60' ' ' LYS . 16.2 p90 -151.75 164.65 36.53 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.735 -174.66 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -125.45 163.91 21.6 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-O 120.749 0.309 . . . . 0.0 110.958 -178.648 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 98.4 m-85 -116.06 130.17 56.68 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-N 115.783 -0.644 . . . . 0.0 109.286 176.214 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' ALA . . . . . 0.583 ' HB1' ' HB ' ' A' ' 54' ' ' VAL . . . -121.4 154.64 36.24 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-O 121.195 0.521 . . . . 0.0 111.778 -175.504 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 30.1 tt0 -101.87 116.41 32.64 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-N 115.243 -0.89 . . . . 0.0 111.531 -177.294 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . 0.612 ' HB2' HD11 ' A' ' 52' ' ' ILE . 15.5 ttt-85 -54.03 108.06 0.33 Allowed 'General case' 0 CA--C 1.536 0.405 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.678 172.159 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.428 ' O ' HG12 ' A' ' 69' ' ' VAL . 12.2 t -82.01 12.26 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.328 0 CA-C-O 122.211 1.005 . . . . 0.0 110.324 179.707 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 54.9 mt . . . . . 0 C--N 1.316 -0.877 0 CA-C-N 114.932 -1.031 . . . . 0.0 109.148 176.773 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo . . . . . 0 N--CA 1.473 0.267 0 N-CA-C 113.143 0.401 . . . . 0.0 113.143 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 24.0 m -130.51 134.78 61.73 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.584 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.09 -178.577 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . 0.657 ' HB2' ' HG3' ' A' ' 17' ' ' LYS . 2.9 mp0 -110.24 136.33 49.62 Favored 'General case' 0 C--N 1.318 -0.798 0 CA-C-O 120.827 0.346 . . . . 0.0 110.671 179.191 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . 0.463 ' HA ' ' O ' ' A' ' 56' ' ' VAL . . . -64.12 117.77 7.58 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 115.795 -0.638 . . . . 0.0 110.551 176.578 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 112.23 -7.49 26.9 Favored Glycine 0 N--CA 1.446 -0.652 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.633 179.753 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' LYS . . . . . 0.657 ' HG3' ' HB2' ' A' ' 14' ' ' GLU . 12.8 mmmm -93.08 155.69 17.34 Favored 'General case' 0 C--N 1.326 -0.448 0 O-C-N 122.604 -0.35 . . . . 0.0 110.448 -179.867 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . 0.486 ' HB3' ' OD1' ' A' ' 53' ' ' ASN . 0.7 OUTLIER -113.85 118.49 34.37 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 109.065 -0.717 . . . . 0.0 109.065 172.71 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' TYR . . . . . 0.408 ' CE2' ' HB2' ' A' ' 17' ' ' LYS . 64.7 m-85 -112.37 140.77 46.82 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-O 121.142 0.496 . . . . 0.0 111.614 -177.334 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 36.2 tt0 -84.42 99.21 10.52 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.09 -0.959 . . . . 0.0 109.193 176.727 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 35.8 m -114.58 171.25 4.45 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.57 0 CA-C-O 121.21 0.529 . . . . 0.0 112.168 -170.986 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 23.4 m -115.36 153.37 31.13 Favored 'General case' 0 N--CA 1.45 -0.445 0 CA-C-N 115.244 -0.889 . . . . 0.0 109.749 175.917 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.615 HG13 ' HB1' ' A' ' 46' ' ' ALA . 37.5 mm -119.1 65.33 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-O 122.056 0.931 . . . . 0.0 108.927 -173.984 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -64.46 -17.43 63.83 Favored 'General case' 0 C--N 1.318 -0.796 0 CA-C-N 113.977 -1.465 . . . . 0.0 111.816 177.737 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.529 ' HB3' ' HB ' ' A' ' 33' ' ' ILE . 27.0 t0 -136.02 151.46 49.9 Favored 'General case' 0 C--N 1.324 -0.517 0 C-N-CA 121.064 -0.254 . . . . 0.0 110.824 -176.539 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' MET . . . . . 0.668 ' SD ' ' HB2' ' A' ' 48' ' ' LYS . 70.1 mtp -137.33 152.75 50.07 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.724 0.297 . . . . 0.0 110.22 175.521 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.448 -0.507 0 C-N-CA 120.969 -0.634 . . . . 0.0 111.56 177.726 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . 0.625 ' HA ' ' HA ' ' A' ' 44' ' ' PRO . 27.6 m-20 . . . . . 0 CA--C 1.522 -0.103 0 CA-C-O 121.021 0.439 . . . . 0.0 111.331 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -106.62 143.24 15.76 Favored Glycine 0 N--CA 1.444 -0.778 0 N-CA-C 110.2 -1.16 . . . . 0.0 110.2 171.614 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.529 ' HB ' ' HB3' ' A' ' 25' ' ' ASP . 2.1 mp -103.49 105.36 18.19 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.752 0 CA-C-O 121.354 0.597 . . . . 0.0 111.123 -173.761 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -86.99 155.77 20.04 Favored 'General case' 0 N--CA 1.444 -0.733 0 N-CA-C 108.134 -1.061 . . . . 0.0 108.134 166.572 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 37.0 ttt180 -141.93 118.36 10.88 Favored 'General case' 0 C--N 1.314 -0.956 0 C-N-CA 120.031 -0.668 . . . . 0.0 110.376 179.278 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 27.0 mt -109.27 108.7 26.0 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.664 0 CA-C-N 115.458 -0.792 . . . . 0.0 110.397 -179.37 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 31.7 t70 65.29 19.55 11.7 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.121 -0.945 . . . . 0.0 110.932 179.006 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 99.81 -9.39 60.16 Favored Glycine 0 N--CA 1.449 -0.445 0 C-N-CA 120.207 -0.997 . . . . 0.0 111.788 -177.43 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 54.1 t80 -82.75 118.84 23.66 Favored 'General case' 0 C--N 1.322 -0.62 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 177.672 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 17.0 t -75.08 122.93 29.74 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-O 120.993 0.425 . . . . 0.0 111.193 -174.961 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 45.3 t -115.86 109.29 27.69 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-N 116.202 -0.454 . . . . 0.0 109.863 179.646 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 85.6 m-85 -80.35 119.22 22.78 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 121.039 0.447 . . . . 0.0 110.752 -178.327 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.464 HG11 HD13 ' A' ' 52' ' ' ILE . 3.2 t -115.13 101.41 54.47 Favored Pre-proline 0 C--N 1.32 -0.706 0 CA-C-N 115.677 -0.692 . . . . 0.0 109.379 178.567 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . 0.625 ' HA ' ' HA ' ' A' ' 31' ' ' ASP . 16.9 Cg_exo -68.12 5.27 1.19 Allowed 'Trans proline' 0 CA--C 1.531 0.374 0 C-N-CA 123.383 2.722 . . . . 0.0 114.818 -168.721 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 47.5 m-80 -143.43 14.61 1.81 Allowed 'General case' 0 N--CA 1.464 0.225 0 CA-C-O 120.632 0.253 . . . . 0.0 111.609 179.553 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.615 ' HB1' HG13 ' A' ' 23' ' ' ILE . . . -86.43 134.1 33.72 Favored 'General case' 0 C--N 1.32 -0.713 0 N-CA-C 112.018 0.377 . . . . 0.0 112.018 -178.86 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 44.2 mt-10 -92.83 146.18 23.83 Favored 'General case' 0 N--CA 1.454 -0.266 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.976 177.281 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . 0.668 ' HB2' ' SD ' ' A' ' 26' ' ' MET . 46.8 tttp -65.43 129.93 41.51 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.051 -0.522 . . . . 0.0 111.136 -177.916 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 88.17 -5.42 84.83 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.827 -0.702 . . . . 0.0 113.397 176.005 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 51.1 m -95.14 147.78 23.08 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.872 0.336 . . . . 0.0 110.796 -179.329 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 46.0 t -91.91 109.59 21.54 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 N-CA-C 109.23 -0.656 . . . . 0.0 109.23 178.14 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.842 HG13 HD21 ' A' ' 70' ' ' LEU . 2.5 tt -119.57 143.41 31.13 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.819 0 CA-C-O 121.853 0.835 . . . . 0.0 112.403 -170.568 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . 0.486 ' OD1' ' HB3' ' A' ' 18' ' ' GLU . 23.5 t-20 -89.56 114.19 25.72 Favored 'General case' 0 C--N 1.316 -0.869 0 CA-C-N 114.051 -1.432 . . . . 0.0 108.543 175.406 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . 0.533 ' HB ' ' HB1' ' A' ' 66' ' ' ALA . 32.6 m -114.67 128.26 71.84 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 CA-C-O 121.264 0.554 . . . . 0.0 111.856 -175.601 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . 0.589 ' HA ' ' O ' ' A' ' 17' ' ' LYS . 38.2 ttmt -95.13 104.44 16.32 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 115.912 -0.585 . . . . 0.0 109.496 173.976 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.463 ' O ' ' HA ' ' A' ' 15' ' ' ALA . 66.0 t -66.09 110.48 1.35 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 N-CA-C 109.681 -0.489 . . . . 0.0 109.681 179.575 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 11.5 p -105.83 -28.86 10.39 Favored 'General case' 0 C--N 1.324 -0.54 0 N-CA-C 112.247 0.462 . . . . 0.0 112.247 -174.449 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -136.99 92.42 2.73 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 121.12 0.486 . . . . 0.0 110.978 -175.47 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 22.4 t -81.62 125.1 39.58 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.667 0 CA-C-N 115.623 -0.717 . . . . 0.0 110.017 176.225 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 32.2 mmtp -109.47 -150.21 0.45 Allowed 'General case' 0 C--N 1.325 -0.458 0 N-CA-C 109.951 -0.389 . . . . 0.0 109.951 178.484 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 20.2 mm-40 -70.78 -76.89 0.09 Allowed 'General case' 0 C--N 1.331 -0.239 0 N-CA-C 112.18 0.437 . . . . 0.0 112.18 -176.105 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 63.7 mttm -98.22 -2.57 39.39 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 121.182 0.515 . . . . 0.0 110.821 -175.652 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 35.7 p90 -151.37 164.97 35.5 Favored 'General case' 0 C--N 1.318 -0.761 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.725 -173.138 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -137.91 171.02 15.04 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.603 178.182 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 96.8 m-85 -118.92 133.81 55.59 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 109.493 -0.558 . . . . 0.0 109.493 176.702 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' ALA . . . . . 0.533 ' HB1' ' HB ' ' A' ' 54' ' ' VAL . . . -133.95 145.11 49.24 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.464 -179.001 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' GLU . . . . . 0.504 ' HG2' ' HB3' ' A' ' 55' ' ' LYS . 9.6 pt-20 -93.67 142.22 27.6 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-O 121.179 0.514 . . . . 0.0 111.408 -177.83 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . 0.567 ' HB2' HD11 ' A' ' 52' ' ' ILE . 17.8 ttt180 -71.17 109.96 5.54 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.341 -0.845 . . . . 0.0 110.043 173.721 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.489 ' O ' HG12 ' A' ' 69' ' ' VAL . 40.7 t -81.66 12.75 0.58 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.518 0 CA-C-O 122.076 0.941 . . . . 0.0 111.505 -176.415 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.842 HD21 HG13 ' A' ' 52' ' ' ILE . 1.0 OUTLIER . . . . . 0 C--N 1.314 -0.952 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.397 -179.333 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 94.8 Cg_endo . . . . . 0 N--CA 1.47 0.134 0 N-CA-C 113.18 0.415 . . . . 0.0 113.18 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.539 ' HB ' HG21 ' A' ' 56' ' ' VAL . 17.0 m -97.34 124.36 50.2 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.724 0 CA-C-N 115.857 -0.611 . . . . 0.0 110.779 -175.714 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . 0.475 ' OE2' ' HE2' ' A' ' 17' ' ' LYS . 31.7 tt0 -104.04 129.04 51.65 Favored 'General case' 0 C--N 1.322 -0.613 0 C-N-CA 120.85 -0.34 . . . . 0.0 110.105 -179.734 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -54.42 118.49 4.18 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.79 -0.641 . . . . 0.0 111.155 -178.477 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.31 -25.75 10.98 Favored Glycine 0 N--CA 1.444 -0.826 0 C-N-CA 120.671 -0.776 . . . . 0.0 112.448 179.941 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' LYS . . . . . 0.475 ' HE2' ' OE2' ' A' ' 14' ' ' GLU . 68.6 mttm -85.55 160.48 19.64 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 120.938 0.399 . . . . 0.0 110.457 179.034 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . 0.51 ' HA ' ' HA ' ' A' ' 55' ' ' LYS . 0.0 OUTLIER -126.87 133.32 50.74 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.449 179.052 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' TYR . . . . . 0.416 ' CE2' ' HA ' ' A' ' 13' ' ' VAL . 64.4 m-85 -123.14 162.6 22.19 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.331 -176.589 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 45.4 tt0 -96.58 122.39 39.44 Favored 'General case' 0 C--N 1.321 -0.665 0 N-CA-C 109.398 -0.593 . . . . 0.0 109.398 176.323 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.527 ' HB ' ' HB1' ' A' ' 34' ' ' ALA . 28.0 m -128.84 168.88 21.21 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-O 121.131 0.491 . . . . 0.0 111.587 -174.62 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 26.2 m -118.88 143.22 47.11 Favored 'General case' 0 N--CA 1.446 -0.65 0 CA-C-N 115.755 -0.657 . . . . 0.0 109.359 175.313 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.559 HG13 ' HB1' ' A' ' 46' ' ' ALA . 19.9 mm -111.77 59.53 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.664 0 CA-C-O 121.997 0.903 . . . . 0.0 108.755 -173.284 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -78.17 9.69 3.57 Favored 'General case' 0 C--N 1.315 -0.921 0 CA-C-N 114.573 -1.194 . . . . 0.0 112.229 -177.555 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.445 ' HB3' ' HB ' ' A' ' 33' ' ' ILE . 29.1 t0 -150.11 148.31 28.82 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.444 -0.344 . . . . 0.0 110.119 176.91 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' MET . . . . . 0.652 ' HA ' ' HA2' ' A' ' 32' ' ' GLY . 39.4 mtp -123.99 151.93 43.13 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.999 0.428 . . . . 0.0 111.157 178.649 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.445 -0.758 0 CA-C-N 115.554 -0.748 . . . . 0.0 112.709 -177.421 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.7 p30 . . . . . 0 N--CA 1.452 -0.333 0 CA-C-O 120.882 0.372 . . . . 0.0 110.013 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . 0.652 ' HA2' ' HA ' ' A' ' 26' ' ' MET . . . -128.57 172.78 19.33 Favored Glycine 0 N--CA 1.442 -0.95 0 C-N-CA 120.824 -0.703 . . . . 0.0 112.46 -177.384 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.445 ' HB ' ' HB3' ' A' ' 25' ' ' ASP . 2.2 mp -114.03 121.93 67.14 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.71 0 CA-C-O 120.947 0.403 . . . . 0.0 110.34 -179.949 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . 0.527 ' HB1' ' HB ' ' A' ' 21' ' ' VAL . . . -116.92 117.18 28.98 Favored 'General case' 0 C--N 1.317 -0.805 0 N-CA-C 108.804 -0.813 . . . . 0.0 108.804 172.663 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' ARG . . . . . 0.404 HH11 ' HD3' ' A' ' 35' ' ' ARG . 28.2 ttp180 -104.25 110.67 22.97 Favored 'General case' 0 C--N 1.318 -0.795 0 CA-C-O 121.143 0.497 . . . . 0.0 111.224 -172.735 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 43.7 mt -99.75 110.11 26.19 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-N 115.443 -0.799 . . . . 0.0 110.385 178.992 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 56.6 27.71 12.87 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.217 -0.902 . . . . 0.0 112.081 -179.837 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 100.17 -14.61 59.71 Favored Glycine 0 C--N 1.33 0.207 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.014 -179.627 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 65.9 t80 -85.04 135.44 34.01 Favored 'General case' 0 C--N 1.321 -0.65 0 N-CA-C 109.554 -0.536 . . . . 0.0 109.554 -178.585 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 34.0 t -88.2 117.06 31.17 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-O 121.162 0.506 . . . . 0.0 111.239 -175.424 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 40.8 t -112.51 118.78 58.7 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.686 0 CA-C-N 115.695 -0.684 . . . . 0.0 109.273 174.952 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 76.3 m-85 -87.07 132.04 33.94 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-O 121.194 0.521 . . . . 0.0 111.47 -177.474 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.554 HG21 HD12 ' A' ' 23' ' ' ILE . 15.5 m -111.54 124.2 33.09 Favored Pre-proline 0 C--N 1.324 -0.513 0 CA-C-N 115.461 -0.79 . . . . 0.0 110.336 178.377 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . 0.494 ' HD3' ' HA ' ' A' ' 43' ' ' VAL . 13.5 Cg_exo -71.42 -34.54 9.47 Favored 'Trans proline' 0 CA--C 1.527 0.175 0 C-N-CA 123.05 2.5 . . . . 0.0 113.667 -175.495 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 4.5 p30 -136.12 34.36 2.82 Favored 'General case' 0 C--N 1.325 -0.46 0 N-CA-C 112.887 0.699 . . . . 0.0 112.887 -167.092 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.559 ' HB1' HG13 ' A' ' 23' ' ' ILE . . . -90.41 161.33 15.62 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 120.991 0.424 . . . . 0.0 112.125 175.562 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' GLU . . . . . 0.526 ' CD ' HH12 ' A' ' 68' ' ' ARG . 2.1 mp0 -102.61 147.16 27.14 Favored 'General case' 0 C--O 1.235 0.302 0 CA-C-N 115.871 -0.604 . . . . 0.0 109.741 170.867 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . 0.505 ' HE3' ' SD ' ' A' ' 26' ' ' MET . 9.3 ptpp? -66.54 139.98 57.95 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.15 0.5 . . . . 0.0 111.061 -179.859 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 73.33 13.94 79.53 Favored Glycine 0 N--CA 1.45 -0.375 0 CA-C-N 115.861 -0.609 . . . . 0.0 112.764 177.513 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 8.5 t -107.46 151.2 25.87 Favored 'General case' 0 C--N 1.323 -0.57 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 178.647 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 57.9 t -104.1 104.92 17.52 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 N-CA-C 109.554 -0.535 . . . . 0.0 109.554 179.266 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.552 HD12 ' HB2' ' A' ' 68' ' ' ARG . 0.9 OUTLIER -113.97 154.94 15.27 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.512 -174.556 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . 0.433 HD22 ' HB ' ' A' ' 69' ' ' VAL . 9.2 t30 -95.29 119.95 34.68 Favored 'General case' 0 C--N 1.321 -0.665 0 N-CA-C 109.001 -0.741 . . . . 0.0 109.001 174.508 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . 0.492 ' HB ' ' HB1' ' A' ' 66' ' ' ALA . 27.8 m -112.08 131.92 62.18 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.664 0 CA-C-O 121.08 0.467 . . . . 0.0 111.738 -175.43 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . 0.51 ' HA ' ' HA ' ' A' ' 18' ' ' GLU . 6.3 ttpm? -100.06 109.54 21.85 Favored 'General case' 0 C--N 1.318 -0.786 0 N-CA-C 108.74 -0.837 . . . . 0.0 108.74 173.321 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.539 HG21 ' HB ' ' A' ' 13' ' ' VAL . 39.1 t -72.28 114.02 10.45 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.551 -176.321 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 7.9 p -108.15 -18.14 13.85 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 116.196 -0.456 . . . . 0.0 112.004 -177.523 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . 0.407 ' HB3' ' HB2' ' A' ' 65' ' ' PHE . . . -134.57 91.1 2.74 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 121.217 0.532 . . . . 0.0 110.591 -177.85 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 19.0 t -90.25 134.61 28.67 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.781 0 CA-C-N 115.298 -0.865 . . . . 0.0 110.801 179.156 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . 0.509 ' HB2' ' O ' ' A' ' 63' ' ' PHE . 75.4 mmtt -119.03 172.52 7.49 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 121.172 0.51 . . . . 0.0 110.563 174.351 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 42.2 tt0 -69.75 -29.34 66.68 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.072 -0.967 . . . . 0.0 109.428 173.691 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . 0.465 ' O ' ' CG ' ' A' ' 63' ' ' PHE . 38.6 mtmt -129.11 87.26 2.54 Favored 'General case' 0 N--CA 1.416 -2.154 0 N-CA-C 105.314 -2.106 . . . . 0.0 105.314 177.587 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' PHE . . . . . 0.509 ' O ' ' HB2' ' A' ' 60' ' ' LYS . 20.5 p90 78.89 142.25 0.08 Allowed 'General case' 0 N--CA 1.488 1.462 0 CA-C-N 112.903 -1.953 . . . . 0.0 112.17 164.658 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -117.1 169.58 9.32 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.452 -0.795 . . . . 0.0 111.894 -170.322 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' PHE . . . . . 0.407 ' HB2' ' HB3' ' A' ' 58' ' ' ALA . 79.5 m-85 -120.26 133.55 55.45 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 115.359 -0.837 . . . . 0.0 109.396 177.949 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' ALA . . . . . 0.537 ' HB2' HG22 ' A' ' 56' ' ' VAL . . . -134.81 148.04 50.09 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 120.922 0.391 . . . . 0.0 111.23 -177.271 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 11.1 pt-20 -94.27 132.63 38.65 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.914 -178.826 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . 0.926 ' HE ' HD12 ' A' ' 70' ' ' LEU . 31.0 ttt180 -67.02 106.39 1.93 Allowed 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.449 -0.796 . . . . 0.0 110.728 175.717 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.433 ' HB ' HD22 ' A' ' 53' ' ' ASN . 18.9 t -80.53 66.45 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.535 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.015 179.55 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.926 HD12 ' HE ' ' A' ' 68' ' ' ARG . 70.8 mt . . . . . 0 C--O 1.246 0.896 0 CA-C-N 115.687 -0.688 . . . . 0.0 109.466 178.266 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . 0.436 ' HG2' ' HB2' ' A' ' 39' ' ' PHE . 16.9 Cg_exo . . . . . 0 C--O 1.233 0.253 0 CA-C-O 121.364 0.485 . . . . 0.0 112.095 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.793 HG12 HD12 ' A' ' 36' ' ' ILE . 31.0 m -107.49 149.84 10.55 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 CA-C-N 115.267 -0.878 . . . . 0.0 110.465 -176.715 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -124.35 136.71 54.3 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-O 120.862 0.363 . . . . 0.0 110.393 177.905 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -70.54 106.59 3.51 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.996 -178.217 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 120.68 -13.1 10.02 Favored Glycine 0 N--CA 1.446 -0.653 0 C-N-CA 120.924 -0.655 . . . . 0.0 112.329 -179.719 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 8.1 mtpm? -102.56 156.74 17.41 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.724 0.297 . . . . 0.0 110.907 -178.87 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . 0.563 ' HA ' ' O ' ' A' ' 54' ' ' VAL . 0.0 OUTLIER -112.16 142.01 45.14 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 121.166 0.508 . . . . 0.0 111.375 -179.074 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' TYR . . . . . 0.563 ' O ' ' HA ' ' A' ' 53' ' ' ASN . 81.4 m-85 -130.64 141.74 50.43 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 116.051 -0.522 . . . . 0.0 111.121 -176.085 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 37.7 mt-10 -79.79 98.85 7.21 Favored 'General case' 0 C--N 1.326 -0.456 0 N-CA-C 109.3 -0.63 . . . . 0.0 109.3 174.835 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.488 ' HB ' ' HB1' ' A' ' 34' ' ' ALA . 35.8 m -110.3 156.2 11.36 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.81 0 CA-C-N 115.787 -0.642 . . . . 0.0 111.526 -174.275 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 24.2 m -105.09 148.73 26.51 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 115.407 -0.815 . . . . 0.0 109.77 176.07 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.534 HG13 ' HB1' ' A' ' 46' ' ' ALA . 33.6 mm -114.45 65.91 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.783 0 N-CA-C 108.053 -1.091 . . . . 0.0 108.053 -174.662 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 -62.25 -24.89 67.52 Favored 'General case' 0 C--N 1.312 -1.025 0 CA-C-N 113.621 -1.627 . . . . 0.0 111.552 178.974 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.529 ' HB3' ' HB ' ' A' ' 33' ' ' ILE . 5.9 t70 -133.7 152.03 51.78 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.521 -0.309 . . . . 0.0 111.125 -170.166 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' MET . . . . . 0.522 ' SD ' ' HB2' ' A' ' 48' ' ' LYS . 18.0 mtp -129.84 161.7 30.18 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 121.018 0.437 . . . . 0.0 110.73 176.341 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.448 -0.52 0 CA-C-N 115.74 -0.664 . . . . 0.0 111.957 177.282 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 16.2 m-20 . . . . . 0 CA--C 1.514 -0.442 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -96.53 122.35 7.34 Favored Glycine 0 N--CA 1.444 -0.815 0 N-CA-C 110.563 -1.015 . . . . 0.0 110.563 174.468 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.529 ' HB ' ' HB3' ' A' ' 25' ' ' ASP . 1.9 mp -95.84 100.67 11.32 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.698 0 CA-C-O 121.426 0.631 . . . . 0.0 110.462 -176.798 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . 0.488 ' HB1' ' HB ' ' A' ' 21' ' ' VAL . . . -99.4 162.04 13.27 Favored 'General case' 0 CA--C 1.495 -1.16 0 CA-C-N 115.265 -0.879 . . . . 0.0 108.947 168.563 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' ARG . . . . . 0.4 ' HA ' ' O ' ' A' ' 39' ' ' PHE . 29.0 ptt180 -156.65 119.64 4.12 Favored 'General case' 0 N--CA 1.43 -1.47 0 CA-C-O 121.423 0.63 . . . . 0.0 110.859 -177.379 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.793 HD12 HG12 ' A' ' 13' ' ' VAL . 43.9 mt -96.67 111.21 26.25 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.829 0 CA-C-N 115.186 -0.915 . . . . 0.0 110.349 -175.175 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 25.9 t0 57.97 29.18 17.3 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 114.685 -1.143 . . . . 0.0 110.836 -177.871 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 103.63 -22.69 34.98 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.957 -0.639 . . . . 0.0 112.347 179.401 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' PHE . . . . . 0.436 ' HB2' ' HG2' ' A' ' 12' ' ' PRO . 63.3 t80 -74.86 112.54 11.19 Favored 'General case' 0 C--N 1.324 -0.519 0 N-CA-C 109.959 -0.386 . . . . 0.0 109.959 -178.299 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 41.2 t -69.14 123.9 23.71 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 CA-C-O 121.42 0.628 . . . . 0.0 111.84 -174.791 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 25.5 t -121.8 109.23 24.0 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.691 0 CA-C-N 115.233 -0.894 . . . . 0.0 109.18 -179.884 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 87.9 m-85 -77.11 124.47 27.85 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.176 -176.39 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.42 ' CG1' ' HB2' ' A' ' 46' ' ' ALA . 2.7 t -122.01 98.96 44.37 Favored Pre-proline 0 C--N 1.325 -0.48 0 CA-C-N 115.753 -0.658 . . . . 0.0 110.534 -179.377 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -74.11 -0.16 9.2 Favored 'Trans proline' 0 CA--C 1.53 0.312 0 C-N-CA 122.704 2.269 . . . . 0.0 113.458 -175.752 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' ASN . . . . . 0.441 ' HB2' ' HB3' ' A' ' 68' ' ' ARG . 12.6 m120 -125.57 8.25 7.66 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 121.099 0.476 . . . . 0.0 110.91 -175.132 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.534 ' HB1' HG13 ' A' ' 23' ' ' ILE . . . -91.03 153.25 20.27 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 112.069 0.396 . . . . 0.0 112.069 -176.176 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 5.4 mm-40 -105.04 135.9 45.52 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.444 -0.798 . . . . 0.0 110.433 176.426 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . 0.522 ' HB2' ' SD ' ' A' ' 26' ' ' MET . 14.3 tmtt? -65.14 136.65 56.95 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.494 -179.895 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 70.64 23.44 77.73 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.993 -0.622 . . . . 0.0 112.522 179.069 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 23.3 t -122.36 145.89 47.83 Favored 'General case' 0 C--N 1.321 -0.654 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 179.518 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 52.8 t -90.44 101.62 12.51 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 N-CA-C 109.53 -0.545 . . . . 0.0 109.53 177.839 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.561 HD11 ' HB2' ' A' ' 68' ' ' ARG . 0.9 OUTLIER -119.29 140.96 41.48 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.749 0 CA-C-N 115.768 -0.651 . . . . 0.0 111.034 -175.29 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . 0.563 ' HA ' ' O ' ' A' ' 19' ' ' TYR . 7.1 p-10 -97.81 118.06 33.5 Favored 'General case' 0 C--N 1.313 -0.99 0 CA-C-N 115.128 -0.942 . . . . 0.0 109.016 176.288 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . 0.563 ' O ' ' HA ' ' A' ' 18' ' ' GLU . 35.3 m -111.67 140.96 28.66 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.765 0 CA-C-N 115.304 -0.862 . . . . 0.0 111.731 -173.481 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 25.6 ttmt -94.96 109.22 21.26 Favored 'General case' 0 C--N 1.319 -0.724 0 N-CA-C 109.212 -0.662 . . . . 0.0 109.212 177.389 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.456 HG21 ' HB ' ' A' ' 13' ' ' VAL . 60.5 t -70.56 113.26 6.37 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 N-CA-C 109.53 -0.544 . . . . 0.0 109.53 179.516 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.9 p -111.42 -14.97 13.66 Favored 'General case' 0 C--N 1.323 -0.587 0 N-CA-C 112.32 0.489 . . . . 0.0 112.32 -173.077 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . 0.433 ' HB3' ' HB2' ' A' ' 65' ' ' PHE . . . -145.82 93.38 2.33 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.947 0.403 . . . . 0.0 111.048 -176.214 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 21.9 t -87.6 122.93 39.93 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 CA-C-N 116.061 -0.518 . . . . 0.0 109.919 176.085 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 32.3 mmtp -109.15 -165.26 1.0 Allowed 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.668 -0.242 . . . . 0.0 110.375 179.832 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . 0.471 ' CD ' ' H ' ' A' ' 61' ' ' GLU . 4.1 mp0 -64.25 -54.05 39.44 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.752 -175.925 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 88.9 mttt -108.82 -19.78 13.29 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.838 -171.533 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 23.9 p90 -150.13 175.02 12.13 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.589 -175.111 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -137.29 167.45 21.56 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-O 120.808 0.337 . . . . 0.0 111.024 179.378 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' PHE . . . . . 0.433 ' HB2' ' HB3' ' A' ' 58' ' ' ALA . 90.8 m-85 -119.63 135.17 54.92 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.753 -0.658 . . . . 0.0 109.822 177.211 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' ALA . . . . . 0.513 ' HB1' ' HB ' ' A' ' 54' ' ' VAL . . . -132.38 154.99 49.24 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.321 -0.399 . . . . 0.0 111.043 -178.926 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 13.7 pt-20 -111.81 143.49 42.67 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 121.088 0.471 . . . . 0.0 111.11 -179.408 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . 0.561 ' HB2' HD11 ' A' ' 52' ' ' ILE . 27.3 ttt180 -66.69 114.18 5.4 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.469 -0.787 . . . . 0.0 111.135 174.255 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.482 ' HB ' ' ND2' ' A' ' 53' ' ' ASN . 3.7 t -83.14 5.85 1.9 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 121.7 0.762 . . . . 0.0 110.915 176.761 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.408 ' HB2' ' HG3' ' A' ' 68' ' ' ARG . 68.7 mt . . . . . 0 C--N 1.315 -0.935 0 CA-C-N 115.305 -0.861 . . . . 0.0 110.588 -177.602 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo . . . . . 0 C--O 1.231 0.173 0 CA-C-O 121.342 0.476 . . . . 0.0 112.51 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.583 HG12 HD12 ' A' ' 36' ' ' ILE . 6.0 m -73.51 130.9 35.61 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.718 0 CA-C-N 115.06 -0.973 . . . . 0.0 111.932 -173.525 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -102.45 119.09 38.22 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.754 -0.657 . . . . 0.0 109.372 177.858 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -68.17 108.69 3.24 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 120.975 0.417 . . . . 0.0 110.752 -178.565 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 127.54 -23.87 5.33 Favored Glycine 0 N--CA 1.443 -0.854 0 C-N-CA 120.814 -0.708 . . . . 0.0 112.409 -179.695 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' LYS . . . . . 0.407 ' HE3' ' HB3' ' A' ' 17' ' ' LYS . 24.0 mtpp -104.19 165.95 10.72 Favored 'General case' 0 C--O 1.235 0.336 0 CA-C-O 121.019 0.438 . . . . 0.0 111.28 179.613 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . 0.561 ' HG3' HD21 ' A' ' 53' ' ' ASN . 0.2 OUTLIER -117.8 151.06 38.09 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.719 -0.673 . . . . 0.0 111.067 -177.584 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 72.6 m-85 -139.01 145.68 39.94 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.694 -0.684 . . . . 0.0 109.504 179.245 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . 0.551 ' HG2' HG12 ' A' ' 51' ' ' VAL . 42.6 tt0 -85.32 108.18 17.68 Favored 'General case' 0 C--N 1.32 -0.692 0 N-CA-C 109.529 -0.545 . . . . 0.0 109.529 176.756 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 34.4 m -122.8 165.66 18.56 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.968 -172.61 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 9.0 m -102.31 148.01 25.99 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-O 120.965 0.412 . . . . 0.0 110.543 179.801 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.455 HG13 ' HB1' ' A' ' 46' ' ' ALA . 29.3 mm -112.97 61.59 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 N-CA-C 107.916 -1.142 . . . . 0.0 107.916 -177.471 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 13.1 tp10 -64.12 -17.07 63.09 Favored 'General case' 0 C--N 1.317 -0.843 0 CA-C-N 113.283 -1.78 . . . . 0.0 111.67 -177.29 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 33.3 t70 -145.41 152.21 39.47 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 116.483 -0.326 . . . . 0.0 110.196 -173.236 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' MET . . . . . 0.655 ' HA ' ' HA2' ' A' ' 32' ' ' GLY . 33.3 mtp -128.25 157.18 41.61 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 121.171 0.51 . . . . 0.0 110.974 177.866 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.503 ' HA3' ' OD2' ' A' ' 31' ' ' ASP . . . . . . . . 0 N--CA 1.445 -0.732 0 CA-C-N 115.66 -0.7 . . . . 0.0 112.724 -176.564 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . 0.503 ' OD2' ' HA3' ' A' ' 27' ' ' GLY . 12.1 p-10 . . . . . 0 N--CA 1.453 -0.311 0 N-CA-C 109.611 -0.514 . . . . 0.0 109.611 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . 0.655 ' HA2' ' HA ' ' A' ' 26' ' ' MET . . . -117.78 158.79 14.46 Favored Glycine 0 N--CA 1.445 -0.709 0 C-N-CA 121.032 -0.604 . . . . 0.0 112.154 -179.154 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 2.2 mp -108.88 106.89 21.56 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.5 0 CA-C-O 121.175 0.512 . . . . 0.0 110.103 178.682 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . 0.445 ' HB3' ' HB ' ' A' ' 41' ' ' VAL . . . -90.84 152.92 20.57 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.6 -0.727 . . . . 0.0 109.842 172.278 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -122.14 113.46 19.53 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.556 -178.274 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.583 HD12 HG12 ' A' ' 13' ' ' VAL . 38.7 mt -110.39 105.81 19.53 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.758 0 CA-C-O 121.085 0.469 . . . . 0.0 109.985 175.2 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 26.9 t0 55.18 36.69 27.55 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 114.852 -1.067 . . . . 0.0 110.663 -178.528 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 94.27 -19.93 50.68 Favored Glycine 0 C--N 1.333 0.394 0 C-N-CA 120.976 -0.63 . . . . 0.0 112.787 -179.807 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 78.3 t80 -77.13 142.54 39.66 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 110.098 -0.334 . . . . 0.0 110.098 -175.258 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 11.1 t -88.25 114.64 27.12 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 CA-C-N 115.888 -0.596 . . . . 0.0 111.113 -175.7 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.445 ' HB ' ' HB3' ' A' ' 34' ' ' ALA . 54.6 t -109.8 108.14 24.64 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.649 0 CA-C-N 116.033 -0.531 . . . . 0.0 109.913 177.265 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 67.6 m-85 -76.84 119.03 20.04 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 121.351 0.596 . . . . 0.0 110.256 178.822 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.731 HG11 HD11 ' A' ' 52' ' ' ILE . 17.5 t -117.9 100.49 52.17 Favored Pre-proline 0 C--N 1.315 -0.93 0 CA-C-N 115.474 -0.784 . . . . 0.0 110.512 -175.769 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 33.7 Cg_exo -64.62 -9.32 20.22 Favored 'Trans proline' 0 N--CA 1.476 0.476 0 C-N-CA 123.799 2.999 . . . . 0.0 114.412 -175.563 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' ASN . . . . . 0.43 ' HB2' ' HB3' ' A' ' 68' ' ' ARG . 0.9 OUTLIER -128.35 17.77 6.49 Favored 'General case' 0 C--N 1.324 -0.511 0 C-N-CA 120.907 -0.317 . . . . 0.0 110.7 -175.192 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.601 ' HB2' ' HB ' ' A' ' 43' ' ' VAL . . . -67.75 154.32 41.77 Favored 'General case' 0 C--N 1.32 -0.696 0 N-CA-C 113.334 0.864 . . . . 0.0 113.334 -175.655 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 10.9 mm-40 -105.76 121.33 43.8 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 114.695 -1.139 . . . . 0.0 109.64 174.522 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . 0.622 ' HB2' ' SD ' ' A' ' 26' ' ' MET . 63.2 tttm -60.84 123.99 19.14 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 120.947 0.404 . . . . 0.0 110.918 -177.119 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 89.06 -33.62 4.2 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 121.006 -0.616 . . . . 0.0 112.853 178.122 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 17.7 m -71.08 155.62 40.58 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 120.906 0.384 . . . . 0.0 110.627 -179.05 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.551 HG12 ' HG2' ' A' ' 20' ' ' GLU . 21.8 t -102.82 87.95 1.25 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 177.498 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.731 HD11 HG11 ' A' ' 43' ' ' VAL . 0.1 OUTLIER -92.49 144.98 8.18 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-N 115.622 -0.717 . . . . 0.0 110.688 -171.002 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . 0.561 HD21 ' HG3' ' A' ' 18' ' ' GLU . 8.5 t30 -83.36 112.52 19.99 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-N 115.691 -0.686 . . . . 0.0 109.794 175.229 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . 0.513 ' HB ' ' HB1' ' A' ' 66' ' ' ALA . 33.9 m -104.44 137.38 33.71 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.264 -176.72 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . 0.536 ' HA ' ' HA ' ' A' ' 18' ' ' GLU . 35.9 ttpt -103.49 110.93 23.15 Favored 'General case' 0 C--N 1.318 -0.8 0 N-CA-C 108.958 -0.756 . . . . 0.0 108.958 172.644 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 60.4 t -65.21 118.08 7.0 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 CA-C-N 116.45 -0.341 . . . . 0.0 110.157 -179.294 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 12.3 p -104.35 -24.53 13.08 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 116.248 -0.433 . . . . 0.0 112.001 -174.992 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -154.75 102.31 2.36 Favored 'General case' 0 N--CA 1.451 -0.422 0 CA-C-O 121.097 0.475 . . . . 0.0 111.007 -175.131 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.412 HG13 ' HB2' ' A' ' 64' ' ' ALA . 17.9 t -88.22 122.72 40.12 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.705 0 CA-C-N 115.676 -0.693 . . . . 0.0 110.2 174.755 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . 0.433 ' N ' ' HD2' ' A' ' 60' ' ' LYS . 0.6 OUTLIER -101.35 -171.23 1.95 Allowed 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 176.634 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 39.4 mm-40 -59.51 -48.81 80.19 Favored 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 112.667 0.618 . . . . 0.0 112.667 -174.466 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 64.4 mttm -116.03 -5.45 11.96 Favored 'General case' 0 C--N 1.328 -0.326 0 N-CA-C 112.346 0.499 . . . . 0.0 112.346 -171.811 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 16.1 p90 -162.63 156.11 20.28 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 120.682 0.277 . . . . 0.0 110.761 -176.059 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.412 ' HB2' HG13 ' A' ' 59' ' ' VAL . . . -121.39 159.0 27.07 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.698 -178.65 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 96.2 m-85 -116.39 137.15 52.39 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.269 -0.423 . . . . 0.0 109.926 176.374 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' ALA . . . . . 0.513 ' HB1' ' HB ' ' A' ' 54' ' ' VAL . . . -137.48 152.89 50.02 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 116.443 -0.344 . . . . 0.0 111.161 -177.962 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' GLU . . . . . 0.4 ' O ' ' HA ' ' A' ' 54' ' ' VAL . 9.6 pt-20 -102.84 144.07 31.63 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.932 -179.11 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . 0.672 ' HB2' HD12 ' A' ' 52' ' ' ILE . 9.2 ttp180 -70.95 109.29 4.98 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.341 172.793 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.537 ' HB ' HD22 ' A' ' 53' ' ' ASN . 3.8 t -81.95 28.34 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.468 0 CA-C-O 121.506 0.67 . . . . 0.0 110.856 -179.587 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.441 HD23 ' N ' ' A' ' 70' ' ' LEU . 1.3 pt? . . . . . 0 C--O 1.243 0.744 0 CA-C-N 116.136 -0.484 . . . . 0.0 109.748 178.75 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo . . . . . 0 CA--C 1.519 -0.254 0 CA-C-O 121.449 0.52 . . . . 0.0 112.379 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 9.4 m -121.8 -175.61 1.04 Allowed 'Isoleucine or valine' 0 C--N 1.314 -0.94 0 CA-C-N 115.16 -0.927 . . . . 0.0 109.722 179.806 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . 0.539 ' HG3' ' HD2' ' A' ' 17' ' ' LYS . 74.5 mm-40 -116.82 -159.46 0.73 Allowed 'General case' 0 C--N 1.314 -0.94 0 N-CA-C 109.587 -0.523 . . . . 0.0 109.587 177.21 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . 0.454 ' HA ' ' O ' ' A' ' 56' ' ' VAL . . . -162.56 101.11 1.04 Allowed 'General case' 0 C--N 1.317 -0.837 0 CA-C-N 115.591 -0.732 . . . . 0.0 109.315 174.862 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 124.81 -18.41 7.12 Favored Glycine 0 N--CA 1.446 -0.65 0 CA-C-N 114.82 -1.082 . . . . 0.0 111.571 -173.623 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' LYS . . . . . 0.539 ' HD2' ' HG3' ' A' ' 14' ' ' GLU . 61.6 mttm -102.31 164.11 11.86 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 120.597 0.237 . . . . 0.0 110.663 -178.76 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . 0.493 ' HA ' ' O ' ' A' ' 54' ' ' VAL . 2.1 mp0 -111.15 144.22 40.63 Favored 'General case' 0 N--CA 1.455 -0.179 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.072 -179.383 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 98.0 m-85 -132.58 -179.66 5.59 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.69 -0.686 . . . . 0.0 109.492 173.775 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 6.5 pt-20 -124.8 113.32 17.76 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-O 121.583 0.706 . . . . 0.0 109.495 175.07 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.436 ' O ' ' HA ' ' A' ' 51' ' ' VAL . 30.2 m -116.82 173.9 3.88 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.91 0 CA-C-N 115.26 -0.882 . . . . 0.0 111.202 -173.031 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 5.8 m -112.82 152.19 29.49 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.028 179.431 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.533 HG13 ' HB1' ' A' ' 46' ' ' ALA . 19.9 mm -115.23 61.22 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.678 0 N-CA-C 108.355 -0.98 . . . . 0.0 108.355 -176.064 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 6.9 mm-40 -66.12 -18.18 65.18 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 114.006 -1.452 . . . . 0.0 111.405 -179.259 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.498 ' HB3' ' HB ' ' A' ' 33' ' ' ILE . 26.0 t0 -138.53 137.01 36.66 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.472 -172.397 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' MET . . . . . . . . . . . . . 10.8 mmt -114.89 144.03 44.19 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.886 174.929 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.447 -0.607 0 N-CA-C 110.809 -0.916 . . . . 0.0 110.809 172.934 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . 0.468 ' HA ' ' HA ' ' A' ' 44' ' ' PRO . 4.7 t70 . . . . . 0 C--O 1.236 0.358 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -98.67 154.18 19.98 Favored Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.924 -173.732 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.498 ' HB ' ' HB3' ' A' ' 25' ' ' ASP . 2.5 mp -105.94 113.53 42.96 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.582 0 CA-C-O 121.136 0.493 . . . . 0.0 110.451 179.258 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . 0.429 ' HB1' ' HB ' ' A' ' 21' ' ' VAL . . . -106.37 160.62 15.24 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.775 -0.648 . . . . 0.0 109.9 175.902 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' ARG . . . . . 0.418 HH11 ' HD3' ' A' ' 35' ' ' ARG . 0.1 OUTLIER -130.05 128.02 41.1 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-O 120.652 0.263 . . . . 0.0 111.062 -175.027 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 54.7 mt -127.25 110.1 21.95 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 172.145 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 57.95 23.48 9.92 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 115.319 -0.855 . . . . 0.0 111.539 -175.946 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 99.88 -12.94 60.89 Favored Glycine 0 C--N 1.333 0.393 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.008 -178.605 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 52.6 t80 -76.18 139.28 41.16 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 109.652 -0.499 . . . . 0.0 109.652 -178.202 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 26.0 t -89.44 114.84 28.07 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 CA-C-O 121.097 0.475 . . . . 0.0 111.029 -175.475 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 37.1 t -115.24 118.23 58.13 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.661 0 CA-C-N 115.924 -0.58 . . . . 0.0 109.828 179.28 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 94.6 m-85 -87.09 142.31 28.02 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.773 -177.535 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.467 ' HA ' ' HD3' ' A' ' 44' ' ' PRO . 1.4 m -138.55 102.8 7.84 Favored Pre-proline 0 C--N 1.325 -0.496 0 CA-C-N 115.762 -0.654 . . . . 0.0 110.79 -179.115 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . 0.468 ' HA ' ' HA ' ' A' ' 31' ' ' ASP . 4.9 Cg_exo -77.23 3.39 6.75 Favored 'Trans proline' 0 CA--C 1.531 0.354 0 C-N-CA 123.564 2.842 . . . . 0.0 113.956 -170.943 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' ASN . . . . . 0.461 ' O ' ' HD3' ' A' ' 68' ' ' ARG . 57.2 m-80 -136.53 25.49 3.15 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 121.263 0.554 . . . . 0.0 110.489 -179.431 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.533 ' HB1' HG13 ' A' ' 23' ' ' ILE . . . -86.01 163.8 17.75 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 115.98 -0.554 . . . . 0.0 111.741 -179.682 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 42.9 mt-10 -116.93 134.4 54.8 Favored 'General case' 0 N--CA 1.446 -0.647 0 CA-C-N 115.472 -0.785 . . . . 0.0 109.297 172.224 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 27.0 ttpp -65.56 140.07 58.51 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-O 120.967 0.413 . . . . 0.0 111.493 -174.207 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 70.52 35.79 68.27 Favored Glycine 0 N--CA 1.448 -0.504 0 CA-C-N 115.525 -0.761 . . . . 0.0 112.704 177.367 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 50.8 m -142.18 162.23 35.99 Favored 'General case' 0 C--N 1.321 -0.663 0 O-C-N 122.772 -0.252 . . . . 0.0 110.747 179.07 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.436 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 88.9 t -98.86 122.9 51.1 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 N-CA-C 108.994 -0.743 . . . . 0.0 108.994 174.327 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.587 HD12 ' HB2' ' A' ' 68' ' ' ARG . 3.4 pt -121.62 142.97 35.67 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.703 0 C-N-CA 120.615 -0.434 . . . . 0.0 110.371 -178.8 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . 0.425 ' O ' ' HA ' ' A' ' 68' ' ' ARG . 16.5 t-20 -76.71 129.48 36.4 Favored 'General case' 0 C--N 1.323 -0.556 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 174.053 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . 0.683 ' HB ' ' HB1' ' A' ' 66' ' ' ALA . 25.0 m -128.24 128.49 68.61 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 CA-C-O 121.163 0.506 . . . . 0.0 112.032 -176.202 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . 0.426 ' HB2' ' HG3' ' A' ' 18' ' ' GLU . 22.8 ttmm -98.95 102.14 13.77 Favored 'General case' 0 C--N 1.314 -0.945 0 N-CA-C 108.611 -0.885 . . . . 0.0 108.611 170.044 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.556 HG22 ' HB2' ' A' ' 66' ' ' ALA . 68.1 t -66.27 108.21 0.96 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 N-CA-C 109.459 -0.571 . . . . 0.0 109.459 178.368 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 12.9 p -109.87 -13.81 14.39 Favored 'General case' 0 C--N 1.321 -0.634 0 N-CA-C 112.304 0.483 . . . . 0.0 112.304 -174.405 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . 0.429 ' HB3' ' HB2' ' A' ' 65' ' ' PHE . . . -143.13 92.24 2.36 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.134 0.493 . . . . 0.0 111.256 -176.608 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 20.3 t -84.58 142.8 12.84 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.768 0 CA-C-N 115.95 -0.568 . . . . 0.0 109.7 177.645 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 42.5 mmtm -127.72 -162.33 1.16 Allowed 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 116.716 -0.22 . . . . 0.0 110.779 -179.364 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 6.5 mm-40 -47.34 -64.09 0.87 Allowed 'General case' 0 N--CA 1.468 0.435 0 C-N-CA 123.699 0.799 . . . . 0.0 112.761 -172.302 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 59.9 pttt -138.31 20.59 2.77 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 121.666 0.746 . . . . 0.0 110.198 -178.926 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 28.9 p90 -153.12 153.19 32.3 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 114.939 -1.028 . . . . 0.0 108.906 -179.745 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -127.41 155.66 43.29 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-O 120.825 0.345 . . . . 0.0 111.112 -177.69 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' PHE . . . . . 0.429 ' HB2' ' HB3' ' A' ' 58' ' ' ALA . 99.0 m-85 -108.97 124.69 51.09 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 115.836 -0.62 . . . . 0.0 109.476 176.412 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' ALA . . . . . 0.683 ' HB1' ' HB ' ' A' ' 54' ' ' VAL . . . -125.12 151.24 46.0 Favored 'General case' 0 C--N 1.318 -0.793 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.707 -179.001 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 5.3 pt-20 -110.27 128.51 55.56 Favored 'General case' 0 C--N 1.316 -0.882 0 CA-C-O 121.263 0.554 . . . . 0.0 111.117 -178.888 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . 0.587 ' HB2' HD12 ' A' ' 52' ' ' ILE . 22.4 ttt180 -61.74 115.4 3.95 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.008 -0.996 . . . . 0.0 111.515 178.262 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.452 ' O ' HG12 ' A' ' 69' ' ' VAL . 22.0 t -82.07 12.29 0.64 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-N 114.922 -1.036 . . . . 0.0 110.876 179.32 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.456 ' HB2' ' HE ' ' A' ' 68' ' ' ARG . 60.4 mt . . . . . 0 C--O 1.249 1.045 0 CA-C-O 118.317 -0.849 . . . . 0.0 110.692 -178.447 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 15.5 tpt . . . . . 0 N--CA 1.479 1.003 0 CA-C-O 120.877 0.37 . . . . 0.0 110.196 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -156.31 126.27 6.45 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.727 -178.734 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 3.2 p90 -95.22 65.26 2.8 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 121.456 0.646 . . . . 0.0 109.986 176.773 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 96.99 -64.9 0.97 Allowed Glycine 0 N--CA 1.447 -0.601 0 N-CA-C 110.769 -0.932 . . . . 0.0 110.769 -173.379 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.416 ' HA ' ' HD3' ' A' ' 6' ' ' PRO . 98.7 mttt -142.09 150.69 56.65 Favored Pre-proline 0 C--N 1.328 -0.335 0 N-CA-C 109.276 -0.639 . . . . 0.0 109.276 175.422 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.416 ' HD3' ' HA ' ' A' ' 5' ' ' LYS . 5.7 Cg_exo -76.49 94.66 1.04 Allowed 'Trans proline' 0 N--CA 1.459 -0.552 0 C-N-CA 122.553 2.169 . . . . 0.0 111.671 177.72 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . 63.55 -165.14 0.24 Allowed 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.676 -0.693 . . . . 0.0 111.139 178.454 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' MET . . . . . . . . . . . . . 26.4 ttt -99.26 39.8 1.26 Allowed 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 121.327 0.584 . . . . 0.0 109.786 179.579 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 10.5 ttpp 66.7 22.79 10.33 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-N 115.165 -0.925 . . . . 0.0 110.932 177.442 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 2.4 m120 60.52 99.1 0.03 OUTLIER 'General case' 0 N--CA 1.467 0.424 0 CA-C-N 115.707 -0.679 . . . . 0.0 112.126 -178.221 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.513 HG11 HG11 ' A' ' 59' ' ' VAL . 21.2 t -76.02 126.86 86.31 Favored Pre-proline 0 C--N 1.321 -0.641 0 CA-C-N 115.719 -0.673 . . . . 0.0 109.251 175.22 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 16.2 Cg_endo -58.54 -22.15 58.27 Favored 'Trans proline' 0 N--CA 1.475 0.435 0 C-N-CA 123.281 2.654 . . . . 0.0 113.212 -178.562 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.528 HG12 HD12 ' A' ' 36' ' ' ILE . 16.1 m -114.72 121.0 65.93 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.356 179.846 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 49.0 mt-10 -99.29 118.33 35.73 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.782 -177.686 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . 0.428 ' HB2' HG23 ' A' ' 59' ' ' VAL . . . -63.84 125.06 23.16 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.674 -0.694 . . . . 0.0 111.028 179.934 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 112.45 -4.44 26.48 Favored Glycine 0 N--CA 1.449 -0.44 0 C-N-CA 120.891 -0.671 . . . . 0.0 111.814 -177.852 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 97.1 mttt -118.59 158.52 25.28 Favored 'General case' 0 C--N 1.324 -0.542 0 N-CA-C 110.289 -0.263 . . . . 0.0 110.289 178.997 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . 0.506 ' HA ' ' O ' ' A' ' 54' ' ' VAL . 0.0 OUTLIER -120.61 130.7 54.28 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-O 121.606 0.717 . . . . 0.0 111.29 179.878 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 45.8 m-85 -122.66 149.63 43.77 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.257 -0.883 . . . . 0.0 110.179 -174.912 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 2.3 mp0 -84.8 119.13 24.96 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 121.138 0.494 . . . . 0.0 109.693 173.857 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 36.0 m -130.43 165.04 31.74 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.879 0 CA-C-N 115.599 -0.728 . . . . 0.0 110.865 -175.097 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 11.7 m -108.35 149.64 28.42 Favored 'General case' 0 C--N 1.316 -0.87 0 CA-C-N 115.999 -0.546 . . . . 0.0 109.935 175.911 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.621 HG13 ' HB1' ' A' ' 46' ' ' ALA . 36.0 mm -110.67 61.6 0.16 Allowed 'Isoleucine or valine' 0 CA--C 1.509 -0.609 0 N-CA-C 107.652 -1.24 . . . . 0.0 107.652 -176.995 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 31.4 tt0 -62.57 -24.79 67.73 Favored 'General case' 0 C--N 1.311 -1.084 0 CA-C-N 113.062 -1.881 . . . . 0.0 111.207 -179.583 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.566 ' HB2' ' HB ' ' A' ' 33' ' ' ILE . 15.3 m-20 -124.33 149.15 46.91 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.33 -0.396 . . . . 0.0 111.18 -175.213 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' MET . . . . . . . . . . . . . 96.0 mmm -123.19 147.85 46.42 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.092 -0.504 . . . . 0.0 109.932 173.975 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -96.46 173.42 29.86 Favored Glycine 0 N--CA 1.448 -0.544 0 C-N-CA 121.091 -0.576 . . . . 0.0 112.792 -178.02 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 61.4 mttm -75.99 18.29 0.28 Allowed 'General case' 0 N--CA 1.465 0.303 0 N-CA-C 112.484 0.55 . . . . 0.0 112.484 -175.281 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -144.1 28.24 1.98 Allowed Glycine 0 C--N 1.312 -0.754 0 C-N-CA 120.872 -0.68 . . . . 0.0 112.488 -178.898 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 68.47 20.12 73.34 Favored Glycine 0 CA--C 1.518 0.277 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.6 -179.276 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . 0.419 ' OD1' ' HA ' ' A' ' 44' ' ' PRO . 27.5 t70 -97.13 144.53 26.89 Favored 'General case' 0 C--N 1.32 -0.694 0 N-CA-C 109.56 -0.533 . . . . 0.0 109.56 -179.413 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -98.66 132.53 10.97 Favored Glycine 0 N--CA 1.447 -0.615 0 C-N-CA 120.602 -0.808 . . . . 0.0 111.897 -177.293 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.566 ' HB ' ' HB2' ' A' ' 25' ' ' ASP . 1.9 mp -101.83 104.1 15.9 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.737 0 CA-C-O 121.492 0.663 . . . . 0.0 110.625 -178.248 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -84.17 157.19 21.75 Favored 'General case' 0 C--N 1.317 -0.809 0 CA-C-N 115.406 -0.816 . . . . 0.0 109.167 169.036 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' ARG . . . . . 0.403 HH11 ' HD2' ' A' ' 35' ' ' ARG . 6.0 ttm180 -142.18 107.87 5.11 Favored 'General case' 0 C--N 1.313 -0.982 0 C-N-CA 120.644 -0.422 . . . . 0.0 110.819 -176.769 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.528 HD12 HG12 ' A' ' 13' ' ' VAL . 37.2 mt -99.43 108.68 22.96 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 CA-C-N 115.733 -0.667 . . . . 0.0 110.11 178.093 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 58.2 16.46 3.95 Favored 'General case' 0 N--CA 1.468 0.473 0 CA-C-N 115.26 -0.882 . . . . 0.0 112.079 -176.539 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 110.28 -16.99 29.36 Favored Glycine 0 N--CA 1.449 -0.447 0 C-N-CA 120.856 -0.688 . . . . 0.0 111.764 -178.057 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 34.0 t80 -71.68 117.59 13.44 Favored 'General case' 0 C--N 1.328 -0.362 0 N-CA-C 109.576 -0.527 . . . . 0.0 109.576 179.334 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.448 HG13 HG23 ' A' ' 33' ' ' ILE . 29.1 t -70.61 117.59 13.9 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 CA-C-N 115.824 -0.625 . . . . 0.0 111.301 -178.43 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 49.1 t -119.34 108.39 23.65 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 CA-C-N 115.481 -0.781 . . . . 0.0 109.594 -179.812 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 93.7 m-85 -78.58 129.55 34.92 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.086 -175.411 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 5.6 t -125.73 105.57 26.65 Favored Pre-proline 0 C--N 1.321 -0.659 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.246 -177.948 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . 0.419 ' HA ' ' OD1' ' A' ' 31' ' ' ASP . 34.9 Cg_endo -65.75 -8.26 19.01 Favored 'Trans proline' 0 N--CA 1.477 0.538 0 C-N-CA 123.537 2.825 . . . . 0.0 114.476 -172.561 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 1.2 p30 -142.54 20.35 2.03 Favored 'General case' 0 C--N 1.321 -0.65 0 N-CA-C 112.264 0.468 . . . . 0.0 112.264 -167.603 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.621 ' HB1' HG13 ' A' ' 23' ' ' ILE . . . -97.18 155.89 16.64 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.082 176.126 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 48.9 mt-10 -106.38 144.9 32.39 Favored 'General case' 0 N--CA 1.451 -0.421 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.093 178.54 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 60.8 tttm -66.2 137.36 56.93 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.457 -0.338 . . . . 0.0 111.352 -175.676 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 82.86 -2.24 86.84 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 121.017 -0.611 . . . . 0.0 113.121 175.943 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 29.7 m -93.56 152.08 19.27 Favored 'General case' 0 C--N 1.324 -0.538 0 O-C-N 122.654 -0.321 . . . . 0.0 111.085 -179.529 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 46.6 t -98.46 101.65 12.42 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 N-CA-C 108.456 -0.942 . . . . 0.0 108.456 172.897 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.571 HD11 ' HB2' ' A' ' 68' ' ' ARG . 0.8 OUTLIER -115.2 145.23 21.22 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.851 0 CA-C-N 115.789 -0.641 . . . . 0.0 112.018 -170.281 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 58.1 t30 -88.3 112.86 23.31 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 114.923 -1.035 . . . . 0.0 109.005 176.306 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . 0.555 ' HB ' ' HB1' ' A' ' 66' ' ' ALA . 35.2 m -115.01 134.56 57.69 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.724 0 CA-C-O 121.115 0.483 . . . . 0.0 111.609 -175.259 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 2.3 ttmp? -93.42 111.06 22.63 Favored 'General case' 0 C--N 1.32 -0.709 0 N-CA-C 109.124 -0.695 . . . . 0.0 109.124 175.52 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.467 HG21 ' HB ' ' A' ' 13' ' ' VAL . 87.6 t -67.88 113.08 3.41 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 N-CA-C 109.189 -0.671 . . . . 0.0 109.189 177.693 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.7 p -109.36 -26.02 10.24 Favored 'General case' 0 C--N 1.324 -0.53 0 N-CA-C 112.455 0.539 . . . . 0.0 112.455 -173.104 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . 0.434 ' HB3' ' HB2' ' A' ' 65' ' ' PHE . . . -143.38 92.17 2.34 Favored 'General case' 0 C--N 1.325 -0.476 0 C-N-CA 120.679 -0.408 . . . . 0.0 111.738 -175.301 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.513 HG11 HG11 ' A' ' 11' ' ' VAL . 15.6 t -79.9 125.89 39.07 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.735 0 CA-C-N 116.109 -0.496 . . . . 0.0 109.781 174.079 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 46.0 mmtm -106.01 -164.17 0.99 Allowed 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.439 -179.559 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . 0.41 ' OE1' ' HE3' ' A' ' 62' ' ' LYS . 40.8 tt0 -66.03 -48.84 69.77 Favored 'General case' 0 CA--C 1.533 0.297 0 N-CA-C 112.623 0.601 . . . . 0.0 112.623 -175.3 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . 0.41 ' HE3' ' OE1' ' A' ' 61' ' ' GLU . 93.1 mttt -120.6 3.89 10.66 Favored 'General case' 0 C--N 1.328 -0.332 0 N-CA-C 111.934 0.346 . . . . 0.0 111.934 -172.982 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 15.1 p90 -166.6 169.01 14.06 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 116.42 -0.355 . . . . 0.0 110.21 -174.273 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -129.42 158.76 38.26 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-O 120.878 0.37 . . . . 0.0 111.095 -179.95 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . 0.434 ' HB2' ' HB3' ' A' ' 58' ' ' ALA . 95.3 m-85 -114.47 136.14 53.34 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.579 -0.737 . . . . 0.0 109.824 176.827 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' ALA . . . . . 0.555 ' HB1' ' HB ' ' A' ' 54' ' ' VAL . . . -127.35 -179.3 4.82 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.571 -179.155 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' GLU . . . . . 0.43 ' O ' ' HA ' ' A' ' 54' ' ' VAL . 8.1 pt-20 -141.67 143.82 33.79 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 120.861 0.362 . . . . 0.0 111.212 178.85 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.571 ' HB2' HD11 ' A' ' 52' ' ' ILE . 31.2 ttt180 -67.73 106.16 2.15 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.405 -0.816 . . . . 0.0 111.707 178.185 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 2.6 t -83.54 21.66 0.19 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.361 0 CA-C-O 121.501 0.667 . . . . 0.0 110.405 175.286 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.551 HD11 ' HA ' ' A' ' 52' ' ' ILE . 64.2 mt . . . . . 0 C--O 1.249 1.074 0 CA-C-O 118.351 -0.833 . . . . 0.0 110.064 -179.255 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.479 1.015 0 CA-C-O 120.616 0.246 . . . . 0.0 110.573 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -106.68 -80.86 0.56 Allowed 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.529 -179.96 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . 0.602 ' HA ' ' HD2' ' A' ' 6' ' ' PRO . 34.6 m-85 -124.1 -174.11 2.92 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 120.951 0.405 . . . . 0.0 111.49 -173.004 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 123.39 -24.68 6.48 Favored Glycine 0 N--CA 1.451 -0.358 0 N-CA-C 109.807 -1.317 . . . . 0.0 109.807 -171.579 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.541 ' HB2' ' HD3' ' A' ' 6' ' ' PRO . 32.4 mmmt -121.94 -47.18 0.04 OUTLIER Pre-proline 0 C--N 1.325 -0.49 0 CA-C-N 114.201 -1.0 . . . . 0.0 110.274 172.802 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.602 ' HD2' ' HA ' ' A' ' 3' ' ' PHE . 6.7 Cg_endo -92.84 164.98 2.68 Favored 'Trans proline' 0 C--N 1.355 0.88 0 C-N-CA 122.649 2.233 . . . . 0.0 111.923 174.46 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . 62.68 14.28 7.07 Favored 'General case' 0 N--CA 1.47 0.553 0 C-N-CA 123.446 0.698 . . . . 0.0 112.677 175.956 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' MET . . . . . . . . . . . . . 23.6 ttt -100.13 32.83 2.82 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 121.573 0.701 . . . . 0.0 109.907 -179.821 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . 0.438 ' HD3' ' H ' ' A' ' 9' ' ' LYS . 0.0 OUTLIER -107.67 27.77 8.84 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.604 179.56 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 20.3 p-10 -79.25 53.98 1.59 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.449 178.289 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.526 HG11 HG11 ' A' ' 59' ' ' VAL . 69.6 t -159.28 124.79 2.3 Favored Pre-proline 0 C--N 1.328 -0.352 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 -172.713 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 10.9 Cg_endo -55.11 -31.49 75.51 Favored 'Trans proline' 0 C--N 1.345 0.393 0 C-N-CA 123.518 2.812 . . . . 0.0 113.125 -176.625 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.504 ' HB ' HG21 ' A' ' 56' ' ' VAL . 15.6 m -103.64 126.8 58.09 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-N 116.09 -0.504 . . . . 0.0 111.214 -178.311 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . 0.423 ' CB ' ' HD3' ' A' ' 17' ' ' LYS . 37.6 mt-10 -101.06 123.96 46.05 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.058 176.398 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . 0.483 ' HA ' ' O ' ' A' ' 56' ' ' VAL . . . -60.94 110.16 1.27 Allowed 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.355 177.227 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 123.64 -18.76 7.6 Favored Glycine 0 N--CA 1.447 -0.613 0 C-N-CA 121.029 -0.605 . . . . 0.0 112.436 -178.29 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . 0.423 ' HD3' ' CB ' ' A' ' 14' ' ' GLU . 2.4 mptm? -94.1 162.97 13.66 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.935 0.398 . . . . 0.0 111.393 -179.99 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . 0.563 ' HG2' ' HB2' ' A' ' 55' ' ' LYS . 31.4 mt-10 -118.84 128.41 54.43 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.538 -0.755 . . . . 0.0 110.036 179.611 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' TYR . . . . . 0.421 ' O ' HG22 ' A' ' 54' ' ' VAL . 62.0 m-85 -127.87 127.17 42.94 Favored 'General case' 0 C--N 1.322 -0.627 0 N-CA-C 110.065 -0.346 . . . . 0.0 110.065 179.412 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . 0.628 ' HA ' ' HA ' ' A' ' 53' ' ' ASN . 34.8 tt0 -78.24 119.12 21.16 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 121.149 0.5 . . . . 0.0 109.764 177.03 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 23.3 m -129.82 162.81 36.77 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-N 115.499 -0.773 . . . . 0.0 111.702 -170.116 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 9.7 m -97.33 149.12 22.44 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.021 177.215 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.493 ' CD1' ' HB2' ' A' ' 34' ' ' ALA . 24.0 mm -121.33 65.94 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 108.572 -0.899 . . . . 0.0 108.572 -175.546 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 35.5 tt0 -86.98 -5.34 59.12 Favored 'General case' 0 C--N 1.31 -1.116 0 CA-C-N 114.445 -1.252 . . . . 0.0 110.465 -178.209 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.543 ' HB2' ' HB ' ' A' ' 33' ' ' ILE . 25.1 m-20 -118.59 134.42 55.11 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 115.526 -0.761 . . . . 0.0 109.396 -178.874 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' MET . . . . . . . . . . . . . 98.1 mmm -124.82 147.03 48.95 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-O 120.697 0.284 . . . . 0.0 110.91 -179.842 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -87.64 -50.92 3.4 Favored Glycine 0 N--CA 1.445 -0.757 0 N-CA-C 110.71 -0.956 . . . . 0.0 110.71 175.667 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 51.5 tptt -164.76 -79.27 0.03 OUTLIER 'General case' 0 CA--C 1.514 -0.431 0 CA-C-O 121.243 0.544 . . . . 0.0 111.411 173.439 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -124.85 73.42 0.42 Allowed Glycine 0 C--N 1.306 -1.118 0 CA-C-N 115.338 -0.846 . . . . 0.0 113.588 -171.906 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 107.0 -29.9 10.1 Favored Glycine 0 CA--C 1.507 -0.449 0 C-N-CA 120.906 -0.664 . . . . 0.0 111.586 174.783 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 4.4 p-10 -73.54 105.62 4.97 Favored 'General case' 0 C--N 1.317 -0.814 0 N-CA-C 109.203 -0.666 . . . . 0.0 109.203 173.394 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -109.38 160.87 13.28 Favored Glycine 0 N--CA 1.443 -0.863 0 CA-C-N 115.526 -0.761 . . . . 0.0 112.588 -175.347 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.546 HG23 HG13 ' A' ' 40' ' ' VAL . 2.5 mp -114.1 110.08 30.81 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.836 0 N-CA-C 109.962 -0.385 . . . . 0.0 109.962 -179.973 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . 0.493 ' HB2' ' CD1' ' A' ' 23' ' ' ILE . . . -94.03 155.17 17.26 Favored 'General case' 0 C--N 1.318 -0.761 0 CA-C-O 121.732 0.777 . . . . 0.0 111.098 173.868 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 29.1 mmt180 -121.4 103.11 8.71 Favored 'General case' 0 N--CA 1.437 -1.114 0 CA-C-N 114.552 -1.204 . . . . 0.0 110.629 -172.52 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.413 HD12 ' CG1' ' A' ' 13' ' ' VAL . 26.1 mt -100.61 101.4 12.04 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.601 0 CA-C-O 121.1 0.476 . . . . 0.0 109.917 175.623 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 33.2 t70 67.06 -4.14 0.86 Allowed 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 114.669 -1.151 . . . . 0.0 111.006 -173.522 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 122.61 -19.28 8.01 Favored Glycine 0 N--CA 1.446 -0.673 0 N-CA-C 110.845 -0.902 . . . . 0.0 110.845 -172.207 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 51.7 t80 -65.84 126.08 27.38 Favored 'General case' 0 C--O 1.237 0.399 0 N-CA-C 109.126 -0.694 . . . . 0.0 109.126 176.702 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.546 HG13 HG23 ' A' ' 33' ' ' ILE . 39.9 t -76.77 113.45 15.84 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.757 0 CA-C-N 115.78 -0.646 . . . . 0.0 111.292 -175.344 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 68.0 t -109.31 111.65 37.03 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 CA-C-N 115.48 -0.782 . . . . 0.0 109.885 177.347 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 60.6 m-85 -77.95 120.12 22.37 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.376 -179.625 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.533 ' HB ' ' HB2' ' A' ' 46' ' ' ALA . 8.7 t -120.81 104.56 41.83 Favored Pre-proline 0 C--N 1.319 -0.725 0 CA-C-N 115.587 -0.733 . . . . 0.0 110.398 -177.304 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -77.32 16.84 0.96 Allowed 'Trans proline' 0 CA--C 1.53 0.324 0 C-N-CA 123.379 2.719 . . . . 0.0 113.584 -174.187 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -152.04 21.43 0.67 Allowed 'General case' 0 C--N 1.321 -0.65 0 CA-C-O 121.523 0.678 . . . . 0.0 110.266 -178.042 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.533 ' HB2' ' HB ' ' A' ' 43' ' ' VAL . . . -78.63 168.86 19.14 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 115.224 -0.898 . . . . 0.0 111.488 177.923 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . 0.466 ' O ' ' HB ' ' A' ' 23' ' ' ILE . 0.0 OUTLIER -126.16 134.76 51.2 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.549 -0.75 . . . . 0.0 109.594 178.21 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 1.8 tmtp? -63.37 120.84 12.39 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.891 -176.15 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 81.96 5.91 89.36 Favored Glycine 0 N--CA 1.45 -0.412 0 CA-C-N 115.776 -0.647 . . . . 0.0 112.821 177.097 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 20.0 t -101.78 163.34 12.3 Favored 'General case' 0 C--N 1.324 -0.538 0 N-CA-C 110.123 -0.325 . . . . 0.0 110.123 -178.478 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.52 HG12 ' HG2' ' A' ' 20' ' ' GLU . 32.2 t -114.35 101.46 12.46 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.463 0 N-CA-C 109.106 -0.702 . . . . 0.0 109.106 179.269 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.591 HD12 ' HB2' ' A' ' 68' ' ' ARG . 6.4 pt -108.58 145.47 15.5 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-O 121.054 0.454 . . . . 0.0 110.934 -173.131 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . 0.628 ' HA ' ' HA ' ' A' ' 20' ' ' GLU . 39.6 t30 -82.55 115.81 21.69 Favored 'General case' 0 C--N 1.318 -0.765 0 N-CA-C 109.328 -0.619 . . . . 0.0 109.328 172.157 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . 0.54 HG13 HG13 ' A' ' 52' ' ' ILE . 28.8 m -107.97 130.81 59.81 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-O 121.358 0.599 . . . . 0.0 111.816 -177.198 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . 0.563 ' HB2' ' HG2' ' A' ' 18' ' ' GLU . 39.8 ttmt -97.98 106.65 18.98 Favored 'General case' 0 C--N 1.318 -0.772 0 N-CA-C 108.959 -0.756 . . . . 0.0 108.959 172.304 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.504 HG21 ' HB ' ' A' ' 13' ' ' VAL . 47.1 t -68.12 112.88 3.44 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.079 179.559 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 21.0 p -109.41 -17.94 13.67 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 112.071 0.397 . . . . 0.0 112.071 -174.86 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -143.58 92.58 2.37 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.063 0.458 . . . . 0.0 110.984 -177.607 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.526 HG11 HG11 ' A' ' 11' ' ' VAL . 13.4 t -85.24 129.61 37.55 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.638 0 CA-C-N 115.854 -0.612 . . . . 0.0 109.913 175.868 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 74.8 mmtt -106.76 -173.07 2.21 Favored 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 109.979 -0.378 . . . . 0.0 109.979 178.437 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -72.42 -41.22 66.45 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.35 -0.386 . . . . 0.0 111.859 179.648 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 56.3 mttp -92.13 -45.3 8.35 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 121.036 0.446 . . . . 0.0 111.295 -178.269 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 10.4 p90 -142.84 -171.3 3.42 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.969 -0.559 . . . . 0.0 110.492 -172.538 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -138.91 158.51 44.07 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-O 120.814 0.34 . . . . 0.0 111.113 -179.462 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 93.2 m-85 -113.85 138.72 49.91 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.694 -0.684 . . . . 0.0 109.43 175.492 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' ALA . . . . . 0.524 ' HB1' ' HB ' ' A' ' 54' ' ' VAL . . . -142.6 159.14 42.82 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 116.553 -0.294 . . . . 0.0 110.906 -178.668 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' GLU . . . . . 0.411 ' O ' ' HA ' ' A' ' 54' ' ' VAL . 10.8 pt-20 -113.72 137.75 51.19 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 121.303 0.573 . . . . 0.0 111.254 179.142 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.591 ' HB2' HD12 ' A' ' 52' ' ' ILE . 25.0 ttt180 -66.41 109.86 2.89 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 115.237 -0.892 . . . . 0.0 109.98 172.458 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 2.8 t -81.92 25.13 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.536 0.41 0 CA-C-O 121.526 0.679 . . . . 0.0 111.867 -174.767 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.463 ' CD2' ' HG3' ' A' ' 68' ' ' ARG . 0.8 OUTLIER . . . . . 0 C--O 1.245 0.838 0 CA-C-O 118.759 -0.639 . . . . 0.0 110.329 179.218 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 25.4 ttt . . . . . 0 N--CA 1.478 0.93 0 CA-C-O 120.705 0.288 . . . . 0.0 110.624 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -146.04 -168.06 2.89 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.902 0.382 . . . . 0.0 110.985 -179.51 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 17.6 p90 -84.13 50.75 1.91 Allowed 'General case' 0 C--N 1.324 -0.505 0 CA-C-O 121.467 0.651 . . . . 0.0 110.754 -179.441 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 97.65 -64.47 0.9 Allowed Glycine 0 N--CA 1.446 -0.687 0 CA-C-N 115.752 -0.658 . . . . 0.0 111.711 -178.56 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 64.0 tttp -124.16 116.82 27.08 Favored Pre-proline 0 C--N 1.321 -0.653 0 N-CA-C 110.026 -0.361 . . . . 0.0 110.026 179.164 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.432 ' HD2' ' OD1' ' A' ' 10' ' ' ASN . 18.9 Cg_endo -90.34 -162.55 0.12 Allowed 'Trans proline' 0 N--CA 1.453 -0.905 0 C-N-CA 122.987 2.458 . . . . 0.0 112.717 178.533 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -98.26 -144.1 0.31 Allowed 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.322 -0.854 . . . . 0.0 110.71 -178.656 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' MET . . . . . . . . . . . . . 60.5 mtt 69.65 18.98 7.49 Favored 'General case' 0 N--CA 1.468 0.433 0 C-N-CA 122.838 0.455 . . . . 0.0 111.028 177.564 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . 0.439 ' C ' ' H ' ' A' ' 11' ' ' VAL . 12.5 mmmm 54.5 85.23 0.06 Allowed 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.328 -0.851 . . . . 0.0 112.028 -177.782 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . 0.432 ' OD1' ' HD2' ' A' ' 6' ' ' PRO . 5.8 m120 -81.55 40.84 0.6 Allowed 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 121.543 0.687 . . . . 0.0 109.175 171.158 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.439 ' H ' ' C ' ' A' ' 9' ' ' LYS . 47.2 t -160.58 106.25 1.33 Allowed Pre-proline 0 C--N 1.327 -0.397 0 N-CA-C 107.276 -1.379 . . . . 0.0 107.276 -174.587 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -68.08 -31.44 30.04 Favored 'Trans proline' 0 CA--C 1.516 -0.403 0 C-N-CA 123.218 2.612 . . . . 0.0 112.507 -173.625 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.604 HG12 HD12 ' A' ' 36' ' ' ILE . 16.1 m -80.5 163.03 3.53 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.896 0 CA-C-N 115.175 -0.921 . . . . 0.0 110.906 -177.989 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 9.8 tp10 -147.14 119.72 8.53 Favored 'General case' 0 C--N 1.322 -0.588 0 N-CA-C 108.918 -0.771 . . . . 0.0 108.918 178.471 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . 0.456 ' HA ' ' O ' ' A' ' 56' ' ' VAL . . . -58.91 117.55 4.78 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-O 121.111 0.482 . . . . 0.0 111.377 -177.207 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 119.09 -24.84 8.1 Favored Glycine 0 N--CA 1.447 -0.625 0 CA-C-N 115.653 -0.703 . . . . 0.0 112.218 -179.246 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . 0.408 ' HE2' ' HB3' ' A' ' 17' ' ' LYS . 53.1 mtpt -90.55 156.37 18.21 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.871 0.367 . . . . 0.0 110.734 179.077 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . 0.484 ' HA ' ' O ' ' A' ' 54' ' ' VAL . 46.0 mt-10 -113.96 128.34 56.35 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.824 -0.625 . . . . 0.0 109.858 -179.864 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 81.5 m-85 -122.58 143.42 49.75 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 121.173 0.511 . . . . 0.0 111.583 -175.887 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 32.7 tt0 -82.98 111.06 18.49 Favored 'General case' 0 C--N 1.317 -0.808 0 CA-C-N 115.548 -0.751 . . . . 0.0 109.475 175.069 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.486 ' HB ' ' HB1' ' A' ' 34' ' ' ALA . 32.7 m -121.81 151.32 25.28 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-O 121.053 0.454 . . . . 0.0 112.023 -172.714 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 17.0 m -97.62 152.44 19.06 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.658 -0.701 . . . . 0.0 109.721 176.474 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.491 HD13 ' HB2' ' A' ' 34' ' ' ALA . 18.9 mm -121.89 64.5 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-O 121.791 0.805 . . . . 0.0 108.908 -174.423 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 26.1 mm-40 -69.02 -19.15 64.11 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-N 114.782 -1.099 . . . . 0.0 111.835 -179.663 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.56 ' HB2' ' HB ' ' A' ' 33' ' ' ILE . 5.6 m-20 -126.34 138.7 53.6 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 116.392 -0.367 . . . . 0.0 111.277 -176.093 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' MET . . . . . . . . . . . . . 92.9 mmm -120.28 142.09 49.39 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 115.814 -0.63 . . . . 0.0 109.917 175.655 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -81.19 -67.07 1.56 Allowed Glycine 0 N--CA 1.444 -0.773 0 N-CA-C 111.559 -0.616 . . . . 0.0 111.559 179.537 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 37.2 ttmt -170.2 78.57 0.09 Allowed 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 121.972 0.891 . . . . 0.0 110.571 178.591 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 82.54 -64.85 4.21 Favored Glycine 0 C--N 1.304 -1.205 0 CA-C-N 114.194 -1.366 . . . . 0.0 113.304 173.741 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -111.47 38.19 3.38 Favored Glycine 0 C--N 1.321 -0.294 0 C-N-CA 120.896 -0.669 . . . . 0.0 112.642 -173.96 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 30.3 t70 -156.64 117.84 3.77 Favored 'General case' 0 C--N 1.319 -0.74 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 179.069 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . 0.55 ' HA3' ' HB3' ' A' ' 46' ' ' ALA . . . -114.42 141.71 17.15 Favored Glycine 0 N--CA 1.441 -1.022 0 N-CA-C 111.178 -0.769 . . . . 0.0 111.178 177.994 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.56 ' HB ' ' HB2' ' A' ' 25' ' ' ASP . 2.6 mp -97.93 98.19 7.03 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.767 0 CA-C-O 121.329 0.585 . . . . 0.0 110.276 -178.09 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . 0.491 ' HB2' HD13 ' A' ' 23' ' ' ILE . . . -99.85 123.01 43.65 Favored 'General case' 0 CA--C 1.497 -1.065 0 CA-C-N 115.747 -0.661 . . . . 0.0 109.398 171.706 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' ARG . . . . . 0.525 ' HA ' ' O ' ' A' ' 39' ' ' PHE . 0.0 OUTLIER -118.56 108.66 15.23 Favored 'General case' 0 C--N 1.303 -1.453 0 CA-C-N 115.6 -0.727 . . . . 0.0 111.363 -174.11 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.604 HD12 HG12 ' A' ' 13' ' ' VAL . 53.1 mt -84.43 112.62 21.9 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.702 0 CA-C-N 115.208 -0.905 . . . . 0.0 109.604 177.649 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 36.7 t70 60.43 19.07 8.76 Favored 'General case' 0 CA--C 1.539 0.523 0 CA-C-N 115.495 -0.775 . . . . 0.0 110.702 -175.451 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 100.78 -9.26 58.41 Favored Glycine 0 C--N 1.329 0.189 0 C-N-CA 120.583 -0.818 . . . . 0.0 112.143 -178.794 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . 0.525 ' O ' ' HA ' ' A' ' 35' ' ' ARG . 60.8 t80 -77.43 114.76 16.59 Favored 'General case' 0 C--N 1.323 -0.576 0 N-CA-C 109.708 -0.479 . . . . 0.0 109.708 178.779 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.521 HG13 HG23 ' A' ' 33' ' ' ILE . 21.5 t -68.98 110.09 2.3 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 CA-C-O 121.6 0.714 . . . . 0.0 111.968 -175.347 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 17.6 t -108.26 110.42 31.91 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.824 0 CA-C-N 115.092 -0.958 . . . . 0.0 108.896 175.503 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 65.9 m-85 -74.3 134.7 42.57 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-O 121.126 0.489 . . . . 0.0 111.284 -176.653 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.695 HG11 HD11 ' A' ' 52' ' ' ILE . 8.1 t -131.56 113.93 15.55 Favored Pre-proline 0 N--CA 1.449 -0.524 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.794 -174.943 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 59.8 Cg_endo -74.71 -9.41 21.17 Favored 'Trans proline' 0 CA--C 1.531 0.359 0 C-N-CA 122.692 2.262 . . . . 0.0 113.681 -176.943 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' ASN . . . . . 0.564 ' HB2' ' HB3' ' A' ' 68' ' ' ARG . 12.5 m120 -124.64 9.78 8.37 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.008 0.432 . . . . 0.0 111.34 -175.163 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.55 ' HB3' ' HA3' ' A' ' 32' ' ' GLY . . . -71.43 150.63 44.76 Favored 'General case' 0 C--N 1.319 -0.755 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.878 -179.542 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 48.8 mt-10 -123.6 141.77 51.68 Favored 'General case' 0 N--CA 1.448 -0.567 0 CA-C-N 115.669 -0.696 . . . . 0.0 109.972 178.335 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 33.1 ttpt -55.19 129.52 38.54 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.8 -176.818 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 67.08 22.46 72.47 Favored Glycine 0 C--N 1.33 0.218 0 CA-C-N 115.947 -0.57 . . . . 0.0 112.902 174.327 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 18.4 m -113.78 158.89 20.38 Favored 'General case' 0 C--N 1.319 -0.731 0 O-C-N 122.609 -0.348 . . . . 0.0 110.179 179.651 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 51.1 t -118.39 99.87 8.86 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 N-CA-C 109.444 -0.576 . . . . 0.0 109.444 -178.69 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.695 HD11 HG11 ' A' ' 43' ' ' VAL . 0.5 OUTLIER -110.0 152.98 11.89 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.695 0 CA-C-N 116.044 -0.525 . . . . 0.0 109.861 -174.831 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . 0.54 HD22 ' HB ' ' A' ' 69' ' ' VAL . 12.4 t30 -92.56 120.5 33.08 Favored 'General case' 0 C--N 1.317 -0.826 0 N-CA-C 108.926 -0.768 . . . . 0.0 108.926 178.018 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . 0.666 ' HB ' ' HB1' ' A' ' 66' ' ' ALA . 34.9 m -114.67 139.83 38.74 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 N-CA-C 112.405 0.52 . . . . 0.0 112.405 -174.561 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . 0.434 ' HB2' ' HG2' ' A' ' 18' ' ' GLU . 3.2 ttmp? -98.54 109.21 22.0 Favored 'General case' 0 C--N 1.319 -0.758 0 N-CA-C 109.026 -0.731 . . . . 0.0 109.026 171.339 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.456 ' O ' ' HA ' ' A' ' 15' ' ' ALA . 90.7 t -69.39 113.16 4.82 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 178.554 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 17.5 p -101.97 -28.92 12.1 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 116.216 -0.447 . . . . 0.0 112.009 -175.096 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -140.58 94.09 2.69 Favored 'General case' 0 N--CA 1.452 -0.365 0 CA-C-O 121.121 0.486 . . . . 0.0 111.343 -173.536 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 39.5 t -81.34 133.08 30.05 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.833 0 CA-C-N 115.595 -0.73 . . . . 0.0 109.865 174.426 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 72.9 mmtt -112.82 -164.74 0.94 Allowed 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.397 -0.365 . . . . 0.0 110.368 178.555 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 8.9 mm-40 -67.56 -47.21 70.49 Favored 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 112.17 0.433 . . . . 0.0 112.17 -171.873 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 66.6 mttm -124.1 -2.45 8.15 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-O 120.625 0.25 . . . . 0.0 111.636 -176.574 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 9.9 p90 -153.73 174.73 14.14 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 116.26 -0.427 . . . . 0.0 109.871 -174.45 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -142.22 166.76 23.8 Favored 'General case' 0 C--N 1.322 -0.59 0 C-N-CA 120.876 -0.33 . . . . 0.0 111.465 -179.177 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 89.4 m-85 -117.14 131.86 56.79 Favored 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 175.033 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' ALA . . . . . 0.666 ' HB1' ' HB ' ' A' ' 54' ' ' VAL . . . -124.68 155.58 38.99 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-O 121.463 0.649 . . . . 0.0 112.433 -175.926 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 10.8 tt0 -104.71 120.28 40.98 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 114.946 -1.024 . . . . 0.0 110.324 178.557 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.564 ' HB3' ' HB2' ' A' ' 45' ' ' ASN . 41.0 ttt180 -66.19 107.71 2.04 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 121.624 0.726 . . . . 0.0 111.18 174.573 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.566 ' O ' ' HB3' ' A' ' 70' ' ' LEU . 2.6 t -80.57 -177.52 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.759 0 N-CA-C 106.241 -1.762 . . . . 0.0 106.241 167.005 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.578 HD23 ' OXT' ' A' ' 70' ' ' LEU . 0.0 OUTLIER . . . . . 0 C--O 1.247 0.935 0 CA-C-O 118.257 -0.878 . . . . 0.0 110.85 179.614 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 85.5 mtp . . . . . 0 N--CA 1.482 1.14 0 CA-C-O 120.888 0.375 . . . . 0.0 110.393 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -90.18 162.09 15.42 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.318 -0.401 . . . . 0.0 109.974 178.811 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 77.4 t80 -155.64 -37.63 0.09 Allowed 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 121.017 0.437 . . . . 0.0 110.814 -177.411 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 124.5 -15.03 7.65 Favored Glycine 0 N--CA 1.449 -0.483 0 N-CA-C 110.669 -0.972 . . . . 0.0 110.669 -175.411 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.569 ' HB3' ' HD3' ' A' ' 6' ' ' PRO . 31.7 ttmt -71.09 -45.14 14.47 Favored Pre-proline 0 CA--C 1.537 0.472 0 CA-C-N 114.848 -0.676 . . . . 0.0 111.063 176.15 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.569 ' HD3' ' HB3' ' A' ' 5' ' ' LYS . 6.4 Cg_exo -78.21 171.32 17.22 Favored 'Trans proline' 0 C--N 1.353 0.786 0 C-N-CA 122.26 1.973 . . . . 0.0 111.199 171.297 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . 65.69 -177.09 0.18 Allowed 'General case' 0 N--CA 1.467 0.4 0 O-C-N 123.627 0.579 . . . . 0.0 110.572 -174.19 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' MET . . . . . . . . . . . . . 15.7 tpt 56.55 52.51 9.71 Favored 'General case' 0 N--CA 1.465 0.31 0 CA-C-O 121.439 0.638 . . . . 0.0 109.823 -178.175 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . 0.45 ' HB3' ' NZ ' ' A' ' 9' ' ' LYS . 3.0 mmmp? 64.67 8.39 4.43 Favored 'General case' 0 N--CA 1.471 0.615 0 CA-C-N 115.402 -0.817 . . . . 0.0 111.539 -177.876 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 15.7 t-20 61.39 13.02 4.68 Favored 'General case' 0 N--CA 1.468 0.469 0 CA-C-N 115.363 -0.835 . . . . 0.0 110.233 -176.523 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.408 HG12 ' H ' ' A' ' 13' ' ' VAL . 96.8 t -160.87 111.84 1.3 Allowed Pre-proline 0 C--N 1.326 -0.427 0 CA-C-N 114.755 -1.111 . . . . 0.0 108.423 -173.388 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 42.0 Cg_endo -68.5 -10.22 28.38 Favored 'Trans proline' 0 C--O 1.232 0.204 0 C-N-CA 122.92 2.414 . . . . 0.0 113.584 -174.34 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.468 HG12 HD12 ' A' ' 36' ' ' ILE . 13.9 m -119.97 120.72 63.99 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.819 0 CA-C-O 121.106 0.479 . . . . 0.0 111.017 -176.808 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 15.6 mm-40 -92.15 122.09 34.31 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.035 -177.678 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . 0.406 ' HA ' ' O ' ' A' ' 56' ' ' VAL . . . -67.09 96.74 0.47 Allowed 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.711 -0.677 . . . . 0.0 110.705 179.261 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 142.76 -30.15 2.07 Favored Glycine 0 N--CA 1.443 -0.887 0 C-N-CA 120.977 -0.63 . . . . 0.0 112.278 -178.298 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 8.8 mtpm? -95.7 168.79 10.45 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 121.64 0.733 . . . . 0.0 111.562 -179.478 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . 0.515 ' HB2' ' OD1' ' A' ' 53' ' ' ASN . 0.0 OUTLIER -115.5 149.63 37.82 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 114.557 -1.201 . . . . 0.0 110.621 -179.176 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 80.0 m-85 -137.67 141.21 41.12 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.259 178.125 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 8.1 tt0 -79.05 107.55 11.89 Favored 'General case' 0 C--N 1.325 -0.458 0 N-CA-C 109.408 -0.59 . . . . 0.0 109.408 174.356 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 35.2 m -118.08 164.13 14.64 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 CA-C-O 120.969 0.414 . . . . 0.0 110.756 -176.186 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 6.1 m -112.0 140.12 46.94 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-O 121.207 0.527 . . . . 0.0 110.202 177.833 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.57 HG13 ' HB1' ' A' ' 46' ' ' ALA . 30.7 mm -104.39 59.59 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.804 0 N-CA-C 108.188 -1.041 . . . . 0.0 108.188 -177.487 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 36.8 tt0 -65.69 -7.89 17.84 Favored 'General case' 0 C--N 1.315 -0.902 0 CA-C-N 113.724 -1.58 . . . . 0.0 110.873 -179.089 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.523 ' HB3' ' HB ' ' A' ' 33' ' ' ILE . 28.5 t70 -138.7 138.51 37.81 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 120.849 0.357 . . . . 0.0 110.86 -176.869 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -120.85 114.01 20.97 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.952 -0.567 . . . . 0.0 109.863 178.024 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -112.51 173.09 15.06 Favored Glycine 0 N--CA 1.446 -0.649 0 C-N-CA 120.981 -0.628 . . . . 0.0 111.848 -178.439 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.465 ' HD2' ' CB ' ' A' ' 31' ' ' ASP . 77.5 mttt 57.2 14.57 2.11 Favored 'General case' 0 N--CA 1.462 0.153 0 N-CA-C 112.894 0.702 . . . . 0.0 112.894 175.685 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 83.08 -16.92 25.66 Favored Glycine 0 C--N 1.317 -0.504 0 C-N-CA 121.172 -0.537 . . . . 0.0 113.527 -179.768 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -170.31 31.75 0.15 Allowed Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.111 -1.042 . . . . 0.0 113.173 -178.406 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . 0.487 ' OD1' ' HA ' ' A' ' 44' ' ' PRO . 24.2 t70 -120.65 132.01 54.89 Favored 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 108.908 -0.775 . . . . 0.0 108.908 178.459 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -88.06 129.22 9.45 Favored Glycine 0 N--CA 1.449 -0.476 0 C-N-CA 120.627 -0.797 . . . . 0.0 112.381 -176.461 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.523 ' HB ' ' HB3' ' A' ' 25' ' ' ASP . 1.8 mp -100.16 101.74 12.5 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.46 0 CA-C-O 121.403 0.621 . . . . 0.0 110.423 178.864 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -95.47 151.71 19.06 Favored 'General case' 0 C--N 1.321 -0.66 0 N-CA-C 108.71 -0.848 . . . . 0.0 108.71 167.328 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 11.9 ttp-105 -139.95 104.28 4.83 Favored 'General case' 0 C--N 1.319 -0.726 0 C-N-CA 120.15 -0.62 . . . . 0.0 110.431 -178.883 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.468 HD12 HG12 ' A' ' 13' ' ' VAL . 29.8 mt -86.95 103.5 13.24 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-N 115.594 -0.73 . . . . 0.0 110.765 -175.938 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 13.7 t70 61.41 12.54 4.4 Favored 'General case' 0 N--CA 1.469 0.49 0 CA-C-N 114.372 -1.286 . . . . 0.0 111.737 179.323 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 120.12 -17.61 9.83 Favored Glycine 0 N--CA 1.448 -0.514 0 C-N-CA 120.472 -0.871 . . . . 0.0 112.007 -177.482 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 56.6 t80 -82.58 118.89 23.62 Favored 'General case' 0 C--N 1.326 -0.425 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 178.473 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 19.4 t -73.63 116.75 16.43 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-O 121.205 0.526 . . . . 0.0 111.057 -175.695 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 47.9 t -112.09 107.16 22.27 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 CA-C-N 115.586 -0.734 . . . . 0.0 109.322 178.038 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 94.3 m-85 -77.92 128.29 33.7 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.156 -178.28 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.446 HG11 ' HB2' ' A' ' 46' ' ' ALA . 3.3 t -115.82 98.38 50.9 Favored Pre-proline 0 C--N 1.317 -0.822 0 CA-C-N 115.883 -0.599 . . . . 0.0 109.905 -177.946 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . 0.487 ' HA ' ' OD1' ' A' ' 31' ' ' ASP . 48.6 Cg_exo -59.51 -17.73 42.92 Favored 'Trans proline' 0 N--CA 1.476 0.451 0 C-N-CA 124.07 3.18 . . . . 0.0 114.277 -173.486 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -131.62 8.36 4.55 Favored 'General case' 0 C--N 1.317 -0.817 0 N-CA-C 112.707 0.632 . . . . 0.0 112.707 -167.8 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.57 ' HB1' HG13 ' A' ' 23' ' ' ILE . . . -81.93 159.74 23.54 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-O 120.705 0.288 . . . . 0.0 110.892 175.272 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 46.0 mt-10 -108.16 159.48 16.57 Favored 'General case' 0 N--CA 1.448 -0.575 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.505 178.724 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -65.12 123.34 19.25 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.624 -175.211 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 74.49 22.71 76.97 Favored Glycine 0 C--N 1.331 0.29 0 CA-C-N 115.79 -0.641 . . . . 0.0 113.476 175.003 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 68.8 p -96.86 153.51 17.84 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-O 121.089 0.471 . . . . 0.0 111.101 -178.578 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 59.2 t -99.37 106.81 19.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 N-CA-C 108.195 -1.039 . . . . 0.0 108.195 172.562 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.563 HD11 ' HA ' ' A' ' 68' ' ' ARG . 0.8 OUTLIER -128.45 145.81 34.89 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.761 0 CA-C-O 121.772 0.796 . . . . 0.0 112.591 -166.647 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . 0.515 ' OD1' ' HB2' ' A' ' 18' ' ' GLU . 49.3 t30 -94.29 111.2 22.92 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 114.598 -1.183 . . . . 0.0 108.759 175.384 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . 0.562 ' HB ' ' HB1' ' A' ' 66' ' ' ALA . 34.6 m -108.69 128.52 64.34 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 CA-C-O 121.169 0.509 . . . . 0.0 111.399 -175.957 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . 0.505 ' HA ' ' HA ' ' A' ' 18' ' ' GLU . 2.7 ttpm? -96.34 106.43 18.65 Favored 'General case' 0 C--N 1.319 -0.757 0 N-CA-C 109.173 -0.677 . . . . 0.0 109.173 175.027 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.466 HG22 ' HB2' ' A' ' 66' ' ' ALA . 55.6 t -70.11 112.82 5.26 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 N-CA-C 109.875 -0.417 . . . . 0.0 109.875 -178.812 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 19.1 p -113.88 -9.6 13.05 Favored 'General case' 0 C--N 1.324 -0.516 0 N-CA-C 111.994 0.368 . . . . 0.0 111.994 -176.518 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -142.04 92.03 2.4 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.129 0.49 . . . . 0.0 111.064 -176.954 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 29.4 t -90.9 131.94 36.76 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.818 0 CA-C-N 115.917 -0.583 . . . . 0.0 109.89 177.363 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 32.2 mmtp -113.56 -178.18 3.31 Favored 'General case' 0 C--N 1.326 -0.452 0 N-CA-C 109.316 -0.624 . . . . 0.0 109.316 177.427 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 35.3 mt-10 -70.98 -26.42 63.14 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 113.054 0.761 . . . . 0.0 113.054 -172.179 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . 0.636 ' HB2' ' CD2' ' A' ' 63' ' ' PHE . 68.9 mmtt -114.97 -28.31 7.06 Favored 'General case' 0 N--CA 1.468 0.444 0 CA-C-O 121.162 0.506 . . . . 0.0 111.313 -177.03 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' PHE . . . . . 0.636 ' CD2' ' HB2' ' A' ' 62' ' ' LYS . 10.7 p90 -153.15 170.44 20.52 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.737 -0.665 . . . . 0.0 109.664 -172.074 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -131.57 160.18 36.04 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-O 120.769 0.318 . . . . 0.0 111.235 -179.01 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 97.8 m-85 -117.45 134.66 54.59 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 115.661 -0.699 . . . . 0.0 109.635 176.152 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' ALA . . . . . 0.562 ' HB1' ' HB ' ' A' ' 54' ' ' VAL . . . -124.73 177.21 6.1 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.806 -178.917 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' GLU . . . . . 0.557 ' O ' ' HA ' ' A' ' 54' ' ' VAL . 11.6 pt-20 -127.05 141.13 51.85 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 121.015 0.436 . . . . 0.0 111.103 -179.129 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.563 ' HA ' HD11 ' A' ' 52' ' ' ILE . 74.5 ttt-85 -71.07 98.21 1.61 Allowed 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.979 176.211 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.41 ' O ' HD23 ' A' ' 70' ' ' LEU . 3.1 t -82.34 64.82 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-N 116.469 -0.332 . . . . 0.0 110.275 177.4 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.506 HD12 ' NE ' ' A' ' 68' ' ' ARG . 73.7 mt . . . . . 0 C--O 1.248 0.982 0 CA-C-O 118.212 -0.899 . . . . 0.0 110.092 -178.245 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 22.9 mmt . . . . . 0 N--CA 1.482 1.171 0 CA-C-O 120.91 0.386 . . . . 0.0 110.96 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -97.18 4.25 51.2 Favored 'General case' 0 C--N 1.33 -0.27 0 N-CA-C 112.908 0.707 . . . . 0.0 112.908 -171.233 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 56.7 t80 -83.31 108.64 16.65 Favored 'General case' 0 C--N 1.326 -0.437 0 C-N-CA 120.091 -0.644 . . . . 0.0 110.246 -178.793 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 136.27 -42.73 1.3 Allowed Glycine 0 N--CA 1.444 -0.809 0 N-CA-C 110.009 -1.236 . . . . 0.0 110.009 -174.531 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.529 ' HG3' ' O ' ' A' ' 5' ' ' LYS . 1.8 pttp -166.13 90.96 0.84 Allowed Pre-proline 0 C--N 1.328 -0.355 0 CA-C-O 121.434 0.635 . . . . 0.0 109.928 173.96 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 5.6 Cg_exo -78.58 29.08 0.46 Allowed 'Trans proline' 0 N--CA 1.463 -0.316 0 C-N-CA 123.06 2.507 . . . . 0.0 111.705 178.468 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -157.59 -153.37 0.4 Allowed 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.582 -0.735 . . . . 0.0 110.162 -175.395 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' MET . . . . . . . . . . . . . 18.7 ttt 81.48 21.13 0.35 Allowed 'General case' 0 N--CA 1.468 0.446 0 O-C-N 124.332 1.02 . . . . 0.0 110.762 179.251 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 56.8 mtpt 54.31 49.74 17.85 Favored 'General case' 0 N--CA 1.464 0.236 0 CA-C-N 115.113 -0.949 . . . . 0.0 112.146 171.256 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 3.8 p-10 -81.63 60.67 4.7 Favored 'General case' 0 C--O 1.235 0.334 0 CA-C-O 121.687 0.756 . . . . 0.0 111.355 -178.259 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.517 HG11 HG11 ' A' ' 59' ' ' VAL . 60.9 t -65.38 128.52 93.87 Favored Pre-proline 0 C--N 1.326 -0.43 0 CA-C-N 115.503 -0.772 . . . . 0.0 109.658 175.424 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 12.3 Cg_endo -56.9 -31.35 88.97 Favored 'Trans proline' 0 CA--C 1.529 0.271 0 C-N-CA 123.052 2.501 . . . . 0.0 113.264 -176.484 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 12.3 m -103.07 125.97 57.43 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.602 0 CA-C-O 121.062 0.458 . . . . 0.0 111.097 -178.275 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 47.3 mt-10 -95.3 113.59 25.29 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.511 178.896 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -58.25 121.45 10.8 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.95 -0.568 . . . . 0.0 111.469 -179.016 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 115.26 -31.39 6.24 Favored Glycine 0 N--CA 1.448 -0.534 0 CA-C-N 115.895 -0.593 . . . . 0.0 112.057 -179.328 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -89.04 150.47 22.76 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 121.096 0.474 . . . . 0.0 111.02 -178.126 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . 0.588 ' HA ' ' HA ' ' A' ' 55' ' ' LYS . 0.7 OUTLIER -107.72 142.17 38.13 Favored 'General case' 0 C--N 1.317 -0.823 0 CA-C-N 115.546 -0.752 . . . . 0.0 110.518 179.192 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 67.1 m-85 -128.37 145.51 51.05 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.695 -176.032 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 6.2 tp10 -80.03 105.1 11.05 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 108.534 -0.913 . . . . 0.0 108.534 172.725 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 32.2 m -118.14 170.58 7.37 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-O 121.246 0.546 . . . . 0.0 112.176 -172.614 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 20.7 m -114.56 155.71 25.99 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.214 -0.903 . . . . 0.0 109.539 176.328 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.64 HG13 ' HB1' ' A' ' 46' ' ' ALA . 36.5 mm -118.62 64.66 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-O 122.127 0.965 . . . . 0.0 108.641 -175.239 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 -72.65 -8.51 55.65 Favored 'General case' 0 C--N 1.314 -0.944 0 CA-C-N 113.84 -1.527 . . . . 0.0 112.189 179.759 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.434 ' HB2' ' HB ' ' A' ' 33' ' ' ILE . 5.5 m-20 -134.61 153.93 51.74 Favored 'General case' 0 N--CA 1.465 0.288 0 N-CA-C 109.976 -0.379 . . . . 0.0 109.976 176.401 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' MET . . . . . 0.583 ' SD ' ' HB2' ' A' ' 48' ' ' LYS . 59.1 mtp -138.06 155.33 48.9 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.744 0.307 . . . . 0.0 110.777 174.226 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -86.31 0.19 87.06 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.944 -0.646 . . . . 0.0 111.779 177.206 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 55.5 tttp 68.75 14.13 8.94 Favored 'General case' 0 N--CA 1.466 0.359 0 CA-C-O 121.783 0.802 . . . . 0.0 111.578 175.674 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -127.2 24.05 5.4 Favored Glycine 0 C--N 1.314 -0.642 0 CA-C-N 115.451 -0.795 . . . . 0.0 111.903 178.815 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 98.21 -35.84 4.34 Favored Glycine 0 N--CA 1.451 -0.351 0 N-CA-C 110.946 -0.862 . . . . 0.0 110.946 -175.722 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 7.6 t70 -70.13 137.57 51.2 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.405 -0.397 . . . . 0.0 110.68 175.926 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . 0.552 ' HA2' ' HA ' ' A' ' 26' ' ' MET . . . -118.06 156.6 15.57 Favored Glycine 0 N--CA 1.447 -0.613 0 N-CA-C 111.515 -0.634 . . . . 0.0 111.515 178.008 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.461 HG23 HG13 ' A' ' 40' ' ' VAL . 2.3 mp -111.5 110.21 31.37 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 CA-C-O 121.326 0.584 . . . . 0.0 110.859 -177.598 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -83.59 161.21 21.23 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.582 -0.735 . . . . 0.0 110.176 170.627 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -133.84 103.7 5.97 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.431 -179.232 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 65.5 mt -103.32 112.24 36.05 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.714 0 N-CA-C 110.006 -0.368 . . . . 0.0 110.006 177.338 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 28.9 t70 67.35 5.59 4.35 Favored 'General case' 0 N--CA 1.47 0.558 0 O-C-N 123.969 0.793 . . . . 0.0 110.899 -178.565 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 105.42 -6.26 41.9 Favored Glycine 0 C--N 1.333 0.37 0 C-N-CA 120.762 -0.732 . . . . 0.0 111.308 -173.913 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 46.6 t80 -81.57 135.56 35.57 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 109.067 -0.716 . . . . 0.0 109.067 178.09 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.461 HG13 HG23 ' A' ' 33' ' ' ILE . 43.4 t -81.98 120.79 34.18 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.196 -175.348 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 52.3 t -122.63 110.66 27.38 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.612 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.679 -179.397 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 73.9 m-85 -76.87 130.3 37.4 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.095 -178.174 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.479 ' HA ' ' HD3' ' A' ' 44' ' ' PRO . 11.7 t -123.41 110.55 30.42 Favored Pre-proline 0 C--N 1.323 -0.579 0 CA-C-N 115.644 -0.707 . . . . 0.0 109.886 -179.378 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . 0.479 ' HD3' ' HA ' ' A' ' 43' ' ' VAL . 32.0 Cg_exo -58.53 -30.94 93.28 Favored 'Trans proline' 0 CA--C 1.531 0.375 0 C-N-CA 123.805 3.004 . . . . 0.0 115.427 -168.154 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 34.1 m-80 -132.63 22.11 4.29 Favored 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 112.687 0.625 . . . . 0.0 112.687 -173.413 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.64 ' HB1' HG13 ' A' ' 23' ' ' ILE . . . -87.03 134.09 33.53 Favored 'General case' 0 C--N 1.318 -0.801 0 CA-C-O 120.721 0.296 . . . . 0.0 111.637 176.104 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 70.4 mm-40 -86.91 156.18 19.93 Favored 'General case' 0 C--O 1.235 0.314 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.806 178.081 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . 0.583 ' HB2' ' SD ' ' A' ' 26' ' ' MET . 49.7 tttm -65.44 123.68 20.26 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.864 0.364 . . . . 0.0 110.462 -179.411 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 90.93 0.05 75.39 Favored Glycine 0 N--CA 1.446 -0.67 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.784 178.097 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 69.3 m -78.82 138.52 38.21 Favored 'General case' 0 C--N 1.322 -0.601 0 C-N-CA 120.784 -0.367 . . . . 0.0 110.82 177.967 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 44.5 t -92.16 100.7 11.65 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 N-CA-C 107.859 -1.163 . . . . 0.0 107.859 173.149 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.612 HD11 ' HB2' ' A' ' 68' ' ' ARG . 2.9 tt -123.27 140.17 47.71 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.824 0 CA-C-O 121.969 0.89 . . . . 0.0 112.636 -168.455 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 48.4 t30 -86.93 114.88 23.93 Favored 'General case' 0 C--N 1.313 -0.999 0 CA-C-N 113.801 -1.545 . . . . 0.0 108.588 175.389 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . 0.583 ' HB ' ' HB1' ' A' ' 66' ' ' ALA . 35.7 m -118.87 132.15 69.58 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.723 0 CA-C-O 120.763 0.316 . . . . 0.0 111.329 -176.287 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . 0.588 ' HA ' ' HA ' ' A' ' 18' ' ' GLU . 22.5 ttmm -96.78 106.92 19.3 Favored 'General case' 0 C--N 1.324 -0.519 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 177.071 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.466 ' HA ' ' HA ' ' A' ' 66' ' ' ALA . 48.5 t -70.83 107.12 2.0 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 N-CA-C 109.901 -0.407 . . . . 0.0 109.901 -177.985 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 8.9 p -103.22 -21.86 13.81 Favored 'General case' 0 C--N 1.323 -0.578 0 N-CA-C 112.13 0.419 . . . . 0.0 112.13 -174.293 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -135.41 92.15 2.81 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 121.225 0.536 . . . . 0.0 110.781 -175.882 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.517 HG11 HG11 ' A' ' 11' ' ' VAL . 45.3 t -88.49 117.16 31.53 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.735 0 CA-C-N 115.583 -0.735 . . . . 0.0 110.591 177.509 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . 0.527 ' HB2' ' O ' ' A' ' 63' ' ' PHE . 4.9 mptp? -97.59 -168.84 1.74 Allowed 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 109.61 -0.515 . . . . 0.0 109.61 174.894 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 34.6 mt-10 -70.54 -53.77 14.79 Favored 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 111.979 0.362 . . . . 0.0 111.979 -176.903 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -93.46 -29.35 15.6 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 120.976 0.417 . . . . 0.0 112.113 -174.293 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' PHE . . . . . 0.527 ' O ' ' HB2' ' A' ' 60' ' ' LYS . 16.2 p90 -151.75 164.65 36.53 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.735 -174.66 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -125.45 163.91 21.6 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-O 120.749 0.309 . . . . 0.0 110.958 -178.648 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 98.4 m-85 -116.06 130.17 56.68 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-N 115.783 -0.644 . . . . 0.0 109.286 176.214 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' ALA . . . . . 0.583 ' HB1' ' HB ' ' A' ' 54' ' ' VAL . . . -121.4 154.64 36.24 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-O 121.195 0.521 . . . . 0.0 111.778 -175.504 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 30.1 tt0 -101.87 116.41 32.64 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-N 115.243 -0.89 . . . . 0.0 111.531 -177.294 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.612 ' HB2' HD11 ' A' ' 52' ' ' ILE . 15.5 ttt-85 -54.03 108.06 0.33 Allowed 'General case' 0 CA--C 1.536 0.405 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.678 172.159 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.428 ' O ' HG12 ' A' ' 69' ' ' VAL . 12.2 t -82.01 12.26 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.328 0 CA-C-O 122.211 1.005 . . . . 0.0 110.324 179.707 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 54.9 mt . . . . . 0 C--N 1.316 -0.877 0 CA-C-N 114.932 -1.031 . . . . 0.0 109.148 176.773 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 52.5 mtt . . . . . 0 N--CA 1.483 1.197 0 CA-C-O 121.133 0.492 . . . . 0.0 111.434 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -110.54 99.5 8.47 Favored 'General case' 0 C--N 1.321 -0.661 0 N-CA-C 109.253 -0.647 . . . . 0.0 109.253 174.851 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 71.1 m-85 -85.34 39.95 0.81 Allowed 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.894 -0.594 . . . . 0.0 111.093 -174.627 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 96.54 -48.63 1.67 Allowed Glycine 0 N--CA 1.449 -0.481 0 N-CA-C 110.96 -0.856 . . . . 0.0 110.96 -177.802 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 18.2 ptpt -115.2 124.66 29.88 Favored Pre-proline 0 C--N 1.321 -0.666 0 CA-C-N 115.089 -0.556 . . . . 0.0 110.004 177.6 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 25.8 Cg_exo -65.0 139.37 61.2 Favored 'Trans proline' 0 C--O 1.239 0.534 0 C-N-CA 122.394 2.063 . . . . 0.0 110.907 173.279 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . 61.97 -147.68 0.39 Allowed 'General case' 0 CA--C 1.533 0.3 0 O-C-N 123.685 0.616 . . . . 0.0 110.757 -176.639 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' MET . . . . . . . . . . . . . 25.7 mmt 62.81 43.46 7.06 Favored 'General case' 0 C--O 1.234 0.26 0 CA-C-O 121.234 0.54 . . . . 0.0 111.168 178.817 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 16.2 pttp -115.09 71.42 0.76 Allowed 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 121.447 0.641 . . . . 0.0 110.556 178.936 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 3.3 t30 72.98 110.32 0.07 Allowed 'General case' 0 C--O 1.232 0.158 0 CA-C-N 114.741 -1.118 . . . . 0.0 110.731 179.58 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.508 HG12 ' H ' ' A' ' 13' ' ' VAL . 39.0 t -57.88 126.16 75.78 Favored Pre-proline 0 C--N 1.326 -0.432 0 CA-C-N 115.493 -0.776 . . . . 0.0 110.29 178.213 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -69.86 -9.82 26.99 Favored 'Trans proline' 0 C--N 1.345 0.374 0 C-N-CA 123.072 2.515 . . . . 0.0 113.143 -175.406 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.508 ' H ' HG12 ' A' ' 11' ' ' VAL . 24.0 m -130.51 134.78 61.73 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.584 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.09 -178.577 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . 0.657 ' HB2' ' HG3' ' A' ' 17' ' ' LYS . 2.9 mp0 -110.24 136.33 49.62 Favored 'General case' 0 C--N 1.318 -0.798 0 CA-C-O 120.827 0.346 . . . . 0.0 110.671 179.191 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . 0.463 ' HA ' ' O ' ' A' ' 56' ' ' VAL . . . -64.12 117.77 7.58 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 115.795 -0.638 . . . . 0.0 110.551 176.578 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 112.23 -7.49 26.9 Favored Glycine 0 N--CA 1.446 -0.652 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.633 179.753 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . 0.657 ' HG3' ' HB2' ' A' ' 14' ' ' GLU . 12.8 mmmm -93.08 155.69 17.34 Favored 'General case' 0 C--N 1.326 -0.448 0 O-C-N 122.604 -0.35 . . . . 0.0 110.448 -179.867 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . 0.486 ' HB3' ' OD1' ' A' ' 53' ' ' ASN . 0.7 OUTLIER -113.85 118.49 34.37 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 109.065 -0.717 . . . . 0.0 109.065 172.71 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' TYR . . . . . 0.408 ' CE2' ' HB2' ' A' ' 17' ' ' LYS . 64.7 m-85 -112.37 140.77 46.82 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-O 121.142 0.496 . . . . 0.0 111.614 -177.334 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 36.2 tt0 -84.42 99.21 10.52 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.09 -0.959 . . . . 0.0 109.193 176.727 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 35.8 m -114.58 171.25 4.45 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.57 0 CA-C-O 121.21 0.529 . . . . 0.0 112.168 -170.986 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 23.4 m -115.36 153.37 31.13 Favored 'General case' 0 N--CA 1.45 -0.445 0 CA-C-N 115.244 -0.889 . . . . 0.0 109.749 175.917 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.615 HG13 ' HB1' ' A' ' 46' ' ' ALA . 37.5 mm -119.1 65.33 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-O 122.056 0.931 . . . . 0.0 108.927 -173.984 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -64.46 -17.43 63.83 Favored 'General case' 0 C--N 1.318 -0.796 0 CA-C-N 113.977 -1.465 . . . . 0.0 111.816 177.737 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.529 ' HB3' ' HB ' ' A' ' 33' ' ' ILE . 27.0 t0 -136.02 151.46 49.9 Favored 'General case' 0 C--N 1.324 -0.517 0 C-N-CA 121.064 -0.254 . . . . 0.0 110.824 -176.539 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' MET . . . . . 0.668 ' SD ' ' HB2' ' A' ' 48' ' ' LYS . 70.1 mtp -137.33 152.75 50.07 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.724 0.297 . . . . 0.0 110.22 175.521 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -86.75 -1.33 85.35 Favored Glycine 0 N--CA 1.448 -0.507 0 C-N-CA 120.969 -0.634 . . . . 0.0 111.56 177.726 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 97.7 mttt 58.64 23.51 11.06 Favored 'General case' 0 CA--C 1.523 -0.073 0 CA-C-O 121.712 0.768 . . . . 0.0 111.938 178.89 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -138.65 35.28 2.02 Favored Glycine 0 N--CA 1.445 -0.736 0 CA-C-N 114.884 -1.053 . . . . 0.0 111.026 175.894 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 98.02 -41.52 2.26 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 121.06 -0.59 . . . . 0.0 111.975 -178.252 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . 0.625 ' HA ' ' HA ' ' A' ' 44' ' ' PRO . 27.6 m-20 -73.53 127.68 33.41 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 121.021 0.439 . . . . 0.0 111.331 -179.216 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -106.62 143.24 15.76 Favored Glycine 0 N--CA 1.444 -0.778 0 N-CA-C 110.2 -1.16 . . . . 0.0 110.2 171.614 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.529 ' HB ' ' HB3' ' A' ' 25' ' ' ASP . 2.1 mp -103.49 105.36 18.19 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.752 0 CA-C-O 121.354 0.597 . . . . 0.0 111.123 -173.761 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -86.99 155.77 20.04 Favored 'General case' 0 N--CA 1.444 -0.733 0 N-CA-C 108.134 -1.061 . . . . 0.0 108.134 166.572 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 37.0 ttt180 -141.93 118.36 10.88 Favored 'General case' 0 C--N 1.314 -0.956 0 C-N-CA 120.031 -0.668 . . . . 0.0 110.376 179.278 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 27.0 mt -109.27 108.7 26.0 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.664 0 CA-C-N 115.458 -0.792 . . . . 0.0 110.397 -179.37 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 31.7 t70 65.29 19.55 11.7 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.121 -0.945 . . . . 0.0 110.932 179.006 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 99.81 -9.39 60.16 Favored Glycine 0 N--CA 1.449 -0.445 0 C-N-CA 120.207 -0.997 . . . . 0.0 111.788 -177.43 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 54.1 t80 -82.75 118.84 23.66 Favored 'General case' 0 C--N 1.322 -0.62 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 177.672 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 17.0 t -75.08 122.93 29.74 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-O 120.993 0.425 . . . . 0.0 111.193 -174.961 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 45.3 t -115.86 109.29 27.69 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-N 116.202 -0.454 . . . . 0.0 109.863 179.646 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 85.6 m-85 -80.35 119.22 22.78 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 121.039 0.447 . . . . 0.0 110.752 -178.327 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.464 HG11 HD13 ' A' ' 52' ' ' ILE . 3.2 t -115.13 101.41 54.47 Favored Pre-proline 0 C--N 1.32 -0.706 0 CA-C-N 115.677 -0.692 . . . . 0.0 109.379 178.567 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . 0.625 ' HA ' ' HA ' ' A' ' 31' ' ' ASP . 16.9 Cg_exo -68.12 5.27 1.19 Allowed 'Trans proline' 0 CA--C 1.531 0.374 0 C-N-CA 123.383 2.722 . . . . 0.0 114.818 -168.721 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 47.5 m-80 -143.43 14.61 1.81 Allowed 'General case' 0 N--CA 1.464 0.225 0 CA-C-O 120.632 0.253 . . . . 0.0 111.609 179.553 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.615 ' HB1' HG13 ' A' ' 23' ' ' ILE . . . -86.43 134.1 33.72 Favored 'General case' 0 C--N 1.32 -0.713 0 N-CA-C 112.018 0.377 . . . . 0.0 112.018 -178.86 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 44.2 mt-10 -92.83 146.18 23.83 Favored 'General case' 0 N--CA 1.454 -0.266 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.976 177.281 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . 0.668 ' HB2' ' SD ' ' A' ' 26' ' ' MET . 46.8 tttp -65.43 129.93 41.51 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.051 -0.522 . . . . 0.0 111.136 -177.916 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 88.17 -5.42 84.83 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.827 -0.702 . . . . 0.0 113.397 176.005 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 51.1 m -95.14 147.78 23.08 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.872 0.336 . . . . 0.0 110.796 -179.329 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 46.0 t -91.91 109.59 21.54 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 N-CA-C 109.23 -0.656 . . . . 0.0 109.23 178.14 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.842 HG13 HD21 ' A' ' 70' ' ' LEU . 2.5 tt -119.57 143.41 31.13 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.819 0 CA-C-O 121.853 0.835 . . . . 0.0 112.403 -170.568 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . 0.486 ' OD1' ' HB3' ' A' ' 18' ' ' GLU . 23.5 t-20 -89.56 114.19 25.72 Favored 'General case' 0 C--N 1.316 -0.869 0 CA-C-N 114.051 -1.432 . . . . 0.0 108.543 175.406 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . 0.533 ' HB ' ' HB1' ' A' ' 66' ' ' ALA . 32.6 m -114.67 128.26 71.84 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 CA-C-O 121.264 0.554 . . . . 0.0 111.856 -175.601 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . 0.589 ' HA ' ' O ' ' A' ' 17' ' ' LYS . 38.2 ttmt -95.13 104.44 16.32 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 115.912 -0.585 . . . . 0.0 109.496 173.976 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.463 ' O ' ' HA ' ' A' ' 15' ' ' ALA . 66.0 t -66.09 110.48 1.35 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 N-CA-C 109.681 -0.489 . . . . 0.0 109.681 179.575 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 11.5 p -105.83 -28.86 10.39 Favored 'General case' 0 C--N 1.324 -0.54 0 N-CA-C 112.247 0.462 . . . . 0.0 112.247 -174.449 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -136.99 92.42 2.73 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 121.12 0.486 . . . . 0.0 110.978 -175.47 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 22.4 t -81.62 125.1 39.58 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.667 0 CA-C-N 115.623 -0.717 . . . . 0.0 110.017 176.225 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 32.2 mmtp -109.47 -150.21 0.45 Allowed 'General case' 0 C--N 1.325 -0.458 0 N-CA-C 109.951 -0.389 . . . . 0.0 109.951 178.484 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 20.2 mm-40 -70.78 -76.89 0.09 Allowed 'General case' 0 C--N 1.331 -0.239 0 N-CA-C 112.18 0.437 . . . . 0.0 112.18 -176.105 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 63.7 mttm -98.22 -2.57 39.39 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 121.182 0.515 . . . . 0.0 110.821 -175.652 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 35.7 p90 -151.37 164.97 35.5 Favored 'General case' 0 C--N 1.318 -0.761 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.725 -173.138 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -137.91 171.02 15.04 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.603 178.182 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 96.8 m-85 -118.92 133.81 55.59 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 109.493 -0.558 . . . . 0.0 109.493 176.702 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' ALA . . . . . 0.533 ' HB1' ' HB ' ' A' ' 54' ' ' VAL . . . -133.95 145.11 49.24 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.464 -179.001 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' GLU . . . . . 0.504 ' HG2' ' HB3' ' A' ' 55' ' ' LYS . 9.6 pt-20 -93.67 142.22 27.6 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-O 121.179 0.514 . . . . 0.0 111.408 -177.83 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.567 ' HB2' HD11 ' A' ' 52' ' ' ILE . 17.8 ttt180 -71.17 109.96 5.54 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.341 -0.845 . . . . 0.0 110.043 173.721 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.489 ' O ' HG12 ' A' ' 69' ' ' VAL . 40.7 t -81.66 12.75 0.58 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.518 0 CA-C-O 122.076 0.941 . . . . 0.0 111.505 -176.415 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.842 HD21 HG13 ' A' ' 52' ' ' ILE . 1.0 OUTLIER . . . . . 0 C--N 1.314 -0.952 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.397 -179.333 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 25.9 ttt . . . . . 0 N--CA 1.479 1.01 0 CA-C-O 120.924 0.393 . . . . 0.0 110.479 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -85.85 137.97 32.38 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.397 178.998 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 79.9 m-85 -83.98 121.67 27.7 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.756 -172.853 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 97.38 -15.92 61.45 Favored Glycine 0 N--CA 1.448 -0.524 0 C-N-CA 120.875 -0.679 . . . . 0.0 111.785 -179.657 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 22.6 tptm 61.51 95.34 0.05 OUTLIER Pre-proline 0 C--O 1.234 0.241 0 C-N-CA 123.071 0.548 . . . . 0.0 110.97 -178.277 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.533 ' HG2' ' HG3' ' A' ' 8' ' ' MET . 92.3 Cg_endo -79.88 -162.84 0.2 Allowed 'Trans proline' 0 N--CA 1.46 -0.48 0 C-N-CA 122.671 2.247 . . . . 0.0 111.549 177.753 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -80.45 -65.17 1.04 Allowed 'General case' 0 C--N 1.322 -0.626 0 CA-C-O 120.562 0.22 . . . . 0.0 110.473 -179.756 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' MET . . . . . 0.533 ' HG3' ' HG2' ' A' ' 6' ' ' PRO . 84.0 mtp 58.92 24.6 12.73 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.632 -179.368 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 26.5 mtpp 63.9 -90.8 0.03 OUTLIER 'General case' 0 CA--C 1.516 -0.341 0 CA-C-N 115.389 -0.823 . . . . 0.0 110.188 -171.998 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 7.1 t30 62.39 11.01 4.28 Favored 'General case' 0 C--N 1.316 -0.859 0 CA-C-N 115.016 -0.993 . . . . 0.0 111.066 176.649 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 54.9 t -159.69 123.91 2.1 Favored Pre-proline 0 C--N 1.32 -0.677 0 CA-C-N 115.034 -0.985 . . . . 0.0 109.185 -171.107 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 94.8 Cg_endo -78.65 -21.37 9.98 Favored 'Trans proline' 0 C--N 1.343 0.246 0 C-N-CA 123.272 2.648 . . . . 0.0 113.18 -177.677 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.539 ' HB ' HG21 ' A' ' 56' ' ' VAL . 17.0 m -97.34 124.36 50.2 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.724 0 CA-C-N 115.857 -0.611 . . . . 0.0 110.779 -175.714 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . 0.475 ' OE2' ' HE2' ' A' ' 17' ' ' LYS . 31.7 tt0 -104.04 129.04 51.65 Favored 'General case' 0 C--N 1.322 -0.613 0 C-N-CA 120.85 -0.34 . . . . 0.0 110.105 -179.734 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -54.42 118.49 4.18 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.79 -0.641 . . . . 0.0 111.155 -178.477 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.31 -25.75 10.98 Favored Glycine 0 N--CA 1.444 -0.826 0 C-N-CA 120.671 -0.776 . . . . 0.0 112.448 179.941 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . 0.475 ' HE2' ' OE2' ' A' ' 14' ' ' GLU . 68.6 mttm -85.55 160.48 19.64 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 120.938 0.399 . . . . 0.0 110.457 179.034 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . 0.51 ' HA ' ' HA ' ' A' ' 55' ' ' LYS . 0.0 OUTLIER -126.87 133.32 50.74 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.449 179.052 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' TYR . . . . . 0.416 ' CE2' ' HA ' ' A' ' 13' ' ' VAL . 64.4 m-85 -123.14 162.6 22.19 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.331 -176.589 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 45.4 tt0 -96.58 122.39 39.44 Favored 'General case' 0 C--N 1.321 -0.665 0 N-CA-C 109.398 -0.593 . . . . 0.0 109.398 176.323 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.527 ' HB ' ' HB1' ' A' ' 34' ' ' ALA . 28.0 m -128.84 168.88 21.21 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-O 121.131 0.491 . . . . 0.0 111.587 -174.62 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 26.2 m -118.88 143.22 47.11 Favored 'General case' 0 N--CA 1.446 -0.65 0 CA-C-N 115.755 -0.657 . . . . 0.0 109.359 175.313 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.559 HG13 ' HB1' ' A' ' 46' ' ' ALA . 19.9 mm -111.77 59.53 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.664 0 CA-C-O 121.997 0.903 . . . . 0.0 108.755 -173.284 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -78.17 9.69 3.57 Favored 'General case' 0 C--N 1.315 -0.921 0 CA-C-N 114.573 -1.194 . . . . 0.0 112.229 -177.555 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.445 ' HB3' ' HB ' ' A' ' 33' ' ' ILE . 29.1 t0 -150.11 148.31 28.82 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.444 -0.344 . . . . 0.0 110.119 176.91 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' MET . . . . . 0.652 ' HA ' ' HA2' ' A' ' 32' ' ' GLY . 39.4 mtp -123.99 151.93 43.13 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.999 0.428 . . . . 0.0 111.157 178.649 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -87.49 -63.25 1.43 Allowed Glycine 0 N--CA 1.445 -0.758 0 CA-C-N 115.554 -0.748 . . . . 0.0 112.709 -177.421 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.455 ' HG3' ' OD2' ' A' ' 31' ' ' ASP . 16.7 pttp -163.71 79.88 0.43 Allowed 'General case' 0 N--CA 1.443 -0.782 0 CA-C-O 121.842 0.83 . . . . 0.0 112.876 -175.828 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 64.6 40.53 97.63 Favored Glycine 0 C--N 1.307 -1.054 0 CA-C-N 114.626 -1.17 . . . . 0.0 114.591 169.021 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 158.94 -47.91 0.42 Allowed Glycine 0 CA--C 1.505 -0.541 0 C-N-CA 120.268 -0.968 . . . . 0.0 111.76 173.88 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . 0.455 ' OD2' ' HG3' ' A' ' 28' ' ' LYS . 1.7 p30 -80.91 146.77 30.64 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-O 120.882 0.372 . . . . 0.0 110.013 177.13 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . 0.652 ' HA2' ' HA ' ' A' ' 26' ' ' MET . . . -128.57 172.78 19.33 Favored Glycine 0 N--CA 1.442 -0.95 0 C-N-CA 120.824 -0.703 . . . . 0.0 112.46 -177.384 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.445 ' HB ' ' HB3' ' A' ' 25' ' ' ASP . 2.2 mp -114.03 121.93 67.14 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.71 0 CA-C-O 120.947 0.403 . . . . 0.0 110.34 -179.949 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . 0.527 ' HB1' ' HB ' ' A' ' 21' ' ' VAL . . . -116.92 117.18 28.98 Favored 'General case' 0 C--N 1.317 -0.805 0 N-CA-C 108.804 -0.813 . . . . 0.0 108.804 172.663 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' ARG . . . . . 0.404 HH11 ' HD3' ' A' ' 35' ' ' ARG . 28.2 ttp180 -104.25 110.67 22.97 Favored 'General case' 0 C--N 1.318 -0.795 0 CA-C-O 121.143 0.497 . . . . 0.0 111.224 -172.735 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 43.7 mt -99.75 110.11 26.19 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-N 115.443 -0.799 . . . . 0.0 110.385 178.992 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 56.6 27.71 12.87 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.217 -0.902 . . . . 0.0 112.081 -179.837 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 100.17 -14.61 59.71 Favored Glycine 0 C--N 1.33 0.207 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.014 -179.627 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 65.9 t80 -85.04 135.44 34.01 Favored 'General case' 0 C--N 1.321 -0.65 0 N-CA-C 109.554 -0.536 . . . . 0.0 109.554 -178.585 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 34.0 t -88.2 117.06 31.17 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-O 121.162 0.506 . . . . 0.0 111.239 -175.424 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 40.8 t -112.51 118.78 58.7 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.686 0 CA-C-N 115.695 -0.684 . . . . 0.0 109.273 174.952 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 76.3 m-85 -87.07 132.04 33.94 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-O 121.194 0.521 . . . . 0.0 111.47 -177.474 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.554 HG21 HD12 ' A' ' 23' ' ' ILE . 15.5 m -111.54 124.2 33.09 Favored Pre-proline 0 C--N 1.324 -0.513 0 CA-C-N 115.461 -0.79 . . . . 0.0 110.336 178.377 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . 0.494 ' HD3' ' HA ' ' A' ' 43' ' ' VAL . 13.5 Cg_exo -71.42 -34.54 9.47 Favored 'Trans proline' 0 CA--C 1.527 0.175 0 C-N-CA 123.05 2.5 . . . . 0.0 113.667 -175.495 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 4.5 p30 -136.12 34.36 2.82 Favored 'General case' 0 C--N 1.325 -0.46 0 N-CA-C 112.887 0.699 . . . . 0.0 112.887 -167.092 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.559 ' HB1' HG13 ' A' ' 23' ' ' ILE . . . -90.41 161.33 15.62 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 120.991 0.424 . . . . 0.0 112.125 175.562 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . 0.526 ' CD ' HH12 ' A' ' 68' ' ' ARG . 2.1 mp0 -102.61 147.16 27.14 Favored 'General case' 0 C--O 1.235 0.302 0 CA-C-N 115.871 -0.604 . . . . 0.0 109.741 170.867 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . 0.505 ' HE3' ' SD ' ' A' ' 26' ' ' MET . 9.3 ptpp? -66.54 139.98 57.95 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.15 0.5 . . . . 0.0 111.061 -179.859 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 73.33 13.94 79.53 Favored Glycine 0 N--CA 1.45 -0.375 0 CA-C-N 115.861 -0.609 . . . . 0.0 112.764 177.513 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 8.5 t -107.46 151.2 25.87 Favored 'General case' 0 C--N 1.323 -0.57 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 178.647 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 57.9 t -104.1 104.92 17.52 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 N-CA-C 109.554 -0.535 . . . . 0.0 109.554 179.266 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.552 HD12 ' HB2' ' A' ' 68' ' ' ARG . 0.9 OUTLIER -113.97 154.94 15.27 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.512 -174.556 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . 0.433 HD22 ' HB ' ' A' ' 69' ' ' VAL . 9.2 t30 -95.29 119.95 34.68 Favored 'General case' 0 C--N 1.321 -0.665 0 N-CA-C 109.001 -0.741 . . . . 0.0 109.001 174.508 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . 0.492 ' HB ' ' HB1' ' A' ' 66' ' ' ALA . 27.8 m -112.08 131.92 62.18 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.664 0 CA-C-O 121.08 0.467 . . . . 0.0 111.738 -175.43 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . 0.51 ' HA ' ' HA ' ' A' ' 18' ' ' GLU . 6.3 ttpm? -100.06 109.54 21.85 Favored 'General case' 0 C--N 1.318 -0.786 0 N-CA-C 108.74 -0.837 . . . . 0.0 108.74 173.321 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.539 HG21 ' HB ' ' A' ' 13' ' ' VAL . 39.1 t -72.28 114.02 10.45 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.551 -176.321 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 7.9 p -108.15 -18.14 13.85 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 116.196 -0.456 . . . . 0.0 112.004 -177.523 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . 0.407 ' HB3' ' HB2' ' A' ' 65' ' ' PHE . . . -134.57 91.1 2.74 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 121.217 0.532 . . . . 0.0 110.591 -177.85 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 19.0 t -90.25 134.61 28.67 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.781 0 CA-C-N 115.298 -0.865 . . . . 0.0 110.801 179.156 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . 0.509 ' HB2' ' O ' ' A' ' 63' ' ' PHE . 75.4 mmtt -119.03 172.52 7.49 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 121.172 0.51 . . . . 0.0 110.563 174.351 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 42.2 tt0 -69.75 -29.34 66.68 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.072 -0.967 . . . . 0.0 109.428 173.691 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . 0.465 ' O ' ' CG ' ' A' ' 63' ' ' PHE . 38.6 mtmt -129.11 87.26 2.54 Favored 'General case' 0 N--CA 1.416 -2.154 0 N-CA-C 105.314 -2.106 . . . . 0.0 105.314 177.587 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' PHE . . . . . 0.509 ' O ' ' HB2' ' A' ' 60' ' ' LYS . 20.5 p90 78.89 142.25 0.08 Allowed 'General case' 0 N--CA 1.488 1.462 0 CA-C-N 112.903 -1.953 . . . . 0.0 112.17 164.658 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -117.1 169.58 9.32 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.452 -0.795 . . . . 0.0 111.894 -170.322 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . 0.407 ' HB2' ' HB3' ' A' ' 58' ' ' ALA . 79.5 m-85 -120.26 133.55 55.45 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 115.359 -0.837 . . . . 0.0 109.396 177.949 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' ALA . . . . . 0.537 ' HB2' HG22 ' A' ' 56' ' ' VAL . . . -134.81 148.04 50.09 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 120.922 0.391 . . . . 0.0 111.23 -177.271 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 11.1 pt-20 -94.27 132.63 38.65 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.914 -178.826 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.926 ' HE ' HD12 ' A' ' 70' ' ' LEU . 31.0 ttt180 -67.02 106.39 1.93 Allowed 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.449 -0.796 . . . . 0.0 110.728 175.717 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.433 ' HB ' HD22 ' A' ' 53' ' ' ASN . 18.9 t -80.53 66.45 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.535 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.015 179.55 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.926 HD12 ' HE ' ' A' ' 68' ' ' ARG . 70.8 mt . . . . . 0 C--O 1.246 0.896 0 CA-C-N 115.687 -0.688 . . . . 0.0 109.466 178.266 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 15.5 tpt . . . . . 0 N--CA 1.478 0.935 0 N-CA-C 110.378 -0.23 . . . . 0.0 110.378 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -153.32 98.18 2.23 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.867 0.365 . . . . 0.0 111.063 -179.384 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 85.4 m-85 -106.92 120.81 43.05 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.715 178.225 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 95.77 -5.02 66.44 Favored Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 120.576 -0.821 . . . . 0.0 112.512 175.905 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 49.3 mtpt 57.92 74.66 0.61 Allowed Pre-proline 0 C--O 1.234 0.253 0 CA-C-O 121.194 0.521 . . . . 0.0 109.98 -173.724 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 98.3 Cg_endo -93.41 166.81 2.32 Favored 'Trans proline' 0 N--CA 1.454 -0.85 0 C-N-CA 122.988 2.459 . . . . 0.0 113.774 -171.94 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . 70.7 127.61 0.03 OUTLIER 'General case' 0 N--CA 1.464 0.264 0 CA-C-N 114.956 -1.02 . . . . 0.0 112.854 173.731 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -90.47 19.41 5.29 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.826 -0.624 . . . . 0.0 109.982 175.412 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 1.4 mptm? 62.56 26.81 15.91 Favored 'General case' 0 N--CA 1.466 0.336 0 CA-C-N 114.747 -1.115 . . . . 0.0 112.026 177.867 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . 0.471 ' C ' HD22 ' A' ' 10' ' ' ASN . 0.2 OUTLIER -85.12 66.44 9.74 Favored 'General case' 0 C--N 1.324 -0.53 0 N-CA-C 108.586 -0.894 . . . . 0.0 108.586 175.411 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 25.2 t -64.61 121.44 73.04 Favored Pre-proline 0 C--N 1.322 -0.594 0 CA-C-N 115.082 -0.963 . . . . 0.0 110.027 178.848 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . 0.436 ' HG2' ' HB2' ' A' ' 39' ' ' PHE . 16.9 Cg_exo -62.6 -30.84 79.59 Favored 'Trans proline' 0 C--O 1.233 0.253 0 C-N-CA 123.109 2.54 . . . . 0.0 112.095 -177.659 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.793 HG12 HD12 ' A' ' 36' ' ' ILE . 31.0 m -107.49 149.84 10.55 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 CA-C-N 115.267 -0.878 . . . . 0.0 110.465 -176.715 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -124.35 136.71 54.3 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-O 120.862 0.363 . . . . 0.0 110.393 177.905 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -70.54 106.59 3.51 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.996 -178.217 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 120.68 -13.1 10.02 Favored Glycine 0 N--CA 1.446 -0.653 0 C-N-CA 120.924 -0.655 . . . . 0.0 112.329 -179.719 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 8.1 mtpm? -102.56 156.74 17.41 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.724 0.297 . . . . 0.0 110.907 -178.87 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . 0.563 ' HA ' ' O ' ' A' ' 54' ' ' VAL . 0.0 OUTLIER -112.16 142.01 45.14 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 121.166 0.508 . . . . 0.0 111.375 -179.074 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' TYR . . . . . 0.563 ' O ' ' HA ' ' A' ' 53' ' ' ASN . 81.4 m-85 -130.64 141.74 50.43 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 116.051 -0.522 . . . . 0.0 111.121 -176.085 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 37.7 mt-10 -79.79 98.85 7.21 Favored 'General case' 0 C--N 1.326 -0.456 0 N-CA-C 109.3 -0.63 . . . . 0.0 109.3 174.835 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.488 ' HB ' ' HB1' ' A' ' 34' ' ' ALA . 35.8 m -110.3 156.2 11.36 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.81 0 CA-C-N 115.787 -0.642 . . . . 0.0 111.526 -174.275 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 24.2 m -105.09 148.73 26.51 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 115.407 -0.815 . . . . 0.0 109.77 176.07 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.534 HG13 ' HB1' ' A' ' 46' ' ' ALA . 33.6 mm -114.45 65.91 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.783 0 N-CA-C 108.053 -1.091 . . . . 0.0 108.053 -174.662 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 -62.25 -24.89 67.52 Favored 'General case' 0 C--N 1.312 -1.025 0 CA-C-N 113.621 -1.627 . . . . 0.0 111.552 178.974 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.529 ' HB3' ' HB ' ' A' ' 33' ' ' ILE . 5.9 t70 -133.7 152.03 51.78 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.521 -0.309 . . . . 0.0 111.125 -170.166 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' MET . . . . . 0.522 ' SD ' ' HB2' ' A' ' 48' ' ' LYS . 18.0 mtp -129.84 161.7 30.18 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 121.018 0.437 . . . . 0.0 110.73 176.341 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -104.99 -117.38 4.34 Favored Glycine 0 N--CA 1.448 -0.52 0 CA-C-N 115.74 -0.664 . . . . 0.0 111.957 177.282 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 63.6 mmtt -76.47 19.75 0.25 Allowed 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 112.769 0.655 . . . . 0.0 112.769 -179.613 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 102.6 -42.51 1.88 Allowed Glycine 0 C--N 1.313 -0.739 0 C-N-CA 120.926 -0.654 . . . . 0.0 112.664 178.109 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -100.76 19.74 51.02 Favored Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 120.783 -0.722 . . . . 0.0 111.678 178.593 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 16.2 m-20 -124.64 114.21 19.05 Favored 'General case' 0 C--N 1.324 -0.52 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 179.011 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -96.53 122.35 7.34 Favored Glycine 0 N--CA 1.444 -0.815 0 N-CA-C 110.563 -1.015 . . . . 0.0 110.563 174.468 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.529 ' HB ' ' HB3' ' A' ' 25' ' ' ASP . 1.9 mp -95.84 100.67 11.32 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.698 0 CA-C-O 121.426 0.631 . . . . 0.0 110.462 -176.798 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . 0.488 ' HB1' ' HB ' ' A' ' 21' ' ' VAL . . . -99.4 162.04 13.27 Favored 'General case' 0 CA--C 1.495 -1.16 0 CA-C-N 115.265 -0.879 . . . . 0.0 108.947 168.563 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' ARG . . . . . 0.4 ' HA ' ' O ' ' A' ' 39' ' ' PHE . 29.0 ptt180 -156.65 119.64 4.12 Favored 'General case' 0 N--CA 1.43 -1.47 0 CA-C-O 121.423 0.63 . . . . 0.0 110.859 -177.379 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.793 HD12 HG12 ' A' ' 13' ' ' VAL . 43.9 mt -96.67 111.21 26.25 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.829 0 CA-C-N 115.186 -0.915 . . . . 0.0 110.349 -175.175 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 25.9 t0 57.97 29.18 17.3 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 114.685 -1.143 . . . . 0.0 110.836 -177.871 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 103.63 -22.69 34.98 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.957 -0.639 . . . . 0.0 112.347 179.401 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . 0.436 ' HB2' ' HG2' ' A' ' 12' ' ' PRO . 63.3 t80 -74.86 112.54 11.19 Favored 'General case' 0 C--N 1.324 -0.519 0 N-CA-C 109.959 -0.386 . . . . 0.0 109.959 -178.299 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 41.2 t -69.14 123.9 23.71 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 CA-C-O 121.42 0.628 . . . . 0.0 111.84 -174.791 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 25.5 t -121.8 109.23 24.0 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.691 0 CA-C-N 115.233 -0.894 . . . . 0.0 109.18 -179.884 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 87.9 m-85 -77.11 124.47 27.85 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.176 -176.39 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.42 ' CG1' ' HB2' ' A' ' 46' ' ' ALA . 2.7 t -122.01 98.96 44.37 Favored Pre-proline 0 C--N 1.325 -0.48 0 CA-C-N 115.753 -0.658 . . . . 0.0 110.534 -179.377 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -74.11 -0.16 9.2 Favored 'Trans proline' 0 CA--C 1.53 0.312 0 C-N-CA 122.704 2.269 . . . . 0.0 113.458 -175.752 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' ASN . . . . . 0.441 ' HB2' ' HB3' ' A' ' 68' ' ' ARG . 12.6 m120 -125.57 8.25 7.66 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 121.099 0.476 . . . . 0.0 110.91 -175.132 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.534 ' HB1' HG13 ' A' ' 23' ' ' ILE . . . -91.03 153.25 20.27 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 112.069 0.396 . . . . 0.0 112.069 -176.176 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 5.4 mm-40 -105.04 135.9 45.52 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.444 -0.798 . . . . 0.0 110.433 176.426 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . 0.522 ' HB2' ' SD ' ' A' ' 26' ' ' MET . 14.3 tmtt? -65.14 136.65 56.95 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.494 -179.895 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 70.64 23.44 77.73 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.993 -0.622 . . . . 0.0 112.522 179.069 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 23.3 t -122.36 145.89 47.83 Favored 'General case' 0 C--N 1.321 -0.654 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 179.518 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 52.8 t -90.44 101.62 12.51 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 N-CA-C 109.53 -0.545 . . . . 0.0 109.53 177.839 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.561 HD11 ' HB2' ' A' ' 68' ' ' ARG . 0.9 OUTLIER -119.29 140.96 41.48 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.749 0 CA-C-N 115.768 -0.651 . . . . 0.0 111.034 -175.29 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . 0.563 ' HA ' ' O ' ' A' ' 19' ' ' TYR . 7.1 p-10 -97.81 118.06 33.5 Favored 'General case' 0 C--N 1.313 -0.99 0 CA-C-N 115.128 -0.942 . . . . 0.0 109.016 176.288 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . 0.563 ' O ' ' HA ' ' A' ' 18' ' ' GLU . 35.3 m -111.67 140.96 28.66 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.765 0 CA-C-N 115.304 -0.862 . . . . 0.0 111.731 -173.481 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 25.6 ttmt -94.96 109.22 21.26 Favored 'General case' 0 C--N 1.319 -0.724 0 N-CA-C 109.212 -0.662 . . . . 0.0 109.212 177.389 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.456 HG21 ' HB ' ' A' ' 13' ' ' VAL . 60.5 t -70.56 113.26 6.37 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 N-CA-C 109.53 -0.544 . . . . 0.0 109.53 179.516 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.9 p -111.42 -14.97 13.66 Favored 'General case' 0 C--N 1.323 -0.587 0 N-CA-C 112.32 0.489 . . . . 0.0 112.32 -173.077 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . 0.433 ' HB3' ' HB2' ' A' ' 65' ' ' PHE . . . -145.82 93.38 2.33 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.947 0.403 . . . . 0.0 111.048 -176.214 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 21.9 t -87.6 122.93 39.93 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 CA-C-N 116.061 -0.518 . . . . 0.0 109.919 176.085 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 32.3 mmtp -109.15 -165.26 1.0 Allowed 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.668 -0.242 . . . . 0.0 110.375 179.832 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . 0.471 ' CD ' ' H ' ' A' ' 61' ' ' GLU . 4.1 mp0 -64.25 -54.05 39.44 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.752 -175.925 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 88.9 mttt -108.82 -19.78 13.29 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.838 -171.533 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 23.9 p90 -150.13 175.02 12.13 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.589 -175.111 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -137.29 167.45 21.56 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-O 120.808 0.337 . . . . 0.0 111.024 179.378 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . 0.433 ' HB2' ' HB3' ' A' ' 58' ' ' ALA . 90.8 m-85 -119.63 135.17 54.92 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.753 -0.658 . . . . 0.0 109.822 177.211 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' ALA . . . . . 0.513 ' HB1' ' HB ' ' A' ' 54' ' ' VAL . . . -132.38 154.99 49.24 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.321 -0.399 . . . . 0.0 111.043 -178.926 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 13.7 pt-20 -111.81 143.49 42.67 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 121.088 0.471 . . . . 0.0 111.11 -179.408 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.561 ' HB2' HD11 ' A' ' 52' ' ' ILE . 27.3 ttt180 -66.69 114.18 5.4 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.469 -0.787 . . . . 0.0 111.135 174.255 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.482 ' HB ' ' ND2' ' A' ' 53' ' ' ASN . 3.7 t -83.14 5.85 1.9 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 121.7 0.762 . . . . 0.0 110.915 176.761 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.408 ' HB2' ' HG3' ' A' ' 68' ' ' ARG . 68.7 mt . . . . . 0 C--N 1.315 -0.935 0 CA-C-N 115.305 -0.861 . . . . 0.0 110.588 -177.602 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 2.2 mpt? . . . . . 0 N--CA 1.482 1.131 0 N-CA-C 109.843 -0.429 . . . . 0.0 109.843 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 0.651 ' HA ' ' O ' ' A' ' 6' ' ' PRO . . . 62.99 27.16 15.82 Favored 'General case' 0 N--CA 1.464 0.269 0 O-C-N 123.785 0.678 . . . . 0.0 112.017 174.941 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 26.7 t80 -85.98 68.82 10.44 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-O 121.339 0.59 . . . . 0.0 110.576 -177.621 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 98.25 -70.63 0.64 Allowed Glycine 0 N--CA 1.449 -0.442 0 C-N-CA 120.978 -0.629 . . . . 0.0 113.423 174.305 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.548 ' HB3' ' HD3' ' A' ' 6' ' ' PRO . 8.0 ttpm? -94.35 -50.7 0.26 Allowed Pre-proline 0 CA--C 1.538 0.497 0 N-CA-C 112.933 0.716 . . . . 0.0 112.933 -173.775 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.651 ' O ' ' HA ' ' A' ' 2' ' ' ALA . 8.5 Cg_exo -74.51 152.52 43.46 Favored 'Trans proline' 0 C--N 1.348 0.55 0 C-N-CA 122.038 1.826 . . . . 0.0 112.184 -179.48 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . 59.9 77.57 0.31 Allowed 'General case' 0 N--CA 1.463 0.198 0 O-C-N 123.832 0.707 . . . . 0.0 111.279 -179.387 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' MET . . . . . . . . . . . . . 34.9 tpp -97.43 26.82 4.62 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-O 121.584 0.707 . . . . 0.0 109.97 -179.621 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -77.26 102.14 6.56 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.558 -0.747 . . . . 0.0 110.987 -177.653 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 4.1 p-10 -82.42 36.56 0.48 Allowed 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.614 -0.721 . . . . 0.0 111.124 178.745 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.418 ' HA ' ' HD3' ' A' ' 12' ' ' PRO . 77.7 t -158.52 108.34 1.66 Allowed Pre-proline 0 C--N 1.332 -0.16 0 N-CA-C 109.398 -0.593 . . . . 0.0 109.398 -174.193 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . 0.418 ' HD3' ' HA ' ' A' ' 11' ' ' VAL . 6.0 Cg_exo -76.33 -39.13 0.87 Allowed 'Trans proline' 0 C--N 1.343 0.251 0 C-N-CA 123.253 2.635 . . . . 0.0 112.51 -178.458 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.583 HG12 HD12 ' A' ' 36' ' ' ILE . 6.0 m -73.51 130.9 35.61 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.718 0 CA-C-N 115.06 -0.973 . . . . 0.0 111.932 -173.525 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -102.45 119.09 38.22 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.754 -0.657 . . . . 0.0 109.372 177.858 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -68.17 108.69 3.24 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 120.975 0.417 . . . . 0.0 110.752 -178.565 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 127.54 -23.87 5.33 Favored Glycine 0 N--CA 1.443 -0.854 0 C-N-CA 120.814 -0.708 . . . . 0.0 112.409 -179.695 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . 0.407 ' HE3' ' HB3' ' A' ' 17' ' ' LYS . 24.0 mtpp -104.19 165.95 10.72 Favored 'General case' 0 C--O 1.235 0.336 0 CA-C-O 121.019 0.438 . . . . 0.0 111.28 179.613 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . 0.561 ' HG3' HD21 ' A' ' 53' ' ' ASN . 0.2 OUTLIER -117.8 151.06 38.09 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.719 -0.673 . . . . 0.0 111.067 -177.584 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 72.6 m-85 -139.01 145.68 39.94 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.694 -0.684 . . . . 0.0 109.504 179.245 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . 0.551 ' HG2' HG12 ' A' ' 51' ' ' VAL . 42.6 tt0 -85.32 108.18 17.68 Favored 'General case' 0 C--N 1.32 -0.692 0 N-CA-C 109.529 -0.545 . . . . 0.0 109.529 176.756 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 34.4 m -122.8 165.66 18.56 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.968 -172.61 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 9.0 m -102.31 148.01 25.99 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-O 120.965 0.412 . . . . 0.0 110.543 179.801 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.455 HG13 ' HB1' ' A' ' 46' ' ' ALA . 29.3 mm -112.97 61.59 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 N-CA-C 107.916 -1.142 . . . . 0.0 107.916 -177.471 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 13.1 tp10 -64.12 -17.07 63.09 Favored 'General case' 0 C--N 1.317 -0.843 0 CA-C-N 113.283 -1.78 . . . . 0.0 111.67 -177.29 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 33.3 t70 -145.41 152.21 39.47 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 116.483 -0.326 . . . . 0.0 110.196 -173.236 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' MET . . . . . 0.655 ' HA ' ' HA2' ' A' ' 32' ' ' GLY . 33.3 mtp -128.25 157.18 41.61 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 121.171 0.51 . . . . 0.0 110.974 177.866 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.503 ' HA3' ' OD2' ' A' ' 31' ' ' ASP . . . -83.53 -48.42 5.3 Favored Glycine 0 N--CA 1.445 -0.732 0 CA-C-N 115.66 -0.7 . . . . 0.0 112.724 -176.564 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 79.5 tttt -161.55 21.9 0.12 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 121.513 0.673 . . . . 0.0 111.413 -177.863 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 123.19 -47.58 1.01 Allowed Glycine 0 C--N 1.315 -0.602 0 C-N-CA 120.3 -0.952 . . . . 0.0 113.8 172.387 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -103.23 -35.66 3.58 Favored Glycine 0 C--O 1.228 -0.268 0 C-N-CA 120.524 -0.846 . . . . 0.0 111.919 -179.325 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . 0.503 ' OD2' ' HA3' ' A' ' 27' ' ' GLY . 12.1 p-10 -85.84 133.27 33.98 Favored 'General case' 0 C--N 1.318 -0.768 0 N-CA-C 109.611 -0.514 . . . . 0.0 109.611 177.435 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . 0.655 ' HA2' ' HA ' ' A' ' 26' ' ' MET . . . -117.78 158.79 14.46 Favored Glycine 0 N--CA 1.445 -0.709 0 C-N-CA 121.032 -0.604 . . . . 0.0 112.154 -179.154 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 2.2 mp -108.88 106.89 21.56 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.5 0 CA-C-O 121.175 0.512 . . . . 0.0 110.103 178.682 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . 0.445 ' HB3' ' HB ' ' A' ' 41' ' ' VAL . . . -90.84 152.92 20.57 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.6 -0.727 . . . . 0.0 109.842 172.278 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -122.14 113.46 19.53 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.556 -178.274 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.583 HD12 HG12 ' A' ' 13' ' ' VAL . 38.7 mt -110.39 105.81 19.53 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.758 0 CA-C-O 121.085 0.469 . . . . 0.0 109.985 175.2 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 26.9 t0 55.18 36.69 27.55 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 114.852 -1.067 . . . . 0.0 110.663 -178.528 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 94.27 -19.93 50.68 Favored Glycine 0 C--N 1.333 0.394 0 C-N-CA 120.976 -0.63 . . . . 0.0 112.787 -179.807 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 78.3 t80 -77.13 142.54 39.66 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 110.098 -0.334 . . . . 0.0 110.098 -175.258 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 11.1 t -88.25 114.64 27.12 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 CA-C-N 115.888 -0.596 . . . . 0.0 111.113 -175.7 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.445 ' HB ' ' HB3' ' A' ' 34' ' ' ALA . 54.6 t -109.8 108.14 24.64 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.649 0 CA-C-N 116.033 -0.531 . . . . 0.0 109.913 177.265 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 67.6 m-85 -76.84 119.03 20.04 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 121.351 0.596 . . . . 0.0 110.256 178.822 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.731 HG11 HD11 ' A' ' 52' ' ' ILE . 17.5 t -117.9 100.49 52.17 Favored Pre-proline 0 C--N 1.315 -0.93 0 CA-C-N 115.474 -0.784 . . . . 0.0 110.512 -175.769 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 33.7 Cg_exo -64.62 -9.32 20.22 Favored 'Trans proline' 0 N--CA 1.476 0.476 0 C-N-CA 123.799 2.999 . . . . 0.0 114.412 -175.563 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' ASN . . . . . 0.43 ' HB2' ' HB3' ' A' ' 68' ' ' ARG . 0.9 OUTLIER -128.35 17.77 6.49 Favored 'General case' 0 C--N 1.324 -0.511 0 C-N-CA 120.907 -0.317 . . . . 0.0 110.7 -175.192 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.601 ' HB2' ' HB ' ' A' ' 43' ' ' VAL . . . -67.75 154.32 41.77 Favored 'General case' 0 C--N 1.32 -0.696 0 N-CA-C 113.334 0.864 . . . . 0.0 113.334 -175.655 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 10.9 mm-40 -105.76 121.33 43.8 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 114.695 -1.139 . . . . 0.0 109.64 174.522 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . 0.622 ' HB2' ' SD ' ' A' ' 26' ' ' MET . 63.2 tttm -60.84 123.99 19.14 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 120.947 0.404 . . . . 0.0 110.918 -177.119 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 89.06 -33.62 4.2 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 121.006 -0.616 . . . . 0.0 112.853 178.122 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 17.7 m -71.08 155.62 40.58 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 120.906 0.384 . . . . 0.0 110.627 -179.05 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.551 HG12 ' HG2' ' A' ' 20' ' ' GLU . 21.8 t -102.82 87.95 1.25 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 177.498 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.731 HD11 HG11 ' A' ' 43' ' ' VAL . 0.1 OUTLIER -92.49 144.98 8.18 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-N 115.622 -0.717 . . . . 0.0 110.688 -171.002 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . 0.561 HD21 ' HG3' ' A' ' 18' ' ' GLU . 8.5 t30 -83.36 112.52 19.99 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-N 115.691 -0.686 . . . . 0.0 109.794 175.229 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . 0.513 ' HB ' ' HB1' ' A' ' 66' ' ' ALA . 33.9 m -104.44 137.38 33.71 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.264 -176.72 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . 0.536 ' HA ' ' HA ' ' A' ' 18' ' ' GLU . 35.9 ttpt -103.49 110.93 23.15 Favored 'General case' 0 C--N 1.318 -0.8 0 N-CA-C 108.958 -0.756 . . . . 0.0 108.958 172.644 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 60.4 t -65.21 118.08 7.0 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 CA-C-N 116.45 -0.341 . . . . 0.0 110.157 -179.294 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 12.3 p -104.35 -24.53 13.08 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 116.248 -0.433 . . . . 0.0 112.001 -174.992 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -154.75 102.31 2.36 Favored 'General case' 0 N--CA 1.451 -0.422 0 CA-C-O 121.097 0.475 . . . . 0.0 111.007 -175.131 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.412 HG13 ' HB2' ' A' ' 64' ' ' ALA . 17.9 t -88.22 122.72 40.12 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.705 0 CA-C-N 115.676 -0.693 . . . . 0.0 110.2 174.755 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . 0.433 ' N ' ' HD2' ' A' ' 60' ' ' LYS . 0.6 OUTLIER -101.35 -171.23 1.95 Allowed 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 176.634 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 39.4 mm-40 -59.51 -48.81 80.19 Favored 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 112.667 0.618 . . . . 0.0 112.667 -174.466 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 64.4 mttm -116.03 -5.45 11.96 Favored 'General case' 0 C--N 1.328 -0.326 0 N-CA-C 112.346 0.499 . . . . 0.0 112.346 -171.811 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 16.1 p90 -162.63 156.11 20.28 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 120.682 0.277 . . . . 0.0 110.761 -176.059 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.412 ' HB2' HG13 ' A' ' 59' ' ' VAL . . . -121.39 159.0 27.07 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.698 -178.65 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 96.2 m-85 -116.39 137.15 52.39 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.269 -0.423 . . . . 0.0 109.926 176.374 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' ALA . . . . . 0.513 ' HB1' ' HB ' ' A' ' 54' ' ' VAL . . . -137.48 152.89 50.02 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 116.443 -0.344 . . . . 0.0 111.161 -177.962 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' GLU . . . . . 0.4 ' O ' ' HA ' ' A' ' 54' ' ' VAL . 9.6 pt-20 -102.84 144.07 31.63 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.932 -179.11 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.672 ' HB2' HD12 ' A' ' 52' ' ' ILE . 9.2 ttp180 -70.95 109.29 4.98 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.341 172.793 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.537 ' HB ' HD22 ' A' ' 53' ' ' ASN . 3.8 t -81.95 28.34 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.468 0 CA-C-O 121.506 0.67 . . . . 0.0 110.856 -179.587 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.441 HD23 ' N ' ' A' ' 70' ' ' LEU . 1.3 pt? . . . . . 0 C--O 1.243 0.744 0 CA-C-N 116.136 -0.484 . . . . 0.0 109.748 178.75 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.482 1.128 0 N-CA-C 109.549 -0.537 . . . . 0.0 109.549 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -82.3 118.22 22.98 Favored 'General case' 0 N--CA 1.45 -0.445 0 N-CA-C 109.209 -0.663 . . . . 0.0 109.209 172.614 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 57.1 m-85 -83.97 -25.67 29.86 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-O 120.907 0.384 . . . . 0.0 110.915 -174.112 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 96.91 -21.82 44.01 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.645 -0.788 . . . . 0.0 111.633 -178.446 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.558 ' HB2' ' HD3' ' A' ' 6' ' ' PRO . 53.5 mtmt -73.79 -50.69 5.52 Favored Pre-proline 0 C--N 1.326 -0.428 0 CA-C-N 115.485 -0.357 . . . . 0.0 111.957 177.826 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.558 ' HD3' ' HB2' ' A' ' 5' ' ' LYS . 25.5 Cg_exo -66.2 151.28 83.93 Favored 'Trans proline' 0 C--N 1.354 0.854 0 C-N-CA 122.185 1.924 . . . . 0.0 112.064 -179.475 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . 72.19 -30.59 0.21 Allowed 'General case' 0 N--CA 1.469 0.501 0 C-N-CA 123.87 0.868 . . . . 0.0 112.21 -178.771 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' MET . . . . . 0.41 ' H ' ' C ' ' A' ' 6' ' ' PRO . 14.0 tpt -83.35 21.64 1.13 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 121.925 0.869 . . . . 0.0 110.178 179.443 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . 0.679 ' HA ' ' HE3' ' A' ' 9' ' ' LYS . 0.9 OUTLIER -134.67 24.04 3.68 Favored 'General case' 0 C--N 1.319 -0.719 0 N-CA-C 108.64 -0.874 . . . . 0.0 108.64 176.94 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 18.3 m120 -139.45 104.23 4.91 Favored 'General case' 0 N--CA 1.444 -0.73 0 CA-C-N 114.975 -1.011 . . . . 0.0 109.25 -174.243 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.468 HG12 ' O ' ' A' ' 13' ' ' VAL . 86.6 t -33.09 107.59 0.28 Allowed Pre-proline 0 N--CA 1.471 0.585 0 O-C-N 124.825 1.328 . . . . 0.0 111.42 175.195 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -75.47 -2.47 12.61 Favored 'Trans proline' 0 C--N 1.346 0.43 0 C-N-CA 122.972 2.448 . . . . 0.0 112.379 -176.954 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.468 ' O ' HG12 ' A' ' 11' ' ' VAL . 9.4 m -121.8 -175.61 1.04 Allowed 'Isoleucine or valine' 0 C--N 1.314 -0.94 0 CA-C-N 115.16 -0.927 . . . . 0.0 109.722 179.806 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . 0.539 ' HG3' ' HD2' ' A' ' 17' ' ' LYS . 74.5 mm-40 -116.82 -159.46 0.73 Allowed 'General case' 0 C--N 1.314 -0.94 0 N-CA-C 109.587 -0.523 . . . . 0.0 109.587 177.21 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . 0.454 ' HA ' ' O ' ' A' ' 56' ' ' VAL . . . -162.56 101.11 1.04 Allowed 'General case' 0 C--N 1.317 -0.837 0 CA-C-N 115.591 -0.732 . . . . 0.0 109.315 174.862 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 124.81 -18.41 7.12 Favored Glycine 0 N--CA 1.446 -0.65 0 CA-C-N 114.82 -1.082 . . . . 0.0 111.571 -173.623 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . 0.539 ' HD2' ' HG3' ' A' ' 14' ' ' GLU . 61.6 mttm -102.31 164.11 11.86 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 120.597 0.237 . . . . 0.0 110.663 -178.76 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . 0.493 ' HA ' ' O ' ' A' ' 54' ' ' VAL . 2.1 mp0 -111.15 144.22 40.63 Favored 'General case' 0 N--CA 1.455 -0.179 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.072 -179.383 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 98.0 m-85 -132.58 -179.66 5.59 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.69 -0.686 . . . . 0.0 109.492 173.775 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 6.5 pt-20 -124.8 113.32 17.76 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-O 121.583 0.706 . . . . 0.0 109.495 175.07 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.436 ' O ' ' HA ' ' A' ' 51' ' ' VAL . 30.2 m -116.82 173.9 3.88 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.91 0 CA-C-N 115.26 -0.882 . . . . 0.0 111.202 -173.031 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 5.8 m -112.82 152.19 29.49 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.028 179.431 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.533 HG13 ' HB1' ' A' ' 46' ' ' ALA . 19.9 mm -115.23 61.22 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.678 0 N-CA-C 108.355 -0.98 . . . . 0.0 108.355 -176.064 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 6.9 mm-40 -66.12 -18.18 65.18 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 114.006 -1.452 . . . . 0.0 111.405 -179.259 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.498 ' HB3' ' HB ' ' A' ' 33' ' ' ILE . 26.0 t0 -138.53 137.01 36.66 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.472 -172.397 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' MET . . . . . . . . . . . . . 10.8 mmt -114.89 144.03 44.19 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.886 174.929 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -70.46 -86.53 0.13 Allowed Glycine 0 N--CA 1.447 -0.607 0 N-CA-C 110.809 -0.916 . . . . 0.0 110.809 172.934 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 9.4 ptpp? -164.07 -29.01 0.04 OUTLIER 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 112.346 0.499 . . . . 0.0 112.346 172.179 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -105.38 38.25 3.39 Favored Glycine 0 C--N 1.308 -0.992 0 CA-C-N 115.636 -0.711 . . . . 0.0 113.358 -176.673 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 83.12 -5.84 74.49 Favored Glycine 0 C--N 1.329 0.139 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.909 177.888 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . 0.468 ' HA ' ' HA ' ' A' ' 44' ' ' PRO . 4.7 t70 -82.76 117.96 23.03 Favored 'General case' 0 C--N 1.325 -0.472 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 178.392 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -98.67 154.18 19.98 Favored Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.924 -173.732 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.498 ' HB ' ' HB3' ' A' ' 25' ' ' ASP . 2.5 mp -105.94 113.53 42.96 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.582 0 CA-C-O 121.136 0.493 . . . . 0.0 110.451 179.258 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . 0.429 ' HB1' ' HB ' ' A' ' 21' ' ' VAL . . . -106.37 160.62 15.24 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.775 -0.648 . . . . 0.0 109.9 175.902 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' ARG . . . . . 0.418 HH11 ' HD3' ' A' ' 35' ' ' ARG . 0.1 OUTLIER -130.05 128.02 41.1 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-O 120.652 0.263 . . . . 0.0 111.062 -175.027 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 54.7 mt -127.25 110.1 21.95 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 172.145 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 57.95 23.48 9.92 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 115.319 -0.855 . . . . 0.0 111.539 -175.946 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 99.88 -12.94 60.89 Favored Glycine 0 C--N 1.333 0.393 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.008 -178.605 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 52.6 t80 -76.18 139.28 41.16 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 109.652 -0.499 . . . . 0.0 109.652 -178.202 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 26.0 t -89.44 114.84 28.07 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 CA-C-O 121.097 0.475 . . . . 0.0 111.029 -175.475 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 37.1 t -115.24 118.23 58.13 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.661 0 CA-C-N 115.924 -0.58 . . . . 0.0 109.828 179.28 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 94.6 m-85 -87.09 142.31 28.02 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.773 -177.535 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.467 ' HA ' ' HD3' ' A' ' 44' ' ' PRO . 1.4 m -138.55 102.8 7.84 Favored Pre-proline 0 C--N 1.325 -0.496 0 CA-C-N 115.762 -0.654 . . . . 0.0 110.79 -179.115 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . 0.468 ' HA ' ' HA ' ' A' ' 31' ' ' ASP . 4.9 Cg_exo -77.23 3.39 6.75 Favored 'Trans proline' 0 CA--C 1.531 0.354 0 C-N-CA 123.564 2.842 . . . . 0.0 113.956 -170.943 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' ASN . . . . . 0.461 ' O ' ' HD3' ' A' ' 68' ' ' ARG . 57.2 m-80 -136.53 25.49 3.15 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 121.263 0.554 . . . . 0.0 110.489 -179.431 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.533 ' HB1' HG13 ' A' ' 23' ' ' ILE . . . -86.01 163.8 17.75 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 115.98 -0.554 . . . . 0.0 111.741 -179.682 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 42.9 mt-10 -116.93 134.4 54.8 Favored 'General case' 0 N--CA 1.446 -0.647 0 CA-C-N 115.472 -0.785 . . . . 0.0 109.297 172.224 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 27.0 ttpp -65.56 140.07 58.51 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-O 120.967 0.413 . . . . 0.0 111.493 -174.207 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 70.52 35.79 68.27 Favored Glycine 0 N--CA 1.448 -0.504 0 CA-C-N 115.525 -0.761 . . . . 0.0 112.704 177.367 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 50.8 m -142.18 162.23 35.99 Favored 'General case' 0 C--N 1.321 -0.663 0 O-C-N 122.772 -0.252 . . . . 0.0 110.747 179.07 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.436 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 88.9 t -98.86 122.9 51.1 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 N-CA-C 108.994 -0.743 . . . . 0.0 108.994 174.327 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.587 HD12 ' HB2' ' A' ' 68' ' ' ARG . 3.4 pt -121.62 142.97 35.67 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.703 0 C-N-CA 120.615 -0.434 . . . . 0.0 110.371 -178.8 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . 0.425 ' O ' ' HA ' ' A' ' 68' ' ' ARG . 16.5 t-20 -76.71 129.48 36.4 Favored 'General case' 0 C--N 1.323 -0.556 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 174.053 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . 0.683 ' HB ' ' HB1' ' A' ' 66' ' ' ALA . 25.0 m -128.24 128.49 68.61 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 CA-C-O 121.163 0.506 . . . . 0.0 112.032 -176.202 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . 0.426 ' HB2' ' HG3' ' A' ' 18' ' ' GLU . 22.8 ttmm -98.95 102.14 13.77 Favored 'General case' 0 C--N 1.314 -0.945 0 N-CA-C 108.611 -0.885 . . . . 0.0 108.611 170.044 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.556 HG22 ' HB2' ' A' ' 66' ' ' ALA . 68.1 t -66.27 108.21 0.96 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 N-CA-C 109.459 -0.571 . . . . 0.0 109.459 178.368 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 12.9 p -109.87 -13.81 14.39 Favored 'General case' 0 C--N 1.321 -0.634 0 N-CA-C 112.304 0.483 . . . . 0.0 112.304 -174.405 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . 0.429 ' HB3' ' HB2' ' A' ' 65' ' ' PHE . . . -143.13 92.24 2.36 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.134 0.493 . . . . 0.0 111.256 -176.608 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 20.3 t -84.58 142.8 12.84 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.768 0 CA-C-N 115.95 -0.568 . . . . 0.0 109.7 177.645 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 42.5 mmtm -127.72 -162.33 1.16 Allowed 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 116.716 -0.22 . . . . 0.0 110.779 -179.364 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 6.5 mm-40 -47.34 -64.09 0.87 Allowed 'General case' 0 N--CA 1.468 0.435 0 C-N-CA 123.699 0.799 . . . . 0.0 112.761 -172.302 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 59.9 pttt -138.31 20.59 2.77 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 121.666 0.746 . . . . 0.0 110.198 -178.926 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 28.9 p90 -153.12 153.19 32.3 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 114.939 -1.028 . . . . 0.0 108.906 -179.745 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -127.41 155.66 43.29 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-O 120.825 0.345 . . . . 0.0 111.112 -177.69 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . 0.429 ' HB2' ' HB3' ' A' ' 58' ' ' ALA . 99.0 m-85 -108.97 124.69 51.09 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 115.836 -0.62 . . . . 0.0 109.476 176.412 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' ALA . . . . . 0.683 ' HB1' ' HB ' ' A' ' 54' ' ' VAL . . . -125.12 151.24 46.0 Favored 'General case' 0 C--N 1.318 -0.793 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.707 -179.001 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 5.3 pt-20 -110.27 128.51 55.56 Favored 'General case' 0 C--N 1.316 -0.882 0 CA-C-O 121.263 0.554 . . . . 0.0 111.117 -178.888 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.587 ' HB2' HD12 ' A' ' 52' ' ' ILE . 22.4 ttt180 -61.74 115.4 3.95 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.008 -0.996 . . . . 0.0 111.515 178.262 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.452 ' O ' HG12 ' A' ' 69' ' ' VAL . 22.0 t -82.07 12.29 0.64 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-N 114.922 -1.036 . . . . 0.0 110.876 179.32 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.456 ' HB2' ' HE ' ' A' ' 68' ' ' ARG . 60.4 mt . . . . . 0 C--O 1.249 1.045 0 CA-C-O 118.317 -0.849 . . . . 0.0 110.692 -178.447 . . . . . . . . 1 1 . 1 stop_ save_